Äärimaa, T, 12
Aarsvold, JN, 929(ab)
Abós, MD, 296
Abdel-Dayem, HM, 84(ab), 574, 889(ab)
Abdel-Nabi, HH, 94(ab), 1233
Abe, H, 1465(ab)
Abe, Y, 1179(ab)
Abella-Columna, E, 255(ab)
Abenhardt, W, 1133(ab)
Abi-Dargham, A, 114(ab), 122(ab), 121(ab), 435(ab), 581(ab), 1162(ab)
Abitbol, C, 204(ab)
Abou-Zied, MM, 1069(ab)
Abrahamian, H, 1368(ab)
Abram, U, 1913
Abrams, MJ, 184
Abrams, PG, 75(ab)
Abumrad, N, 406(ab)
Abunku, O, 53(ab)
Aburano, T, 1644
Aburano, T, 211(ab), 212(ab), 216(ab), 569(ab), 747(ab), 855(ab), 1173(ab)
Acampa, W, 194(ab), 338(ab), 725(ab), 777(ab), 1683
Acar, P, 910(ab)
Acharya, SA, 1404(ab)
Achilefu, SI, 996(ab)
Acosta, E, 73(ab)
Acton, PD, 108(ab), 583(ab), 1200(ab), 1345(ab), 1812
Adachi, I, 748(ab), 798(ab), 807(ab), 1204(ab), 1319(ab)
Adachi, Y, 514(ab)
Adam, C, 433(ab)
Adam, LE, 308(ab), 1239(ab)
Adam, M, 283
Adams, BK, 861(ab)
Adams, S, 282(ab), 1152(ab)
Adams, WD, 1298(ab)
Adamson, KL, 541(ab), 1246(ab)
Adelstein, SJ, 986(ab), 1377(ab)
Adem, A, 174(ab)
Adema, GJ, 1028(ab)
Adler, LP, 118
Afriyie, MO, 57(ab), 201(ab), 478(ab), 930(ab)
Agafitei, D, 28(ab)
Agafitei, R, 170(ab)
Aggarwal, K, 174(ab)
Agnese, G, 1123(ab)
Agostini, D, 8(ab), 175(ab), 901(ab), 905(ab)
Agresti, R, 1114(ab)
Agu, R, 610(ab)
Aguade, S, 315(ab)
Aharon, S, 1098
Ahdoot, R, 1080(ab), 1363(ab)
Ahlberg, AW, 517(ab), 518(ab), 711(ab)
Ahlman, H, 2094
Ahmed, S, 1079(ab)
Ahn, IM, 529(ab)
Ahn, JY, 309(ab)
Ahn, SH, 1394(ab)
Ah-See, AK, 552(ab)
Aihara, Y, 217
Aisa, F, 296
Aitken, CL, 1281(ab)
Ajzenberg, C, 1252
Akabani, G, 631, 1197
Akagi, N, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
Akaki, S, 394, 1971
Akamune, A, 1271(ab)
Akashi, K, 814(ab)
Akashi, Y, 1595
Akhurst, T, 912(ab), 1042(ab)
Akinboboye, O, 29(ab)
Akincioglu, C, 39(ab)
Akino, H, 1137(ab)
Akioka, K, 1492
Aktas, A, 849(ab)
Aktay, R, 1434
Al Haider, ZY, 861(ab)
Al Sakhri, HA, 764(ab)
Al Yasi, AR, 764(ab), 1108(ab)
Alam, F, 940(ab)
Alauddin, MM, 103(ab), 334(ab), 1361(ab), 1368(ab)
Alavi, AA, 61(ab), 108(ab), 118(ab), 199(ab), 274(ab), 276(ab), 333(ab), 387(ab), 401(ab), 453(ab), 520(ab), 521(ab), 526(ab), 562(ab), 625, 868(ab), 888(ab), 995, 1054(ab), 1070(ab), 1117(ab), 1143, 1200(ab), 1240(ab), 1241, 1257, 1286(ab), 1812, 2107
Alazraki, NP, 209(ab), 234(ab), 238(ab), 929(ab)
Albayrak, S, 864(ab)
Albelda, SM, 1241
Albers, P, 1133(ab)
Alberto, R, 1913
Alboni, P, 778(ab)
Alderson, PO, 228(ab), 412(ab)
Alenius, ST, 862, 1326(ab), 1330(ab)
Alexoff, DL, 1301(ab)
Alfano, B, 442
Alhaddad, IA, 788(ab)
Ali, H, 1728
Alkan, E, 429
Allen, LW, 579
Allen-Auerbach, M, 184(ab), 186(ab), 189(ab)
Allidina, Y, 769(ab)
Aloj, L, 385(ab), 1547
Alonso, C, 60(ab)
Alperson, M, 45(ab)
Alpert, NM, 391(ab), 579(ab), 1266(ab), 1269(ab)
Al-Sugair, AS, 81(ab)
Al-Tikriti, MS, 154(ab)
Altmann, A, 1011(ab)
Altorki, N, 1303(ab)
Alyafei, S, 1018(ab)
Al-Za'abi, K, 879(ab)
Amano, S, 399
Amanullah, AM, 738(ab)
Amar, MH, 175(ab)
Amaral, H, 59(ab), 904(ab)
Ambrose, KR, 1484
Amici, LA, 1208(ab)
Amin, KC, 236(ab)
Amoachi, GS, 43(ab)
Amthauer, H, 387
An, R, 988(ab)
Anand, A, 580(ab)
Andersen, TT, 1030(ab)
Anderson, A-L, 323(ab)
Anderson, BO, 557(ab)
Anderson, CJ, 997(ab)
Anderson, JH, 1180
Anderson, S, 9(ab)
Ando, A, 728(ab)
Andrade, MA, 11(ab)
Andreas, J, 125(ab), 925(ab)
Andreeff, M, 1385(ab)
Angel, J, 315(ab)
Angelberger, P, 74(ab), 395(ab), 1081(ab)
Angeletti, S, 843(ab)
Angerstein, C, 420(ab), 428(ab), 429(ab), 1029, 1374(ab), 1380(ab)
Anidjar, R, 1459(ab), 1464(ab)
Anjilvel, S, 1211(ab)
Annala, AJ, 20(ab), 826(ab)
Anstett, F, 359(ab)
Anthonio, RL, 507
Antin, JH, 1031(ab)
Antonietti, T, 910(ab)
Antonini, A, 271(ab), 914(ab), 1264
Antoniucci, D, 363
Anwar, K, 970(ab)
Aoki, J, 390(ab), 399
Aoki, S, 574(ab), 1300(ab)
Aomi, S, 744(ab)
Aoyagi, K, 399, 878(ab), 1018(ab)
Aoyagi, T, 1116
Aoyama, T, 191(ab)
Apice, G, 1142(ab)
Apicella, A, 66(ab)
Apostolidis, C, 166, 433(ab), 1375(ab), 1380(ab)
Appelbaum, JW, 75(ab)
Aqel, R, 174(ab)
Arahata, Y, 1179(ab)
Arai, H, 207(ab), 527(ab)
Arai, T, 574(ab), 835(ab)
Araki, T, 574(ab), 835(ab)
Aranda, R, 1083(ab)
Arano, Y, 479, 1371(ab), 1406(ab)
Arap, W, 883
Araujo, WM, 1040(ab)
Arbab, AS, 574(ab), 835(ab)
Arbizu, J, 424(ab), 555(ab)
Arends, AJ, 1257(ab)
Arevalo, A, 1209(ab)
Ariannejad, M, 1468(ab)
Arienzo, S, 1142(ab)
Arisaka, Y, 86(ab), 1095(ab)
Arlauskas, P, 1079(ab)
Armijo, I, 516(ab)
Arnello, F, 52
Arnold, E, 177(ab)
Arnold, J, 238(ab)
Arnold, S, 737
Arora, R, 350(ab)
Arouca, PT, 746(ab)
Ar'Rajab, A, 237(ab)
Arrighi, JA, 21(ab), 346(ab)
Asada, T, 1192(ab)
Asai, S, 793
Asano, T, 1188(ab)
Asenjo, MJ, 296
Asero, S, 1114(ab)
Ashare, AB, 760(ab)
Ashburn, W, 750(ab), 1121(ab), 1225(ab), 1256(ab)
Aslan, S, 1046(ab)
Asselin, M-C, 1666
Astrom, K, 224(ab)
Atcher, RW, 322(ab)
Atkins, HL, 264(ab), 490(ab)
Atochina, O, 888(ab)
Atsma, DE, 740(ab)
Atthey, M, 161(ab)
Aubert, B, 157(ab), 1517
Aubier, M, 962(ab)
Aubriot, JH, 901(ab), 905(ab)
Auer, C, 290(ab)
Augeri, C, 926(ab)
Augustijns, P, 610(ab)
Aula, P, 12
Aung, M, 732(ab)
Austin-Seymour, MM, 69(ab)
Avery, RA, 275(ab), 1199(ab), 1270(ab)
Aviner, S, 522(ab)
Avril, N, 104(ab), 550(ab), 593(ab), 1311(ab)
Awata, S, 244
Axworthy, DB, 75(ab)
Ayabe, K, 86(ab), 1095(ab)
Ayaz, M, 429
Aziz, A, 1098(ab)
Aznar, M, 542(ab)
Azuma, A, 514(ab)
Azuma, H, 1132
Azuma, M, 859(ab)
Azure, MT, 994(ab)
Baba, K, 936(ab)
Babich, JW, 894(ab)
Baccarne, V, 473(ab)
Bacharach, SL, 385(ab), 464(ab), 472(ab), 565(ab), 1029(ab), 1297(ab)
Badawi, RD, 1236(ab)
Badimon, JJ, 355(ab)
Bading, JR, 1361(ab)
Bae, SK, 1045(ab)
Baer, FM, 791(ab)
Baetens, J, 610(ab)
Bagatella, F, 1053(ab)
Bagella, C, 1105(ab)
Baghaei, H, 307(ab), 598(ab), 1233(ab)
Bagni, B, 538(ab)
Bagni, I, 538(ab)
Bahk, YW, 217(ab), 376(ab)
Bähre, M, 540(ab), 605(ab), 730(ab), 921(ab), 944(ab)
Bai, C, 462(ab)
Baidoo, KE, 318(ab), 492(ab)
Bailey, KM, 9N(9), 15N(11)
Bakan, A, 864(ab)
Baker, K, 306(ab)
Baker, LH, 1456
Bakker, J, 58(ab)
Bakker, P, 1107(ab)
Bakker, WH, 320(ab), 414(ab), 416(ab), 762, 2081
Bakker-Woudenberg, IAJM, 2066
Bal, CS, 927(ab), 934(ab)
Bal, G, 1255(ab)
Balan, KK, 249(ab), 1093(ab)
Balatoni, J, 105(ab), 1012(ab)
Balbastro, E, 553(ab)
Baldassarri, AR, 1630
Baldessarini, RJ, 148(ab)
Baldwin, RM, 124(ab), 143(ab), 148(ab), 154(ab), 270(ab), 444(ab), 607(ab), 1208(ab), 1902
Ballangrud, ÅM, 164(ab), 1935
Ballester, M, 911, 5(ab)
Ballinger, J, 1201(ab)
Ballinger, JR, 530, 273(ab), 331(ab), 614(ab), 1019(ab), 1025(ab)
Ballkissoon, AA, 1455(ab)
Ballok, ZE, 381(ab)
Balm, AJM, 1414
Balon, H, 287(ab)
Baltauss, T, 1127(ab)
Baltuch, G, 276(ab)
Balza, E, 434(ab)
Bamder, NH, 1008(ab)
Bander, NH, 1001(ab)
Bandy, D, 717(ab), 1304(ab)
Banerjee, S, 1015(ab), 1402(ab)
Bang, BK, 376(ab)
Banzo, J, 296
Barber, HB, 601(ab)
Barber, RW, 135(ab), 494(ab)
Barbet, J, 198, 1002(ab), 1216
Bareille, R, 1756
Barendswaard, EC, 431(ab), 1764
Bares, R, 245(ab), 247(ab), 460(ab), 871(ab), 933(ab), 946(ab), 956(ab), 957(ab), 1133(ab), 1289(ab)
Bar-Meir, E, 45(ab)
Barnett, CA, 712(ab)
Baron, J-C, 25, 749(ab)
Baron, JM, 480(ab)
Barr, LL, 53(ab)
Barré, L, 25
Barraclough, ED, 625, 108(ab), 1200(ab), 1812, 2107
Barrett, CL, 77(ab)

Barrett, HH, 601(ab)
Barrett, JA, 892(ab)
Barrio, JR, 102(ab), 142(ab), 284(ab), 332(ab), 585(ab), 587(ab)
Barritault, L, 910(ab)
Barron, BJ, 902(ab), 1459(ab), 1462(ab), 1463(ab), 1464(ab)
Barrow, SA, 1161(ab)
Bar-Sever, Z, 51(ab), 522(ab), 880(ab)
Bartenstein, P, 290(ab), 291(ab), 397(ab), 448(ab), 451(ab), 737
Barthe, N, 868
Barthel, H, 570(ab)
Barthel, P, 904
Bartholomeusz, D, 277
Bartlett, ML, 758(ab)
Bartold, SP, 1226
Bartolomei, M, 72(ab), 235(ab), 266(ab), 1125(ab)
Basik, M, 1124(ab)
Basoglu, T, 864(ab)
Basse-Cathalinat, B, 412, 868, 1756
Bastidas, D, 1001(ab), 1008(ab)
Bastien, SA, 615(ab)
Bateman, JE, 1224(ab)
Bateman, TM, 27(ab), 710(ab), 724(ab), 1291(ab)
Batra, SK, 1536
Battelli, LA, 379(ab)
Battisti, P, 1716
Battle, XL, 298(ab), 473(ab)
Baudoux, A, 882(ab)
Baudouy, M, 1301
Baudrexel, S, 881(ab)
Bauer, E, 102(ab)
Baulac, M, 935
Baulieu, JL, 1393(ab)
Baum, M, 560(ab), 1116(ab)
Baum, RP, 1152(ab)
Bauman, BD, 360(ab)
Baumann, G, 195(ab)
Bausart, R, 1109(ab)
Bautovich, G, 218(ab)
Bavaria, G, 1244(ab)
Bax, JJ, 1(ab), 180(ab), 190(ab), 192(ab), 731(ab), 765(ab), 831(ab), 1204, 1866, 1893
Bayhan, HF, 404(ab)
Baza, S, 1524
Beanlands, RS, 732(ab)
Beauchamp, RD, 1784
Becherer, A, 362(ab), 1049(ab), 1347(ab)
Beck, M, 1081(ab)
Becker, K, 433(ab), 550(ab)
Becker, LC, 359(ab), 1263(ab)
Becker, MD, 228(ab), 412(ab)
Becker, MJ, 2066
Becker, W, 48(ab), 396(ab), 420(ab), 428(ab), 429(ab), 537(ab), 907(ab), 992(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
Beck-Peccoz, P, 922(ab)
Bedard, MA, 267(ab)
Bedrošian, I, 1117(ab), 1143
Beets, AL, 1918
Begent, RH, 541(ab), 1246(ab)
Beger, HG, 250, 422(ab)
Béhé, M, 396(ab), 420(ab), 428(ab), 429(ab), 907(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
Behloul, F, 821(ab)
Behnke, A, 1246
Behr, TM, 48(ab), 396(ab), 420(ab), 428(ab), 429(ab), 907(ab), 992(ab), 1029, 1374(ab), 1375(ab), 1380(ab)
Beitzel, MP, 329(ab)
Beju, D, 815(ab)
Belanger, M, 1280(ab)
Belasco, J, 521(ab)
Belezzuoli, E, 750(ab), 1121(ab), 1256(ab)
Belin, A, 8(ab), 175(ab)
Bell, RA, 504(ab)
Bellemann, ME, 1016(ab), 1032(ab), 1251(ab)
Bellen, JC, 277
Beller, GA, 142, 821
Bellina, CR, 926(ab)
Benada, A, 173(ab), 743(ab)
Benali, H, 16(ab), 140(ab), 471(ab), 595(ab), 1314(ab)
Bénard, F, 526(ab), 562(ab), 832(ab), 1241, 1257
Bencherif, B, 446(ab), 447(ab), 1207(ab)
Bender, H, 974(ab), 988(ab), 1133(ab), 1384(ab)
Bender, LW, 967(ab)
Benelhadj, S, 1252
Bengel, FM, 30(ab), 33(ab), 34(ab), 35(ab), 183(ab), 188(ab), 904
Ben-Haim, S, 741(ab), 811(ab)
Benjegård, SA, 2094
Benkelfat, C, 577(ab)
Bennett, JA, 319(ab), 1030(ab)
Bennett, S, 504(ab)
Bennink, RJ, 1107(ab), 1451
Benti, R, 271(ab), 914(ab), 1630
Bentourkia, M, 832(ab)
Benvenuti, C, 917
Benz, P, 125(ab), 1222(ab)
Berberoglu, S, 524(ab), 919(ab)
Beresford, GW, 1536
Bergert, B, 117(ab)
Bergman, J, 12
Bergmann, L, 262(ab)
Bergmann, R, 293(ab)
Bergmann, SR, 29(ab), 182(ab), 310(ab), 720(ab), 911(ab), 1882
Bergmans, P, 106(ab), 111(ab)
Bergner, U, 1154(ab)
Bergsneider, M, 146(ab), 147(ab)
Beric, A, 1184(ab)
Berk, AJ, 102(ab)
Berman, DS, 6(ab), 9(ab), 22(ab), 25(ab), 27(ab), 28(ab), 170(ab), 710(ab), 722(ab), 810
Berman, RM, 576(ab)
Berna, LL, 3(ab), 5(ab), 734(ab), 786(ab)
Bernà, L, 19, 911
Bernard, BF, 2081
Bernard, HF, 317(ab), 320(ab), 414(ab), 418(ab)
Bernardo, M, 123(ab)
Bernardo-Filho, M, 1379(ab)
Bernatz, S, 1702
Bernay, I, 864(ab)
Berndorff, D, 434(ab)
Bernecker, P, 1277
Bernhardt, P, 2094
Berridge, MS, 383(ab), 886(ab)
Berrouschot, J, 570(ab)
Berry, G, 38(ab)
Besnard, JC, 1343(ab), 1393(ab)
Bestetti, A, 77
Betman, L, 265(ab)
Betteridge, J, 737(ab)
Bettinardi, V, 302(ab), 459(ab)
Bettinsoli, G, 375(ab)
Beu, M, 977, 575(ab)
Beuthien-Baumann, B, 543(ab)
Beyer, T, 597(ab), 1134(ab)
Beyer, W, 1041(ab)
Bezante, GP, 1832
Bezerra, RJ, 1379(ab)
Bhargava, KK, 57(ab), 961(ab), 1404(ab)
Bhatnagar, A, 562(ab), 904(ab)
Bhosale, P, 902(ab)
Bianchi, C, 1556
Bianchi, J, 1104(ab)
Bianchi, PA, 1123(ab), 1630
Bianchi, R, 926(ab)
Bianco, J, 723(ab)
Bidani, N, 1334(ab)
Biedenstein, S, 185(ab)
Bier, D, 1342
Biersack, HJ, 78(ab), 974(ab), 988(ab), 1133(ab), 1384(ab)
Bigner, DD, 631
Bihl, H, 248(ab), 254(ab), 1059(ab), 1068(ab), 1149(ab)
Bilger, K, 460(ab), 1289(ab)
Bilkay, UY, 753(ab)
Binkert, BL, 1024
Bird, NJ, 135(ab)
Bird, V, 206(ab)
Birnbaumer, L, 1083(ab)
Birrell, A, 144(ab)
Bishayee, A, 978(ab)
Bishop, HA, 229(ab), 230(ab), 379(ab), 468(ab), 548(ab), 1320(ab)
Bishop, MC, 399(ab)
Bissoli, S, 1053(ab)
Bizais, YJ, 298(ab), 473(ab)
Black, K, 1182(ab)
Black, SE, 1193(ab)
Blais, M, 753(ab), 1262(ab)
Blanco, P, 1524
Blankenberg, FG, 38(ab), 184, 846(ab)
Blanksma, PK, 507, 351(ab), 717(ab), 755(ab)
Blasberg, RG, 1012(ab)
Blatt, SA, 225(ab), 226(ab), 408(ab)
Blatter, J, 1011(ab)
Blaufox, MD, 1352
Bleckmann, C, 941(ab), 2021
Blend, MJ, 347, 394(ab), 1138(ab), 1276(ab)
Bleza, M, 83(ab)
Blier, P, 577(ab)
Blijham, GH, 639
Blocklet, DC, 1333(ab), 1978
Blockmans, D, 899(ab)
Blondet, C, 585
Blood, CH, 485(ab)
Blood, DK, 182(ab)
Bloodworth, GA, 1454(ab)
Blum, J, 231(ab)
Blum, JE, 36(ab)
Blum, S, 788(ab)
Blumenthal, RD, 428(ab), 429(ab), 981(ab), 1380(ab), 1609
Blundell, P, 153(ab)
Bobbaers, H, 899(ab)
Boccio, JR, 1080
Bocciolone, L, 235(ab)
Bocher, M, 545(ab), 1037(ab)
Bockisch, A, 475(ab), 923(ab), 1918
Boellaard, R, 1235(ab), 1313(ab)
Boer, G, 1107(ab)
Boerman, OC, 58(ab), 192, 432(ab), 829, 892(ab), 1028(ab), 2066
Boersma, E, 731(ab), 1866
Bofilias, I, 931(ab)
Bohdiewicz, P, 83(ab)
Bohnen, NI, 850(ab)
Bohuslavizki, KH, 46(ab), 71(ab), 257(ab), 776, 941(ab), 1041(ab), 1033(ab), 1150(ab), 1246, 1657, 2021
Bokemeyer, C, 1133(ab)
Bokhari, S, 182(ab)
Bolch, WE, 978(ab), 1327, 1947, 2115
Boldrini, E, 1148(ab)
Bolinger, B, 427(ab)
Bolognese, L, 363
Bolzati, C, 1382(ab)
Bom, HS, 286(ab), 549(ab), 1202(ab), 1378(ab)
Bomanji, J, 737(ab)
Bombardieri, E, 251(ab), 1114(ab)
Bonab, AA, 579(ab), 1161(ab), 1266(ab)
Bonaduce, D, 194(ab), 1683
Bonapace, ES, 366(ab)
Boni, G, 926(ab)
Böni, R, 79(ab)
Böning, G, 1234(ab)
Bönisch, H, 1342
Bonow, RO, 342(ab)
Bonte, FJ, 896(ab)
Bontemps, L, 1466(ab)
Booij, J, 106(ab), 111(ab), 113(ab), 272(ab), 753, 1091, 1216(ab)
Bookheimer, SY, 283(ab)
Boon, P, 277(ab)
Boonstra, H, 432(ab), 1132(ab)
Booth, BJM, 1536
Borbath, I, 1013(ab), 1109(ab)
Bordenave, L, 1756
Borgers, M, 19(ab), 822(ab)
Borges, AC, 195(ab)
Borges-Neto, S, 26(ab), 477(ab)
Borggrefe, M, 1, 834(ab)
Bormans, G, 19(ab), 98(ab), 822(ab), 899(ab)
Bormans, GM, 288(ab), 610(ab), 898(ab), 1353(ab)
Börner, AR, 566(ab)
Bornstein, A, 171(ab), 176(ab)
Borrón, M, 768
Borsi, L, 434(ab)
Boschi, A, 1382(ab)
Bossle, F, 1342
Bossuyt, A, 256(ab), 413(ab), 488(ab), 703(ab), 709(ab), 872(ab)
Bøtker, HE, 1186, 1292
Böttcher, M, 1292
Botti, C, 46
Bottlaender, M, 1374
Bouchareb, Y, 31(ab)
Boucher, L, 41(ab)
Bouchet, LG, 978(ab), 1327, 1524, 1947, 2115
Boudraa, A, 821(ab)
Bouhnik, JP, 136(ab)
Bourguet, P, 140(ab), 1314(ab)
Bourque, CR, 1369(ab)
Bousson, V, 1092(ab)
Bouvard, G, 8(ab), 175(ab), 901(ab), 905(ab)
Bouwens, L, 1250(ab)
Bowen, WD, 486(ab)
Bowsher, JE, 139(ab), 1260(ab)
Brag, JM, 729(ab)
Braga, HM, 1148(ab)
Brambs, H, 422(ab)
Brandalise, S, 1148(ab)
Brandalise, SR, 958(ab)
Brandt-Mainz, K, 923(ab)
Brans, B, 277(ab)
Brasseur, N, 876
Braunstein, RH, 206(ab)
Bray, M, 1370(ab)
Breau, JL, 1092(ab)
Brechbiel, MW, 166, 268, 322(ab), 327(ab), 329(ab), 415(ab), 431(ab)
Brecht-Krauss, D, 1637
Bredow, J, 543(ab)
Breeman, WA, 317(ab), 320(ab), 414(ab) 418(ab)
Breidert-Backes, I, 1152(ab)
Breithardt, G, 1, 834(ab)
Breitz, HB, 75(ab), 1355(ab)
Bremner, JD, 578(ab), 1220(ab)
Brenner, W, 46(ab), 47(ab), 71(ab), 776, 1033(ab), 1246
Breuning, A, 254(ab)
Bricker, JA, 613(ab)
Brigger, P, 1297(ab)
Brill, AB, 590(ab), 1364(ab), 1524
Brink, I, 340(ab)
Brinkbarumer, K, 1243(ab)
Brinkbaumer, K, 1048(ab)
Brinkmann, BH, 677, 1098
Brinkschmidt, C, 388(ab)
Briscoe, E, 553(ab)
Britten, AE, 161(ab)
Britton, A, 984(ab)
Britton, KA, 60(ab)
Britton, KE, 467(ab), 764(ab), 904(ab), 1108(ab)
Britz-Cunningham, SH, 714(ab)
Brix, G, 1016(ab), 1032(ab)
Brockmann, H, 830(ab)

Broder, JD, 206(ab)
Brotherton, JH, 347(ab)
Brouillaud, B, 1756
Brouwers, AH, 892(ab)
Brown, BM, 1383(ab)
Brown, CA, 9(ab)
Brown, KL, 492(ab)
Brown, RP, 373(ab)
Brown, RS, 88(ab), 89(ab), 87(ab), 556
Brownell, A, 582(ab)
Brücher, BL, 550(ab)
Bruckbauer, T, 1316(ab)
Bruland, ØS, 1197
Brun, T, 597(ab)
Brunelli, C, 1832
Brunetti, A, 442
Brunken, R, 773(ab)
Brunner, C, 395(ab)
Bruno, A, 338(ab), 725(ab), 777(ab), 914(ab), 1630
Brust, JC, 1205(ab)
Brust, P, 293(ab), 584(ab)
Bruyant, PP, 1676
Buchert, R, 257(ab), 1150(ab), 1657, 2021
Buchmann, I, 247(ab), 945(ab)
Buchpiguel, CA, 870(ab), 916(ab)
Buchsbaum, MS, 355(ab)
Buck, A, 1158(ab)
Buck, AK, 368(ab)
Buckley, KS, 1453(ab)
Bucky, LP, 1143
Budinger, T, 352(ab)
Budinger, TF, 311(ab)
Buell, U, 450(ab)
Buffoni, F, 1123(ab)
Bugaj, J, 320(ab)
Bugaj, JE, 993(ab), 996(ab)
Bugeon, S, 1393(ab)
Büll, U, 1133(ab)
Bunjes, D, 262(ab)
Buonamici, P, 363
Buranapong, P, 131
Burchert, W, 543(ab), 719(ab), 1272(ab)
Burckhardt, D, 359(ab)
Burckhardt, DD, 1244(ab)
Burg, M, 346(ab)
Burger, A, 1342
Burger, C, 1288(ab)
Burke, G, 377(ab)
Burke, R, 776(ab)
Burke, RJ, 771(ab)
Burkhardt, H, 537(ab)
Burnham, CA, 1258(ab)
Burns, HD, 400(ab), 1014(ab)
Burns, RJ, 721(ab), 771(ab), 776(ab)
Burrascano, JJ, 1197(ab)
Buscombe, JR, 68(ab), 536(ab), 541(ab), 1038(ab)
Busemann Sokole, E, 1091
Bush, LR, 994(ab)
Bush, V, 218(ab)
Buskens, E, 311
Bussière, F, 1301
Butterworth, EA, 1279(ab)
Buvat, I, 16(ab), 140(ab), 471(ab), 595(ab), 1301, 1314(ab)
Byars, LG, 597(ab)
Bybel, B, 707(ab)
Byrd, DR, 557(ab)
Byrne, CL, 1312(ab)
Byrne, FR, 1083(ab)
Cabral-Neto, JB, 1379(ab)
Cabrejas, RC, 60(ab)
Cabrera, A, 555(ab)
Cacavio, A, 84(ab)
Cadiot, G, 1602
Cadorette, J, 832(ab), 876
Cai, H, 485(ab)
Caillat-Vigneron, N, 40, 960(ab)
Caló, G, 1168(ab), 1556
Calame, W, 2073
Calcagno, ML, 1080
Caldeira-de-Araujo, A, 1379(ab)
Caldwell, CB, 1193(ab)
Caldwell, JH, 339(ab), 1279(ab), 1400(ab)
Calegaro/Manzini, JU, 11(ab)
Callahan, MJ, 913(ab)
Callahan, RJ, 1161(ab)
Callans, LS, 1143
Callen, DJ, 1193(ab)
Calmanovici, GP, 1080
Calne, DB, 283
Calnon, DA, 821
Calvo, R, 555(ab), 1096(ab), 1145(ab)
Camargo, EE, 746(ab), 848(ab), 958(ab), 1148(ab)
Cameron, R, 1370(ab)
Camici, PG, 507, 834(ab), 1848
Camp, V, 1344(ab)
Camp, VM, 331
Campbell, C, 1211(ab)
Campion, L, 198
Campisi, R, 32(ab)
Campos, LP, 165(ab)
Campos, R, 1040(ab)
Campreciós, M, 911
Camprecios, M, 5(ab)
Canavese, G, 1123(ab)
Candell-Riera, J, 315(ab)
Caner, B, 849(ab)
Canesi, M, 271(ab)
Cannas, P, 843(ab)
Cantin, J, 1124(ab)
Cantwell, MN, 2053
Canzi, C, 914(ab), 1928
Caporali, C, 538(ab)
Caputo, G, 574
Capuzzi, DM, 1458(ab)
Caracò, C, 1547
Carbon, C, 893(ab)
Carey, J, 990(ab)
Cargnel, S, 1053(ab)
Carhart, C, 1245(ab)
Carli, F, 1123(ab)
Carlisle, M, 545(ab)
Carlson, KA, 846, 495(ab)
Carlson, SM, 554(ab), 1099(ab), 1130(ab)
Caro, RA, 1080
Carola, F, 77
Carpenter, R, 1108(ab)
Carr, CE, 2014
Carrasquillo, JA, 268, 327(ab), 385(ab), 464(ab), 565(ab), 837, 1006(ab), 1027(ab), 1029(ab), 1391
Carretta, RF, 21N(9)
Carrio, I, 3(ab), 5(ab), 734(ab), 786(ab), 1212(ab)
Carrió, I, 19, 911
Carroll, MJ, 467(ab), 1108(ab)
Carson, RE, 119(ab), 168(ab), 464(ab), 472(ab), 1321(ab)
Carter, EA, 370(ab), 391(ab), 894(ab), 895(ab)
Carter, PC, 324(ab)
Casas, M, 19
Casati, R, 251(ab)
Case, JA, 27(ab), 604, 724(ab), 1291(ab)
Casey, ME, 306(ab), 1316(ab)
Caskey, C, 1463(ab)
Casolo, GC, 196(ab)
Castaigne, A, 224, 917
Castellani, M, 251(ab), 338(ab), 1085(ab), 1928
Castellari, M, 725(ab), 777(ab)
Castellucci, P, 387(ab)
Castle, VP, 519(ab)
Castronovo, F, 1031(ab)
Catafau, A, 5(ab)
Catafau, AM, 3(ab), 19, 123(ab), 734(ab), 786(ab), 911, 1212(ab)
Catsafados, E, 522
Caveliers, V, 488(ab), 872(ab)
Cayre, A, 672
Ceccarelli, C, 1716
Celerier, C, 1756
Cengiz, K, 864(ab)
Centi Colella, A, 556(ab)
Cerisano, G, 363
Cesani, F, 553(ab), 906(ab)
Cessna, JT, 1508
Chae, SC, 735(ab)
Chakder, S, 352
Chakrabarty, S, 737(ab)
Chaljub, G, 906(ab)
Chalon, S, 1343(ab)
Chaly, TC, 1339(ab)
Champailler, A, 733(ab)
Champlin, RE, 160(ab)
Chan, GL, 283
Chan, H, 382(ab)
Chan, T, 297(ab)
Chandra, P, 507(ab)
Chandra, S, 279(ab)
Chang, CP, 1065(ab), 1186(ab)
Chang, C-S, 1106
Chang, CW, 244(ab), 1365(ab)
Chang, CY, 285(ab)
Chang, L, 443(ab)
Chang, SM, 349(ab)
Chang, W, 896(ab)
Chang, Y, 402(ab)
Chang, YS, 1275(ab), 1350(ab)
Changlai, S, 225(ab), 226(ab), 408(ab)
ChangLai, S-P, 1446
Channing, MA, 464(ab)
Chapman, JT, 1245(ab)
Chapman, WC, 1784
Charache, P, 454(ab)
Charbonnier, B, 223(ab)
Charkes, ND, 1313
Charlop, A, 69(ab), 551(ab)
Charney, DS, 124(ab), 143(ab), 576(ab), 578(ab), 580(ab), 1208(ab), 1220(ab), 1902
Charon, Y, 602(ab)
Charpak, G, 868
Charron, M, 50(ab), 597(ab), 850(ab), 1134(ab)
Chatal, J-F, 198, 1216
Chatterton, BE, 277
Chatziioannou, AF, 303(ab), 1164
Chatziioannou, SN, 17(ab), 348(ab)
Chatzimavroudis, G, 753(ab)
Chaudhuri, G, 32(ab)
Chaudhuri, TR, 994(ab)
Chauvot, P, 585
Chechik, A, 63(ab)
Chefer, S, 1349(ab)
Chen, CC, 539
Chen, C-H, 118
Chen, FD, 1365(ab)
Chen, G-H, 1106
Chen, HJ, 1365(ab)
Chen, JQ, 484(ab)
Chen, K, 717(ab), 1045, 1304(ab)
Chen, L, 494(ab)
Chen, M, 1391(ab)
Chen, P, 1344(ab)
Chen, SH, 1012(ab)
Chen, T, 846, 1091(ab), 1111(ab)
Chen, W, 1315(ab)
Chen, WS, 1024(ab)
Chen, Y, 1373(ab), 1395(ab)
Chen, Y-C, 582(ab)
Chen, Z, 1370(ab)
Cheng, KT, 1383(ab), 1390(ab)
Cheng, SH, 1052(ab)
Cheng, Z, 484(ab)
Cheon, GJ, 2(ab), 23(ab), 358(ab), 386(ab), 742(ab), 789(ab), 790(ab), 1143(ab), 1275(ab)
Cheon, KJ, 1195(ab)
Cherry, SR, 20(ab), 131(ab), 303(ab), 304(ab), 826(ab), 1083(ab), 1156(ab), 1164, 1223(ab)
Chessa, F, 1105(ab)
Cheung, NK, 1007(ab)
Chezmar, JL, 92(ab)
Chiaramida, P, 1105(ab)
Chiba, T, 1792
Chicco, P, 85, 218(ab)
Chierichetti, F, 1053(ab)
Chilcott, F, 552(ab)
Childers, S, 1346(ab)
Childs, J, 13N(10)
Chin, B, 940(ab)
Chin, LK, 1072
Chin, P, 1462(ab)
Chinen, L, 1389(ab)
Chinol, M, 72(ab), 266(ab), 1125(ab)
Chiou, Y-H, 60
Chirakal, R, 604(ab)
Chiron, C, 786
Chisin, R, 91, 1037(ab)
Chittenden, SJ, 983(ab)
Cho, BY, 986, 938(ab)
Cho, IH, 515(ab)
Cho, KH, 286(ab), 1202(ab)
Cho, KS, 205(ab)
Cho, MJ, 1221(ab)
Cho, S, 1214(ab)
Cho, SH, 833(ab)
Cho, YP, 568(ab)
Choe, W, 505(ab)
Choe, YS, 49(ab), 380(ab), 736(ab), 884(ab), 1076(ab), 1141(ab), 1226(ab)
Choi, CW, 166(ab), 386(ab), 986, 1043(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1128(ab), 1151(ab), 1358(ab), 1359(ab), 1360(ab)
Choi, IS, 10(ab)
Choi, J, 825(ab)
Choi, JY, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1141(ab), 1194(ab)
Choi, NC, 547(ab), 1090(ab)
Choi, P, 891(ab)
Choi, SR, 339, 1352(ab)
Choi, SW, 1023(ab), 1340(ab), 1341(ab)
Choi, TH, 166(ab), 1359(ab)
Choi, Y, 49(ab), 380(ab), 736(ab), 851(ab), 884(ab), 1045, 1076(ab), 1141(ab), 1226(ab)
Choi, YJ, 819(ab)
Choi, YS, 851(ab)
Chosidow, D, 1602
Chou, KL, 244(ab), 1065(ab)
Chou, RL, 29(ab), 911(ab)
Chou, Y, 151(ab), 1343(ab)
Chouraqui, P, 749(ab)
Chowdhury, S, 1391(ab)
Choyke, P, 565(ab), 1029(ab)
Christ, M, 282(ab)
Christian, BT, 1267(ab)
Christian, PE, 132(ab), 137(ab), 1298(ab)
Chronos, NA, 753(ab)
Chu, J, 250(ab)
Chu, JM, 544(ab), 1153(ab)
Chu, LS, 244(ab), 909(ab), 1062(ab)
Chu, YK, 1062(ab)
Chuang, R, 1268(ab)
Chugani, DC, 592(ab), 1985
Chugani, HT, 1985
Chun, KA, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab)

Chun, KJ, 810(ab)
Chun, KS, 1394(ab)
Chung, CK, 1195(ab)
Chung, J, 2(ab), 23(ab), 309(ab), 358(ab), 386(ab), 452(ab), 476(ab), 529(ab), 742(ab), 789(ab), 790(ab), 819(ab), 938(ab), 998(ab), 999(ab), 1143(ab), 1171(ab), 1195(ab), 1196(ab), 1198(ab), 1214(ab), 1221(ab), 1275(ab), 1350(ab), 1387(ab), 1392(ab)
Chung, J-K, 339, 986
Chung, SK, 217(ab), 376(ab)
Chung, WS, 1358(ab)
Chung, YA, 376(ab)
Ciancio, G, 377(ab)
Ciarmiello, A, 442
Cieuta, C, 786
Ciftci, I, 849(ab)
Cila, A, 524(ab)
Cirignano, L, 304(ab)
Cittanti, C, 167(ab), 778(ab), 1168(ab), 1556
Civelek, AC, 454(ab), 940(ab)
Clackdoyle, R, 1255(ab)
Clairand, I, 157(ab), 1517
Clausen, M, 46(ab), 71(ab), 257(ab), 776, 941(ab), 1033(ab), 1041(ab), 1133(ab), 1150(ab), 1246, 1657, 2021
Cleveland, W, 799
Clinthorne, NH, 133(ab)
Clorius, JH, 372(ab)
Cloutier, S, 1100(ab)
Clulow, J, 1263(ab)
Cnaan, A, 520(ab)
Coco-Graham, WA, 894(ab)
Cody, K, 983(ab)
Coelho, OR, 746(ab)
Coenen, HH, 501(ab), 575(ab)
Cohen, A, 539(ab)
Cohen, C, 238(ab)
Cohen, I, 6(ab), 28(ab), 170(ab), 346(ab), 378(ab)
Cohen, RM, 119(ab)
Cohen, W, 572(ab)
Cokgor, I, 631
Colacci, C, 843(ab)
Colamussi, P, 167(ab), 778(ab), 1168(ab), 1556
Colcher, D, 1536
Cole, C, 204(ab)
Cole, GM, 284(ab)
Cole, WC, 1165(ab)
Coleman, RE, 26(ab), 81(ab), 136(ab), 339(ab), 477(ab), 631, 814, 1241(ab), 1176
Colin, P, 743(ab)
Collart, JP, 219(ab)
Collier, BD, 1369(ab)
Collins, P, 1232(ab)
Colnot, DR, 263(ab)
Colombo, F, 914(ab)
Comans, EF, 407(ab), 827(ab)
Comans, EFI, 1204
Comtat, C, 2053
Conant, R, 1138(ab)
Conciato, L, 77
Condos, S, 21(ab)
Connell, EJ, 20N(3)
Connelly, K, 119(ab)
Connolly, LP, 51(ab), 52(ab), 56(ab), 908(ab), 1896
Connors, JM, 1031(ab)
Conrad, B, 290(ab)
Consigny, PM, 491(ab)
Constable, C, 144(ab), 382(ab)
Constantine, E, 377(ab)
Conti, PS, 103(ab), 334(ab), 465(ab), 1361(ab), 1368(ab)
Contoreggi, C, 441(ab)
Conwell, R, 1225(ab)
Cook, C, 513(ab), 517(ab)
Cooke, CD, 508(ab), 511(ab), 650, 787(ab), 1290(ab)
Cooper, MS, 615(ab)
Copello, F, 522
Coppola, RC, 1348(ab)
Corazzari, T, 538(ab)
Corbett, JR, 15(ab), 232, 361(ab), 506(ab), 817(ab)
Cordero, M, 768
Corleto, VD, 843(ab)
Corne, R, 707(ab)
Cornel, JH, 1(ab), 190(ab), 192(ab), 731(ab), 1866
Cornelius, EA, 73(ab), 987(ab)
Corone, C, 546(ab)
Cörper, S, 871(ab)
Correia, JA, 1258(ab)
Corsi, M, 275(ab), 730, 1199(ab), 1270(ab)
Corstens, FH, 58(ab), 432(ab), 192, 829, 892(ab), 1028(ab), 2066
Cortelazzi, D, 922(ab)
Cortino, GR, 66(ab)
Costa, DC, 737(ab)
Costa, PL, 916(ab)
Cottu, P, 1105(ab)
Coulden, R, 1093(ab)
Coulon, C, 1374
Coulon, MA, 1092(ab)
Coulon, P, 868
Counsell, RE, 155(ab)
Couturier, O, 1286(ab)
Covelli, EM, 442
Crandell, PS, 459(ab)
Crane, PD, 1369(ab)
Cremerius, U, 1133(ab)
Cremieux, AC, 893(ab)
Cremonesi, M, 72(ab), 266(ab)
Crepin, M, 1127(ab)
Crespo-Jara, AA, 424(ab), 555(ab), 1096(ab), 1145(ab)
Crestani, B, 962(ab)
Cribier, A, 179(ab), 513, 805
Crijns, HJ, 507
Criss, JS, 1144(ab)
Croisille, P, 821(ab)
Croon, CD, 740(ab)
Cross, DJ, 294(ab)
Crouzel, C, 1374
Crow, J, 68(ab)
Crow, W, 906(ab)
Cullom, SJ, 724(ab), 1262(ab), 1291(ab)
Cummings, JL, 283(ab), 285(ab)
Cunha, ML, 1040(ab)
Cuocolo, A, 194(ab), 338(ab), 725(ab), 777(ab), 1683
Cupps, B, 4(ab)
Curcio, MJ, 166, 431(ab)
Curran, KM, 409(ab)
Curtis, JL, 1205(ab)
Curtis, KS, 771(ab)
Cutler, DP, 1304(ab)
Cwajg, E, 1857
Cwajg, J, 1857
Cwikla, JB, 68(ab), 536(ab), 1038(ab)
Cyr, JE, 321(ab), 887(ab)
Czech, N, 47(ab)
Czech, NJ, 730(ab)
Czerniecki, BJ, 1117(ab), 1143
Czernin, J, 130(ab), 184(ab), 186(ab), 189(ab), 225(ab), 226(ab), 227(ab), 285(ab), 408(ab), 1083(ab), 1293(ab), 1468(ab), 2043
Czuczman, M, 949(ab)
Da Silva, AJ, 596(ab), 820(ab), 1248(ab)
Dachille, MA, 597(ab), 1134(ab)
Dadparvar, S, 856(ab)
Dae, M, 352(ab)
Dae, MW, 820(ab), 1249(ab)
Dafermou, A, 778(ab), 1168(ab)
Daffin, FC, 479(ab)
D'Agnolo, A, 246(ab), 280(ab), 378(ab), 883(ab), 959(ab)
Dahl, JR, 1339(ab)
Dahlberg, ST, 456(ab)
Dahlbom, M, 131(ab), 225(ab), 226(ab), 303(ab), 1083(ab), 1231(ab), 1468(ab)
Dahlheimer, JL, 316(ab), 1024(ab)
Dahman, BA, 986(ab)
Dai, D, 775(ab)
D'Aiuto, G, 66(ab)
Daldrup, H, 392(ab)
Daley, L, 480(ab)
Dalipaj, M, 732(ab)
Damien, J, 1466(ab)
Dams, ET, 58(ab), 192, 2066
Daneker, GW, 92(ab)
Dangas, G, 1322(ab)
Danias, PG, 711(ab)
Danieli, R, 556(ab), 843(ab)
Dannals, RF, 115(ab), 373(ab), 446(ab), 447(ab), 454(ab), 1014(ab), 1164(ab), 1180, 1207(ab), 1349(ab)
Dansereau, RN, 616(ab), 1030(ab), 1399(ab)
Dantas, FJ, 1379(ab)
Daou, D, 173(ab), 369(ab), 411(ab), 701(ab), 794(ab), 743(ab), 809(ab), 1602
Darabaneanu, A, 429(ab)
Darcourt, J, 1301
Darlas, Y, 8(ab), 175(ab), 901(ab), 905(ab)
Darling, J, 1293(ab)
Darsow, U, 451(ab)
Dartevelle, P, 173(ab)
Das, SS, 904(ab)
Dasgupta, B, 464
Dass, C, 889
D'Asseler, Y, 1250(ab)
Daube-Witherspoon, ME, 472(ab), 1321(ab)
Davidoff, S, 366(ab)
Davids, E, 125(ab)
Davidson, T, 560(ab), 1116(ab)
Davies, G, 343(ab), 344(ab)
Davies, HM, 1346(ab)
Davila-Roman, VG, 4(ab)
Davis, RE, 184
Davis, RT, 1896
Daviskas, E, 382(ab)
Dawant, BM, 1364(ab)
Dawson, S, 738(ab)
d'Azemar, P, 223(ab)
De Beco, V, 1092(ab)
De Bree, R, 263(ab)
de Bruin, K, 753
De Caestecker, J, 899(ab)
De Cesare, A, 31(ab)
De Coster, P, 219(ab), 766(ab), 792(ab)
De Cristofaro, M, 573(ab)
de Groot, T, 19(ab), 822(ab)
de Groot, TJ, 288(ab), 898(ab), 1353(ab)
de Herder, WW, 416(ab)
de Jong, M, 317(ab), 320(ab), 322(ab), 414(ab), 415(ab), 418(ab), 1389(ab), 2081
de Jong, RM, 507
de Klerk, JM, 311, 639
De La Pena, RC, 1180(ab)
De Leyn, P, 98(ab)
de los Cobos, JP, 19
de Marie, S, 2066
de Mattos, JC, 1379(ab)
de Notaristefani, F, 46
De Paoli, T, 1080
de Rooij, L, 667
De Rosch, MA, 321(ab), 887(ab), 950(ab), 954(ab)
De Sadeleer, C, 210(ab)
De Scheerder, I, 822(ab)
de Silva, R, 747
De Toffol, B, 1393(ab)
de Voigt, M, 1257(ab)
De Vos, F, 1354(ab)
de Vries, DJ, 1011
de Vries, E, 890(ab)
de Vries, EG, 393(ab), 1159(ab)
De Vries, J, 70(ab), 1119(ab)
De Wever, W, 98(ab)
de Wit, M, 941(ab), 1133(ab)
de Zeeuw, D, 373(ab)
Dean, RT, 40(ab), 57(ab), 321(ab), 417(ab), 887(ab), 950(ab), 954(ab), 994(ab)
DeBeco, V, 1127(ab)
Debonnel, G, 577(ab)
DeBraal, L, 1290(ab)
DeBruin, SW, 15(ab), 361(ab)
Debruyne, FM, 829
DeCicco, C, 235(ab), 266(ab), 1125(ab)
Deery, A, 68(ab)
Defebvre, LJ, 956
Defeo, R, 520(ab), 521(ab)
DeFrance, A, 9(ab)
DeGrado, TR, 187(ab), 354(ab), 502(ab)
Dei, S, 802(ab), 885(ab), 1188(ab)
DeJesus, OT, 437(ab), 1163(ab), 1169(ab)
deKemp, RA, 732(ab)
Del Guerra, A, 167(ab), 302(ab)
del Rosario, RB, 232
Delahay, N, 809(ab)
Delahaye, N, 224, 369(ab), 701(ab), 794(ab), 903(ab), 1602
Delaney, R, 1220(ab)
Delanney, LE, 587(ab)
Delano, DA, 4(ab)
Delaunois, L, 219(ab)
Delbeke, D, 110, 591, 1706, 1784
Delle Fave, G, 843(ab)
Delling, G, 1637
Demange, MR, 958(ab)
Den Hollander, W, 263(ab)
Den, RB, 162(ab)
DeNardo, DA, 302, 1317
DeNardo, DG, 324(ab)
DeNardo, GL, 159(ab), 302, 324(ab), 963(ab), 965(ab), 969(ab), 980(ab), 1317, 1381(ab), 2014, 2102
DeNardo, SJ, 159(ab), 302, 324(ab), 963(ab), 965(ab), 969(ab), 980(ab), 1317, 1381(ab), 2014, 2102
Dence, CS, 824(ab), 836(ab), 842(ab)
Deng, HF, 1386(ab)
Dennis, RA, 1468(ab)
Dentamaro, VF, 935(ab)
DePuey, EG, 171(ab), 176(ab), 181(ab), 215(ab), 345(ab), 507(ab), 650, 715(ab), 716(ab), 891(ab), 924
DeRisi, D, 406(ab)
DeRosa, CM, 90(ab)
Destée, A, 956
Destine, M, 882(ab)
Desuzinges, C, 585
Desvignes, P, 1301
Dettori, G, 1105(ab)
Deutsch, G, 1181(ab)
Devizzi, L, 251(ab)
Devous, MD, 449(ab), 896(ab)
Devys, A, 1216
Dewanjee, MK, 947(ab)
Dewaraja, YK, 77(ab)
Dewey, SL, 1154
Dey, D, 448
Dezutter, NA, 288(ab), 898(ab)
Dhawan, V, 1178(ab), 1264, 1339(ab)
Dhekne, RD, 17(ab), 348(ab)
Di Bella, E, 128(ab), 816(ab), 829(ab)
Di Domenico, G, 302(ab)
Di Lorenzo, C, 50(ab)
Di Luzio, E, 556(ab)
Di Paola, M, 157(ab), 1517
Di Paola, R, 16(ab), 140(ab), 471(ab), 595(ab), 1314(ab)
Diamond, GA, 507(ab)
Diamond, JA, 363(ab), 759(ab)
Dibbets, P, 180(ab), 740(ab)
DiBella, E, 1298(ab)
DiBella, EV, 132(ab), 313(ab)
DiCanzio, J, 52(ab), 56(ab)
Diederichs, CG, 250, 368(ab), 422(ab)

Diefenbach, B, 1061
Diegeler, A, 337(ab)
Diemling, M, 1049(ab), 1347(ab)
Dierckx, RA, 269(ab), 277(ab), 783, 1250(ab), 1354(ab)
Dierickx, L, 703(ab), 709(ab)
Dierickx, LO, 256(ab), 413(ab)
Dietlein, M, 202(ab), 973(ab)
Diggles, L, 1080(ab), 1363(ab)
Diggles, LE, 1233
Diksic, M, 577(ab)
Dimattia, DG, 350(ab)
DiMattia, DG, 810(ab)
Dimitrakopoulou-Strauss, A, 1061(ab), 1288(ab), 1323(ab)
Din, SU, 711(ab)
Dinanian, S, 743(ab)
Ding, H-J, 1446
Ding, Y, 1377(ab)
Ding, Y-S, 1154
Ding, YS, 406(ab), 439(ab), 442(ab), 1218(ab)
Dinkelborg, L, 434(ab)
Dinkelborg, LM, 837(ab)
Dione, DP, 21(ab)
Dionne, G, 1100(ab)
Dirschinger, J, 24(ab)
Dispersyn, GD, 19(ab)
Dittmann, H, 946(ab), 957(ab)
Djokich, D, 1716
Dobbeleir, AA, 706(ab), 707, 1468
Dobko, T, 283
Dobrzeniecki, AB, 1280(ab)
Dodig, D, 531(ab), 937(ab)
Doenst, T, 1186
Doerr, RJ, 1069(ab)
Dogan, S, 441(ab)
Dohmen, BM, 245(ab), 460(ab), 933(ab), 946(ab), 956(ab), 957(ab), 1133(ab)
Dohr, D, 262(ab)
Doi, K, 1160(ab)
Dolbier, WR, 401(ab)
Dolin, RJ, 562(ab)
Dollé, F, 1374
Dom, RJ, 288(ab)
Domingo, P, 3(ab)
Donnetti, M, 556(ab)
Donohoe, KJ, 1236
Dopichaj-Meuge, U, 920(ab)
Dopichj-Menge, U, 948(ab)
Doppman, JL, 539
Dorbala, S, 924, 507(ab), 716(ab)
Dormeier, A, 540(ab)
Dörner, J, 48(ab)
Dose, J, 2021
Doshi, NK, 1223(ab)
Doting, MH, 70(ab), 1119(ab)
Dou, Y, 856(ab)
Doudet, DJ, 283
Dougherty, DD, 579(ab)
Downs, H, 942
Dowrkin, H, 83(ab)
Doze, P, 292(ab), 351(ab), 496(ab), 1167(ab), 1177(ab)
Drane, WE, 371(ab), 406
Dresel, S, 150, 1048(ab), 1243(ab)
Dresel, SH, 625, 660
Dresser, T, 174(ab)
Driedger, A, 41(ab)
Drumm, D, 837
Drzezga, A, 451(ab), 737
Duarte, P, 61(ab), 387(ab), 453(ab), 868(ab), 1286(ab)
Duatti, A, 1168(ab), 1382(ab)
Dubois, EA, 22(ab), 25(ab)
Dubois Rande, JL, 31(ab)
Dubois-Randé, J-L, 224, 917
Dubovsky, EV, 1122
Dubrovin, M, 105(ab)
Ducassou, D, 412, 868
Duchesne, N, 267(ab), 1100(ab)
Duda, S, 837(ab)
Dudczak, R, 74(ab), 362(ab), 1049(ab), 1081(ab)
Dudzcak, R, 395(ab)
Duet, M, 1252
Dufour, M, 1100(ab)
Duhamel, A, 956
Dulac, O, 786
Dummer, R, 79(ab)
Dumont, F, 1354(ab)
Dumont, M, 1103(ab)
Dumont, MJ, 1100(ab)
Duncan, BH, 711(ab)
Duncan, JS, 1220(ab)
Duncan, R, 747
Duncker, C, 262(ab)
Dunkelmann, S, 528(ab), 558(ab)
Dunn-Dufault, R, 614(ab)
Dunnwald, LK, 551(ab), 557(ab)
Dupont, JO, 422
Dupont, P, 98(ab)
Dupont, S, 935
Durband, M, 79(ab)
Durie, B, 246(ab), 959(ab)
Durigon, M, 157(ab)
Dutschka, K, 1342
Duval, A-M, 917
Duverney, C, 18(ab)
Duxbury, DM, 1224(ab)
Dwivedi, SN, 927(ab)
Dworkin, H, 287(ab)
Dworkin, HJ, 993
Dyer, SM, 1263(ab)
Dymond, DS, 764(ab)
Early, ML, 107(ab)
Eary, JF, 557(ab), 614, 1237(ab)
Easton, EJ, 42(ab)
Eberl, S, 144(ab), 312(ab), 382(ab)
Ebner, SA, 1453(ab)
Echt, EA, 236(ab)
Eck, SL, 333(ab), 995
Eckelman, WC, 119(ab), 149(ab), 150(ab), 168(ab), 329(ab), 472(ab), 1547
Edell, SL, 613(ab)
Edelstein, Y, 1144(ab)
Edenbrandt, L, 96, 224(ab)
Edlin, J, 73(ab)
Edmondson, SJ, 764(ab)
Edwards, C, 1184(ab)
Edwards, DS, 892(ab), 1369(ab)
Edwards, GK, 1112(ab)
Eersels, J, 765(ab)
Efange, SM, 1356(ab)
Efsen, F, 290
Egawa, S, 859(ab)
Egert, S, 828(ab)
Eggert, AA, 1028(ab)
Egli, A, 1913
Ehrenkaufer, RL, 1356(ab)
Ehritt-Braun, C, 423(ab)
Eichstaedt, H, 387
Eidelberg, D, 1178(ab), 1184(ab), 1264, 1339(ab)
Eidson, M, 799
Eigler, N, 356(ab)
Eigtved, A, 1136(ab)
Eilles, C, 1154(ab)
Eisbruch, A, 1125, 1130(ab)
Eisenberg, DA, 1457(ab)
Eisenhut, M, 1011(ab), 487(ab), 1484
Eisensehr, I, 112(ab)
Ejiri, K, 847(ab)
Eke, S, 524(ab)
El Fakhri, G, 16(ab), 595(ab)
El Gohary, MA, 861(ab)
El Mallah, M, 942
El Tom, F, 861(ab)
Eldeiry, S, 446(ab)
Elder, DE, 1143
El-Desouki, M, 928(ab)
El-Doza, B, 879(ab)
Eldridge, KR, 963(ab)
Elgamel, AA, 1138(ab)
Elgazzar, AH, 785(ab), 879(ab)
Elhendy, A, 1(ab), 731(ab), 1866
Eliashiv, DS, 280(ab)
Ell, PJ, 343(ab), 344(ab), 560(ab), 737(ab), 1113(ab), 1115(ab), 1116(ab)
Elliot, DG, 967(ab)
Elliott, MD, 509(ab), 513(ab), 517(ab)
Ellis, GK, 69(ab), 551(ab)
Ellison, D, 1108(ab)
Elmaleh, DR, 1340(ab), 1341(ab)
Elsinga, PH, 116(ab), 292(ab), 351(ab), 1167(ab), 1270
Elsner, K, 1623
Elstodt, J, 373(ab)
Ely, T, 1344(ab)
El-Zeftawy, H, 889(ab)
El-Zeftawy, HA, 84(ab)
Emmanouilides, C, 260(ab)
Emmett, L, 869(ab)
Emmi, L, 573(ab)
Emond, P, 1343(ab)
Ende, JF, 406
Enderle, M, 871(ab)
Endo, K, 217, 336(ab), 390(ab), 399, 878(ab), 1003(ab), 1005(ab), 1018(ab)
Endres, CJ, 1169(ab)
Eng, W, 400(ab), 1014(ab)
Ensing, K, 1270
Enterottacher, A, 1311(ab)
Enterrottacher, A, 1243(ab)
Epelman, S, 1148(ab)
Epstein, S, 29(ab), 911(ab)
Erami, SS, 530
Ercakmak, N, 919(ab), 1046(ab)
Ercoli, LM, 281(ab), 283(ab)
Erdi, AK, 466(ab)
Erdi, YE, 466(ab), 1238(ab), 1935
Erdman, WA, 237(ab), 896(ab)
Eremin, O, 552(ab)
Eriksson, L, 306(ab)
Erion, J, 320(ab)
Erion, JL, 993(ab), 996(ab)
Erlandsson, K, 1224(ab), 1232(ab)
Ernst, N, 840(ab)
Erwin, WD, 712(ab), 1278(ab), 1327(ab)
Escher, P, 1243(ab)
Eschmann, SM, 871(ab), 933(ab)
Eschner, W, 202(ab)
Eshima, D, 331, 419(ab), 497(ab), 504(ab), 995(ab)
Eshima, L, 331
Estes, JM, 76(ab)
Estorch, M, 3(ab), 5(ab), 19, 734(ab), 786(ab), 911
Etchebehere, EC, 746(ab), 848(ab), 958(ab), 1148(ab)
Etcheberrigaray, A, 19
Eubank, WB, 69(ab)
Eubanks, S, 1329(ab)
Euhus, DM, 237(ab)
Evander, E, 224(ab)
Evans, D, 1121(ab)
Evans, DG, 62(ab)
Evans, SM, 401(ab)
Evenepoel, P, 1451
Everaert, H, 256(ab), 488(ab), 703(ab), 709(ab)
Everett, JR, 168(ab), 472(ab)
Ezquerra, NF, 508(ab), 1290(ab)
Ezuddin, SH, 799, 768(ab)
Faber, TL, 315(ab), 650, 753(ab)
Fagundes, JJ, 848(ab)
Fahey, FH, 1356(ab)
Fain, R, 495(ab)
Fain, RL, 846
Faivre-Chauvet, A, 198, 1216
Falchi, A, 1105(ab)
Fallon, BA, 1197(ab)
Fan, C, 1373(ab), 1395(ab)
Fang, B, 1459(ab), 1464(ab)
Fantuzzi, E, 1716
Faraggi, M, 701(ab), 794(ab), 805, 809(ab), 893(ab), 903(ab), 1602
Farahani, K, 142(ab)
Farahati, J, 1342
Farde, L, 102, 120(ab), 151(ab), 436(ab), 1343(ab)
Faries, MB, 1117(ab)
Farnsworth, RH, 54(ab), 55(ab), 1805
Farquhar, TH, 130(ab), 1164, 2043
Farrell, R, 304(ab)
Fauconnier, TK, 504(ab), 995(ab)
Fava, M, 579(ab)
Fawwaz, RA, 90(ab), 228(ab), 611(ab)
Fawwaz, RJ, 412(ab)
Fazio, F, 302(ab), 1617
Fazzini, PF, 363
Felder, CA, 715, 1217(ab), 1301(ab)
Feldmann, HJ, 397(ab)
Felecan, RC, 1466(ab)
Felix, R, 387
Felix, SB, 795(ab)
Feng, B, 816(ab), 829(ab)
Feng, D, 717(ab)
Ferdeghini, M, 926(ab)
Ferlin, G, 1053(ab)
Fernandez, P, 412, 1756
Ferrari, C, 1928
Ferraro-Borgida, M, 518(ab)
Ferretti, JA, 825(ab)
Fessler, JA, 15(ab)
Fevravi, M, 72(ab)
Feyerabend, B, 1033(ab)
Ficaro, EF, 817(ab)
Ficaro, EP, 15(ab), 361(ab), 506(ab)
Fiche, M, 198
Fieber, S, 337(ab)
Fields, L, 1383(ab)
Fig, LM, 1292(ab)
Figdor, CG, 1028(ab)
Fikrle, A, 752(ab)
Filmont, JE, 8(ab), 175(ab), 901(ab), 905(ab)
Finat-Duclos, F, 672
Finestone, H, 1144(ab)
Fini, A, 1053(ab)
Fink, U, 550(ab)
Fink-Bennett, DM, 287(ab), 1226
Finke, J, 247(ab)
Finkelman, C, 625
Finlay, WH, 383(ab)
Finn, R, 105(ab), 1012(ab), 1042(ab)
Finn, RD, 95(ab), 166, 328(ab), 431(ab), 1238(ab), 1722, 1764, 1935
Finzi, A, 338(ab)
Fioravanti, C, 400(ab), 1014(ab)
Fiorenza, M, 72(ab), 266(ab)
Fioretti, PM, 1(ab), 190(ab), 192(ab), 731(ab), 1866
Fiovenza, M, 1125(ab)
Fischer, K, 433(ab)
Fischer, KC, 525(ab)
Fischer, S, 840(ab), 1227(ab)
Fischer, T, 403(ab), 1036(ab), 1372(ab)
Fischman, AJ, 153(ab), 193(ab), 370(ab), 391(ab), 421(ab), 547(ab), 579(ab), 729(ab), 783(ab), 894(ab), 895(ab), 908(ab), 1090(ab), 1161(ab), 1258(ab), 1266(ab), 1269(ab), 1340(ab), 1341(ab)
Fisher, A, 177(ab)
Fisher, AD, 169(ab)
Fisher, DA, 922(ab)
Fisher, DR, 75(ab)
Fisher, RS, 366(ab), 854(ab)
Fisher, SJ, 76(ab), 88(ab), 89(ab), 155(ab), 405(ab), 612(ab), 991(ab)
Fissekis, JD, 334(ab), 1361(ab), 1368(ab)
Fitzgerald, J, 614(ab), 995(ab)
Flamen, P, 98(ab), 899(ab)
Flameng, W, 19(ab)
Fleckenstein, J, 896(ab)
Fleming, D, 553(ab)

Fleming, JS, 1503
Fletcher, JW, 15N(4)
Flint, A, 556
Flores, J, 74(ab), 395(ab)
Flores, LG, 1057(ab)
Florimonte, L, 725(ab)
Flotats, A, 3(ab), 5(ab), 19, 734(ab), 786(ab), 911
Flower, MA, 161(ab), 983(ab), 1224(ab), 1232(ab)
Flugelman, MY, 741(ab), 811(ab)
Flux, GD, 983(ab)
Foa, P, 1085(ab)
Foder, B, 1136(ab)
Foetzsch, R, 268(ab)
Fogarasi, M, 484
Foged, C, 435(ab)
Fogelman, I, 409(ab), 410(ab)
Folks, RD, 315(ab), 508(ab), 511(ab), 650, 787(ab), 1290(ab)
Fong, W, 758(ab)
Foody, JM, 773(ab)
Forastiere, A, 594(ab)
Ford, C, 1083(ab)
Ford, PV, 17(ab), 348(ab), 1226
Forman, J, 1079(ab)
Formiconi, AR, 1310(ab)
Forssell-Aronsson, E, 2094
Forster, GJ, 925(ab)
Forster, J, 144(ab)
Fourme, T, 173(ab), 743(ab)
Fournier, RS, 1070(ab)
Fowler, JS, 145(ab), 406(ab), 439(ab), 440(ab), 442(ab), 443(ab), 588(ab), 715, 1154, 1176(ab), 1215(ab), 1217(ab), 1218(ab), 1285, 1301(ab)
Fox, PT, 942
Fraker, DF, 1143
Franceschi, D, 145(ab), 442(ab), 443(ab), 588(ab), 1215(ab), 1217(ab), 1218(ab), 1176(ab)
Franceschini, R, 1382(ab)
Francis, B, 400(ab)
Francis, IR, 77(ab)
Frank, JW, 455(ab)
Frank, TL, 1263(ab)
Franke, W-G, 1484
Franke, WG, 268(ab), 374(ab), 543(ab), 975(ab), 1385(ab)
Franken, PR, 256(ab), 707, 703(ab), 706(ab), 709(ab), 1468
Frantzis, A, 976(ab)
Franzius, C, 388(ab), 392(ab)
Frater, C, 869(ab)
Fratkin, MJ, 1455(ab)
Freedman, M, 1183(ab)
Freeman, LM, 810(ab)
French, J, 276(ab)
Frenkel, A, 265(ab)
Frey, EC, 134(ab), 470(ab), 1252(ab)
Frey, M, 340(ab)
Frezza, F, 46
Friberg, L, 1136(ab)
Friebe, M, 487(ab)
Friedl, M, 1277
Friedman, AH, 631
Friedman, HS, 631
Friedman, JD, 6(ab), 9(ab), 22(ab), 25(ab), 28(ab), 170(ab)
Frier, M, 365(ab), 399(ab)
Frisch, M, 451(ab)
Fröhlich, A, 250
Froles, LG, 1047(ab)
Frölich, L, 282(ab)
Front, A, 741(ab), 811(ab)
Front, D, 265(ab)
Frost, J, 1304(ab)
Frost, JJ, 446(ab), 447(ab), 1207(ab)
Frouin, F, 31(ab)
Frouin, V, 31(ab)
Fryer, TD, 135(ab)
Fu, FH, 909(ab)
Fu, JJC, 1106
Fu, X, 148(ab), 498(ab)
Fujibayashi, Y, 91(ab), 177, 330(ab), 471, 493(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1174(ab), 1332(ab)
Fujii, H, 563(ab), 1026(ab), 1155(ab)
Fujii, K, 240(ab), 767(ab)
Fujii, R, 1590
Fujimori, K, 713(ab)
Fujimoto, T, 70
Fujino, K, 1884
Fujino, S, 191(ab), 512(ab), 812(ab)
Fujioka, H, 1271(ab)
Fujita, K, 713(ab)
Fujita, M, 124(ab), 143(ab), 270(ab), 471, 781(ab), 1902
Fujita, T, 1273(ab)
Fujiwara, H, 2036
Fujiwara, M, 1091(ab), 1203(ab)
Fujiwara, S, 1999
Fujiwara, T, 70
Fukuchi, K, 239, 796(ab), 799(ab), 800(ab), 801(ab), 854, 1187(ab)
Fukuchi, M, 780(ab)
Fukuda, H, 244, 317, 567(ab), 1022(ab)
Fukui, M, 1203(ab)
Fukumitsu, N, 874(ab)
Fukumoto, M, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
Fukumura, T, 1111(ab)
Fukushi, K, 289(ab)
Fukushima, K, 426(ab), 796(ab), 799(ab), 800(ab), 801(ab), 1072(ab), 1187(ab)
Fukuyama, H, 1992
Fukuzawa, S, 13(ab), 745(ab)
Fulham, MJ, 144(ab)
Fumey, R, 224
Furhang, EE, 131
Furman, V, 1197(ab), 1205(ab)
Fuseau, C, 1374
Fussell, BA, 107(ab)
Fuster, D, 123(ab)
Fuster, V, 355(ab)
Futami, S, 1047(ab)
Futatsubashi, M, 1088(ab), 1282(ab)
Gabriel, JL, 492(ab)
Gabruk-Szostak, B, 1036(ab), 1372(ab)
Gabrys, J, 769(ab)
Gadsbøll, N, 290
Gaebel, W, 575(ab)
Gaffney, R, 277
Gagnon, A, 1244(ab)
Gagnon, D, 137(ab)
Gagnon, JH, 542(ab)
Gaines, T, 96(ab)
Gainey, W, 27(ab)
Gainey, WE, 1291(ab)
Gal, R, 376
Galelli, M, 1928
Galley, N, 268(ab)
Galt, JR, 753(ab), 1262(ab)
Galynker, B, 1144(ab)
Gambhir, SS, 102(ab), 130(ab), 131(ab), 225(ab), 226(ab), 227(ab), 231(ab), 285(ab), 295(ab), 323(ab), 332(ab), 408(ab), 1468(ab), 1507, 2043
Gameren, A, 414(ab)
Gamez, C, 1145(ab)
Ganes, J, 984(ab)
Gänsbacher, B, 104(ab)
Gansow, OA, 166, 268, 329(ab)
Gao, DW, 352(ab), 1249(ab)
Garcez, AT, 870(ab)
Garcia, EV, 92(ab), 315(ab), 508(ab), 511(ab), 650, 753(ab), 787(ab), 1262(ab), 1290(ab)
Garcia, M, 773(ab)
Garcia, MJ, 424(ab), 1096(ab), 1145(ab)
Garcia, N, 845(ab), 1401(ab)
García-López, F, 296
Gardin, I, 786
Garfinkle, WB, 1457(ab)
Garg, PK, 1208(ab), 1362(ab)
Garmestani, K, 166, 322(ab), 329(ab), 415(ab)
Garreau, L, 1343(ab)
Garty, B, 51(ab)
Garza, V, 439(ab)
Gaskill, M, 287(ab)
Gasparini, M, 251(ab), 1085(ab)
Gasperi, M, 1716
Gates, M, 574
Gatley, SJ, 438(ab), 440(ab), 442(ab), 443(ab), 586(ab), 1218(ab)
Gatti, S, 914(ab)
Gautherot, E, 198, 1002(ab), 1216
Gauthier, H, 37(ab), 223(ab), 1147(ab)
Gayed, I, 1463(ab)
Geerlings, MW, Jr., 166
Geerlings, MW, Sr., 166
Geibel, A, 220(ab)
Geldof, AA, 667
Gelfand, MJ, 53(ab)
Genereau, T, 962(ab)
Genin, R, 701(ab), 794(ab), 809(ab), 1602
Gennari, R, 1125(ab)
Gentili, A, 1456(ab)
George, J, 766(ab), 792(ab)
George, M, 258(ab)
Georges, B, 210(ab)
Georgi, P, 570(ab)
Georgiou, MF, 204(ab), 208(ab), 377(ab)
Geraghty, S, 44(ab)
Gerali, A, 1114(ab)
Gerber, B, 558(ab)
Gerdsen, I, 268(ab)
Gerhard, A, 571(ab)
Gerlach, L, 1016(ab), 1032(ab)
Germano, G, 6(ab), 22(ab), 25(ab), 28(ab), 170(ab), 710(ab), 722(ab), 810, 839(ab)
Gerson, MC, 360(ab)
Gerundini, P, 251(ab), 271(ab), 338(ab), 914(ab), 1085(ab), 1630, 1928
Gewirtz, H, 757(ab)
Geworski, L, 920(ab)
Geyer, BC, 486(ab)
Geypens, B, 1451
Ghesani, M, 215(ab), 891(ab)
Ghesani, NV, 856(ab)
Ghez, C, 1178(ab)
Ghilardi, MF, 1178(ab)
Ghoos, Y, 1451
Giammarile, F, 585
Gianelli, MV, 522
Gianolli, L, 1617
Gibril, F, 539
Gibson, R, 1014(ab)
Gibson, RE, 400(ab)
Gietzen, F, 185(ab)
Gifford, AN, 438(ab), 440(ab), 586(ab)
Gifford, HC, 590(ab)
Giganti, M, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
Giger, S, 495(ab)
Gil, R, 121(ab)
Gilardi, MC, 302(ab), 1617
Gilbert, F, 552(ab)
Gilbert, HM, 889(ab)
Gilbert, K, 278(ab)
Gildehaus, M, 1311(ab)
Gildersleeve, DL, 232
Gilissen, CM, 1353(ab)
Gilland, DR, 1260(ab)
Gillet, JB, 219(ab)
Gillham, R, 747
Gilligan, D, 1093(ab)
Gillin, A, 144(ab)
Gilsbach, J, 450(ab)
Gimenez, M, 555(ab), 1145(ab)
Gindi, GR, 299(ab), 301(ab)
Giovanazzi, R, 1114(ab)
Gipponi, M, 1123(ab)
Gips, S, 741(ab), 811(ab)
Girard, P, 701(ab)
Gironell, A, 1212(ab)
Giubbini, R, 375(ab)
Giubbini, RM, 172(ab), 178(ab)
Giuliano, AE, 203(ab), 1112(ab), 1120(ab)
Giunta, S, 46
Gjedde, A, 125(ab), 441(ab), 1186, 1292
Glasbrenner, B, 422(ab)
Glaser, C, 985(ab)
Glass, D, 1463(ab)
Glass, EC, 203(ab), 1112(ab), 1120(ab)
Glatting, G, 82(ab), 247(ab), 262(ab), 422(ab), 571(ab), 1272(ab), 1623
Glatz, G, 593(ab)
Glees, J, 984(ab)
Glees, JP, 161(ab)
Glick, SJ, 456
Glover, DK, 142, 821
Gnecchi-Ruscone, T, 1848
Go, RT, 279(ab)
Goddard, S, 96(ab)
Godley, ML, 643
Goebel, SU, 539
Goedemans, W, 1389(ab)
Goes, JR, 848(ab)
Goethals, P, 491
Gold, HK, 193(ab)
Goldberg, M, 917(ab)
Goldenberg, DM, 67(ab), 261(ab), 428(ab), 429(ab), 500(ab), 603(ab), 968(ab), 972(ab), 981(ab), 992(ab), 1002(ab), 1392, 1375(ab), 1380(ab), 1392, 1609
Goldfarb, CR, 1144(ab)
Goldman, D, 445(ab)
Goldman, ME, 1322(ab)
Goldman, MS, 1457(ab)
Goldner, K, 1303(ab)
Goldschmidt, H, 1061(ab)
Goldsmith, SJ, 1001(ab), 1008(ab), 1024, 1303(ab)
Goldstein, CI, 301(ab)
Goldstein, DS, 302, 963(ab), 965(ab), 969(ab), 2014
Golish, SR, 295(ab)
Gomes, EF, 11(ab)
Gomez, D, 1008(ab)
Gomez-Marin, O, 377(ab)
Gona, JM, 94(ab)
Goncalves, JC, 1148(ab)
González, J, 768
González, V, 164(ab)
Gonzalez, N, 768
Gonzalez, P, 516(ab)
Gonzalez, R, 208(ab)
Gonzalez, RS, 970(ab)
Gonzalez Trotter, DE, 139(ab)
Goodbody, AE, 872(ab)
Goodman, MM, 331, 1344(ab)
Goodman, T, 87(ab)
Goodpaster, B, 1798
Goodwin, DA, 1138
Goodwin, GW, 1186
Gordon, EM, 103(ab)
Gordon, I, 643
Gordon, L, 260(ab), 971(ab), 1383(ab), 1390(ab), 1454(ab)
Gorenberg, M, 45(ab), 56
Gorey, JG, 1348(ab)
Görges, R, 923(ab)
Goris, ML, 252(ab)
Gorman, J, 121(ab)
Gormley, J, 1225(ab)
Gosalbez, R, 204(ab)
Goshen, E, 63(ab), 1213(ab)
Gössweiner, S, 1049(ab)
Goswami, RK, 934(ab)
Gotou, E, 874(ab)
Gottschild, D, 1251(ab)
Gould, T, 357(ab), 402(ab)
Gouriou, J, 1517
Govindan, SV, 603(ab), 968(ab)
Goydos, J, 232(ab)

Graeber, GM, 229(ab), 230(ab), 548(ab)
Graefe, K-H, 1342
Graek, D, 1077(ab)
Graf, S, 362(ab)
Graham, LS, 482(ab)
Graham, MM, 614, 784(ab), 1074(ab)
Gralow, JR, 69(ab), 551(ab)
Gramatzki, M, 992(ab)
Grana, C, 72(ab), 1125(ab)
Granowska, M, 764(ab), 1108(ab)
Granowski, A, 1108(ab)
Grant, S, 209(ab), 238(ab)
Grattan, L, 454(ab)
Gratz, S, 48(ab), 396(ab), 420(ab), 1029
Grazioso, R, 304(ab)
Greco, M, 1114(ab)
Green, AJ, 541(ab), 1246(ab)
Green, LA, 102(ab)
Green, MA, 775(ab)
Green, MV, 1321(ab)
Green, SL, 472(ab)
Greenberg, ID, 707(ab)
Greenberg, JH, 118(ab)
Greenspan, B, 174(ab)
Greer, PJ, 2053
Gregoire, V, 1013(ab)
Gregor, RT, 1414
Gregoric, E, 1067(ab)
Gremillet, E, 80(ab), 733(ab)
Gridelli, B, 914(ab)
Grierson, JR, 100(ab), 101(ab), 245(ab), 335(ab)
Grieser, A, 571(ab)
Griesinger, F, 992(ab)
Griffith, IJ, 963(ab), 969(ab)
Griffith, R, 1180(ab)
Griffiths, GL, 500(ab), 603(ab), 968(ab), 1002(ab)
Grigsby, PW, 1129(ab)
Grilley, K, 902(ab)
Groch, MW, 509(ab), 712(ab), 1278(ab), 1327(ab)
Groch, PJ, 712(ab), 1278(ab), 1327(ab)
Groen, HJ, 561(ab)
Groiselle, C, 1305(ab)
Grollier, G, 8(ab), 175(ab)
Gropler, RJ, 4(ab), 824(ab), 836(ab), 842(ab)
Grosev, D, 937(ab)
Groshar, D, 45(ab), 56, 968, 1111
Gross, MD, 554, 1292(ab)
Gross, P, 374(ab)
Grosser, O, 754(ab)
Grossman, Z, 949(ab)
Grosu, A, 397(ab)
Groth, P, 528(ab), 558(ab)
Gruender, W, 537(ab)
Gruenwald, F, 974(ab)
Gründer, G, 125(ab), 1222(ab)
Gualdi, G, 843(ab)
Gualdrini, G, 1716
Guan, CT, 498(ab)
Guana, C, 235(ab), 266(ab)
Guaraldi, MS, 954(ab)
Guardia, J, 19
Guarniero, R, 870(ab)
Gubernick, JA, 1457(ab)
Guelfguat, M, 1144(ab)
Guendish, D, 1349(ab)
Guenther, I, 1374
Guerrero, JL, 391(ab)
Guhlke, S, 974(ab), 988(ab), 1384(ab)
Guhlmann, A, 1623, 1637
Guhlmann, CA, 82(ab), 93(ab), 422(ab)
Guillausseau, P-J, 1252
Guillo, P, 738(ab)
Guilloteau, D, 1343(ab), 1393(ab)
Guirgues, AF, 1457(ab)
Gullberg, GT, 128(ab), 137(ab), 313(ab), 462(ab), 589(ab), 816(ab), 829(ab), 1254(ab), 1296(ab)
Gundry, S, 339(ab)
Gunel, E, 548(ab)
Gunning, WB, 113(ab)
Guo, J, 854(ab)
Guo, NN, 114(ab), 117(ab), 435(ab), 1162(ab)
Guo, W, 1563
Gupta, NC, 229(ab), 230(ab), 379(ab), 548(ab), 1320(ab)
Gupta, P, 280(ab), 1182(ab)
Gupta, PK, 9(ab)
Gur, RC, 108(ab), 1200(ab), 1218(ab), 1812
Gurll, N, 1434
Gutierrez, F, 123(ab)
Guy, MJ, 983(ab)
Gvirtz, G, 860(ab)
Ha, CS, 955(ab)
Ha, JW, 833(ab)
Haaparanta, M, 12, 1163(ab)
Haas, F, 18(ab), 1824
Haase, A, 540(ab), 921(ab), 944(ab)
Haataja, L, 12
Haberkorn, U, 487(ab), 1010(ab), 1011(ab), 1016(ab), 1032(ab), 1261(ab)
Habraken, JBA, 1091
Hachamovitch, R, 710(ab), 722(ab)
Hadjpavlou, A, 906(ab)
Hadley, D, 747
Hagen, R, 254(ab)
Hager, A, 1080
Hagg, B, 1457(ab)
Hagge, RJ, 477(ab)
Hahn, J, 973(ab)
Hahn, K, 112(ab), 126(ab), 389(ab), 853(ab), 1048(ab), 1243(ab)
Hahn, LJ, 448
Haigh, PI, 203(ab), 1112(ab), 1120(ab)
Hain, SF, 409(ab), 425(ab),1135(ab)
Hajjar, G, 1609
Hakimi, M, 719(ab)
Halaç, M, 429
Halfter, H, 1017(ab)
Halkar, R, 209(ab)
Halkar, RK, 929(ab)
Hall, H, 151(ab), 1157(ab)
Halldin, C, 102, 120(ab), 151(ab), 435(ab), 436(ab), 1157(ab), 1343(ab),
Hallkar, RK, 92(ab)
Halon, DA, 741(ab), 811(ab)
Ham, H, 972
Ham, HR, 52, 210(ab)
Hamacher, K, 575(ab)
Hamacher, KA, 162(ab), 158(ab)
Hamamoto, K, 1071(ab)
Hambÿe, A-S, 706(ab)
Hamberg, L, 547(ab)
Hamblen, SM, 1241(ab)
Hambye, AE, 707
Hambye, A-S E, 1468
Hamill, JJ, 1316(ab)
Hamill, T, 400(ab), 1014(ab)
Hamilton, RJ, 347
Hamkens, W, 1222(ab)
Hammersley, PA, 99(ab)
Hamon, M, 8(ab), 175(ab)
Hamper, U, 373(ab)
Han, G, 866(ab), 1277(ab), 1317(ab), 1325(ab)
Han, JH, 1076(ab)
Han, MH, 1094(ab)
Han, SH, 639
Hanaoka, NH, 1040(ab)
Hanauske, A-R, 1771
Hander, TA, 942
Handmaker, H, 36(ab), 231(ab)
Handschuh, G, 433(ab)
Hanelin, L, 359(ab)
Hanke, H, 837(ab)
Hannequin, PP, 839(ab), 1336(ab)
Hanrahan, S, 352(ab)
Hansen, HJ, 500(ab), 603(ab), 968(ab), 1002(ab)
Hansen, L, 1403(ab)
Hansen, N, 1112(ab)
Hansen, NM, 203(ab), 1120(ab)
Hanson, DP, 1098
Hanson, E, 995(ab)
Hanson, JM, 1180(ab)
Hanson, MW, 477(ab)
Hantzopoulos, PA, 104(ab)
Hanzawa, S, 1088(ab)
Hao, X, 1277(ab)
Hapdey, S, 471(ab)
Hara, T, 239(ab), 240(ab), 241(ab)
Harada, J, 874(ab)
Haradahira, T, 1342(ab), 1351(ab)
Haraden, BM, 824(ab), 836(ab), 842(ab)
Harden, G, 1295(ab)
Hardoff, R, 51(ab), 522(ab), 880(ab)
Hareyama, M, 713(ab)
Harkness, BA, 1356(ab)
Harmsen, MC, 890(ab)
Harper Mozley, LM, 1200(ab)
Harper, PG, 425(ab)
Harris, TD, 892(ab)
Harrison, RL, 459(ab), 1236(ab)
Harron, AW, 1140(ab)
Harshbarger, T, 1181(ab)
Hart, R, 732(ab)
Hartman, NG, 267(ab)
Hartsough, N, 1121(ab), 1225(ab)
Hartung, D, 754(ab)
Hartung, WM, 754(ab)
Hartwig, E, 1637
Hasebe, N, 747(ab)
Hasegawa, A, 217
Hasegawa, BH, 127(ab), 458(ab), 596(ab), 820(ab), 1248(ab), 1249(ab)
Hasegawa, K, 728(ab)
Hasegawa, R, 718(ab), 767(ab)
Hasegawa, S, 239, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 1693, 1884
Haseley, DR, 572(ab), 784(ab)
Hashemzadeh-Gargari, H, 318(ab)
Hashikawa, K, 1160(ab), 1175(ab), 1190(ab), 1302(ab)
Hashimoto, A, 193(ab), 783(ab)
Hashimoto, T, 1328(ab), 1337(ab)
Hashizume, I, 1088(ab)
Hashmi, R, 1098(ab)
Hatano, K, 1179(ab)
Hatano, T, 874(ab)
Hatch, S, 553(ab)
Hattori, N, 34(ab), 35(ab), 183(ab), 782(ab), 1840
Hatushiba, K, 943(ab)
Haubner, R, 1061, 104(ab)
Haufe, S, 372(ab)
Hausleiter, J, 356(ab)
Hausmann, D, 719(ab)
Havlik, E, 74(ab), 395(ab), 1081(ab)
Hawkins, RA, 458(ab), 1045, 1248(ab)
Hawman, PC, 15(ab), 361(ab)
Hayase, M, 814(ab)
Hayase, N, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
Hayashi, N, 1441
Hayashi, Y, 426(ab), 1072(ab)
Hayashida, K, 796(ab), 801(ab), 1187(ab)
Hayashida, N, 779(ab)
Haynes, NG, 775(ab)
Hays, MT, 1358
Hayward, RM, 1074(ab)
He, Z-X, 1857
Heald, DL, 383(ab), 886(ab)
Heath, E, 594(ab)
Heeney, T, 721(ab)
Heiba, SI, 785(ab), 879(ab)
Heinz, A, 445(ab), 1219(ab)
Heiss, P, 205, 1367
Heiss, WD, 306(ab)
Helal, BO, 173(ab), 411(ab), 701(ab), 743(ab)
Helfenbein, J, 1343(ab)
Helft, G, 355(ab)
Heller, EN, 788(ab)
Heller, GV, 517(ab), 518(ab), 702(ab), 711(ab)
Hellman, RS, 1369(ab)
Helmholz, T, 754(ab)
Helsabeck, C, 1143
Helvie, MA, 1099(ab)
Hemelaar, JT, 753
Hendel, RC, 342(ab), 509(ab), 513(ab), 517(ab)
Hendler, A, 769(ab), 1370(ab)
Hendler, T, 1213(ab)
Hendrikse, HN, 116(ab)
Hendrikse, NH, 292(ab), 1159(ab)
Henke, K, 1158(ab)
Hennion, C, 868
Henry, H, 912(ab)
Henry, TD, 342(ab)
Henze, E, 46(ab), 47(ab), 71(ab), 776, 1033(ab), 1246
Henze, M, 1011(ab)
Henzlova, MJ, 363(ab), 759(ab), 1322(ab)
Heo, J, 738(ab)
Heriot, AG, 984(ab)
Hermann, BP, 1180(ab)
Hermann, GA, 857(ab)
Hermans, C, 882(ab)
Herment, A, 31(ab)
Hernandez Pampaloni, M, 32(ab)
Hernekamp, C, 47(ab)
Herranz, R, 123(ab)
Herrero, P, 4(ab), 824(ab), 836(ab), 842(ab)
Herrington, B, 1230(ab)
Herscovitch, P, 119(ab), 168(ab)
Hershkop, MS, 769(ab)
Hertel, A, 282(ab), 1152(ab)
Herz, M, 205, 1367
Herzog, H, 977
Herzog, HR, 575(ab), 501(ab), 566(ab)
Hesse, B, 290
Hewitt, T, 732(ab)
Heydari, N, 125(ab)
Heyden, A, 224(ab)
Heys, SD, 552(ab)
Hicke, BJ, 402(ab)
Hidai, H, 1792
Hiddemann, W, 992(ab)
Hiele, M, 98(ab)
Hiemke, C, 1222(ab)
Hiemstra, PS, 2073
Higa, T, 1063(ab)
Higashi, K, 86(ab), 1095(ab)
Higashi, T, 88(ab), 479, 1097(ab), 1424, 1463
Higashino, H, 1071(ab)
Higazy, E, 785(ab)
Higginbotham, C, 419(ab)
Higuchi, T, 727(ab), 761(ab), 915(ab), 1366(ab), 1367(ab)
Hilgers, FJM, 1414
Hill, TC, 714(ab)
Hillier, DA, 510(ab)
Hillier, S, 153(ab), 1161(ab)
Hilson, A, 541(ab)
Hilson, AJ, 68(ab), 536(ab), 1038(ab)
Hilton, J, 373(ab), 1164(ab), 1207(ab)
Himbert, M, 173(ab)
Himeno, S, 1078(ab)
Hines, H, 574, 481(ab)
Hinkle, GH, 1563
Hirai, J, 191(ab)
Hirai, M, 728(ab)
Hirai, T, 471
Hiraki, Y, 394, 1971
Hiramatsu, T, 430(ab), 1020(ab)
Hiraoka, M, 1424
Hirasawa, T, 1131(ab)
Hirata, K, 1492
Hirayama, H, 728(ab)
Hirono, N, 1185(ab)
Hirota, S, 426(ab), 1072(ab)
Hirsch, WS, 1457(ab)
Hirschmann, M, 853(ab)

Hitzel, A, 179(ab), 513
Hitzemann, RJ, 442(ab), 443(ab), 715, 1217(ab), 1285
Hlisces, R, 975(ab)
Hnatowich, DJ, 484, 693, 900(ab), 1397(ab)
Ho, Y-J, 1446
Hode, F, 1301(ab)
Hoefnagel, CA, 70(ab), 1119(ab), 1414
Hoefs, JC, 1745
Hoejgaard, L, 1136(ab)
Hoekstra, CJ, 463(ab), 564(ab)
Hoekstra, HJ, 262, 381, 398(ab), 1146(ab)
Hoekstra, OS, 407(ab), 463(ab), 564(ab), 953(ab)
Hoenl, K, 754(ab)
Hoff, P, 1197
Hoffman, A, 427(ab)
Hoffman, EJ, 130(ab), 599(ab), 2043
Hoffman, JM, 92(ab), 331, 1344(ab)
Hoffman, TJ, 419(ab)
Hoffmann, K-T, 387
Hofstrand, PD, 1072
Höft, S, 776
Högerle, S, 340(ab), 423(ab)
Hoh, C, 408(ab)
Hoh, CK, 130(ab), 225(ab), 285(ab), 1045, 1293(ab), 2043
Hoher, M, 341(ab)
Hohn, A, 501(ab)
Hojo, S, 65(ab)
Hol, CK, 226(ab)
Holden, JE, 187(ab), 283, 354(ab), 1169(ab), 1186
Hollema, H, 1132(ab)
Hollo, A, 786
Holloway, B, 68(ab)
Holly, TA, 513(ab), 517(ab)
Holm, S, 1136(ab)
Holopainen, I, 12
Holst, H, 224(ab)
Hombach, V, 341(ab)
Homma, N, 512(ab)
Hommer, D, 445(ab), 1219(ab)
Homs, C, 844(ab)
Honda, N, 802(ab), 877(ab), 885(ab), 1188(ab)
Hong, KP, 736(ab)
Hong, MK, 166(ab), 1359(ab), 1387(ab)
Hong, SJ, 529(ab)
Hong, SW, 986, 1043(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1128(ab), 1151(ab)
Hong, T, 1468(ab)
Hör, G, 282(ab), 1152(ab)
Hordijk, GJ, 259(ab), 1056(ab)
Hori, M, 803(ab), 804(ab), 1190(ab), 1302(ab), 1693, 1884
Horibe, K, 1179(ab)
Horikawa, E, 70
Horiuchi, KS, 330(ab), 493(ab)
Horowitz, S, 63(ab)
Horti, AG, 1349(ab)
Hosea, S, 9(ab)
Hoshizaki, H, 217
Hosokawa, R, 471
Hosono, M, 802(ab), 877(ab), 885(ab), 1188(ab), 1216
Hospers, G, 890(ab)
Hossfeld, DK, 941(ab)
Hosten, N, 387
Hou, C, 660, 1345(ab)
Houry, S, 1077(ab)
Houston, T, 377(ab)
Hove, J, 295(ab)
Hovey-Andersen, R, 1230(ab)
Hoving, B, 1313(ab)
How, MS, 935(ab)
Howard Jones, E, 560(ab)
Howarth, DM, 64(ab), 579
Howell, RW, 978(ab)
Hrastnik, D, 1067(ab)
Hsiao, I, 299(ab)
Hsiao, JY, 244(ab)
Hsieh, J-F, 1446
Hsu, C, 130(ab), 1299(ab), 2043
Hsu, HB, 1269(ab)
Hsu, L, 947(ab)
Hsu, PI, 367(ab)
Hu, G, 863(ab), 866(ab), 1087(ab)
Hu, J, 21(ab)
Hua, C, 133(ab)
Huang, CC, 465(ab)
Huang, MT, 1065(ab)
Huang, S, 142(ab), 147(ab), 297(ab)
Huang, S-C, 1045
Huang, SC, 146(ab), 281(ab), 283(ab), 284(ab), 585(ab), 587(ab), 717(ab)
Huang, WS, 1170(ab)
Huang, X-F, 660
Hubbs, AH, 379(ab)
Huber, JS, 305(ab)
Huberty, JP, 1248(ab)
Hübinger, A, 977
Hubner, KF, 96(ab), 469(ab)
Huddart, RA, 425(ab)
Hudson, W, 350(ab)
Huesman, RH, 457(ab)
Hüfner, M, 396(ab)
Hughes, OD, 399(ab)
Huglo, D, 33
Huguier, M, 1077(ab)
Huic, D, 952(ab)
Huijgens, PC, 953(ab)
Huiskes, AW, 311
Hültenschmidt, B, 248(ab)
Humm, JL, 131, 156(ab), 328(ab), 1238(ab), 1764, 1935
Humphries, J, 1383(ab)
Hung, JC, 1391(ab)
Hunter, A, 277
Hunter, CJ, 1008(ab)
Hunter, G, 547(ab)
Hunter, J, 520(ab)
Hunter, KM, 96(ab)
Hupp, BD, 1264(ab)
Husain, SS, 94(ab)
Hustinx, R, 333(ab), 401(ab), 453(ab), 562(ab), 995, 1054(ab), 1239(ab), 1257, 1286(ab)
Hutcheon, AW, 552(ab)
Hutchins, GD, 846, 495(ab)
Hutchinson, RJ, 519(ab)
Hutton, I, 364(ab)
Huynh, P, 1463(ab)
Hwang, BT, 909(ab)
Hwang, DR, 114(ab), 117(ab), 435(ab), 609(ab), 1162(ab), 1209(ab)
Hwang, E, 915(ab)
Hwang, E-H, 1644
Hwang, EH, 216(ab), 727(ab), 761(ab)
Hwang, JH, 49(ab)
Hwang, SB, 994(ab)
Hwang, WS, 1857
Hyun, IY, 505(ab), 918(ab)
Hyun, MC, 883(ab)
Iacopi, F, 46
Iannettoni, MD, 1089(ab)
Ibbotson, ME, 764(ab)
Ichihara, T, 12(ab), 895, 1300(ab), 1331(ab)
Ichise, M, 143(ab), 273(ab), 530, 1183(ab), 1201(ab), 1902
Ichiya, Y, 1091(ab), 1595, 1778
Ida, I, 399
Ide, C, 253(ab)
Ide, M, 563(ab), 1078(ab), 1155(ab)
Ido, A, 352(ab), 747(ab), 1249(ab)
Ido, T, 70
Igarashi, H, 874(ab)
Ihling, C, 423(ab)
Iida, H, 312(ab), 841(ab), 862
Iida, Y, 685, 1003(ab)
Ikeda, DM, 1122(ab)
Ikeda, E, 1818
Ikegami, H, 744(ab)
Ikezoe, J, 1071(ab), 1271(ab), 1287(ab)
Ilgan, S, 404(ab), 1366(ab), 1367(ab)
Ilgin, N, 446(ab), 447(ab)
Ilhan, I, 524(ab)
Im, KC, 1226(ab)
Imahashi, K, 823(ab)
Imahori, Y, 1590
Imamura, M, 1097(ab), 1424
Imamura, T, 1185(ab)
Imon, Y, 1583
Imran, MB, 244
Inagaki, K, 240(ab)
Inagaki, M, 13(ab), 745(ab)
Inagaki, T, 569(ab)
Ingram, L, 1463(ab)
Innis, RB, 107(ab), 124(ab), 143(ab), 148(ab), 154(ab), 270(ab), 444(ab), 576(ab), 578(ab), 580(ab), 607(ab), 1208(ab), 1902
Inoshiro, N, 781(ab)
Inoue, M, 943(ab)
Inoue, T, 336(ab), 390(ab), 399, 404(ab), 878(ab), 1005(ab), 1018(ab), 1271(ab)
Inoue, Y, 418, 793, 862(ab), 867(ab)
Intenzo, CM, 1458(ab)
Inubushi, M, 7(ab), 782(ab), 1840
Investigators of USSC TMLR Clinica, I, 339(ab)
Iosilevski, G, 265(ab)
Irie, S, 569(ab)
Irie, T, 289(ab)
Irngartinger, G, 1061(ab)
Irwin, I, 587(ab)
Isaka, N, 895
Isaki, K, 1174(ab)
Ishibashi, K, 859(ab)
Ishida, Y, 796(ab), 799(ab), 800(ab), 801(ab), 1187(ab)
Ishigaki, T, 1179(ab)
Ishii, K, 426(ab), 1072(ab), 1185(ab)
Ishii, Y, 243(ab), 704(ab), 1085, 1132, 1441
Ishikawa, Y, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
Ishimaru, Y, 1271(ab)
Ishiwata, S, 705(ab), 808(ab)
Ishizaki, A, 211(ab), 212(ab), 855(ab)
Ishizu, K, 243(ab), 1282(ab), 1332(ab)
Iskandrian, AE, 339(ab), 738(ab)
Islam, QT, 533(ab)
Isner, JM, 760(ab)
Isobe, S, 728(ab)
Israel, O, 265(ab)
Issa, M, 209(ab)
Issaq, E, 968, 1111
Iterbeke, K, 1913
Ito, H, 102, 841(ab)
Ito, K, 1179(ab)
Ito, T, 728(ab)
Ito, Y, 859(ab)
Itoh, M, 70, 567(ab)
Itoh, N, 713(ab)
Itoh, Y, 748(ab), 798(ab), 807(ab)
Itti, R, 1466(ab)
Ivancevic, V, 897(ab), 952(ab), 1227(ab)
Ivanovic, M, 1264(ab)
Iversen, P, 1136(ab)
Iwaki, T, 1160(ab)
Iwanaga, K, 371
Iwanczyk, JS, 599(ab)
Iwanochko, RM, 721(ab), 771(ab), 776(ab)
Iwasaki, T, 217, 780(ab)
Iwata, K, 127(ab)
Iwata, M, 530(ab)
Iwata, Y, 1652
Iyer, M, 102(ab)
Iyo, M, 289(ab)
Izak, M, 810(ab)
Iznaga-Escobar, N, 768
Jääskeläinen, S, 12
Jacobson, AF, 784(ab), 410(ab)
Jacobson, D, 990(ab)
Jadvar, H, 255(ab), 421(ab), 908(ab), 1122(ab), 1451(ab)
Jaeckle, KA, 1206(ab)
Jaenicke, L, 1033(ab)
Jaffe, R, 741(ab), 811(ab)
Jager, PL, 70(ab), 393(ab), 398(ab), 1119(ab), 1146(ab)
Jagoda, E, 149(ab), 150(ab), 1547
Jakse, G, 1133(ab)
Jamart, J, 219(ab)
James, JL, 490(ab)
Jamil, G, 517(ab), 711(ab)
Jan, HA, 764(ab), 1108(ab)
Jana, S, 84(ab), 889(ab)
Janakiraman, N, 260(ab)
Jang, J-J, 339
Jang, JS, 1066(ab)
Jang, MJ, 1171(ab), 1195(ab), 1196(ab)
Jang, S, 274(ab), 562(ab)
Jänicke, F, 2021
Janier, MF, 821(ab)
Jank, J, 1049(ab)
Janowitz, WR, 347(ab)
Jansen, HM, 1354(ab)
Jansen, L, 70(ab), 1119(ab)
Janssen, AG, 106(ab), 753, 1107(ab)
Janssen, ML, 432(ab)
Jao, G-H, 60
Jarritt, PH, 343(ab), 344(ab)
Jaszczak, RJ, 138(ab), 139(ab), 1176, 1260(ab)
Jeandot, R, 412
Jeannin, L, 1913
Jeffrey, SS, 559(ab), 1122(ab)
Jenison, JD, 357(ab)
Jenkin, B, 381(ab)
Jenkins, BG, 582(ab)
Jenkins, WT, 401(ab)
Jenner, N, 420(ab), 1029
Jensen, M, 1136(ab)
Jensen, RT, 539
Jeon, TJ, 833(ab)
Jeong, H, 327(ab), 1006(ab)
Jeong, HJ, 286(ab), 549(ab), 1202(ab), 1378(ab)
Jeong, JM, 339, 309(ab), 529(ab), 938(ab), 998(ab), 999(ab), 1143(ab), 1275(ab), 1350(ab), 1387(ab), 1392(ab)
Jerin, J, 597(ab)
Jermann, E, 72(ab)
Jian, JJ, 1052(ab)
Jiang, S, 1010(ab), 1011(ab)
Jinnouchi, S, 1047(ab), 1057(ab)
Johannsen, B, 584(ab)
Johkoh, T, 566
John, CS, 405(ab), 486(ab), 488(ab)
Johnson, CA, 1321(ab)
Johnson, G, 813(ab), 815(ab)
Johnson, LL, 350(ab)
Johnson, LS, 1197(ab)
Joja, I, 1971
Jokisch, DW, 1947
Jolles, PR, 1455(ab), 1226
Jomura, H, 858(ab)
Jonas, SP, 1205(ab)
Jones, AG, 1031(ab)
Jones, AL, 1038(ab)
Jones, DW, 445(ab), 1348(ab)
Jones, JC, 1180(ab)
Jones, T, 592(ab)
Jones, WF, 305(ab), 306(ab)
Jonkhoff, AR, 953(ab)
Joo, KS, 1226(ab)
Joshi, R, 1012(ab)
Joshi, V, 489(ab)
Josson, E, 297(ab)
Jousse, F, 385(ab), 464(ab), 565(ab)
Judy, PF, 590(ab)
Juengling, FD, 220(ab)
Jung, DJ, 205(ab)
Jung, HY, 918(ab)
Jungbluth, A, 328(ab)

Junghans, U, 337(ab)
Jungkind, D, 1398(ab)
Juni, JE, 287(ab)
Jurcic, JG, 163(ab), 1935
Jürgens, H, 388(ab), 392(ab)
Jurisson, SS, 484(ab)
Juweid, ME, 261(ab), 972(ab), 1609
Kabasakal, L, 429, 1369(ab)
Kachi, T, 1179(ab)
Kachur, AV, 401(ab)
Kadrmas, DJ, 132(ab), 589(ab), 1298(ab)
Kaepplinger, S, 1251(ab)
Kage, R, 385(ab)
Kagetsu, NJ, 891(ab)
Kageyama, M, 1138
Kahaly, GJ, 925(ab)
Kahl, F, 224(ab)
Kaiser, LR, 1241
Kaji, T, 207(ab)
Kajihara, M, 563(ab)
Kakuda, K, 865(ab)
Kakuma, K, 865(ab)
Kalden, JR, 537(ab)
Kalender, B, 429
Kalff, V, 381(ab)
Kalinowski, EA, 1080(ab), 1363(ab)
Kamano, T, 802(ab), 885(ab)
Kameyama, S, 418
Kaminska, A, 786
Kaminski, MS, 76(ab), 77(ab), 990(ab), 991(ab)
Kamoto, Y, 1273(ab)
Kampen, WU, 46(ab), 47(ab)
Kamran, M, 716(ab)
Kanamaru, H, 1137(ab)
Kanamori, S, 1424
Kanaya, K, 818(ab)
Kanayama, S, 812(ab)
Kanazawa, S, 394
Kanegae, K, 963
Kaneko, N, 818(ab)
Kanel, G, 1745
Kanemitsu, S, 812(ab)
Kanetsuki, I, 222(ab)
Kang, DY, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab)
Kang, H, 1394(ab)
Kang, WJ, 23(ab)
Kang, X, 22(ab), 25(ab), 170(ab)
Kanjiram, J, 810(ab)
Kanmaz, B, 429
Kanno, I, 317
Kanno, T, 1282(ab)
Kantlehner, R, 1243(ab)
Kanz, L, 946(ab), 957(ab)
Kao, A, 378(ab)
Kao, AH, 346(ab)
Kao, C, 1334(ab)
Kao, C-H, 327(ab), 1006(ab), 1106, 1446
Kao, PF, 109(ab)
Kao, P-F, 1180
Kao, T, 1452(ab)
Kapczinski, F, 577(ab)
Kaplinsky, E, 749(ab)
Kapucu, N, 524(ab), 919(ab)
Kapur, A, 343(ab), 344(ab)
Karacay, H, 500(ab), 1002(ab)
Karak, P, 987(ab)
Karak, PK, 1228(ab)
Karamychev, VN, 1405(ab)
Karanikas, G, 74(ab)
Karkabi, B, 741(ab), 811(ab)
Karlsson, P, 120(ab), 1343(ab)
Karner, I, 739(ab)
Karp, J, 481(ab)
Karp, JS, 308(ab), 401(ab), 1239(ab), 1257
Kartamihardja, H, 904(ab)
Karvelis, KC, 1140(ab)
Kasagi, K, 530(ab)
Kasai, S, 211(ab), 212(ab), 855(ab)
Kasai, T, 779(ab)
Kasamatsu, N, 1088(ab)
Kasanuki, H, 744(ab)
Kasegai, A, 1465(ab)
Kashimada, A, 802(ab), 877(ab), 885(ab), 1188(ab)
Kashiwagi, T, 859(ab)
Kassiou, M, 144(ab), 1164(ab)
Kassis, AI, 986(ab), 1377(ab)
Kastin, A, 968
Kastrati, A, 24(ab)
Katafuchi, T, 801(ab)
Katayama, K, 859(ab)
Katayama, N, 867(ab)
Kates, AM, 4(ab)
Kato, H, 91(ab), 1000(ab)
Kato, T, 1179(ab)
Katoh, C, 527(ab), 862, 963, 1204(ab), 1247(ab), 1319(ab)
Katoh, K, 770(ab)
Katon, D, 518(ab), 702(ab)
Katsifis, A, 144(ab)
Katsikis, PD, 184
Katsuda, N, 1331(ab)
Katsuura, H, 207(ab)
Katz, J, 10N(1), 9N(4), 22N(7)
Katzir, Z, 860(ab)
Kaufman, D, 1258(ab)
Kaufman, G, 759(ab)
Kaufmann, PA, 1848
Kauppinen, TA, 1326(ab)
Kawabe, J, 858(ab), 1652
Kawabe, K, 418, 1342(ab), 1351(ab)
Kawaguchi, T, 1332(ab)
Kawai, Y, 14(ab)
Kawakami, T, 943(ab)
Kawamura, M, 770(ab)
Kawashima, R, 244, 317
Kawasuji, M, 761(ab)
Kawasumi, Y, 1179(ab)
Kawata, K, 514(ab)
Kazzimudin, M, 788(ab)
Keane, MJ, 379(ab)
Keeble, W, 364(ab)
Kegeles, LS, 114(ab), 117(ab), 121(ab), 122(ab), 1210(ab), 1211(ab)
Keidar, Z, 265(ab)
Keller, S, 1144(ab)
Kelley, DE, 1798
Kelly, MJ, 381(ab)
Kema, IP, 393(ab)
Kemp, BJ, 1306(ab)
Kemp, G, 1532
Kemp, PM, 1503
Kempf, JS, 232(ab)
Kenemans, P, 966(ab)
Keng, F, 349(ab), 1857
Kengen, RA, 1118(ab)
Keppler, P, 1637
Kerenyi, L, 373(ab), 594(ab)
Kerenyi, LL, 115(ab)
Kerich, M, 1219(ab)
Kerner, M, 126(ab)
Kerr, KR, 412(ab)
Kerrou, K, 1077(ab)
Kertesz, A, 1306(ab)
Keshtgar, M, 560(ab), 1113(ab), 1115(ab)
Keshtgar, MR, 1116(ab)
Kessler, H, 1061
Ketchum, LE, 9N(3)
Kettner, B, 936(ab)
Kettner, BI, 795(ab)
Keyeux, A, 882(ab)
Khalkhali, I, 1233, 1256(ab)
Khandekar, S, 773(ab)
Khandekar, SP, 236(ab)
Khanvali, B, 574
Khatri, A, 1468(ab)
Khaw, BA, 815(ab), 838(ab), 1832
Khazaeli, MB, 967(ab)
Khedkar, NY, 1126(ab)
Khorsand, A, 362(ab)
Kida, T, 1342(ab), 1351(ab)
Kiernan, FJ, 711(ab)
Kiesewetter, DO, 119(ab)
Kijewski, MF, 475(ab)
Kikuchi, K, 747(ab)
Kikuchi, T, 1071(ab), 1287(ab)
Kilcoyne, R, 44(ab)
Kilroy, K, 1070(ab)
Kilts, C, 1344(ab)
Kim, B, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1141(ab), 1194(ab)
Kim, BG, 1128(ab)
Kim, BI, 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1151(ab)
Kim, BK, 999(ab), 1387(ab)
Kim, BN, 1214(ab)
Kim, B-T, 1045
Kim, BT, 386(ab), 1226(ab)
Kim, C, 339
Kim, CK, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab), 1322(ab)
Kim, CS, 452(ab)
Kim, D, 49(ab), 751(ab)
Kim, DY, 852(ab)
Kim, E, 1462(ab)
Kim, EE, 404(ab), 955(ab), 1005(ab), 1206(ab), 1366(ab), 1367(ab), 1467(ab)
Kim, EH, 166(ab), 1359(ab), 1358(ab), 1360(ab)
Kim, ES, 534(ab)
Kim, GS, 205(ab)
Kim, GY, 1086(ab)
Kim, H, 751(ab)
Kim, IS, 1006(ab)
Kim, I-S, 837
Kim, J, 452(ab)
Kim, JH, 10(ab), 1128(ab), 1226(ab)
Kim, JS, 214(ab), 534(ab), 568(ab), 955(ab)
Kim, JY, 286(ab), 549(ab), 1045, 1076(ab), 1202(ab), 1226(ab), 1378(ab)
Kim, KB, 2(ab), 742(ab)
Kim, KE, 568(ab)
Kim, KM, 529(ab), 1221(ab), 1275(ab)
Kim, KW, 1128(ab)
Kim, M, 327(ab), 339, 1006(ab)
Kim, M-K, 837, 1381
Kim, MK, 286(ab), 1202(ab)
Kim, S, 773(ab), 1094(ab), 1458(ab)
Kim, SE, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1141(ab), 1194(ab), 1226(ab)
Kim, SH, 217(ab), 376(ab)
Kim, SK, 452(ab), 476(ab), 529(ab), 742(ab), 938(ab), 1171(ab)
Kim, SM, 534(ab)
Kim, WB, 1350(ab)
Kim, YC, 549(ab)
Kim, YJ, 273(ab), 530, 1201(ab), 1392(ab)
Kim, YK, 2(ab), 386(ab), 1143(ab)
Kimble, LP, 753(ab)
Kimura, Y, 1269(ab)
Kinahan, PE, 597(ab), 1134(ab), 2053
King, D, 276(ab)
King, MA, 456, 456(ab), 590(ab), 604, 1011, 1312(ab)
King, P, 439(ab)
Kinget, R, 610(ab)
Kinne, RW, 537(ab)
Kino, S, 211(ab), 212(ab), 855(ab)
Kinomura, S, 244
Kinoshita, N, 514(ab)
Kinoshita, T, 841(ab)
Kinser, JA, 752(ab)
Kinuya, S, 430(ab), 761(ab), 855(ab), 1020(ab), 1138, 1644, 1874
Kipper, M, 1256(ab)
Kipper, S, 1121(ab)
Kipper, SL, 62(ab)
Kira, T, 1331(ab)
Kirchner, PT, 1434
Kirihara, Y, 239(ab)
Kirk, GA, 339(ab)
Kirkman, E, 1361(ab)
Kishi, H, 241(ab)
Kison, PV, 76(ab), 87(ab), 556, 1130(ab), 1125, 1456
Kitabatake, A, 748(ab), 807(ab)
Kitagaki, H, 1185(ab)
Kitagawa, Y, 1132
Kitamura, K, 1302(ab)
Kiuchi, T, 1463
Klauber, GT, 913(ab)
Klein, A, 571(ab)
Klein, GJ, 457(ab)
Klein, JL, 315(ab)
Kleinz, R, 1222(ab)
Kletter, K, 362(ab), 1049(ab), 1347(ab)
Klimke, A, 575(ab)
Klippenstein, D, 949(ab)
Kloiber, R, 448
Kloos, RT, 532(ab)
Klose, E, 1261(ab)
Klosterman, L, 469(ab)
Kluge, R, 337(ab)
Klummp, H, 444(ab)
Klutmann, S, 46(ab), 71(ab), 257(ab), 776, 1033(ab), 1041(ab), 1150(ab), 1246, 2021
Knapp, FF Jr, 356(ab), 608(ab), 765(ab), 827(ab), 831(ab), 974(ab), 975(ab), 1204, 1384(ab), 1385(ab), 1484, 1508, 1918
Knapp, WH, 719(ab)
Knesaurek, K, 1322(ab), 1324(ab)
Knickmeier, M, 834(ab)
Knight, LC, 492(ab)
Knight, M, 984(ab)
Knockaert, D, 899(ab)
Knuuti, J, 862
Ko, YH, 1102(ab)
Kobayakawa, N, 1116
Kobayashi, H, 327(ab), 744(ab), 818(ab), 837, 1027(ab), 1381
Kobayashi, J, 1204(ab)
Kobayashi, K, 865(ab)
Kobayashi, T, 239
Kobayashi, Y, 1063(ab)
Kober, B, 220(ab)
Kobori, O, 239(ab)
Koch, CJ, 401(ab)
Koch, L, 1375(ab), 1380(ab)
Köchl, H, 1376(ab)
Kochs, E, 291(ab)
Kochunov, PV, 942
Kocjan, G, 1115(ab)
Koenders, EB, 192
Koeppe, RA, 1265(ab)
Koga, S, 847(ab), 1172(ab), 1335(ab)
Kogure, D, 1192(ab), 1583
Koh, JW, 1055(ab)
Koh, KK, 10(ab)
Kohelet, D, 860(ab)
Kohlmyer, SG, 459(ab), 1236(ab), 1237(ab)
Kohsaka, T, 867(ab)
Kohya, T, 748(ab), 798(ab), 807(ab)
Koivunen, E, 883
Koizumi, K, 835(ab)
Koizumi, M, 137
Kojima, A, 1331(ab)
Kokochis, SA, 50(ab)
Kokudo, N, 137
Kolansinka, AD, 68(ab)
Kolasinka, AD, 536(ab)
Kolasinska, AD, 1038(ab)
Kolb, HJ, 992(ab)
Kolbert, KS, 163(ab)
Kole, AC, 262, 381
Kolesnikov-Gauthier, H, 33
Kolsky, KL, 489(ab)

Komai, K, 727(ab)
Komatsu, M, 1971
Komeda, M, 1840
Komiyama, N, 705(ab)
Komo, S, 281(ab), 283(ab)
Kondas, D, 287(ab)
Kondo, F, 779(ab)
Koning, R, 179(ab), 513
Konings, IR, 322(ab), 415(ab)
Konishi, J, 7(ab), 471, 479, 530(ab), 685, 782(ab), 1003(ab), 1097(ab), 1273(ab), 1371(ab), 1406(ab), 1424, 1463, 1840, 1992
Konishi, S, 430(ab), 1020(ab), 1644
Konishi, T, 895
Konno, M, 748(ab), 798(ab), 807(ab)
Konstantinides, S, 220(ab)
Kontaxakis, G, 1288(ab), 1323(ab)
Kooij, PP, 762
Koole, M, 1250(ab)
Koops, HS, 262
Koops, W, 1414
Kopiwoda, S, 184, 814(ab)
Kopiwoda, SK, 846(ab)
Kopka, K, 1017(ab), 1064(ab)
Koplan, BA, 142
Kopp, AF, 871(ab)
Koral, KF, 77(ab)
Koren, AO, 1349(ab)
Koren, R, 376
Korenreich, L, 51(ab), 522(ab)
Korf, J, 1354(ab)
Kosaka, N, 239(ab), 240(ab), 241(ab)
Koshiji, T, 1840
Koskinen, MO, 1326(ab)
Kostakoglu, L, 1303(ab)
Kosten, TR, 444(ab)
Kosuda, S, 1125
Kotani, J, 781(ab)
Kothari, KK, 1015(ab), 1402(ab)
Kotler, MN, 1457(ab)
Kotz, D, 13N(5), 16N(5), 13N(7), 9N(12)
Kotzerke, J, 82(ab), 262(ab), 341(ab), 368(ab), 1272(ab), 1407, 1623, 1637
Kouji, T, 12(ab)
Kouyoumdjian, JC, 1127(ab)
Kovacs, M, 41(ab)
Kowell, AP, 285(ab)
Koyama, K, 858(ab)
Koyama, T, 1204(ab)
Kozak, RW, 166
Kraan, J, 1270
Kraeber-Bodéré, F, 198, 1216
Kragh, TJ, 133(ab)
Kramer, EL, 62(ab), 1281(ab)
Kramer, MR, 880(ab)
Krams, S, 846(ab)
Kranenborg, MH, 829
Kranert, WT, 1152(ab)
Krasnow, AZ, 1369(ab)
Krause, TM, 220(ab)
Krausz, Y, 252(ab), 880(ab), 1122(ab)
Krawczynska, EG, 508(ab), 511(ab), 787(ab), 1290(ab)
Krch, D, 1184(ab)
Krenning, BJ, 322(ab), 415(ab)
Krenning, EP, 317(ab), 320(ab), 414(ab), 416(ab), 418(ab), 762, 2081
Krevsky, B, 366(ab)
Krijanovski, OI, 1031(ab)
Krishnamurthy, GT, 264(ab)
Kritz, F, 13N(11)
Kritz, H, 1277
Kritzman, JN, 15(ab), 361(ab), 506(ab), 817(ab)
Kroger, LA, 302, 324(ab), 1381(ab)
Kröger, S, 46(ab), 257(ab), 776, 1150(ab), 1246
Krohn, KA, 614
Kroll, DJ, 350(ab)
Kroll, S, 76(ab), 990(ab), 991(ab)
Kronauge, JF, 1031(ab)
Kronenberg, MW, 1699
Kroon, B, 70(ab), 1119(ab)
Kropp, J, 374(ab), 543(ab), 975(ab), 1385(ab), 1484, 1918
Kross, B, 468(ab)
Krumm, RP, 857(ab)
Kuan, P, 825(ab)
Kuang, A, 1373(ab), 1395(ab)
Kubo, A, 1021(ab), 1026(ab)
Kubo, H, 1300(ab)
Kubo, N, 798(ab), 807(ab), 1247(ab), 1319(ab)
Kubo, S, 7(ab), 1840
Kubo, T, 779(ab), 1160(ab), 1175(ab)
Kubota, K, 70, 567(ab), 1022(ab)
Kubota, T, 1085
Kudo, T, 20(ab), 826(ab)
Kudoh, T, 7(ab), 782(ab), 1840
Kuehne, A, 975(ab)
Kuhar, M, 441(ab)
Kuhl, DC, 1306(ab)
Kuhl, DE, 294(ab)
Kuhn, HH, 185(ab)
Kuhne, A, 543(ab)
Kuikka, JT, 1326(ab)
Kuji, I, 1818
Kukis, DL, 302, 965(ab), 969(ab), 980(ab), 1381(ab), 2014
Kula, NS, 148(ab)
Kumagai, H, 574(ab)
Kumakura, Y, 1284(ab)
Kumar, A, 927(ab), 934(ab)
Kumar, VV, 1268(ab)
Kundley, K, 1191(ab)
Kundu, NG, 1361(ab)
Kung, HF, 108(ab), 150, 152(ab), 583(ab), 660, 1200(ab), 1345(ab), 1352(ab), 1812
Kung, M-P, 150, 660
Kung, MP, 152(ab), 583(ab), 1345(ab), 1352(ab)
Kuniyasu, Y, 1318(ab), 1328(ab), 1337(ab)
Kuntzsch, M, 245(ab)
Kupferschläger, J, 460(ab)
Kurata, C, 6, 2088
Kurdziel, KA, 1455(ab), 1456(ab)
Kurian, V, 1349(ab)
Kuribayashi, T, 2007
Kuroda, M, 1971
Kuroda, T, 718(ab), 767(ab)
Kuroki, M, 685, 1003(ab), 1005(ab)
Kuroki, T, 858(ab), 1652
Kurtaran, A, 74(ab), 395(ab), 1081(ab), 1082(ab)
Kusakabe, K, 744(ab), 818(ab)
Kushner, SA, 150, 583(ab)
Kusuoka, H, 566, 708(ab), 823(ab), 854, 1003, 1166(ab), 1884
Kuten, A, 265(ab)
Kuwabara, H, 293(ab), 584(ab)
Kuwabara, Y, 718(ab), 767(ab), 1091(ab), 1111(ab), 1203(ab), 1595, 1778
Kuwert, T, 1, 185(ab), 1017(ab)
Kuzuya, T, 803(ab), 804(ab)
Kvols, LK, 322(ab), 415(ab)
Kwan, YC, 1052(ab)
Kwekkeboom, DJ, 416(ab), 762, 2081
Kweon, J, 505(ab)
Kwok, CG, 60
La Madeleine, C, 876
Laatsch, H, 907(ab)
Labbie, AS, 204(ab)
Lacaine, F, 1077(ab)
Lacan, G, 1156(ab)
Lacrosse, M, 219(ab)
Lacy, J, 723(ab)
Lacy, JL, 775(ab)
Laffin, SP, 52(ab), 56(ab)
Laffont, S, 140(ab), 1314(ab)
Lage, C, 1379(ab)
Lahdenranta, J, 883
Lahiri, A, 345(ab), 464
Lahorte, P, 269(ab)
Lai, KH, 367(ab)
Lai, L, 431(ab)
Lai, S, 6(ab), 22(ab), 25(ab), 170(ab), 710(ab)
Laine, AF, 310(ab), 720(ab)
Laine, H, 862
Lajeunie, E, 1252
Lakhani, SR, 1115(ab)
Lalush, DS, 134(ab), 461(ab), 1252(ab), 1253(ab)
Lamb, HJ, 180(ab)
Lambert, C, 1396(ab)
Lambert, R, 41(ab), 1124(ab), 2029
Lamborn, KR, 963(ab), 1317, 2014
Lamki, L, 1462(ab)
Lamki, LM, 902(ab), 1459(ab), 1463(ab), 1464(ab)
Lammertsma, AA, 407(ab), 463(ab), 507, 564(ab), 953(ab), 1235(ab), 1313(ab)
Lamonica, D, 949(ab)
Lamy-Lhullier, C, 956
Lan, J-L, 1446
Lan, L, 579, 64(ab)
Lancaster, JL, 942
Landeau, B, 25
Landoni, C, 1617
Landsman, D, 62(ab)
Landsnes, DG, 232(ab)
Lang, AE, 273(ab), 530, 1201(ab)
Lang, L, 149(ab), 150(ab), 168(ab), 1547
Lang, O, 248(ab), 254(ab), 1059(ab), 1068(ab), 1149(ab)
Lang, S, 985(ab), 1277
Lange, D, 1261(ab)
Langleben, D, 1122(ab)
Langston, JW, 587(ab)
Laniece, P, 602(ab)
Lanke, J, 96
Lapointe, D, 832(ab), 876
Larena-Avellaneda, A, 202(ab)
Larger, E, 903(ab)
Larisch, R, 575(ab)
Larobina, M, 442
Larsen, P, 1136(ab)
Larsen, RH, 1197
Larsen, T, 238(ab), 929(ab)
Larson, SM, 95(ab), 131, 156(ab), 163(ab), 328(ab), 912(ab), 970(ab), 1007(ab), 1012(ab), 1039(ab), 1042(ab), 1044(ab), 1238(ab), 1722, 1764, 1935
Laruelle, M, 114(ab), 117(ab), 121(ab), 122(ab), 141(ab), 435(ab), 474(ab), 581(ab), 606(ab), 609(ab), 1162(ab), 1209(ab), 1210(ab), 1211(ab), 1242(ab)
Lasic, M, 1017(ab)
Lastoria, S, 66(ab), 1142(ab)
Laterza, C, 123(ab)
Latus, KA, 343(ab), 344(ab)
Lauer, B, 337(ab)
Lauer, I, 540(ab), 730(ab), 944(ab)
Laufer, J, 1103(ab)
Laver, O, 376
Laverman, P, 58(ab), 192, 892(ab), 2066
Lawhorn-Crews, HM, 101(ab)
Lawhorn-Crews, JM, 1079(ab)
Lawrence, B, 497(ab), 995(ab)
Lawson, G, 253(ab)
Lawson, M, 717(ab), 1304(ab)
Lawton, T, 1117(ab)
Laymon, CM, 136(ab)
Le Boterff, J, 198
Le Cloirec, J, 140(ab), 369(ab), 1314(ab)
Le Guludec, D, 369(ab), 701(ab), 794(ab), 805, 809(ab), 893(ab), 903(ab), 962(ab), 1602
Le, N, 268, 327(ab), 837, 1381
Le Rest, C, 298(ab), 473(ab)
Le Roux, G, 40
Leach, SD, 1784
Leahy, RM, 129(ab), 130(ab)
Lear, JL, 44(ab), 200(ab), 221(ab), 296(ab), 314(ab), 797(ab), 1165(ab)
Learoyd, DL, 924(ab)
LeBlanc, JW, 133(ab)
Lebtahi, R, 369(ab), 701(ab), 794(ab), 805, 809(ab), 893(ab), 903(ab), 962(ab), 1602
Leclercq, S, 905(ab)
Lecomte, R, 876, 832(ab)
Lecouffe, P, 956
Ledges, M, 169(ab)
Leduc, V, 956
Lee, B, 49(ab), 751(ab)
Lee, BH, 1023(ab)
Lee, BY, 1359(ab)
Lee, CJ, 1094(ab)
Lee, CK, 1182(ab)
Lee, DS, 2(ab), 23(ab), 309(ab), 339, 358(ab), 386(ab), 452(ab), 476(ab), 529(ab), 742(ab), 789(ab), 790(ab), 819(ab), 938(ab), 986, 998(ab), 999(ab), 1143(ab), 1171(ab), 1195(ab), 1196(ab), 1198(ab), 1214(ab), 1221(ab), 1275(ab), 1350(ab), 1387(ab), 1392(ab)
Lee, DW, 1221(ab)
Lee, E, 221(ab)
Lee, ED, 1128(ab)
Lee, EJ, 529(ab)
Lee, FT, 328(ab)
Lee, HB, 1352
Lee, HG, 217(ab)
Lee, HK, 166(ab), 205(ab), 214(ab), 534(ab), 568(ab), 1359(ab)
Lee, J, 213(ab), 515(ab), 735(ab), 819(ab), 1023(ab), 1086(ab)
Lee, JD, 704(ab), 833(ab)
Lee, JH, 888(ab), 1301(ab)
Lee, JI, 1073(ab)
Lee, J-K, 1446
Lee, JS, 309(ab), 386(ab), 452(ab), 476(ab), 986, 1043(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1151(ab) 1171(ab), 1196(ab), 1198(ab), 1214(ab), 1221(ab)
Lee, K, 339, 1194(ab)
Lee, KB, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab)
Lee, KH, 49(ab), 380(ab), 736(ab), 751(ab), 851(ab), 884(ab), 1076(ab), 1102(ab), 1128(ab), 1141(ab), 1194(ab), 1226(ab)
Lee, KS, 955(ab), 1348(ab)
Lee, KU, 1198(ab)
Lee, LS, 1065(ab)
Lee, MC, 2(ab), 23(ab), 339, 309(ab), 358(ab), 386(ab), 452(ab), 476(ab), 529(ab), 742(ab), 789(ab), 790(ab), 819(ab), 938(ab), 986, 998(ab), 999(ab), 1143(ab), 1171(ab), 1195(ab), 1196(ab), 1198(ab), 1214(ab), 1221(ab), 1275(ab), 1350(ab), 1387(ab), 1392(ab)
Lee, MM, 2(ab), 23(ab), 358(ab), 789(ab), 790(ab), 819(ab)
Lee, MY, 1226(ab)
Lee, RJ, 1563
Lee, S, 476(ab), 1045(ab), 1171(ab), 1194(ab)
Lee, SC, 367(ab), 1460(ab)
Lee, SG, 214(ab)
Lee, SH, 736(ab), 1066(ab), 1143(ab)
Lee, SK, 1195(ab), 1196(ab)
Lee, SW, 213(ab), 515(ab), 735(ab), 1023(ab), 1086(ab)
Lee, SY, 205(ab), 376(ab), 217(ab)
Lee, TW, 1058(ab)
Lee, WH, 505(ab)
Lee, WR, 736(ab)

Lee, YJ, 23(ab), 214(ab), 339, 938(ab), 998(ab), 999(ab), 1392(ab)
Lee, YS, 1051(ab), 1151(ab)
Lee, Z, 383(ab), 886(ab)
Leenders, KL, 1264
Lefebvre, B, 1728
Leimer, M, 395(ab), 1081(ab), 1082(ab)
Leitao, AC, 1379(ab)
Leitha, T, 881(ab), 985(ab), 1376(ab), 1477
Leitinger, I, 362(ab)
Leitman, N, 169(ab), 177(ab)
Lele, RD, 1191(ab)
Lele, VR, 1191(ab)
Lemahieu, I, 491
Lenox, M, 306(ab)
Leonard, SM, 342(ab), 509(ab), 513(ab), 1327(ab)
Leppo, JA, 456(ab)
Lerch, H, 1, 185(ab)
Lerut, A, 98(ab)
Leslie, MD, 425(ab), 1135(ab)
Leslie, WD, 422
Leta, R, 3(ab)
Leung, AN, 574
Leung, C, 1370(ab)
Leung, JY, 556
Levame, M, 37(ab)
Léveillé, J, 1124(ab)
Leveillee, RJ, 204(ab), 206(ab)
Leveque, FC, 930(ab)
Levine, RA, 193(ab)
Levy, AV, 145(ab), 715, 1176(ab), 1301(ab)
Levy, E, 1147(ab)
Lew, W, 981(ab)
Lewellen, TK, 459(ab), 1236(ab), 1237(ab)
Lewin, HC, 6(ab), 9(ab), 22(ab), 25(ab), 28(ab), 170(ab), 710(ab), 722(ab)
Lewis, BS, 741(ab), 811(ab)
Lewis, DH, 572(ab)
Lewis, JS, 177, 997(ab)
Lewis, LD, 763(ab)
Lewis, MR, 997(ab)
Lewis, PJ, 278(ab), 763(ab)
Lewkowiez, LA, 177(ab)
Lexow, N, 150
Leyton, M, 577(ab)
Li, AN, 356(ab), 1508
Li, B, 1004(ab)
Li, H, 307(ab), 598(ab), 1233(ab)
Li, J, 77(ab), 1373(ab)
Li, JM, 97(ab)
Li, L, 1386(ab)
Li, P, 2107
Li, SR, 1081(ab)
Li, WI, 383(ab)
LI, YC, 498(ab)
Liang, JZ, 1317(ab)
Liang, Z, 1277(ab), 1325(ab)
Liang, ZL, 498(ab)
Liani, M, 880(ab)
Liao, SQ, 909(ab), 1062(ab), 1065(ab), 1186(ab)
Liberson, A, 45(ab)
Libutti, SK, 385(ab), 464(ab), 565(ab), 1029(ab), 1297(ab)
Licho, R, 258(ab), 456, 590(ab), 604
Liebenhoff, S, 1036(ab)
Lieberman, G, 541(ab)
Liebig, JR, 574
Liebowitz, M, 581(ab)
Liechty, D, 200(ab)
Liem, IH, 1414
Lien, H-C, 1106
Liepe, K, 374(ab), 975(ab)
Lietzenmayer, R, 946(ab), 956(ab), 957(ab)
Lignelli, A, 228(ab)
Lilien, DL, 1745
Lim, BB, 405(ab), 486(ab)
Lim, HG, 742(ab)
Lim, JI, 1350(ab)
Lim, SC, 549(ab)
Lim, SM, 986, 166(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1128(ab), 1151(ab), 1358(ab), 1359(ab), 1360(ab), 1394(ab), 1043(ab)
Lim, ST, 358(ab), 790(ab)
Lima, MC, 746(ab), 848(ab)
Limouris, GS, 976(ab)
Lin, BH, 1087(ab)
Lin, CH, 1365(ab)
Lin, CK, 1052(ab)
Lin, E, 52(ab), 56(ab)
Lin, HD, 1307(ab)
Lin, HM, 1365(ab)
Lin, JW, 310(ab), 720(ab)
Lin, KP, 1307(ab)
Lin, KQ, 1268(ab)
Lin, KS, 318(ab)
Lin, MP, 2053
Lin, P, 1153(ab)
Lin, PC, 250(ab), 544(ab)
Lin, Q, 1918
Lin, S, 77(ab)
Lin, SH, 581(ab)
Lin, SZ, 1170(ab)
Lincke, T, 570(ab)
Lindahl, D, 96
Lindner, DJ, 1369(ab)
Lindsley, KL, 69(ab)
Line, BR, 319(ab), 1030(ab), 1399(ab)
Link, JM, 614, 1279(ab)
Linke, R, 110(ab), 112(ab), 126(ab), 853(ab)
Links, J, 359(ab)
Links, JM, 38N(8), 1349(ab)
Linnoila, M, 445(ab)
Liow, J, 1304(ab)
Lipszyc, H, 355(ab)
Lisbona, R, 542(ab)
Lisciandrano, D, 1630
Lister-James, J, 36(ab), 40(ab), 57(ab), 321(ab), 417(ab), 887(ab), 950(ab), 954(ab), 1081(ab), 1082(ab)
Litofsky, NS, 258(ab)
Liu, A, 1151
Liu, H, 1008(ab), 1181(ab)
Liu, JC, 1170(ab)
Liu, JZ, 866(ab), 1087(ab)
Liu, M, 94(ab)
Liu, P, 769(ab)
Liu, Q, 438(ab)
Liu, RS, 244(ab), 367(ab), 909(ab), 1050(ab), 1062(ab), 1065(ab), 1170(ab), 1186(ab), 1307(ab), 1365(ab), 1452(ab), 1460(ab)
Liu, WS, 1050(ab)
Liu, XS, 822(ab)
Liu, Y, 21(ab), 339(ab), 1369(ab)
Liu, YH, 817(ab)
Liu, Z, 815(ab), 813(ab)
Liuand, R-S, 60
Livingston, RB, 69(ab), 551(ab)
Livni, E, 582(ab)
Livshitz, S, 749(ab)
Ljungberg, M, 1524
Llacer, J, 130(ab), 2043
Llhan, I, 919(ab)
Loc'h, C, 935
Lockman, J, 539(ab)
Locko, RC, 1205(ab)
Lodge, MA, 1029(ab)
Loehr, H, 403(ab), 1036(ab)
Loftus, BM, 1414
Logan, J, 439(ab), 442(ab), 588(ab), 1176(ab), 1215(ab), 1218(ab), 1285, 1301(ab)
Löhr, M, 1374(ab)
Loisance, D, 917
Lombardo, I, 435(ab)
Lomena, F, 123(ab)
Loncaric, S, 937(ab)
London, ED, 1349(ab)
Long, R, 287(ab)
Longari, V, 251(ab), 338(ab), 725(ab), 777(ab), 1085(ab)
Longino, MA, 155(ab)
Lonneux, M, 253(ab), 1109(ab)
Lonneux, MG, 1316(ab)
Loogemann, J, 247(ab)
Lopatin, G, 1151
Löpez, G, 424(ab)
Lopez, MA, 1229(ab)
Lopez, R, 427(ab)
Lopez-Carrero, C, 123(ab)
Lorberboym, M, 539(ab), 860(ab)
Lord, EM, 401(ab)
Lorenz, E, 1234(ab)
Lormeau, B, 1252
Losman, MJ, 500(ab)
Losordo, DW, 760(ab)
Lötter, MG, 1532
Lottgen, J, 1064(ab)
Loutfi, A, 542(ab)
Loutfi, I, 879(ab)
Lovqvist, A, 328(ab), 1007(ab)
Lowe, J, 339(ab)
Lu, JG, 909(ab)
Lu, L, 497(ab), 504(ab), 995(ab), 1346(ab)
Lubberink, M, 982(ab)
Luciani, A, 1716
Lucignani, G, 1617
Luddens, H, 1222(ab)
Luder, H, 279(ab)
Ludolph, AC, 571(ab)
Ludwig, W-D, 387
Luescher, D, 752(ab)
Lugo, D, 427(ab)
Lukasiewicz, RL, 1030(ab), 1399(ab)
Lukes, J, 360(ab)
Lull, RJ, 935(ab), 1226
Lundin, A, 96
Lundqvist, H, 982(ab)
Luo, H, 1918
Luo, SZ, 1386(ab)
Lustig, M, 1213(ab)
Lutter, G, 340(ab)
Lüttges, J, 1033(ab)
Luttropp, CA, 159
Luu, AN, 1009(ab)
Luurtsema, G, 393(ab)
Lysionek, AE, 1080
Ma, D, 431(ab), 1722
Ma, KH, 1170(ab)
Macapinlac, H, 1042(ab), 1044(ab)
Macapinlac, HA, 95(ab), 912(ab), 1039(ab)
MacDonald, LA, 509(ab)
MacDonald, LR, 599(ab)
Macey, DJ, 160(ab), 967(ab), 979(ab), 1317
Mach, RH, 1356(ab)
Machac, J, 355(ab), 363(ab), 759(ab), 1322(ab), 1324(ab)
Machida, K, 802(ab), 877(ab), 885(ab), 1188(ab)
Machulla, H, 245(ab)
Machulla, HJ, 933(ab)
Mäcke, H, 72(ab)
Mäcke, HR, 762
Mackey, D, 218(ab)
Mackey, DW, 85
MacLaren, D, 102(ab)
MacLean, AB, 541(ab)
MacMullan, J, 730
Madar, I, 1180
Maddahi, J, 1(ab)
Madeddu, G, 1105(ab)
Madras, BK, 153(ab), 1161(ab)
Madsen, MT, 1315(ab)
Maeda, H, 12(ab), 847(ab), 1131(ab), 1335(ab)
Maeda, J, 1342(ab), 1351(ab)
Maeda, M, 289(ab)
Maehara, Y, 1778
Maekawa, M, 1137(ab)
Maes, A, 19(ab), 822(ab), 899(ab)
Maes, B, 1451
Maetani, S, 1063(ab)
Maeyama, S, 859(ab)
Maffioli, L, 251(ab), 1114(ab)
Magata, Y, 7(ab), 150(ab), 1406(ab)
Magee, M, 869(ab)
Maggioni, A, 235(ab)
Magnani, P, 1617
Magnussen, J, 218(ab), 869(ab)
Magnussen, JS, 85
Magri, GC, 178(ab), 375(ab)
Maguire, GQ, 1281(ab)
Mahowald, JL, 1259(ab)
Mainenti, P, 338(ab)
Maini, CL, 46
Mainolfi, C, 442
Maisey, MN, 409(ab), 410(ab)
Majd, M, 523(ab)
Majewski, S, 468(ab), 600(ab)
Majstorov, V, 1036(ab)
Makino, K, 12(ab)
Makino, T, 1131(ab)
Makriyannis, A, 438(ab)
Makuuchi, H, 1078(ab)
Malamitsi, J, 904(ab)
Malatesta, T, 46
Male, TA, 873(ab)
Malguria, N, 1138(ab)
Malison, RT, 444(ab), 576(ab)
Mallet, J-J, 1676
Malloch, C, 364(ab)
Malmin, RE, 482(ab), 1245(ab)
Malone, KM, 1211(ab)
Maltz, JS, 311(ab)
Manchanda, R, 321(ab), 950(ab), 954(ab)
Manco-Johnson, M, 44(ab)
Mancuso, NS, 371(ab)
Mandel, S, 526(ab)
Manders, JM, 829
Maneke, E, 828(ab)
Manetou, A, 976(ab)
Mangin, JF, 786
Mangioni, C, 235(ab)
Mangner, TJ, 101(ab)
Mangold, D, 446(ab)
Mankoff, DA, 69(ab), 551(ab), 557(ab), 614
Mann, A, 518(ab)
Mann, JJ, 114(ab), 117(ab), 121(ab), 122(ab), 609(ab), 1162(ab), 1210(ab), 1211(ab)
Mann, K, 923(ab)
Manner, T, 12
Mannting, F, 772(ab), 889, 1031(ab)
Mannting, MG, 772(ab)
Manoj, C, 412(ab)
Manrique, A, 179(ab), 513, 805
Manthey, N, 389(ab)
Marais, J, 1532
Marasini, B, 77
Marchandise, B, 766(ab), 792(ab)
Marchandise, X, 33
Marchione, T, 573(ab)
Marcus, CS, 1080(ab), 1363(ab)
Marcus, RE, 249(ab)
Mardirossian, G, 972(ab), 1524
Marek, K, 107(ab)
Margouleff, C, 1178(ab)
Marí, C, 3(ab), 5(ab), 19, 734(ab), 786(ab), 911
Mariani, G, 522, 926(ab), 1123(ab), 1832
Marini, C, 363
Marion, C, 402(ab)
Marois, M, 1100(ab)
Marsden, PK, 763(ab)
Marshall, RC, 712(ab), 1278(ab)
Marti, JM, 424(ab), 845(ab), 1096(ab), 1401(ab)
Martin, A, 40
Martin, CS, 775(ab)
Martin, G, 1124(ab)

Martin, JC, 3(ab), 5(ab), 786(ab), 1212(ab)
Martin, JM, 734(ab)
Martin, W, 364(ab)
Martin, WH, 110
Martinez, CJ, 1126(ab)
Martinez, D, 435(ab), 1209(ab)
Martinoff, S, 24(ab)
Maruno, H, 705(ab), 808(ab)
Maruyama, A, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 1693
Maruyama, I, 1085
Marwin, SE, 43(ab)
Marzilli, LG, 1403(ab)
Mas, JF, 839(ab), 1336(ab)
Masai, M, 780(ab)
Masaki, K, 858(ab)
Mason, JC, 821(ab)
Masoomi, M, 984(ab)
Massardo, T, 516(ab)
Masson, H, 267(ab)
Massuger, LF, 432(ab)
Mastin, ST, 371(ab)
Mastrippolito, R, 602(ab)
Masuda, I, 782(ab)
Masuda, K, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
Masuda, S, 1465(ab)
Masuda, Y, 718(ab), 767(ab)
Masuyama, K, 512(ab), 812(ab)
Matacchieri, RA, 1339(ab)
Mathai, M, 1367(ab)
Matheja, P, 1, 1064(ab)
Matheoud, R, 338(ab), 1928
Mather, JF, 711(ab)
Mather, SJ, 1108(ab)
Matherson, KJ, 601(ab)
Mathew, T, 1368(ab)
Mathews, D, 237(ab), 896(ab)
Mathews, WB, 115(ab), 373(ab), 446(ab), 447(ab), 1014(ab), 1164(ab), 1207(ab)
Mathur, A, 108(ab), 625, 1200(ab), 1812, 2107
Matsubara, S, 1792
Matsuda, H, 1192(ab), 1583
Matsui, S, 512(ab), 812(ab)
Matsui, T, 1188(ab)
Matsumori, A, 7(ab)
Matsumoto, K, 1590
Matsumoto, M, 1190(ab), 1302(ab), 1331(ab)
Matsumura, K, 1172(ab)
Matsunari, I, 191(ab), 512(ab), 761(ab), 904, 1824, 1874
Matsuno, K, 718(ab), 767(ab)
Matsuoka, M, 1318(ab), 1328(ab), 1337(ab)
Matsuoka, Y, 685, 1005(ab)
Matsushima, T, 1203(ab)
Matsushita, T, 1332(ab)
Matsuta, Y, 1137(ab)
Matsuzawa, Y, 239
Mattes, MJ, 1392
Mattfeldt, T, 368(ab)
Matthay, KK, 1248(ab)
Mattis, P, 1184(ab)
Mattner, F, 144(ab)
Matunari, I, 727(ab)
Matzen, K, 550(ab)
Maublant, J, 672
Maunoury, C, 910(ab)
Maurer, AH, 366(ab), 492(ab), 854(ab), 1226, 1236, 1313
Maurer, G, 362(ab)
Maurer, K, 282(ab)
Mausner, LF, 302, 489(ab), 490(ab)
Mawlawi, O, 114(ab), 117(ab), 435(ab), 474(ab), 1162(ab), 1209(ab), 1242(ab)
Mayer, S, 1367
Mayrin, V, 857(ab)
Maysky, M, 760(ab)
Mazière, B, 935
Maziere, B, 411(ab)
Mazumdar, M, 95(ab)
Mazza, SM, 379(ab)
Mazzadi, A, 821(ab)
Mazzanti, C, 445(ab)
Mazziotta, JC, 283(ab)
McAfee, JG, 1396(ab)
McAlpine, B, 234(ab)
McBride, BC, 357(ab)
McBride, J, 844(ab)
McBride, W, 1002(ab)
McBride, WJ, 500(ab)
McCarthy, DW, 177
McCarthy, G, 1220(ab)
McCarthy, TJ, 177
McCluskey, ER, 342(ab)
McCready, VR, 161(ab), 984(ab)
McCullough, NT, 989(ab)
McCullough, SP, 160(ab)
McDade, M, 364(ab)
McDevitt, MR, 166, 431(ab), 1722, 1935
McDonald, KL, 197(ab), 876(ab)
McElgin, WT, 150
McFalls, EO, 1304(ab)
McGagh, DA, 970(ab)
McGhie, AI, 27(ab), 724(ab), 1291(ab)
McGill, CC, 517(ab), 518(ab), 702(ab)
McGillicuddy, JE, 554(ab)
McGuinness, G, 1281(ab)
McIntyre, R, 200(ab)
McLoud, T, 547(ab)
McPherson, DW, 608(ab), 1918
McSherry, BA, 456(ab)
Meadors, K, 1164
Meares, CF, 302
Mease, RC, 1396(ab)
Mechanic, KY, 444(ab)
Medeiros, FB, 11(ab)
Medeiros, M, 11(ab)
Medina, JF, 845(ab), 1401(ab)
Medvedec, M, 531(ab), 937(ab)
Meegalla, SK, 150, 152(ab), 660
Mega, MS, 283(ab)
Mehanny, S, 507(ab)
Mehilli, J, 24(ab)
Mehta, BM, 1935
Mehta, L, 236(ab)
Meignan, M, 37(ab), 223(ab), 1147(ab)
Meijer, WG, 393(ab)
Meikle, SR, 144(ab)
Meinken, GE, 489(ab), 490(ab)
Meisami, T, 408(ab)
Meisetschläger, G, 593(ab)
Meissner, C, 871(ab)
Meldolesi, U, 573(ab)
Mele, D, 778(ab)
Melega, WP, 1156(ab)
Melin, J, 792(ab)
Meller, B, 540(ab), 605(ab), 921(ab), 944(ab), 1372(ab)
Meller, J, 48(ab)
Melloul, M, 376
Melo, T, 1019(ab)
Meltzer, CC, 2053
Meltzer, CC, 597(ab), 1134(ab)
Meltzer, P, 153(ab), 1161(ab)
Menard, L, 602(ab)
Menditto, C, 1142(ab)
Mentis, M, 1178(ab), 1184(ab)
Mentis, MJ, 119(ab), 1264
Menzel, C, 78(ab)
Merced, M, 715(ab)
Merdler, A, 741(ab), 811(ab)
Meredith, RF, 967(ab), 979(ab)
Merkle, P, 1068(ab)
Merlet, P, 31(ab), 224, 411(ab), 917, 1147(ab)
Mertens, IJ, 311
Mesotten, LV, 19(ab), 822(ab)
Mester, J, 46(ab), 71(ab), 257(ab), 1033(ab), 1041(ab), 1150(ab), 1246, 1657, 2021
Methe, BM, 616(ab)
Metsähonkala, L, 12
Metz, CE, 1011
Meyer, GJ, 719(ab)
Meyer, MA, 951(ab), 1274(ab)
Meyer, P, 450(ab), 537(ab)
Meyers, FJ, 963(ab)
Michalevich, D, 376
Michel, CJ, 1316(ab)
Michigishi, M, 761(ab)
Michigishi, T, 216(ab), 430(ab), 1020(ab), 1644
Mick, R, 1143
Mier, W, 487(ab)
Migneco, O, 1301
Mignon, M, 369(ab), 1602
Mikami, T, 2088
Mikami, Y, 718(ab), 767(ab)
Mikolajczyk, K, 1288(ab)
Mikuni, M, 399
Milan, E, 172(ab), 178(ab)
Miller, I, 552(ab)
Miller, J, 208(ab), 377(ab)
Miller, SD, 306(ab)
Miller, TR, 1129(ab)
Millesi, W, 985(ab)
Milliken, BD, 347
Min, JJ, 286(ab), 549(ab), 1202(ab), 1378(ab)
Minami, C, 1080(ab), 1363(ab)
Mineura, K, 1590
Minguez, J, 424(ab)
Minoshima, S, 294(ab), 737
Miranda, R, 170(ab)
Mirick, GR, 302, 1317, 2014
Misaki, T, 530(ab), 865(ab)
Mishkin, FS, 917(ab), 977(ab)
Missimer, J, 268(ab), 1264
Mitchell, K, 52(ab), 56(ab)
Mitchell, T, 1462(ab)
Mitsumori, A, 394
Miura, S, 812(ab)
Mix, M, 340(ab), 423(ab), 591(ab), 1308(ab), 1309(ab)
Mixon, L, 359(ab)
Miyahara, M, 12(ab)
Miyake, M, 70
Miyamoto, T, 1131(ab)
Miyaoka, RS, 1237(ab)
Miyatake, K, 799(ab), 800(ab)
Miyazaki, Y, 1874
Miyazono, N, 222(ab)
Miyoshi, S, 566
Miziara, H, 11(ab)
Mo, T, 1373(ab), 1395(ab)
Mochiduki, T, 527(ab)
Mochizuki, S, 779(ab)
Mochizuki, T, 207(ab), 798(ab), 807(ab), 963, 1071(ab), 1271(ab), 1287(ab)
Mock, BH, 495(ab), 846
Modlin, I, 73(ab)
Moe, RE, 557(ab)
Moeller, JR, 1178(ab), 1184(ab), 1264
Mognetti, T, 585
Mohammed, A, 487(ab)
Moins, N, 672
Moisan, C, 1100(ab)
Moka, D, 403(ab), 1036(ab)
Moka, DC, 202(ab), 791(ab), 830(ab), 932(ab), 973(ab)
Mokler, FT, 1918
Molenaar, WM, 262, 381
Molinari, E, 926(ab)
Molinet, R, 166, 1375(ab), 1380(ab)
Moller, P, 422(ab)
Molloy, PT, 520(ab), 521(ab)
Molls, M, 397(ab)
Molthoff, CF, 966(ab)
Momen, A, 413(ab)
Momiki, S, 1088(ab)
Momomura, S-i, 1116
Momose, M, 744(ab), 818(ab)
Momose, T, 1284(ab)
Moncayo, R, 74(ab)
Monsieurs, M, 1250(ab)
Montanaro, D, 84(ab)
Montane, BS, 204(ab)
Monteleone, F, 556(ab), 843(ab)
Montenegro, NB, 870(ab)
Montoya, J, 117(ab)
Montravers, F, 1077(ab)
Moog, F, 1407
Moon, DH, 166(ab), 205(ab), 214(ab), 529(ab), 534(ab), 568(ab), 1359(ab)
Moore, A, 131(ab)
Moore, MJ, 1025(ab)
Moore, SC, 475(ab), 482(ab), 483(ab)
Moore, WH, 17(ab), 348(ab)
Morales, A, 768
Morales, B, 59(ab)
Moran, JK, 1352
Morano, GN, 1199(ab), 1270(ab)
Morel, D, 412
Moresco, RM, 302(ab)
Moretti, J, 960(ab), 962(ab), 1092(ab), 1127(ab), 1305(ab)
Moretti, J-L, 40
Moretti, R, 172(ab)
Mori, E, 1185(ab)
Mori, K, 705(ab)
Mori, Y, 779(ab), 874(ab)
Morin, J, 1100(ab)
Morita, DM, 1040(ab)
Morita, K, 527(ab), 748(ab), 798(ab), 807(ab), 963, 1204(ab), 1319(ab)
Morita, T, 240(ab)
Morita, Y, 1319(ab)
Moriwaki, H, 1187(ab)
Moroi, M, 193(ab)
Morozumi, T, 781(ab)
Morpurgo, PS, 922(ab)
Morr, I, 1010(ab), 1011(ab)
Morris, HH, 279(ab)
Morris, JG, 454(ab)
Morris, MM, 997(ab)
Morrison, KS, 283
Mortelmans, L, 19(ab), 98(ab), 610(ab), 822(ab), 1451
Mortelmans, LA, 899(ab)
Morton, KA, 159
Mosada, R, 94(ab)
Moser, AJ, 856(ab)
Moser, E, 220(ab), 247(ab), 423(ab)
Moser, EA, 340(ab), 1308(ab)
Moses, WW, 305(ab)
Moskovitz, B, 968, 1111
Motomura, N, 895, 1300(ab), 1331(ab)
Motzer, RJ, 970(ab)
Mountz, JM, 994(ab), 1181(ab)
Moustafa, H, 904(ab)
Moustakidis, P, 4(ab)
Moutray, K, 27(ab)
Moutray, KL, 724(ab), 1291(ab)
Movahed, A, 1329(ab)
Moyer, BR, 321(ab), 417(ab), 950(ab), 954(ab)
Moyer, C, 950(ab)
Moyna, N, 702(ab)
Moyse, D, 917
Mozley, PD, 108(ab), 150, 199(ab), 583(ab), 625, 1200(ab)
Mozley, PD, 1812, 2107
Mu, M, 150, 152(ab), 660, 1345(ab)
Mueller-Berg, M, 946(ab), 957(ab), 1289(ab)
Muffoletto, A, 906(ab)
Mukherjee, J, 437(ab), 1267(ab), 1338(ab)
Mukhin, AG, 1349(ab)
Mukhopadhyay, SK, 232
Mukovitzky, J, 558(ab)
Mulholland, GK, 495(ab)
Mullan, BP, 677, 1098
Mullani, N, 1462(ab)
Müller, SP, 475(ab), 483(ab), 923(ab)
Müller-Gärtner, HW, 566(ab), 575(ab), 977

Müller-Schauenburg, W, 460(ab)
Mundler, O, 1252
Municino, A, 810(ab)
Munro, SM, 169(ab)
Munz, DL, 195(ab), 795(ab), 840(ab), 897(ab), 920(ab), 936(ab), 948(ab), 952(ab), 1227(ab)
Munz, F, 448(ab), 593(ab)
Murakami, M, 1131(ab)
Muramatsu, T, 1131(ab)
Muramori, A, 1874
Muranoto, S, 243(ab)
Murase, K, 1071(ab), 1271(ab), 1287(ab)
Murata, H, 705(ab), 808(ab), 1005(ab)
Murata, T, 1174(ab)
Murata, Y, 64, 1101(ab), 1874
Murayama, S, 1595
Murguia, JS, 613(ab)
Murphy, GP, 1138(ab)
Murphy, J, 44(ab)
Murray, P, 869(ab)
Murren, J, 73(ab)
Murthy, DR, 518(ab), 702(ab), 711(ab)
Murthy, K, 542(ab)
Murud, KM, 1197
Musachio, J, 1164(ab)
Musachio, JL, 446(ab), 447(ab), 1014(ab), 1207(ab)
Muto, P, 66(ab), 1142(ab)
Muzi, M, 614
Muzic, RF, Jr, 118
Muzik, O, 101(ab), 592(ab), 1079(ab), 1985
Muzzammil, T, 1025(ab)
Myrick, S, 209(ab)
Mzengeza, S, 577(ab)
Nabatame, H, 1992
Nabeshima, S, 1063(ab)
Nabi, H, 949(ab)
Nabi, HA, 67(ab), 1069(ab)
Nachar, O, 1728
Naddaf, S, 84(ab), 889(ab)
Nader, K, 741(ab), 811(ab)
Nader, S, 773(ab)
Nagahama, Y, 1992
Nagai, R, 217
Nagamachi, S, 1047(ab), 1057(ab)
Nagamatsu, H, 744(ab), 818(ab)
Nagano, AS, 1179(ab)
Nagao, M, 1287(ab)
Nagasaka, T, 865(ab)
Nagasawa, M, 859(ab)
Nagata, M, 779(ab)
Nagata, S, 781(ab)
Nagatani, Y, 1792
Nagatsuka, S, 289(ab)
Nagaya, N, 800(ab)
Nagueh, SF, 1857
Nahmias, C, 604(ab), 1666
Nahum, AE, 161(ab)
Naiman, JT, 228(ab), 412(ab)
Nair, N, 256, 1366(ab)
Naito, A, 847(ab)
Naito, M, 859(ab)
Nakabeppu, Y, 222(ab), 726(ab)
Nakada, K, 88(ab), 89(ab), 527(ab), 963
Nakagawa, M, 514(ab), 1091(ab), 1111(ab), 1203(ab), 1595, 1778, 2007
Nakagawa, T, 239, 1971
Nakahara, H, 1047(ab)
Nakai, H, 1173(ab)
Nakai, M, 1137(ab)
Nakajima, K, 216(ab), 727(ab), 761(ab), 855(ab), 915(ab), 1644, 1874
Nakajo, M, 222(ab), 726(ab)
Nakamoto, Y, 479, 685, 1003(ab), 1097(ab), 1424, 1463
Nakamura, A, 1179(ab)
Nakamura, F, 1204(ab)
Nakamura, H, 566, 942(ab), 1166(ab)
Nakamura, K, 1021(ab), 1026(ab)
Nakamura, M, 895
Nakamura, S, 243(ab), 704(ab), 1441
Nakamura, T, 514(ab), 713(ab), 1264
Nakano, A, 704(ab)
Nakano, T, 12(ab), 895, 1166(ab)
Nakao, K, 782(ab)
Nakashima, S, 865(ab)
Nakata, J, 874(ab)
Nakata, S, 1071(ab)
Nakaya, J, 718(ab), 767(ab)
Nakayama, H, 781(ab)
Nakumura, T, 1178(ab), 1184(ab)
Nam, SJ, 1102(ab)
Namavari, M, 102(ab), 585(ab)
Namba, H, 289(ab)
Nanasato, M, 728(ab)
Nanto, S, 781(ab)
Narayanan, MV, 456(ab), 1312(ab)
Narayanan, TK, 1267(ab), 1338(ab)
Narita, Y, 312(ab)
Narula, J, 3(ab), 5(ab), 738(ab), 786(ab), 838(ab), 911
Naruse, A, 1201(ab)
Naruse, H, 780(ab)
Natale, D, 339(ab)
Natali, PG, 46
Nathan, L, 32(ab)
Nativ, O, 968, 1111
Naumovski, L, 184
Navarro, V, 1001(ab), 1008(ab)
Nayak, N, 775(ab)
Neal, VJ, 1293(ab)
Nejmeddine, F, 40, 960(ab)
Nekolla, S, 24(ab), 30(ab), 33(ab), 34(ab), 35(ab), 183(ab), 188(ab), 1824
Nekolla, SG, 18(ab)
Nel, MG, 1532
Nelson, AD, 118, 886(ab)
Nelson, CA, 321(ab), 417(ab), 887(ab), 950(ab), 954(ab)
Nelson, DL, 268
Neri, D, 434(ab)
Netusil, N, 588(ab), 1285
Neuhoff, AW, 1099(ab)
Neumaier, B, 262(ab), 571(ab), 1388(ab), 1623
Neumann, DR, 236(ab)
Neumann, FJ, 24(ab)
Neumann, RD, 565(ab), 1009(ab), 1547
Neverve, J, 24(ab), 1311(ab), 1824
Newling, DW, 667
Newman, RD, 1405(ab)
Ng, C, 1208(ab)
Ng, CK, 353(ab)
Ng, CS, 249(ab)
Ngo, HK, 521(ab)
Nguyen, C, 794(ab)
Nguyen, K, 102(ab), 323(ab)
Nguyen, KN, 131(ab)
Nguyen, N, 34(ab), 828(ab)
N'Guyen, T, 1305(ab)
Nguyen, TV, 582(ab)
Ngyuen, HQ, 1117(ab)
Nibbering, PH, 2073
Nichols, D, 22N(1), 25N(2), 28N(5)
Nichols, K, 171(ab), 176(ab), 181(ab), 507(ab), 716(ab), 715(ab), 924, 1882
Nichols, KJ, 650
Nichols, TE, 2053
Nicholson, RL, 1306(ab)
Nickel, O, 925(ab)
Nickerson, DS, 942
Nickles, RJ, 187(ab), 437(ab), 503(ab), 1163(ab), 1169(ab)
Nicodemus, CF, 40(ab), 57(ab)
Nicolai, E, 194(ab), 1683
Nicolini, J, 1080
Nicolo, G, 1123(ab)
Nielsen, TT, 1292
Niesen, A, 1152(ab)
Nieweg, OE, 70(ab), 262, 1119(ab)
Niida, Y, 1818
Niimura, K, 1985
Niio, Y, 1318(ab), 1328(ab), 1337(ab)
Nikolov, G, 539(ab), 860(ab)
Nikula, T, 433(ab)
Nikula, TK, 166
Nilsson, F, 434(ab)
Nishiguchi, S, 1652
Nishii, R, 1047(ab), 1057(ab)
Nishikawa, J, 418
Nishikawa, T, 1095(ab)
Nishimura, H, 1160(ab), 1175(ab), 1190(ab)
Nishimura, K, 1840
Nishimura, S, 294(ab), 770(ab)
Nishimura, T, 65(ab), 239, 384(ab), 566, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 823(ab), 854, 1003, 1160(ab), 1166(ab), 1175(ab), 1190(ab), 1302(ab), 1693, 1884
Nishimura, Y, 1424
Nishio, M, 781(ab)
Nishioka, A, 1101(ab)
Nishiyama, Y, 198(ab), 875(ab)
Nishizawa, S, 1273(ab), 1463, 1992
Nitobe, J, 1999
Nitzsche, EU, 340(ab), 423(ab), 1308(ab), 1309(ab)
Noachtar, S, 737
Noack, D, 936(ab)
Nobezawa, S, 1088(ab), 1282(ab)
Nobili, F, 522
Nocaudie, M, 33
Noda, A, 294(ab)
Noël, M-H, 25
Noelpp, UB, 1261(ab)
Noguchi, J, 1342(ab), 1351(ab)
Noguchi, S, 65(ab)
Nohara, R, 7(ab), 471
Nomura, Y, 12(ab), 895
Nonokawa, M, 728(ab)
Nonomura, A, 535(ab)
Noorden, PJ, 272(ab)
Noorduyn, L, 1107(ab)
Norenberg, JP, 322(ab), 415(ab)
Nørgaard, MA, 290
Normolle, DN, 77(ab)
Nosotti, M, 1085(ab)
Novak-Hofer, I, 326(ab)
Novikov, I, 749(ab)
Noz, ME, 1281(ab)
Nozaki, S, 239
Nozaki, Y, 14(ab)
Nukata, M, 1190(ab)
Numminen, P, 1330(ab)
Núñez, RF, 912(ab), 1039(ab), 1044(ab)
Nuss, R, 44(ab)
Nüssle, K, 1623
Nüsslin, F, 460(ab)
Nutt, R, 306(ab), 597(ab)
Nuutila, P, 862
Nuvoli, S, 1105(ab)
Nuyts, J, 19(ab), 822(ab), 899(ab)
Oates, E, 913(ab)
Oberdorfer, F, 1016(ab), 1032(ab)
Obradovich, JE, 101(ab)
O'Brien, TJ, 677, 1098
Ochi, H, 858(ab), 1492, 1652
O'Connell, JW, 1249(ab)
O'Connor, MK, 677, 1098, 1259(ab)
Oda, K, 317
Odaka, K, 34 (ab), 35(ab), 183(ab)
Odano, I, 1737
O'Doherty, MJ, 425(ab), 1135(ab)
O'Donnell, JK, 1138(ab)
O'Donnell, RT, 159(ab), 963(ab), 965(ab), 969(ab), 980(ab), 1381(ab), 2014, 2102
O'Donoghue, JA, 156(ab), 970(ab), 1337, 1764
Oehme, L, 268(ab)
Oehr, P, 78(ab)
Oellerich, WE, 4(ab)
Oellinger, J, 387
Oestmann, J, 48(ab)
Ofluoglu, S, 395(ab), 1081(ab)
Ogasawara, T, 1132
Ogawa, M, 1583
Ogawa, Y, 1101(ab)
Ogino, M, 471
Oguchi, M, 86(ab), 1095(ab)
Ogura, Y, 846(ab)
Oh, CS, 1366(ab)
Oh, JH, 852(ab)
Oh, SH, 452(ab)
Oh, SJ, 10(ab), 166(ab), 1359(ab)
Ohana, G, 376
Ohara, T, 781(ab)
Ohira, H, 567(ab), 1022(ab)
Ohkawa, M, 198(ab), 875(ab)
Ohkubo, M, 1737
Ohkubo, S, 812(ab)
Ohmori, Y, 1590
Ohno, M, 330(ab)
Ohshima, H, 14(ab)
Ohta, Y, 770(ab)
Ohtake, H, 878(ab)
Ohtake, T, 418, 793, 862(ab), 867(ab), 939(ab), 1116, 1284(ab)
Ohtomo, K, 793, 862(ab), 867(ab), 939(ab), 1116, 1284(ab)
Ohtsuki, K, 184, 814(ab), 2007
Ohyama, N, 243(ab)
Ohyanagi, M, 780(ab)
Oka, H, 801(ab)
Okada, H, 1088(ab), 1282(ab)
Okada, K, 243(ab), 1137(ab)
Okada, N, 64
Okada, RD, 813(ab), 815(ab)
Okada, T, 7(ab)
Okada, Y, 713(ab)
Okamoto, MY, 870(ab)
Okamoto, S, 12(ab)
Okauchi, T, 1342(ab), 1351(ab)
Okawa, T, 744(ab), 818(ab)
Okay, Y, 916(ab)
Okazaki, A, 705(ab), 808(ab)
Okazawa, H, 577(ab)
Okeefe, JH, 1291(ab)
O'Keefe, JH, 724(ab)
Okpaku, AS, 274(ab), 453(ab)
Oksman, Y, 63(ab)
Oku, N, 1175(ab), 1190(ab), 1302(ab)
Oku, S, 1284(ab)
Okuda, K, 471
Okumura, Y, 1971
Okuyama, T, 569(ab)
Olatidoye, AG, 702(ab)
Old, LJ, 970(ab)
Old, SE, 1093(ab)
Oliner, CM, 1457(ab)
Oliva, JP, 768
Oliver, J, 971(ab)
Ollinger, JM, 1236(ab)
Olschewski, M, 220(ab)
Olson, J, 331
Olsson, H, 436(ab)
Omata, M, 1116
Omata, N, 1174(ab)
Omiecinski, E, 1290(ab)
Omote, H, 207(ab), 527(ab)
Onder, M, 39(ab)
Onfroy, M-C, 25
Ong, GL, 1392
Ongseng, F, 1144(ab)
Onishi, T, 1192(ab)
Ono, S, 244, 1057(ab)
Ono, Y, 198(ab), 312(ab)
Onoguchi, M, 705(ab)
Önsel, Ç, 429
Oomichi, M, 802(ab), 885(ab)
Oosterwijk, E, 829
Opitz, M, 48(ab)
Oppermann, HC, 47(ab)
Oquendo, M, 1210(ab), 1211(ab)
Ordonez, C, 1290(ab)
Oriuchi, N, 399, 878(ab), 1005(ab), 1018(ab)
Orringer, MB, 1089(ab)
Osada, H, 802(ab), 877(ab), 885(ab), 1188(ab)

Osaki, S, 825(ab)
Osende, JI, 355(ab)
Oshima, S, 217
Osorio, L, 981(ab)
Oster, ZH, 825(ab)
Ota, K, 942(ab)
Ota, T, 747(ab)
Otsubo, H, 1183(ab)
Otsuki, K, 514(ab)
Ott, K, 550(ab)
Ott, RJ, 1224(ab), 1232(ab)
Ottaviani, M, 1374
Otto, AC, 1532
Otto, HJ, 754(ab)
Ouchi, N, 1022(ab)
Ouchi, Y, 1088(ab), 1282(ab)
Ouellet, R, 832(ab), 1728
Owen, AN, 1457(ab)
Owens, R, 1329(ab)
Oya, S, 1345(ab)
Oyama, N, 1137(ab)
Oyen, WJ, 58(ab), 192, 432(ab), 892(ab), 1028(ab), 2066
Oz, OK, 896(ab)
Ozaki, T, 289(ab)
Ozalp, E, 524(ab), 919(ab), 1046(ab)
Ozawa, S, 13(ab), 745(ab)
Ozker, KS, 1369(ab)
Paans, AM, 300(ab), 755(ab)
Pace, WM, 559(ab)
Pacini, F, 1716
Padhy, AK, 904(ab)
Paganelli, G, 72(ab), 235(ab), 266(ab), 1125(ab)
Pagini, E, 459(ab)
Pahl, MM, 916(ab)
Pai, MS, 756(ab), 1055(ab), 1094(ab)
Paik, CH, 268, 327(ab), 837, 1006(ab), 1027(ab), 1381
Paik, DS, 327(ab), 837
Pak, I, 524(ab), 919(ab)
Pak, KY, 815(ab), 838(ab), 1832
Palestro, CJ, 43(ab), 57(ab), 201(ab), 478(ab), 930(ab), 961(ab), 1404(ab)
Pallela, V, 485(ab), 1080(ab)
Pallela, VR, 352, 491(ab), 1398(ab)
Palmas, W, 181(ab)
Palmedo, H, 974(ab), 988(ab)
Palmer, AW, 85
Palmer, J, 96, 224(ab)
Palombo-Kinne, E, 537(ab)
Pan, D, 332(ab)
Pan, S, 427(ab)
Pan, T-S, 456
Pan, X, 1334(ab)
Panet, R, 1037(ab)
Panin, VY, 1296(ab)
Pansini, F, 538(ab)
Pantelic, MV, 1140(ab)
Panyutin, IG, 1009(ab), 1405(ab)
Papatheofanis, FJ, 750(ab), 1121(ab), 1256(ab), 1420
Papay, FA, 236(ab)
Papazian, V, 144(ab)
Pappas, N, 439(ab), 1215(ab)
Pappas, NR, 145(ab), 442(ab), 443(ab), 588(ab), 715, 1176(ab), 1217(ab), 1218(ab), 1285
Papperl, G, 1048(ab)
Paracchi, A, 1928
Parbhoo, SP, 68(ab), 1038(ab)
Pare, C, 1305(ab)
Parellada, E, 123(ab)
Parent, F, 173(ab)
Park, CH, 756(ab), 1055(ab), 1094(ab)
Park, CM, 549(ab)
Park, JM, 49(ab), 380(ab), 751(ab), 851(ab), 884(ab), 1102(ab)
Park, JY, 1086(ab)
Park, KM, 214(ab)
Park, KO, 549(ab)
Park, KS, 452(ab), 476(ab), 505(ab), 1171(ab), 1198(ab), 1214(ab), 1221(ab)
Park, KY, 10(ab)
Park, MH, 586(ab)
Park, SJ, 166(ab), 1359(ab)
Park, SW, 166(ab), 1359(ab)
Park, SY, 1128(ab)
Park, YH, 376(ab)
Park, YS, 205(ab)
Parker, A, 574
Parker, JA, 483(ab), 714(ab)
Parker, MA, 509(ab)
Parkhouse, HF, 643
Parkman, HP, 366(ab), 854(ab)
Parma, D, 357(ab)
Parmeshwar, P, 1191(ab)
Parry-Jones, DR, 249(ab), 1093(ab)
Parsey, RV, 114(ab), 117(ab), 1162(ab), 1210(ab)
Pasqualini, R, 883
Pasque, MK, 4(ab)
Pasquier, F, 956
Passchier, J, 116(ab), 1167(ab)
Passeri, A, 1310(ab)
Pastan, I, 1381
Patel, M, 625, 2107
Patel, S, 1392
Patel, SJ, 971(ab), 1454(ab)
Patselas, G, 660
Patt, BE, 599(ab)
Patterson, J, 747
Patton, DD, 18N(4), 24N(7), 25N(11)
Patton, JA, 110, 432, 1295(ab)
Pattyn, P, 783
Paul, AK, 805(ab), 1693
Pauli, S, 1157(ab)
Pauls, S, 422(ab)
Paulus, W, 1064(ab)
Paulusma-Annema, A, 2073
Pauwels, E, 180(ab)
Pauwels, EKJ, 740(ab), 2073
Pauwels, S, 253(ab), 1013(ab), 1109(ab)
Pavel, DG, 1268(ab)
Pavia, J, 123(ab)
Pavlinkova, G, 1536
Pavlinovic, Z, 531(ab), 937(ab)
Pay, L, 768(ab)
Payne, JK, 449(ab)
Paz, A, 376
Pearson, DA, 321(ab), 417(ab), 887(ab), 950(ab)
Pecking, AP, 546(ab)
Pedarsani, M, 1164
Peeters, M, 1451
Pegoix, M, 901(ab), 905(ab)
Peker, C, 893(ab)
Peker, MC, 369(ab), 1602
Pelegrinelli, LR, 848(ab)
Pelikan, H, 180(ab)
Pelizzari, CA, 347
Pellegri, M, 196(ab)
Peller, M, 290(ab)
Peller, PJ, 1126(ab), 1233
Pellot-Barakat, CJ, 1264(ab)
Peng, NJ, 60, 367(ab), 1050(ab)
Pennell, DJ, 343(ab), 344(ab)
Penney, BC, 456, 1334(ab)
Pentlow, KS, 328(ab), 1238(ab)
Penuelas, I, 845(ab), 1096(ab), 1145(ab), 1401(ab)
Pereira, PL, 956(ab)
Perek, B, 19(ab)
Perentesis, P, 268
Perera, A, 768
Peressini, A, 1123(ab)
Pérez, R, 768
Pérez, V, 1212(ab)
Perkins, AC, 365(ab), 399(ab)
Perlman, SB, 1180(ab)
Permanetter, B, 188(ab)
Perrine, K, 1184(ab)
Perrot, JL, 80(ab)
Peschl, S, 340(ab), 591(ab), 1308(ab)
Peter, J, 1260(ab)
Peterdy, AE, 422
Peters, GN, 237(ab)
Peterson, LM, 614, 1074(ab)
Pethig, K, 719(ab)
Petit-Taboué, M-C, 25
Petretta, M, 194(ab), 1683
Petric, A, 284(ab)
Petrov, A, 838(ab)
Pettersson, G, 290
Pettigrew, RI, 650, 753(ab)
Pezzoli, G, 271(ab)
Pham, HL, 1080(ab), 1363(ab)
Phelps, ME, 20(ab), 184(ab), 186(ab), 189(ab), 225(ab), 226(ab), 227(ab), 281(ab), 283(ab), 284(ab), 285(ab), 295(ab), 323(ab), 332(ab), 408(ab), 826(ab), 1045, 1083(ab), 1468(ab), 1164
Philip, PA, 1079(ab)
Phillips, KE, 329(ab)
Phillips, PC, 520(ab)
Pi, B, 1225(ab)
Picardi, V, 556(ab)
Piccolo, S, 66(ab), 1142(ab)
Pichler, BJ, 1234(ab)
Pidcock, J, 1162(ab), 1242(ab)
Piel, M, 1222(ab)
Piepsz, A, 52, 210(ab), 972
Pierantoni, M, 1716
Piers, DA, 70(ab), 393(ab), 398(ab), 1119(ab), 1146(ab)
Pieterman, RM, 116(ab), 351(ab), 561(ab)
Piffanelli, A, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
Pikul, R, 1182(ab)
Pillai, M, 1015(ab), 1402(ab)
Pimentel, G, 768
Pinchera, A, 1716
Pinheiro, VR, 958(ab)
Pinkert, J, 268(ab)
Pinot, L, 602(ab)
Pinson, CW, 1784
Pio, BS, 1083(ab)
Pippin, CG, 166
Pirich, C, 1277, 1499
Pitts, J, 455(ab)
Piwnica-Worms, DR, 316(ab), 1024(ab)
Pizzocaro, C, 375(ab)
Plaat, BE, 381, 398(ab), 1146(ab)
Plaizier, MA, 966(ab)
Plascjak, PS, 329(ab), 472(ab)
Plössl, K, 108(ab), 150, 152(ab), 583(ab), 660, 1200(ab), 1345(ab), 1812
Plotkin, M, 1041(ab)
Plouin, P, 786
Pocock, N, 250(ab), 544(ab), 1153(ab)
Podda, M, 1085(ab)
Podoloff, DA, 160(ab), 404(ab), 955(ab), 1206(ab), 1366(ab), 1367(ab), 1467(ab)
Pointon, BW, 1461(ab)
Pointurier, I, 173(ab), 743(ab)
Poirier, C, 821(ab)
Polak, E, 311(ab)
Polastri, L, 1053(ab)
Poldermans, D, 1(ab), 1866
Poldermanss, D, 731(ab)
Polettini, E, 843(ab)
Pollak, A, 331(ab), 497(ab), 499(ab), 504(ab), 614(ab), 1346(ab)
Pollock, CM, 497(ab), 499(ab)
Polyakov, VR, 316(ab)
Ponath, C, 988(ab)
Pongratz, D, 853(ab)
Pons-Llado, G, 3(ab)
Ponto, JA, 613(ab)
Ponto, R, 287(ab)
Pontvianne, V, 513
Popa, N, 1333(ab), 1978
Popilskis, S, 117(ab)
Popov, V, 468(ab), 600(ab)
Porenta, G, 362(ab)
Porrino, L, 1346(ab)
Potaux, L, 412
Potier, JC, 8(ab), 175(ab)
Potter, R, 883(ab)
Potts, N, 836(ab)
Potts, NV, 824(ab), 842(ab)
Pötzi, C, 1049(ab)
Pouillart, F, 224, 917
Pounds, TR, 255(ab)
Pourdehnad, M, 387(ab), 453(ab), 888(ab)
Powsner, RA, 1453(ab)
Prakesh, K, 279(ab)
Prat, T, 734(ab)
Prato, FS, 1306(ab)
Prats, E, 296
Pratt, JP, 200(ab), 296(ab), 314(ab), 797(ab), 1165(ab)
Predic, P, 1067(ab)
Press, O, 75(ab)
Pressler, H, 871(ab)
Pretorius, PH, 456(ab), 590(ab)
Prevost, R, 192
Price, DC, 935(ab), 1248(ab)
Price, JC, 1798, 2053
Price, MR, 399(ab)
Prieto, J, 845(ab), 1401(ab)
Prigent, A, 743(ab)
Prillwitz, A, 528(ab)
Prince, S, 1245(ab)
Printz, D, 121(ab)
Provost, N, 1124(ab)
Pruckmayer, M, 1477
Prueter, I, 944(ab)
Pruim, J, 116(ab), 262, 561(ab), 1132(ab)
Prunier-Levillon, C, 1393(ab)
Pruzzo, R, 59(ab)
Pryor, M, 983(ab)
Pugliese, PV, 478(ab)
Puig, M, 5(ab)
Puigdemont, D, 1212(ab)
Pullman, J, 484
Pupi, A, 196(ab), 573(ab)
Pyatt, B, 406(ab)
Pyatt, BE, 438(ab)
Pyzalski, RW, 1180(ab)
Qaim, SM, 501(ab)
Qi, J, 129(ab), 130(ab), 2043
Qiao, J, 1386(ab)
Qu, T, 900(ab), 1397(ab)
Quach, T, 250(ab), 544(ab), 1153(ab)
Quaife, RA, 169(ab), 177(ab)
Quak, JJ, 263(ab)
Quarantelli, M, 442
Que, TH, 561(ab), 1132(ab)
Quereshi, E, 171(ab), 176(ab), 181(ab)
Quesada, R, 347(ab)
Quinn, TP, 484(ab)
Quint, LE, 1089(ab)
Quintana, JC, 394(ab), 1268(ab), 1276(ab)
Quirijnen, JM, 639
R, 6(ab), 970(ab)
Raab, D, 925(ab)
Rabitti, C, 926(ab)
Rabøl, A, 290
Radau, P, 570(ab)
Radau, PE, 110(ab)
Radauer, M, 1277
Raderer, M, 395(ab), 1081(ab), 1082(ab)
Raedler, TJ, 1348(ab)
Rafecas, M, 1234(ab)
Raffel, DM, 232, 323
Raffelt, K, 973(ab)
Rafique, I, 215(ab)
Rai, A, 548(ab)
Raja, S, 279(ab)
Rajeevan, N, 124(ab), 143(ab), 1902
Rajotte, D, 883
Rakowski, H, 776(ab)
Ramirez, C, 427(ab)

Ramos, CD, 746(ab), 848(ab), 958(ab), 1148(ab)
Ramos, D, 911(ab)
Ramos-Suzarte, M, 768
Ransley, PG, 643
Ranzi, T, 1630
Rao, DV, 978(ab)
Rao, PS, 485(ab), 491(ab), 1398(ab)
Raphael, M, 40, 960(ab)
Rappoport, V, 1244(ab)
Rasey, JS, 100(ab), 1072
Raspe, J, 398(ab), 1146(ab)
Rattan, S, 352
Rau, F, 85(ab)
Raubitschek, A, 260(ab), 268
Raubitschek, AA, 323(ab), 325(ab), 1151
Rauch, SL, 579(ab)
Raue, F, 1029
Rauth, AM, 331(ab), 1019(ab)
Raval, U, 464
Ravert, HT, 115(ab), 373(ab), 446(ab), 447(ab), 1014(ab), 1180, 1164(ab), 1207(ab)
Raviv, U, 860(ab)
Ravizzini, G, 26(ab)
Raylman, RR, 468(ab), 600(ab)
Razola, P, 296
Reader, AJ, 1224(ab), 1232(ab)
Recker, BE, 1089(ab), 1125
Redvanly, RD, 92(ab)
Reed, JH, 306(ab)
Reed, MW, 1405(ab)
Regan, D, 990(ab)
Regan, DD, 77(ab), 989(ab)
Reichart, B, 30(ab)
Reidl, G, 397(ab)
Reilly, RM, 1370(ab)
Reiman, E, 717(ab), 1304(ab)
Reimold, M, 460(ab), 1289(ab)
Reinauer, H, 977
Reinhard, P, 389(ab)
Reinhardt, M, 247(ab), 977
Reinhardt, MJ, 340(ab), 423(ab)
Reischl, G, 933(ab)
Reising, A, 981(ab)
Reist, CJ, 631
Remacle, M, 253(ab)
Rempel, TD, 1245(ab)
Reneman, L, 113(ab), 1216(ab)
Renlund, M, 12
Rentschler, M, 1623
Reschini, E, 271(ab), 1928
Reske, SN, 82(ab), 93(ab), 247(ab), 250, 262(ab), 341(ab), 368(ab), 422(ab), 571(ab), 945(ab), 1272(ab), 1388(ab), 1407, 1623, 1637
Reubi, J-C, 2081
Reuning, U, 1061
Reutter, BW, 457(ab)
Revel, D, 821(ab)
Reyes, J, 850(ab)
Reynolds, C, 1117(ab)
Reynolds, JC, 268, 539
Rhee, CH, 1066(ab)
Rhodes, BA, 2107
Rhodes, CG, 507, 834(ab)
Ribic, CM, 497(ab)
Ricard, M, 157(ab), 602(ab), 1517
Ricaurte, GA, 115(ab)
Riccabona, G, 74(ab)
Rice, KC, 1348(ab)
Richman, CM, 969(ab)
Richter, E, 540(ab), 605(ab), 730(ab), 921(ab), 944(ab)
Richter, JA, 424(ab), 555(ab), 845(ab), 1096(ab), 1145(ab), 1401(ab)
Richter, T, 85(ab)
Richter, WS, 195(ab), 795(ab), 840(ab)
Ricke, J, 387
Rickert, C, 1064(ab)
Rickford, MS, 329(ab)
Riddell, CA, 1297(ab)
Riemann, B, 1017(ab), 1064(ab)
Ries, V, 571(ab)
Riggert, J, 992(ab)
Righini, A, 271(ab)
Rigo, P, 359(ab)
Rijks, LJ, 1107(ab)
Rijk-van Andel, JF, 272(ab)
Rimoldi, O, 1848
Ringelstein, EB, 1017(ab)
Rini, J, 1044(ab)
Rini, JN, 912(ab)
Rinne, NA, 36(ab)
Ripke, B, 268(ab)
Risdon, RA, 643
Risse, J, 974(ab), 988(ab)
Ritter, EP, 752(ab)
Roach, PJ, 924(ab)
Roarke, MC, 525(ab)
Robb, RA, 677, 1098
Robbins, RJ, 1042(ab), 1044(ab)
Roberts, AD, 437(ab), 503(ab)
Roberts, DW, 278(ab)
Robertson, A, 144(ab)
Robidoux, A, 1124(ab)
Robillard, P, 2029
Robins, PD, 1259(ab)
Robinson, BG, 924(ab)
Rocchisani, J, 1305(ab)
Rockey, DC, 502(ab)
Roddy, R, 597(ab)
Rodenhiser, J, 121(ab), 1210(ab)
Rodrigue, S, 832(ab), 876
Rodrigues, CJ, 870(ab)
Rodriguez, G, 522
Rodríguez, N, 768
Rodríguez, T, 768
Roe, DG, 497(ab), 499(ab), 1346(ab)
Roelants, V, 219(ab), 766(ab), 792(ab)
Rogers, JS, 548(ab)
Rogers, WL, 133(ab)
Rohmer, V, 1252
Rojas, A, 59(ab)
Rojter, S, 427(ab)
Roland, PS, 449(ab)
Romano, JE, 492(ab)
Rombaut, E, 766(ab), 792(ab)
Römer, W, 247(ab), 737
Rommelfanger, SG, 76(ab), 77(ab), 989(ab), 991(ab)
Roos, A, 180(ab)
Roos, JC, 263(ab), 966(ab)
Rosa, P, 577(ab)
Rosai, J, 1042(ab)
Rösch, F, 1222(ab)
Rose, DM, 1784
Rose, GE, 455(ab)
Rose, P, 232
Rosen, G, 84(ab)
Rosen, SD, 507
Rosenthal, DI, 1054(ab)
Ross, SG, 459(ab)
Rossettin, PF, 1832
Rossini, PL, 172(ab), 178(ab), 375(ab)
Rossleigh, MA, 54(ab), 55(ab), 1805
Rossman, MD, 888(ab)
Rosso, J, 223(ab)
Rosso, L, 1085(ab)
Rotenberg, G, 63(ab)
Roth, D, 377(ab)
Rothman, RB, 441(ab)
Rotman, M, 268
Roussakis, G, 343(ab), 344(ab)
Rousseau, JA, 1728
Rousseaux, M, 721
Rouvier, E, 1002(ab)
Rovai, D, 363
Roveri, R, 1168(ab), 1556
Roy, L, 16N(4)
Royal, HD, 1236
Royen, EA, 111(ab)
Rozanski, A, 171(ab), 176(ab), 181(ab), 507(ab), 715(ab), 716(ab), 924
Ruan, S, 156(ab)
Rubenstein, W, 850(ab)
Rubinov, R, 265(ab)
Rubins, DJ, 1156(ab)
Rückert, RI, 795(ab)
Ruddy, TD, 732(ab)
Rudolph, F, 528(ab), 558(ab)
Ruechel, R, 907(ab)
Ruhlmann, J, 78(ab)
Ruiz, M, 142, 821
Runge, R, 1385(ab)
Ruotsalainen, U, 12, 862, 1330(ab)
Rupcic, V, 739(ab)
Rusckowski, M, 484, 900(ab), 1397(ab)
Rushman, RW, 536(ab)
Rusic, AM, 739(ab)
Russell, CD, 1122
Russo, JE, 1089(ab)
Rutecki, P, 1180(ab)
Rutgeerts, P, 1451
Rutgers, E, 70(ab)
Rutgers, EJ, 1119(ab)
Rüth, F, 1702
Ruth, TJ, 283
Rutkowski, JV, 321(ab), 417(ab), 887(ab), 950(ab), 954(ab)
Rypins, EB, 62(ab)
Ryu, JS, 214(ab), 534(ab), 547(ab), 568(ab), 1090(ab)
Sabahi, R, 856(ab)
Saboorian, H, 237(ab)
Sabri, O, 450(ab)
Sadato, N, 91(ab), 243(ab), 317, 1000(ab), 1034(ab), 1085, 1132, 1137(ab), 1174(ab), 1332(ab), 1441
Sadek, A, 520(ab)
Sadek, S, 84(ab)
Sadler, LL, 1268(ab)
Saeed, S, 1080(ab), 1363(ab)
Saffer, J, 108(ab), 1812
Saffer, JR, 660
Safi, N, 1092(ab), 1127(ab)
Saga, T, 191(ab), 512(ab), 685, 1003(ab), 1463
Saha, GB, 279(ab)
Sahin, M, 864(ab)
Saidi, L, 173(ab), 411(ab), 743(ab)
Saï-Maurel, C, 198
Saito, K, 12(ab), 569(ab)
Saito, M, 493(ab)
Saito, Y, 895
Saitta, B, 1053(ab)
Saji, H, 493(ab), 1371(ab), 1406(ab)
Sakahara, H, 479, 685, 1003(ab), 1097(ab), 1371(ab), 1424, 1463
Sakai, E, 426(ab), 1072(ab)
Sakaki, T, 780(ab)
Sakanoue, Y, 1492
Sakata, K, 6
Sako, K, 1173(ab)
Sakomura, Y, 744(ab)
Sakurai, M, 14(ab)
Salako, Q, 302
Salamon, E, 882(ab)
Salditt, S, 1036(ab)
Salegh-Mghir, A, 893(ab)
Salem, S, 84(ab), 889(ab)
Salensky, H, 716(ab)
Salgam, M, 319(ab)
Salgueiro, MJ, 1080
Salib, A, 428(ab)
Salisbury, SM, 613(ab)
Saller, B, 923(ab)
Saloum, A, 518(ab)
Salvatore, M, 194(ab), 442
Salzer-Muhar, U, 1477
Samii, A, 283
Sampalis, FS, 1103(ab)
Sampalis, JS, 1103(ab)
Samson, Y, 935
Samuel, G, 1015(ab)
San Pedro, EC, 1181(ab)
Sanacora, G, 576(ab)
Sanchez, JE, 799
Sanchez, P, 768(ab)
Sandberg, K, 373(ab)
Sandell, J, 151(ab), 1343(ab)
Sandhu, J, 1370(ab)
Sandler, MP, 9N(1), 110, 1295(ab)
Sando, Y, 878(ab)
Sandrock, D, 795(ab), 920(ab), 936(ab), 948(ab)
Sanger, JJ, 62(ab)
Sansana, CR, 746(ab), 848(ab)
Santambrogio, L, 1085(ab)
Santana, CA, 315(ab), 508(ab), 511(ab), 787(ab), 1290(ab)
Santens, P, 269(ab)
Santiago, J, 84(ab)
Santiago, JF, 889(ab)
Santjohanser, C, 82(ab)
Santoro, GM, 196(ab), 363
Santos, AO, 746(ab), 848(ab), 958(ab)
Saperstein, LA, 228(ab)
Sapienza, MT, 916(ab)
Saran, PA, 1089(ab), 1099(ab)
Sarda, L, 701(ab), 794(ab), 809(ab), 893(ab), 903(ab)
Sarkar, MR, 1637
Sarkar, SD, 43(ab), 930(ab), 961(ab)
Sarkis, M, 517(ab)
Sarma, HD, 1015(ab), 1402(ab)
Sartor, J, 974(ab)
Sasaki, H, 70
Sasaki, M, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
Sasaki, N, 858(ab), 1652
Sasaki, T, 1056
Sasaki, Y, 418, 1005(ab), 1116
Sasayama, S, 7(ab), 471
Sassaman, MB, 150(ab)
Sassolas, G, 369(ab)
Sasson, Y, 1213(ab)
Sato, J, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
Sato, K, 244, 317
Sato, M, 244
Sato, N, 479, 685, 1003(ab), 1463
Sato, S, 1971
Sato, T, 137
Satoh, A, 371
Satoh, H, 371
Satomi, S, 1022(ab)
Sattler, B, 570(ab)
Satyamurthy, N, 102(ab), 142(ab), 332(ab), 585(ab), 587(ab)
Satyamurthy, NM, 284(ab)
Sau, J, 1676
Saunders, C, 560(ab), 1116(ab)
Sauret, V, 2094
Sautter-Bihl, ML, 248(ab), 1059(ab)
Savi, A, 1617
Sawula, JA, 46(ab)
Saxena, P, 1268(ab)
Saxena, S, 283(ab)
Sayman, HB, 429
Sbrenna, S, 1168(ab), 1556
Scardigno, R, 1329(ab)
Schaar, M, 320(ab), 414(ab)
Schäfer, J, 1272(ab)
Schäfer, W, 830(ab)
Schäfers, K, 1, 185(ab), 834(ab)
Schäfers, M, 1
Schäfers, MA, 185(ab), 834(ab)
Schaffland, A, 1913
Schaffrinski, M, 907(ab)
Schaub, J, 47(ab)
Scheff, AM, 1117(ab), 1143
Scheffel, U, 115(ab), 318(ab), 1180
Scheidhauer, K, 403(ab)
Scheinberg, DA, 163(ab), 166, 431(ab), 1722, 1935
Scheithauer, S, 1384(ab)
Schelbert, HR, 20(ab), 32(ab), 184(ab), 186(ab), 189(ab), 295(ab), 826(ab), 1045
Scherbaum, N, 1217(ab)
Scherer, J, 126(ab)
Scherrer-Crosbie, M, 193(ab)
Scheurs, MW, 1028(ab)

Schibli, R, 1913
Schicha, H, 202(ab), 403(ab), 791(ab), 830(ab), 932(ab), 973(ab), 1036(ab), 1372(ab)
Schiepers, C, 225(ab), 226(ab), 408(ab)
Schillaci, O, 556(ab), 843(ab)
Schima, W, 1082(ab)
Schirmacher, A, 1017(ab)
Schirrmeister, H, 82(ab), 93(ab), 571(ab), 945(ab), 1623
Schlemmer, M, 1477
Schlosser, R, 125(ab)
Schloter, B, 1041(ab)
Schmaljohann, J, 1049(ab), 1347(ab)
Schmand, M, 306(ab)
Schmickler, H, 1372(ab)
Schmidt, G, 904
Schmidt, M, 320(ab), 2081
Schmidt, MA, 993(ab), 996(ab), 997(ab)
Schmidt, PG, 357(ab), 402(ab)
Schneider, CA, 791(ab)
Schneider, CM, 774(ab)
Schneider, D, 121(ab), 122(ab)
Schneider, JS, 1200(ab)
Schneider, K, 254(ab)
Schneider, ML, 437(ab)
Schneider, P, 590(ab)
Schneider, PW, 287(ab)
Schneier, F, 581(ab)
Schober, O, 1, 185(ab), 388(ab), 392(ab), 834(ab), 1017(ab), 1064(ab)
Schöder, H, 32(ab), 186(ab), 189(ab)
Schoenberger, JA, 1154(ab)
Schoeneich, G, 974(ab)
Schomaecker, K, 403(ab), 1036(ab), 1372(ab)
Schomaeker, K, 830(ab)
Schömig, A, 24(ab), 34(ab)
Schottler, T, 372(ab)
Schoutens, A, 1978
Schoutens, AC, 1333(ab)
Schramm, M, 282(ab)
Schreck, CE, 458(ab)
Schreckenberger, M, 450(ab)
Schretlen, D, 441(ab)
Schricke, U, 24(ab)
Schrobilgen, GJ, 604(ab)
Schroeder, E, 766(ab)
Schryvers, F, 766(ab), 792(ab)
Schubiger, PA, 326(ab), 399(ab), 1913
Schueller, MJ, 437(ab), 503(ab)
Schuemichen, C, 528(ab), 558(ab)
Schuetz, C, 448(ab)
Schuhmacher, C, 433(ab)
Schul, C, 1064(ab)
Schulte, M, 1637
Schulzer, M, 283
Schurrer, ME, 1434
Schwaiger, M, 18(ab), 24(ab), 30(ab), 33(ab), 34(ab), 35(ab), 85(ab), 104(ab), 183(ab), 188(ab), 205, 247(ab), 291(ab), 397(ab), 433(ab), 448(ab), 451(ab), 550(ab), 593(ab), 828(ab), 904, 1061, 1234(ab), 1311(ab), 1367, 1499, 1771, 1824
Schwameis, E, 1277
Schwartz, A, 63(ab)
Schwarz, J, 571(ab)
Schwarz, M, 422(ab)
Schwarz, UP, 329(ab)
Schweizer, HP, 871(ab)
Schwenzer, K, 1048(ab)
Sciacca, R, 29(ab), 720(ab), 911(ab)
Sciagrá, R, 196(ab), 363, 573(ab)
Sciot, RM, 898(ab)
Sciuk, J, 388(ab), 392(ab)
Sciuto, R, 46
Scopinaro, F, 556(ab), 843(ab)
Scopinaro, G, 926(ab)
Scott, AM, 328(ab)
Seabold, JE, 613(ab), 1226, 1434
Seaton, D, 758(ab)
Sébahoun, S, 910(ab)
Sedagathian, MR, 861(ab)
Sedelnikova, OA, 1009(ab)
Sedvall, G, 120(ab), 1157(ab)
Seemann, A, 374(ab)
Segall, GM, 252(ab), 255(ab), 545(ab), 1358
Seibyl, J, 480(ab), 730
Seibyl, JP, 124(ab), 143(ab), 107(ab), 270(ab), 275(ab), 444(ab), 576(ab), 580(ab), 1199(ab), 1228(ab), 1270(ab), 1362(ab), 1902
Seidel, J, 1321(ab)
Seidenberg, M, 1180(ab)
Seifert, B, 79(ab)
Seike, Y, 1175(ab), 1190(ab), 1302(ab)
Seitz, U, 262(ab), 1388(ab)
Seki, H, 86(ab), 1095(ab)
Seki, M, 137
Sekimoto, T, 1590
Seldin, DW, 590(ab)
Seltzer, M, 226(ab)
Seltzer, MA, 130(ab), 225(ab), 408(ab), 2043
Selzer, E, 985(ab), 1376(ab)
Semah, F, 903(ab), 935
Semprebene, A, 46
Sen Gupta, S, 897(ab), 952(ab)
Senda, K, 847(ab)
Senda, M, 317, 808(ab), 1056, 1269(ab)
Senekowitsch-Schmidtke, R, 85(ab), 205, 433(ab), 1061, 1367, 1702
Sengupta, S, 282(ab)
Senior, R, 464
Senitko, M, 258(ab)
Senma, J, 191(ab)
Seo, IS, 844(ab)
Seo, JD, 736(ab)
Seo, JG, 1141(ab)
Seregni, E, 1114(ab)
Seret, A, 1978
Seret, AE, 1333(ab)
Serita, T, 371
Serra-Grima, R, 734(ab), 786(ab)
Serrano, J, 539
Sestini, S, 196(ab), 363, 573(ab)
Seto, H, 1138
Seto, M, 371
Severiche, FA, 958(ab)
Sevigny, SA, 406
Seymour, KM, 1400(ab)
Sfakianakis, G, 574
Sfakianakis, GN, 204(ab), 206(ab), 208(ab), 377(ab), 768(ab), 799
Sgouros, G, 105(ab), 158(ab), 159(ab), 162(ab), 163(ab), 164(ab), 1380(ab), 1935, 2102
Shaban, N, 956(ab)
Shah, KS, 304(ab)
Shahinian, A, 103(ab)
Shahzad, K, 215(ab), 716(ab)
Shai, E, 1295(ab)
Shaker, R, 279(ab)
Shalaby-Rana, EI, 523(ab)
Shankar, LK, 199(ab), 526(ab)
Shanley, TJ, 69(ab)
Shao, L, 481(ab)
Shao, Y, 303(ab), 304(ab), 599(ab), 1164
Shapiro, B, 554, 1292(ab), 1457(ab)
Sharir, T, 6(ab), 25(ab), 28(ab)
Sharkey, RM, 428(ab), 500(ab), 992(ab), 1002(ab), 1380(ab), 1609
Sharma, A, 924
Sharma, R, 287(ab)
Sharma, SD, 485(ab)
Sharp, PF, 552(ab)
Sharp, TL, 824(ab), 836(ab), 842(ab)
Shaw, L, 27(ab)
Shaw, LJ, 347(ab), 710(ab), 722(ab)
Shaw, LK, 26(ab)
Sheerin, A, 603(ab)
Sheerin, AA, 500(ab)
Sheikh, A, 970(ab), 1044(ab)
Sheikh, MA, 711(ab)
Shelton, DK, 1264(ab)
Shelton, SE, 437(ab), 1169(ab)
Shen, C, 592(ab), 1985
Shen, S, 159(ab), 302, 965(ab), 969(ab), 980(ab), 1317, 2014, 2102
Shepherd, J, 231(ab)
Shepherd, JE, 227(ab)
Sher, L, 427(ab)
Sherman, AL, 199(ab)
Shevlak, G, 1303(ab)
Shi, B, 1267(ab), 1338(ab)
Shi, R, 491(ab)
Shi, XB, 324(ab)
Shi, Y, 485(ab)
Shiba, E, 65(ab), 1003
Shiba, T, 1057(ab)
Shibasaki, T, 399
Shibuya, H, 64
Shields, AF, 101(ab), 245(ab), 335(ab), 614, 1079(ab)
Shiga, T, 527(ab), 963, 1204(ab), 1247(ab)
Shih, LB, 500(ab)
Shim, YM, 1076(ab)
Shim, YS, 1051(ab), 1151(ab)
Shimada, I, 770(ab)
Shimizu, H, 895
Shimizu, M, 1138
Shimizu, Y, 802(ab), 877(ab), 885(ab), 1188(ab)
Shimono, T, 1273(ab)
Shin, EK, 10(ab)
Shin, JW, 166(ab), 214(ab)
Shin, MJ, 534(ab)
Shin, SA, 819(ab)
Shin, SK, 166(ab)
Shinn, A, 114(ab)
Shinn, AK, 1242(ab)
Shinohara, H, 1318(ab), 1328(ab), 1337(ab)
Shinotsuka, T, 1131(ab)
Shinozaki, T, 390(ab)
Shio, H, 1992
Shiomi, S, 858(ab), 1652
Shiozaki, T, 1273(ab)
Shirakawa, S, 1335(ab)
Shirotani, M, 6
Shiue, C, 118(ab), 333(ab)
Shiue, CY, 401(ab)
Shiue, GG, 118(ab), 333(ab), 401(ab)
Shively, JE, 323(ab), 325(ab)
Shnier, D, 61(ab), 868(ab)
Shoghi-Jadid, K, 142(ab), 587(ab)
Shohtsu, A, 563(ab), 1078(ab), 1131(ab), 1155(ab)
Shoner, SC, 1237(ab)
Short, MD, 1116(ab)
Shouda, S, 2088
Shoup, TM, 331
Shreve, PD, 242(ab), 1139(ab)
Shuke, N, 211(ab), 212(ab), 216(ab), 569(ab), 747(ab), 855(ab), 1138, 1173(ab), 1644
Shukla, SK, 976(ab)
Shulkin, BL, 519(ab)
Shyr, Y, 1784
Siciliano, M, 1345(ab)
Siddiqui, F, 1281(ab)
Sideni, M, 235(ab)
Siebelink, HJ, 755(ab)
Siebner, HR, 290(ab)
Sieckman, GL, 419(ab)
Sieff, C, 1031(ab)
Siegel, AH, 278(ab)
Siegel, AM, 278(ab)
Siegel, BA, 525(ab)
Siegel, JA, 990(ab)
Siegel, MJ, 525(ab)
Siessmeier, T, 291(ab)
Siewert, JR, 550(ab)
Silberstein, EB, 264(ab)
Sillanpää, M, 12
Sillar, R, 64(ab)
Silva, AM, 1148(ab)
Silverman, D, 225(ab), 1468(ab)
Silverman, DH, 130(ab), 260(ab), 281(ab), 283(ab), 285(ab), 408(ab), 1083(ab), 2043
Silverman, RW, 304(ab), 1164, 1223(ab)
Simcic, V, 1245(ab)
Simkin, PH, 590(ab)
Simmons, J, 419(ab)
Simms, MS, 399(ab)
Simonneau, G, 173(ab)
Simons, GT, 1197(ab)
Simpson, N, 114(ab), 117(ab), 435(ab), 609(ab), 1162(ab), 1209(ab)
Simpson, SD, 419(ab), 499(ab)
Singer, FR, 203(ab)
Singh, B, 360(ab)
Singh, D, 1205(ab)
Siniscalchi, A, 1556
Sink, J, 339(ab)
Sinusas, AJ, 21(ab), 339(ab), 353(ab)
Sinzinger, H, 1277
Sisini, F, 167(ab)
Sisson, JC, 519(ab)
Sitbon, O, 173(ab)
Sitek, A, 128(ab), 816(ab), 829(ab)
Siu, S, 776(ab)
Sixl, M, 282(ab)
Skiest, D, 896(ab)
Skopek, J, 37(ab)
Slama, M, 173(ab), 743(ab)
Slates, RB, 131(ab), 303(ab)
Slegers, G, 1354(ab)
Slifstein, M, 114(ab), 141(ab), 435(ab), 474(ab), 1162(ab), 1211(ab), 1242(ab)
Slizofski, WJ, 856(ab)
Sloggett, C, 776(ab)
Slomka, PJ, 110(ab), 448, 1091
Sloof, G, 1107(ab)
Sloof, GW, 190(ab), 192(ab), 731(ab), 765(ab), 827(ab), 831(ab), 1204, 1866
Small, GW, 281(ab), 283(ab), 284(ab), 285(ab)
Smekhov, M, 1213(ab)
Smetana, S, 860(ab)
Smit, EF, 564(ab)
Smith, CJ, 419(ab)
Smith, EO, 1228(ab)
Smith, GT, 96(ab), 469(ab), 1283(ab)
Smith, IC, 552(ab)
Smith, KF, 844(ab)
Smith, MF, 138(ab), 472(ab)
Smith, RJ, 308(ab), 562(ab), 1054(ab), 1286(ab), 1239(ab), 1241, 1257
Smith, T, 464, 625, 2107
Smith, WJM, 26N(1), 16N(2), 26N(3), 24N(4), 23N(5)
Smith-Jones, P, 74(ab), 395(ab), 1082(ab)
Smith-Jones, PM, 1001(ab), 1008(ab)
Smolarz, K, 202(ab), 932(ab), 973(ab)
Snead, C, 1183(ab)
Snell, GI, 381(ab)
Snow, GB, 263(ab)
Snowdon, GM, 924(ab)
Snyder, LC, 1240(ab)
So, EL, 677
So, Y, 529(ab), 938(ab), 986, 1143(ab)
Soares, EJ, 1011
Soares, J, 1208(ab)
Soares, JP, 21(ab)
Sobnack, RK, 764(ab)
Sochor, H, 362(ab)
Socolsky, RC, 1104(ab)
Sodee, DB, 1138(ab)
Soeda, H, 1778
Soejima, Y, 770(ab)
Soekler, M, 946(ab), 956(ab), 957(ab)
Sohn, HS, 376(ab)
Sojkova, J, 278(ab)
Sokiranski, R, 422(ab)
Solal, M, 602(ab)
Solanki, KK, 60(ab), 904(ab)
Soler, C, 80(ab), 733(ab)
Solin, O, 12, 1163(ab)

Solinas, ME, 1105(ab)
Solinas, P, 1105(ab)
Sollitto, R, 574
Soloviev, D, 552(ab)
Som, P, 825(ab)
Soman, P, 345(ab)
Somani, Z, 771(ab)
Son, JW, 10(ab)
Son, M, 1350(ab)
Son, MS, 10(ab)
Sondak, V, 233(ab)
Song, HC, 286(ab), 549(ab), 1202(ab), 1378(ab)
Song, MH, 1083(ab)
Sönmezoğlu, K, 429
Sonnemann, U, 1150(ab)
Soong, TC, 1052(ab)
Sorensen, B, 250(ab), 544(ab)
Sorenson, B, 1153(ab)
Soroa, V, 904(ab)
Soroa, VE, 60(ab)
Sossi, V, 481(ab)
Soucy, JP, 267(ab)
Soufer, R, 21(ab), 346(ab)
Soufer, RS, 1220(ab)
Souladaki, M, 1342
Soulen, RL, 1079(ab)
Soulez, G, 2029
Southwick, SM, 578(ab)
Soyka, M, 448(ab)
Soyne, D, 981(ab)
Spahn, G, 387
Spallarossa, P, 1832
Spanaki, MV, 275(ab), 730
Spanu, A, 1105(ab)
Sparks, R, 261(ab)
Sparks, RB, 625, 1357(ab)
Sparr, G, 224(ab)
Spaulding, M, 94(ab)
Speelman, JD, 753
Spencer, RP, 533(ab)
Spencer, SS, 275(ab), 730, 1199(ab), 1270(ab)
Spetsieres, P, 1264
Spetzger, U, 450(ab)
Spicer, KM, 971(ab), 1383(ab), 1390(ab), 1454(ab)
Spiegel, S, 290(ab), 593(ab)
Spies, S, 260(ab)
Spies, SM, 509(ab), 712(ab), 1278(ab), 1327(ab)
Spill, EJ, 1224(ab)
Spiller, RC, 365(ab)
Spillert, AM, 729(ab)
Spinelli, L, 194(ab), 338(ab), 777(ab), 1683
Spirnak, P, 1138(ab)
Spitz, FR, 1143
Spitzer, S, 1165(ab)
Spivack, D, 363(ab)
Spottswood, SE, 1455(ab)
Springer, CS, 1301(ab)
Srinivasan, A, 317(ab), 320(ab), 322(ab), 415(ab), 418(ab), 993(ab), 996(ab), 997(ab), 2081
Srivastava, SC, 264(ab), 302, 489(ab), 490(ab), 978(ab)
Stabin, M, 331, 1524
Stabin, MG, 165(ab), 260(ab), 1355(ab), 1357(ab), 1364(ab), 1375(ab), 1380(ab)
Stadalnik, RC, 137, 1149
Stagg, B, 76(ab)
Stahl, F, 337(ab)
Stahl, TJ, 232(ab)
Staib, L, 93(ab), 250
Staib, LH, 578(ab), 1220(ab)
Staley, CA, 92(ab)
Staley, JK, 576(ab), 1208(ab)
Stallings, L, 1383(ab)
Stallings, LE, 1390(ab)
Standke, R, 1152(ab)
Stauch, S, 1251(ab)
Staudenherz, A, 1376(ab)
Stauraka, A, 976(ab)
Stav, I, 1037(ab)
Stavropoulos, SW, 406
Stayanoff, JC, 101(ab)
Stearns, CW, 466(ab), 1236(ab)
Steen, K, 78(ab)
Steffens, MG, 829
Stegemann, G, 78(ab)
Stehr, B, 427(ab)
Stein, R, 968(ab), 1392
Steinbach, J, 293(ab), 584(ab)
Steinberg, T, 51(ab)
Steinert, HC, 79(ab)
Steinke, R, 754(ab)
Steinling, M, 721, 956
Steinmetz, AP, 51(ab), 522(ab), 880(ab)
Stekhova, S, 494(ab)
Stephane, M, 441(ab), 1164(ab)
Stephens, AW, 357(ab)
Stephenson, R, 1224(ab)
Sterman, D, 1241
Stern, R, 825(ab)
Steuer, J, 9N(2)
Stevens, SC, 873(ab)
Stevenson, A, 152(ab)
Steventon, RS, 1292(ab)
Stewart, R, 723(ab)
Stiévenart, JL, 786
Stix, G, 362(ab)
Stöcklin, G, 205, 1061
Stodilka, RZ, 1306(ab)
Stoegbauer, F, 1017(ab)
Stoessl, AJ, 283
Stoeter, P, 125(ab)
Stokkel, MP, 259(ab), 574, 1056(ab)
Stokking, R, 311, 1199(ab), 1270(ab)
Stollfuss, JC, 1824
Stone, CD, 139(ab)
Stone, CK, 187(ab), 354(ab), 723(ab)
Stone, DM, 75(ab)
Stoof, JC, 106(ab), 111(ab)
Stoot, JM, 38(ab)
Storey, G, 218(ab)
Storm, G, 58(ab), 192, 2066
Stout, DB, 142(ab), 585(ab), 587(ab)
Straehler-Pohl, HJ, 988(ab)
Strand, S-E, 1524
Stratton, K, 769(ab)
Strauss, HW, 38(ab), 60, 184, 252(ab), 559(ab), 814(ab), 846(ab), 1122(ab), 1832
Strauss, J, 204(ab)
Strauss, LG, 1061(ab), 1288(ab), 1323(ab)
Strijckmans, V, 935
Stroehlein, K, 902(ab)
Strom, S, 850(ab)
Stroobants, S, 98(ab), 899(ab)
Stroobants, SG, 564(ab)
Stroszczynski, C, 387
Stubbs, JB, 625
Studholme, C, 278(ab), 1199(ab), 1270(ab)
Styblo, T, 238(ab)
Su, MS, 1186(ab)
Su, ZF, 331(ab)
Sugawara, Y, 554(ab), 1089(ab), 1099(ab), 1125, 1130(ab), 1456
Sugihara, H, 514(ab), 2007
Sugimoto, K, 243(ab), 704(ab), 1441
Sugimura, K, 426(ab), 1072(ab)
Sugio, K, 1778
Sugioka, J, 13(ab), 745(ab)
Sugiura, M, 317
Sugiura, S, 1116
Suh, JH, 1055(ab)
Suh, JS, 1023(ab)
Suh, YS, 1394(ab)
Suhara, T, 1342(ab), 1351(ab)
Suhonen-Polvi, H, 12
Sullivan, A, 25N(10), 26N(11), 16N(12)
Sullivan, CL, 67(ab)
Sullivan, T, 572(ab)
Sumiya, H, 535(ab), 1818
Sun, AJ, 97(ab)
Sun, B-F, 1381
Sun, QY, 97(ab)
Sunderland, T, 119(ab)
Sundram, FX, 904(ab)
Sung, C, 1547
Sunohara, N, 1583
Surya Prakash, GK, 1368(ab)
Sutinen, E, 1330(ab)
Suzuki, H, 1018(ab)
Suzuki, K, 207(ab), 527(ab), 847(ab), 1342(ab), 1351(ab)
Suzuki, T, 217, 867(ab), 1021(ab)
Suzuki, Y, 1137(ab)
Swahn, C, 120(ab), 151(ab)
Swahn, CG, 436(ab)
Swaney, CM, 574
Swanson, D, 850(ab)
Sweet, MP, 489(ab)
Sy, WM, 844(ab)
Sychra, JJ, 394(ab), 1276(ab)
Symes, JF, 760(ab)
Symonds-Tayler, JR, 1232(ab)
Syrota, A, 31(ab), 224, 411(ab), 917, 1147(ab)
Szabo, K, 115(ab), 373(ab)
Szabo, Z, 115(ab), 373(ab), 594(ab), 940(ab), 1014(ab), 1180
Szajek, LP, 472(ab)
Sze, P, 844(ab)
Szecsi, J, 737
Szeimies, U, 1048(ab)
Szilard, M, 822(ab)
Taat, CW, 1107(ab)
Tabrizi, MH, 1329(ab)
Tadamura, E, 7(ab), 782(ab), 1840
Taddei, G, 522
Taddei, GZ, 926(ab)
Taegtmeyer, H, 1186
Tagaya, Y, 1027(ab)
Tagesson, M, 1524
Tagil, K, 224(ab)
Taguchi, M, 1332(ab)
Tahmassian, AZ, 935(ab)
Tai, Y, 130(ab)
Taillefer, R, 40(ab), 41(ab), 345(ab), 359(ab), 1103(ab), 1124(ab), 1233, 1244(ab), 2029
Tait, JF, 38(ab), 184, 846(ab)
Takagi, S, 1155(ab)
Takagi, Y, 1792
Takahashi, K, 780(ab), 875(ab), 1999
Takahashi, M, 1318(ab), 1328(ab), 1331(ab), 1337(ab)
Takahashi, N, 207(ab), 243(ab), 704(ab), 1332(ab), 1441
Takahashi, T, 137, 802(ab), 877(ab), 885(ab), 1188(ab)
Takahashi, W, 563(ab), 1155(ab)
Takahashi, Y, 64
Takamiya, M, 796(ab), 1187(ab)
Takano, A, 1204(ab)
Takao, N, 779(ab)
Takashima, H, 371
Takatoku, K, 289(ab)
Takatsu, H, 2036
Takayama, T, 1300(ab)
Takebayashi, S, 1792
Takeda, K, 12(ab), 895, 1172(ab), 1300(ab)
Takeda, Y, 394, 1971
Takei, K, 915(ab)
Takei, T, 527(ab)
Takeishi, Y, 1999
Takekoshi, N, 512(ab), 812(ab)
Takeshita, K, 728(ab)
Takeuchi, A, 847(ab), 1172(ab)
Takeuchi, K, 1492
Takezawa, H, 728(ab)
Taki, J, 191(ab), 216(ab), 512(ab), 535(ab), 727(ab), 761(ab), 915(ab), 1644, 1874
Taki, S, 865(ab)
Takizawa, N, 1818
Talbot, JN, 1077(ab)
Tamagnan, G, 154(ab), 607(ab)
Tamaki, N, 14(ab), 207(ab), 471, 527(ab), 748(ab), 782(ab), 798(ab), 807(ab), 963, 1097(ab), 1204(ab), 1247(ab), 1319(ab), 1424, 1840
Tamaki, T, 770(ab)
Tamamura, H, 1095(ab)
Tamgac, F, 1092(ab)
Tamura, S, 1047(ab), 1057(ab)
Tamura, Y, 312(ab), 841(ab)
Tan, P, 148(ab), 1208(ab)
Tanabe, M, 198(ab), 875(ab)
Tanada, S, 1005(ab)
Tanaka, F, 530, 1183(ab)
Tanaka, H, 1078(ab)
Tanaka, K, 1463
Tanaka, R, 713(ab)
Tanaka, T, 1173(ab)
Tang, CY, 355(ab)
Tang, HR, 458(ab), 596(ab), 820(ab), 1248(ab), 1249(ab)
Taniguchi, K, 217
Taniguchi, M, 915(ab), 1095(ab)
Tanimura, K, 1138
Tannahill, L, 1913
Tansey, LW, 1467(ab)
Tapia-Palacios, M, 377(ab)
Tapscott, E, 13N(10)
Tarlati, M, 1080
Tarli, L, 434(ab)
Tarolo, GL, 77
Tashiro, M, 70
Tateishi, J, 780(ab)
Tateno, M, 939(ab)
Tatsch, K, 110(ab), 112(ab), 389(ab), 737, 853(ab), 1048(ab)
Tatsch, KR, 126(ab)
Tatschida, T, 273(ab)
Tatsumi, M, 65(ab), 384(ab), 566, 854, 1003
Tatum, JL, 1455(ab)
Tatumi, N, 942(ab)
Taylor, A, 209(ab), 1403(ab)
Taylor, I, 560(ab), 1116(ab)
Taylor, MD, 187(ab)
Tazi, A, 962(ab)
Tedeschi, E, 442
Teerlink, T, 827(ab), 1204
Tega, H, 430(ab), 1020(ab)
Teixeira, AB, 1148(ab)
Tellmann, L, 501(ab)
Tembl, A, 3(ab), 5(ab), 734(ab), 786(ab)
ten Broek, FW, 1056(ab)
Tenney, CR, 138(ab)
Tepe, G, 837(ab)
Teratani, T, 1190(ab), 1302(ab)
Terauchi, T, 1465(ab)
Terhaard, CH, 259(ab)
Terno, G, 1114(ab)
Terui, S, 1465(ab)
Terzi, AA, 172(ab), 178(ab)
Tesar, R, 10N(3)
Teshima, H, 942(ab)
Tesoro Tess, JD, 251(ab)
Testori, A, 1125(ab)
Tetrault, T, 52(ab), 56(ab)
Teule, GJ, 407(ab), 667, 953(ab)
Tewson, TJ, 494(ab), 1072, 1400(ab)
Teyssier, F, 80(ab)
Thakrar, DS, 68(ab), 536(ab)
Thakur, ML, 62(ab), 352, 485(ab), 491(ab), 625, 1080(ab), 1363(ab), 1398(ab), 2107
Thanos, PK, 1217(ab)
Thédrez, P, 198, 1216
Thelen, MH, 871(ab), 933(ab)
Thérasse, E, 2029
Thie, JA, 96(ab), 469(ab), 1283(ab)
Thierens, H, 1354(ab)
Thigpen, KA, 169(ab)
Thirion, P, 1147(ab)
Thödtmann, R, 1771
Thomas, C, 917(ab)

Thomas, PA, 579
Thomas, R, 66(ab)
Thompson, CJ, 542(ab)
Thompson, TD, 27(ab), 710(ab), 722(ab)
Thorberg, S, 151(ab)
Thornback, J, 504(ab)
Thornback, JR, 331(ab), 419(ab), 497(ab), 499(ab), 614(ab), 872(ab), 995(ab), 1346(ab)
Tidmarsh, G, 76(ab), 989(ab), 991(ab)
Tiepolt, C, 543(ab)
Tietje, N, 1246
Tiffany-Jones, L, 166
Tiffet, O, 80(ab)
Tikofsky, RS, 1197(ab), 1205(ab)
Tiling, R, 1048(ab)
Timothy, AR, 425(ab), 1135(ab)
Ting, G, 1170(ab)
Tissingh, G, 106(ab)
Tjuvajev, JG, 105(ab), 1012(ab)
Toba, M, 796(ab), 799(ab), 800(ab), 801(ab)
Tobey, EA, 449(ab)
Tocharoenchai, C, 461(ab)
Todd-Pokropek, A, 16(ab), 140(ab), 471(ab), 595(ab), 1314(ab)
Todd-Pokropek, AE, 1294(ab)
Tofani, A, 46
Togami, I, 394
Togasaki, D, 587(ab)
Tojo, T, 1999
Tokita, N, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 1693
Tokunaga, M, 390(ab)
Tölle, TR, 291(ab)
Tolmachev, V, 982(ab)
Tolvanen, T, 1330(ab)
Tomaru, Y, 878(ab), 1018(ab)
Tomas, MB, 43(ab), 57(ab), 201(ab), 478(ab)
Tomczak, R, 571(ab)
Tomiguchi, S, 1331(ab)
Tomita, I, 371
Tomiyama, N, 566
Tomiyama, Y, 239
Tomiyoshi, K, 336(ab), 399, 878(ab), 1018(ab)
Tomoike, H, 1999
Tompkins, EA, 895(ab)
Tompkins, RG, 370(ab), 391(ab)
Ton, A, 1281(ab)
Tonakie, A, 233(ab)
Tonami, H, 1095(ab)
Tonami, N, 191(ab), 216(ab), 430(ab), 535(ab), 727(ab), 761(ab), 855(ab), 915(ab), 1020(ab), 1138, 1644, 1818, 1874
Tondeur, M, 52, 972
Tondini, C, 251(ab)
Top, LE, 268
Topuzovic, NB, 739(ab)
Torizuka, T, 1088(ab), 1424
Tornai, MP, 138(ab), 1260(ab), 1176
Toro, J, 929(ab)
Torp, B, 907(ab)
Torres, L, 768
Torres, O, 768
Tosch, M, 575(ab)
Toth, B, 342(ab)
Toubert, ME, 411(ab)
Toubi, A, 45(ab)
Tourwé, D, 1913
Towbin, RB, 850(ab)
Townsend, DW, 597(ab), 1134(ab)
Toyama, H, 705(ab), 808(ab), 847(ab), 1172(ab), 1269(ab)
Toyama, K, 574(ab), 835(ab)
Toyama, T, 217
Toyoda, H, 1188(ab), 1273(ab)
Toyokuni, T, 102(ab), 332(ab)
Toyokuni, TT, 323(ab)
Traeger, H, 82(ab), 93(ab), 945(ab)
Träger, H, 1623
Tran, HD, 1457(ab)
Trattnig, S, 1277
Traub, T, 395(ab), 1081(ab)
Travaini, L, 1617
Travin, MI, 350(ab), 810(ab)
Trenkwalder, C, 112(ab)
Treves, ST, 51(ab), 52(ab), 56(ab), 908(ab), 1896
Triantafyllou, N, 976(ab)
Trifiro, G, 1125(ab)
Trigaux, JP, 219(ab)
Trojan, H, 1016(ab), 1032(ab)
Tronco, G, 43(ab)
Tronco, GG, 201(ab)
Troychak, MJ, 1138(ab)
Trujillo, N, 797(ab)
Trujillo, NP, 200(ab)
Tsai, S, 323(ab), 325(ab), 1052(ab)
Tsai, S-C, 1106
Tsay, D-G, 60
Tsay, DW, 367(ab), 1050(ab)
Tschmelitsch, J, 1764
Tsuboi, N, 728(ab)
Tsuchida, T, 704(ab), 1085, 1201(ab), 1441
Tsuchimochi, S, 222(ab), 726(ab)
Tsuchiya, H, 535(ab)
Tsuda, T, 1071(ab)
Tsugawa, H, 812(ab)
Tsui, B, 134(ab), 461(ab), 470(ab), 1252(ab)
Tsui, BM, 1011
Tsuji, S, 1818
Tsujihata, M, 371
Tsujimura, E, 805(ab)
Tsukakoshi, M, 878(ab)
Tsukamoto, E, 14(ab), 207(ab), 527(ab), 748(ab), 798(ab), 807(ab), 963, 1204(ab), 1247(ab), 1319(ab)
Tsukamoto, T, 493(ab)
Tsukune, Y, 867(ab)
Tuchida, T, 1183(ab)
Tuji, S, 761(ab)
Tull, CR, 599(ab)
Tung, CH, 137(ab)
Turetskiy, V, 1144(ab)
Turgut, B, 1046(ab)
Turi-Nagy, E, 1158(ab)
Turkington, TG, 136(ab), 432, 477(ab), 1176, 1241(ab)
Turner, JH, 873(ab)
Turpin, S, 1124(ab), 2029
Turzo, A, 298(ab), 473(ab)
Twieg, D, 1181(ab)
Tzakis, AG, 208(ab)
Tzen, K, 1299(ab)
Tzen, KY, 109(ab)
Uccelli, L, 167(ab), 302(ab), 778(ab), 1168(ab), 1382(ab), 1556
Uchiyama, M, 874(ab)
Udelsman, R, 940(ab)
Udelson, JE, 345(ab)
Ueberfuhr, P, 30(ab)
Ueda, S, 1590
Ueda, T, 289(ab)
Ueda, Y, 86(ab), 1095(ab)
Uehara, T, 239, 1884
Uemura, K, 841(ab)
Ueno, M, 1273(ab), 1992
Ueti, OM, 746(ab)
Uffelman, W, 25N(10), 26N(11), 16N(12)
Ugwoke, M, 610(ab)
Ulanski, JS, 1031(ab)
Umehara, I, 64
Underwood, SR, 343(ab), 344(ab)
Ungerer, M, 188(ab)
Unni, PR, 1015(ab)
Uno, H, 1169(ab)
Uno, M, 1192(ab)
Unterberg, R, 34(ab)
Unterreiner, R, 821(ab)
Unterweger, MP, 1508
Urbain, JL, 497, 498, 854(ab), 1236
Urbannek, V, 932(ab)
Urbina, RA, 1348(ab)
Uribe, J, 307(ab), 598(ab), 1233(ab)
Uslu, I, 429
Usui, K, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
Usui, Y, 779(ab)
Utsunomiya, K, 1201(ab)
Vaalburg, W, 116(ab), 262, 292(ab), 300(ab), 351(ab), 381, 496(ab), 507, 561(ab), 890(ab), 1132(ab), 1159(ab), 1167(ab), 1177(ab), 1270
Vaca, A, 1104(ab)
Vainionpää, L, 12
Vaitkevicius, VK, 1079(ab)
Valdavia, AY, 363(ab)
Valdés Olmos, RA, 70(ab), 1119(ab), 1414
Vale, PR, 760(ab)
Valentin, L, 602(ab)
Valette, H, 1374
Valeyre, D, 962(ab), 1092(ab)
Valk, PE, 255(ab)
Valkema, R, 416(ab), 2081
Vallabhajosula, S, 1001(ab), 1008(ab), 1303(ab)
Vallis, K, 1370(ab)
van Aswegen, A, 1532
van Balen, S, 1313(ab)
Van Cutsem, E, 98(ab)
Van de Wiele, C, 783
Van den Eeckhaut, AC, 783
Van den Heuvel, PA, 706(ab), 1468
van den Hoff, J, 719(ab), 1272(ab)
van der Ent, FW, 1118(ab)
Van der Graaf, WT, 1146(ab), 1159(ab)
van der Linden, C, 269(ab)
van der Mark, TW, 1270
van der Meer, JW, 192
van der Meer, JWM, 2066
van der Pol, HA, 1118(ab)
van der Vusse, GJ, 1204
van der Wall, EE, 180(ab), 740(ab)
Van der Wall, H, 85, 218(ab), 869(ab)
van der Wouden, E, 496(ab)
van Dijk, A, 639
Van Dongen, GA, 263(ab)
van Dyck, CH, 1208(ab)
van Eijkeren, M, 491
Van Every, B, 381(ab)
van Gameren, A, 320(ab)
van Ginkel, RJ, 262
Van Heertum, R, 114(ab), 121(ab), 122(ab), 435(ab), 1211(ab)
Van Heertum, RL, 90(ab), 228(ab), 412(ab), 611(ab), 1197(ab), 1205(ab)
van het Schip, AD, 639
van Isselt, JW, 311
van Kaick, G, 372(ab), 1061(ab)
Van Laere, K, 210(ab)
Van Laere, KJ, 269(ab), 277(ab), 1250(ab)
van Lier, JE, 832(ab), 876, 1728
van Lingen, A, 190(ab), 192(ab), 263(ab), 407(ab), 1235(ab), 1257(ab), 1313(ab), 1866
van Loon, M, 1235(ab), 1313(ab)
Van Raemdonck, D, 98(ab)
van Rijk, PP, 259(ab), 311, 639, 1056(ab)
van Royen, EA, 753, 1091
van Staden, JA, 1532
van Tienhoven, G, 1107(ab)
van Waarde, A, 116(ab), 292(ab), 351(ab), 496(ab), 890(ab), 1167(ab), 1177(ab), 1270
Vanbilloen, HP, 610(ab)
VanBrocklin, H, 352(ab)
Vandekerckhove, T, 277(ab)
Vandenberghe, S, 1250(ab)
Vander Borght, T, 219(ab), 766(ab), 792(ab), 882(ab)
Vanderheyden, J, 1389(ab)
vanderMeer, JW, 58(ab)
Vandestreek, PR, 1233
Vandewalle, V, 269(ab)
Vanhove, C, 703(ab), 709(ab)
Vanoverschelde, J, 731(ab)
Vanpee, D, 219(ab)
Vansant, JP, 508(ab), 511(ab), 650, 753(ab), 787(ab), 1262(ab)
Varho, T, 12
Varma, V, 238(ab)
Varrone, A, 124(ab), 270(ab)
Vassileva-Belnikolovska, D, 491(ab), 1398(ab)
Vavrek, MT, 495(ab)
Vavrek, T, 846
Vecchio, C, 1123(ab)
Velasquez, W, 553(ab)
Venkatesh, M, 1015(ab), 1402(ab)
Vera, DR, 137, 1149
Véra, P, 179(ab), 513, 786, 805
Verani, MS, 349(ab), 1857
Verbeke, N, 610(ab)
Verbruggen, AM, 288(ab), 610(ab), 898(ab), 1353(ab), 1532
Verheijen, RH, 966(ab)
Verhoeff, NP, 124(ab), 143(ab), 270(ab), 580(ab)
Verhoeff, NPLG, 1902
Vernaleken, I, 125(ab)
Vernon, P, 1152(ab)
Verreault, J, 1103(ab)
Verrelle, P, 672
Verrier, ED, 339(ab)
Versijpt, JJ, 783, 1354(ab)
Versteegh, RT, 667
Vervaet, AM, 706(ab), 1468
Vessotskie, JM, 150
Vicario, L, 1683
Vidal, R, 1301
Vielpeau, C, 901(ab), 905(ab)
Viergever, EP, 180(ab)
Viergever, MA, 311
Vijayakumar, S, 347
Vilain, D, 794(ab), 805, 809(ab), 1252
Villa, G, 926(ab), 1123(ab), 1832
Villalobos, A, 1207(ab)
Villanueva-Meyer, J, 553(ab), 906(ab), 1104(ab)
Villar, L, 555(ab), 1096(ab)
Villavieja, L, 296
Ville, D, 786
Villeirs, GM, 783
Villemagne, V, 940(ab)
Villemagne, VL, 454(ab)
Vilner, BJ, 486(ab)
Vincent, F, 901(ab)
Vines, D, 273(ab), 530, 1183(ab), 1201(ab)
Vinot, S, 1336(ab)
Viola, S, 287(ab)
Virgolini, I, 74(ab), 395(ab), 1081(ab), 1082(ab)
Visser, CA, 190(ab), 192(ab), 1866
Visser, FC, 190(ab), 192(ab), 765(ab), 827(ab), 831(ab), 1204, 1866
Visser, GW, 966(ab)
Visser, TJ, 317(ab), 414(ab), 418(ab), 496(ab), 1177(ab), 1270
Viswamitra, S, 891(ab)
Vitali, P, 522
Vittori, F, 46
Vivanco, JP, 1104(ab)
Vivino, FB, 857(ab)
Vlahos, L, 976(ab)
Vogel, J, 250
Vogel, SB, 371(ab)
Vogelgesang, D, 423(ab)
Vogg, AT, 1388(ab)
Voliotopoulos, V, 976(ab)
Volkert, W, 419(ab)
Volkow, ND, 145(ab), 406(ab), 438(ab), 439(ab), 440(ab), 442(ab), 443(ab) 586(ab), 588(ab), 715, 1154, 1176(ab), 1215(ab), 1217(ab), 1218(ab), 1285

Vonck, K, 277(ab)
Vosberg, H, 575(ab), 977
Votaw, D, 331
Votaw, J, 331, 1344(ab)
Voth, E, 202(ab), 791(ab), 830(ab), 932(ab)
Voth, M, 952(ab), 1227(ab)
Vriens, P, 38(ab)
Vu, C, 159
Vural, G, 524(ab), 919(ab), 1046(ab)
Wackers, F, 817(ab)
Wackers, FJTh, 1310
Waddington, WA, 560(ab), 1113(ab), 1116(ab)
Wagner, C, 291(ab)
Wagner, HN, 318(ab)
Wagner, HN, Jr., 13N(8), 30N(10), 574, 1009
Wahl, LM, 1666
Wahl, RL, 76(ab), 77(ab), 87(ab), 88(ab), 89(ab), 155(ab), 233(ab), 405(ab), 554(ab), 556, 612(ab), 989(ab), 990(ab), 991(ab), 1089(ab), 1099(ab), 1110(ab), 1125, 1130(ab), 1139(ab), 1456, 2025
Waibel, R, 1913
Waikar, S, 552(ab)
Wainer, N, 136(ab)
Wakabayashi, Y, 2088
Wakasugi, S, 942(ab), 943(ab)
Wakasugi, T, 191(ab)
Waki, A, 91(ab), 243(ab), 330(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1174(ab), 1332(ab), 1441
Wald, JJ, 554(ab)
Wald, M, 1111
Waldman, TA, 329(ab)
Waldmann, TA, 268, 327(ab), 837, 1006(ab), 1027(ab), 1381
Walicka, MA, 1377(ab)
Walker, B, 1745
Wallace, AM, 1149
Wallace, WE, 379(ab)
Wallhaus, TR, 187(ab), 723(ab)
Wallis, JW, 510(ab)
Walter, R, 595(ab)
Wand, G, 446(ab)
Wang, FW, 1745
Wang, G, 145(ab), 588(ab), 1217(ab)
Wang, GJ, 442(ab), 443(ab), 715, 1154, 1176(ab), 1215(ab), 1218(ab), 1285
Wang, HE, 1365(ab)
Wang, J, 307(ab), 598(ab), 997(ab), 1233(ab), 1370(ab)
Wang, JC, 1087(ab)
Wang, JK, 1452(ab)
Wang, MF, 97(ab)
Wang, S, 354(ab), 502(ab)
Wang, S-J, 1106
Wang, TS, 90(ab), 611(ab)
Wang, W, 301(ab), 1042(ab), 1044(ab)
Wang, WT, 470(ab)
Wang, X, 86(ab)
Wang, Y, 1397(ab)
Wängberg, B, 2094
Wanivenhaus, A, 1277
Ward, HB, 1304(ab)
Warnet, A, 1252
Warren, J, 1383(ab)
Warren, S, 402(ab)
Warren, W, 813(ab)
Warren, WK, 815(ab)
Wassmann, H, 1064(ab)
Wastie, ML, 399(ab)
Watabe, H, 464(ab)
Watanabe, A, 1138, 1175(ab)
Watanabe, H, 390(ab)
Watanabe, KA, 334(ab), 1368(ab)
Watanabe, M, 943(ab)
Watanabe, N, 1005(ab), 1138
Watanabe, S, 718(ab), 767(ab)
Watanabe, T, 781(ab)
Watanabe, W, 802(ab), 885(ab)
Watanabe, Y, 566, 1166(ab)
Watanuki, S, 70
Waters, DD, 518(ab), 702(ab), 711(ab)
Watson, CC, 305(ab)
Watson, DD, 142, 821
Waxman, A, 280(ab)
Waxman, AD, 246(ab), 378(ab), 883(ab), 959(ab), 1182(ab)
Waxman, AS, 9(ab)
Wearne, MJ, 455(ab)
Weaver, JP, 604
Weber, B, 1158(ab)
Weber, DA, 1264(ab)
Weber, P, 319(ab)
Weber, PB, 1399(ab)
Weber, W, 85(ab), 205, 574, 737
Weber, WA, 397(ab), 550(ab), 593(ab), 1311(ab), 1771
Weckesser, M, 566(ab), 1017(ab), 1064(ab)
Wegener, WA, 67(ab)
Wegman, T, 1177(ab)
Wehrmann, E, 1375(ab)
Weidel, J, 44(ab)
Weiden, PL, 75(ab)
Weijs, L, 717(ab)
Weilke, F, 451(ab)
Weinberger, DR, 445(ab), 1348(ab)
Weinberger, J, 611(ab)
Weiner, RE, 533(ab)
Weinmann, P, 962(ab)
Weiping, W, 912(ab)
Weir, GJ, 574
Weisenberger, D, 468(ab)
Weiss, R, 121(ab), 1210(ab), 1242(ab)
Weissman, IA, 1334(ab)
Weisz, G, 741(ab), 811(ab)
Welch, A, 552(ab)
Welch, MJ, 177, 704(ab)
Weller, R, 1272(ab)
Welling, MM, 2073
Wells, C, 1108(ab)
Wells, P, 41(ab)
Wells, RG, 590(ab)
Welt, S, 970(ab), 1764
Wendt, RE, 160(ab)
Wenger, M, 74(ab)
Werner, JA, 257(ab), 776, 1150(ab)
Werner, M, 1637
Werner, T, 151(ab)
Wessell, DE, 134(ab)
Wessells, B, 971(ab)
West, JH, 371(ab)
Wester, HJ, 205, 448(ab), 1061, 1367
Westlin, JE, 982(ab)
Wetter, T, 112(ab)
Wevers, RA, 272(ab)
Wey, SP, 1170(ab)
Whang, SC, 1094(ab)
Whatley, M, 385(ab), 565(ab), 1029(ab)
White, CA, 260(ab)
White, CM, 518(ab)
White, JD, 268
White, LL, 1232(ab)
White, MP, 517(ab), 702(ab), 711(ab)
Whiting, JS, 356(ab), 1508
Wichter, T, 1, 834(ab)
Widstrom, C, 982(ab)
Wieland, DM, 232, 323, 519(ab)
Wienhard, K, 306(ab)
Wiens, L, 494(ab), 1400(ab)
Wiggers, H, 1292
Wijns, W, 1893
Wilcut, E, 303(ab)
Wilderman, SJ, 133(ab)
Wilding, P, 2107
Wilhelm, AJ, 263(ab)
Wilhelm, RR, 993(ab), 996(ab)
Wilk, M, 1295(ab)
Willemart, B, 882(ab)
Willemsen, A, 717(ab)
Willemsen, AT, 116(ab), 300(ab), 351(ab), 507, 561(ab), 755(ab), 1159(ab)
Willemsen, ATM, 1270
Williams, C, 1182(ab)
Williams, CM, 378(ab), 959(ab)
Williams, JE, 16N(1), 9N(6), 12N(12)
Williams, KA, 774(ab)
Williams, KV, 1798
Williams, LE, 323(ab), 325(ab), 1151
Williams, NE, 1241(ab)
Williams, S, 1207(ab)
Williams, W, 1219(ab)
Williamson, PD, 278(ab)
Willoch, F, 290(ab), 291(ab), 448(ab)
Wilson, CG, 365(ab)
Wilson, DA, 234(ab)
Wilson, M, 1230(ab)
Winkle, W, 846
Winkler, B, 570(ab)
Winkler, P, 737
Winnard, P, Jr, 484
Winogrodzka, A, 106(ab), 111(ab)
Winsor, D, 427(ab)
Wirquin, V, 37(ab)
Wiseman, GA, 260(ab)
Witzel, C, 195(ab)
Witzel, M, 195(ab)
Witzig, TA, 260(ab)
Witzling, M, 860(ab)
Wodarski, C, 1061(ab)
Wohrle, J, 341(ab)
Wojcik, R, 468(ab), 600(ab)
Wolek, R, 73(ab)
Wolf, F, 537(ab)
Wölfel, R, 1342
Wolloch, Y, 376
Wolpers, HG, 719(ab)
Wolter, A, 897(ab), 952(ab)
Wolters, EC, 106(ab), 111(ab)
Wong, C, 83(ab), 287(ab)
Wong, CO, 993
Wong, CT, 145(ab), 442(ab), 443(ab), 588(ab), 715, 1217(ab), 1285
Wong, DC, 54(ab), 55(ab), 1805
Wong, DF, 125(ab), 441(ab), 1164(ab)
Wong, E, 504(ab)
Wong, FC, 955(ab), 1206(ab)
Wong, J, 323(ab), 325(ab)
Wong, JY, 1151
Wong, KH, 596(ab), 820(ab)
Wong, W, 307(ab), 598(ab)
Wong, WH, 1233(ab)
Woo, JI, 1198(ab)
Woo, KS, 1358(ab)
Woo, SL, 1012(ab)
Woodard, AR, 1180(ab)
Woolfenden, JM, 601(ab)
Wörmann, B, 992(ab)
Worthley, SG, 355(ab)
Wright, GA, 364(ab)
Wright, JK, 1784
Wu, AM, 323(ab), 325(ab)
Wu, C, 166
Wu, HM, 146(ab), 147(ab), 283(ab)
Wu, HR, 1106(ab)
Wu, JC, 1106(ab)
Wu, L, 102(ab)
Wu, LC, 1307(ab), 1452(ab), 1460(ab)
Wu, MC, 596(ab), 820(ab), 1249(ab)
Wu, S, 947(ab)
Wu, SY, 922(ab)
Wu, XF, 1004(ab)
Wun, T, 965(ab)
Wunderlich, G, 1385(ab)
Wurthman, S, 319(ab)
Wuttke, B, 397(ab)
Xanthopoulos, E, 1211(ab)
Xia, W, 456
Xie, Y, 1294(ab)
Xiong, CY, 324(ab)
Xiuli, M, 805(ab), 1693
Xu, L, 86(ab)
Xu, M, 1304(ab)
Xu, Y, 1352(ab)
Yaakob, W, 1454(ab)
Yafai, S, 1083(ab)
Yahanda, A, 233(ab)
Yamac, K, 39(ab)
Yamada, I, 64
Yamada, K, 567(ab)
Yamada, N, 1116
Yamada, T, 1179(ab)
Yamagishi, H, 1492
Yamaguchi, H, 803(ab), 804(ab), 805(ab), 806(ab), 708(ab), 1693, 1884
Yamaguchi, K, 567(ab)
Yamaguchi, T, 1284(ab)
Yamaji, S, 1185(ab)
Yamamoto, H, 1190(ab), 1302(ab)
Yamamoto, I, 86(ab), 1095(ab)
Yamamoto, K, 243(ab), 1441
Yamamoto, S, 191(ab)
Yamamoto, T, 1318(ab), 1328(ab), 1337(ab)
Yamamoto, W, 211(ab), 212(ab), 747(ab), 855(ab), 1173(ab)
Yamamoto, Y, 198(ab), 875(ab)
Yamamura, N, 1406(ab)
Yamaoka, M, 1999
Yamasaki, K, 426(ab), 1072(ab)
Yamashina, A, 779(ab)
Yamashita, S, 239
Yamauchi, DM, 1151
Yamauchi, H, 1992
Yamazaki, S, 418
Yanada, S, 874(ab)
Yanch, JC, 1280(ab)
Yanez, M, 594(ab)
Yang, DJ, 404(ab), 1366(ab), 1367(ab), 1467(ab)
Yang, H, 863(ab), 866(ab)
Yang, HI, 852(ab)
Yang, JH, 1102(ab)
Yang, JY, 821
Yang, KR, 217(ab)
Yang, L, 721(ab), 771(ab)
Yang, S, 1370(ab)
Yang, SD, 1394(ab)
Yang, WD, 1004(ab)
Yang, WH, 485(ab)
Yang, WI, 1043(ab), 1051(ab), 1058(ab), 1066(ab), 1073(ab), 1075(ab), 1151(ab)
Yang, YW, 1252(ab)
Yang, Z, 1087(ab)
Yanovskaya, L, 1458(ab)
Yao, R, 1321(ab)
Yao, S, 171(ab), 176(ab), 181(ab), 507(ab), 716(ab)
Yao, SS, 715(ab), 924
Yao, T, 1006(ab)
Yao, WJ, 1307(ab)
Yao, Z, 479, 685, 1371(ab)
Yap, JT, 1848
Yapar, AF, 429
Yarnitsky, D, 265(ab)
Yasuda, S, 563(ab), 1078(ab), 1131(ab), 1155(ab)
Yasuda, T, 193(ab), 729(ab), 783(ab)
Yasuhara, Y, 1287(ab)
Yasumura, Y, 799(ab)
Yaw, M, 1144(ab)
Yazaki, PJ, 323(ab), 325(ab)
Yazaki, Y, 939(ab), 1116
Yee, RE, 142(ab), 585(ab), 587(ab)
Yeh, EL, 142(ab)
Yeh, S, 912(ab)
Yeh, SD, 1042(ab)
Yeh, SH, 244(ab), 909(ab), 1062(ab), 1065(ab), 1186(ab), 1452(ab)
Yeldell, D, 972(ab)
Yen, LK, 1052(ab)
Yen, SH, 244(ab), 1050(ab), 1062(ab)
Yen, TC, 109(ab)
Yeo, JS, 789(ab), 1195(ab)
Yerlioglu, EM, 821(ab)
Yester, MV, 479(ab)
Yetman, RJ, 236(ab)
Yeung, D, 750(ab)
Yeung, H, 1044(ab)

Yeung, HW, 95(ab), 1039(ab)
Yeung, RS, 557(ab), 1074(ab)
Yiu, JH, 1186(ab)
Yokoi, F, 441(ab), 1164(ab)
Yokoi, T, 859(ab), 1318(ab), 1328(ab), 1337(ab), 1737
Yokota, M, 728(ab)
Yokoyama, A, 704(ab), 1000(ab), 1034(ab)
Yokoyama, I, 762(ab), 793, 841(ab), 862(ab), 867(ab), 939(ab), 1116
Yokoyama, K, 430(ab), 1020(ab), 1138
Yomoda, I, 289(ab)
Yonekura, K, 939(ab), 1116
Yonekura, Y, 91(ab), 243(ab), 317, 330(ab), 704(ab), 1000(ab), 1034(ab), 1085, 1132, 1137(ab), 1174(ab), 1332(ab), 1441
Yonemura, T, 7(ab)
Yoneyama, T, 761(ab)
Yoo, TM, 1381
Yoon, CH, 205(ab)
Yoon, J, 715(ab)
Yoon, JK, 386(ab), 751(ab), 851(ab), 884(ab), 1102(ab)
Yoon, SN, 756(ab)
Yordanov, AT, 329(ab)
Yoriyaz, H, 1364(ab), 1524
Yoshibayashi, M, 7(ab)
Yoshida, D, 1035(ab)
Yoshida, H, 6
Yoshida, M, 1085, 1132
Yoshida, S, 1035(ab), 1084(ab), 1101(ab), 1189(ab)
Yoshida, T, 1091(ab), 1111(ab), 1203(ab), 1595, 1778
Yoshikawa, E, 1282(ab)
Yoshikawa, J, 1492
Yoshikawa, K, 418, 793, 862(ab), 867(ab)
Yoshimoto, M, 91(ab), 1000(ab), 1034(ab), 1174(ab)
Yoshio, Y, 512(ab)
Yoshioka, J, 708(ab), 803(ab), 804(ab), 805(ab), 806(ab), 1693
Yoshioka, S, 244
Yoshizumi, T, 239
You, DL, 1052(ab)
You, J, 1277(ab), 1317(ab), 1325(ab)
Youn, YK, 529(ab), 986
Young, C, 574
Young, IH, 382(ab)
Young, JC, 977(ab)
Young, JW, 306(ab)
Young, MC, 343(ab), 344(ab)
Younsi, N, 1077(ab)
Yu, CL, 1452(ab)
Yu, D, 404(ab)
Yu, DF, 1367(ab)
Yu, EH, 776(ab)
Yu, F, 539
Yu, JN, 525(ab)
Yu, KH, 1394(ab)
Yu, SM, 909(ab), 1186(ab)
Yu, X, 465(ab)
Yu, YM, 391(ab)
Yuan, A, 965(ab), 969(ab), 2014
Yuan, Z, 1018(ab)
Yudd, AP, 232(ab)
Yum, HY, 1045(ab)
Yumoto, K, 770(ab)
Yuri, H, 426(ab), 1072(ab)
Yutani, K, 65(ab), 384(ab), 566, 854, 1003, 1166(ab)
Zabrodina, Y, 772(ab)
Zabrodina, YV, 889
Zacherl, S, 1477
Zagar, I, 933(ab)
Zahedi, A, 882(ab)
Zalupski, MM, 1079(ab)
Zalutsky, MR, 631, 1197
Zamarripa, F, 942
Zamora, PO, 825(ab)
Zamperini, P, 922(ab)
Zanten-Przybysz, I, 966(ab)
Zanzi, I, 264(ab)
Zanzonico, PB, 1007(ab), 1024
Zardi, L, 434(ab)
Zareneyrizi, F, 160(ab), 404(ab), 1366(ab), 1367(ab)
Zaret, BL, 346(ab)
Zasadny, KR, 76(ab), 77(ab), 87(ab), 155(ab), 556, 989(ab), 991(ab), 1099(ab), 1110(ab), 1456
Zavattini, G, 302(ab)
Zea-Ponce, Y, 121(ab), 122(ab), 581(ab), 606(ab), 1210(ab)
Zecchinelli, A, 271(ab)
Zee, A, 1132(ab)
Zeggel, T, 450(ab)
Zellweger, MJ, 25(ab)
Zeng, GL, 137(ab), 462(ab), 1254(ab), 1255(ab), 1296(ab)
Zervos, GD, 729(ab)
Zettinig, G, 881(ab)
Zhang, CG, 863(ab), 866(ab)
Zhang, C-H, 1609
Zhang, M, 479, 685, 1342(ab), 1351(ab), 1371(ab)
Zhang, N, 307(ab), 598(ab), 1233(ab)
Zhang, T, 866(ab)
Zhang, X, 331(ab)
Zhang, ZY, 355(ab)
Zhao, DS, 863(ab), 866(ab)
Zhao, J, 97(ab)
Zhao, JH, 866(ab)
Zhao, S, 479
Zhao, XD, 461(ab)
Zhao, X-G, 631
Zheng, L, 1400(ab)
Zheng, QH, 495(ab)
Zhong, YG, 498(ab)
Zhou, Y, 146(ab), 147(ab)
Zhu, CM, 1004(ab)
Zhuang, HM, 61(ab), 868(ab), 888(ab)
Ziegler, S, 30(ab), 33(ab), 34(ab), 1243(ab), 1824
Ziegler, SI, 397(ab), 593(ab), 1234(ab), 1311(ab), 1771
Ziessman, HA, 1236, 2038
Zietkiewicz, M, 19(ab)
Ziffer, JA, 347(ab), 508(ab), 511(ab), 787(ab)
Zijlstra, JM, 953(ab)
Zilleruelo, G, 204(ab)
Zimmer, L, 1393(ab)
Zimmerman, BE, 1508
Zimmerman, RE, 482(ab), 483(ab), 1896
Zimmermann, K, 326(ab)
Zimny, M, 450(ab)
Zinn, KR, 994(ab)
Zipes, DP, 846
Zito, F, 271(ab), 914(ab)
Zoboli, S, 72(ab)
Zoghbi, S, 73(ab), 576(ab), 578(ab)
Zoghbi, SS, 124(ab), 143(ab), 154(ab), 270(ab), 607(ab), 1902
Zohar, J, 1213(ab)
Zona, T, 153(ab)
Zonnenberg, BA, 639
Zornoza, G, 555(ab)
Zubal, IG, 275(ab), 480(ab), 730, 1199(ab), 1270(ab)
Zubillaga, MB, 1080
Zuna, I, 372(ab)
Zurakowski, D, 52(ab), 56(ab)
Zwas, ST, 63(ab), 1213(ab)

A

Absorbed dose estimation system, radioimmunotherapy, 1151
Absorptiometry, effect on increasing tissue, 929(ab)
Academy of Radiology Research (ARR), advocate for change, 9N(6)
Acceptance testing, gamma camera, 12N(12)
Acetate, precursor for lipid synthesis, 1034(ab)
Acetazolamide challenge
time-dependency of, 1203(ab)
vascular factor affecting pathophysiology of, 1221(ab)
^{99m}Tc ECD SPECT as predictor for carotid stunning, 568(ab)
Acetylcholinesterase
AChE activity imaging agent for SPECT, 289(ab)
Brain, [11C]CP-126,998 as a radioligand for, 1207(ab)
^{11}C neostigmine, potential PET cardiac marker, 495(ab)
Acquired immune deficiency syndrome (AIDS)
brain SPECT to differentiate cerebral infections from lymphoma, 258(ab)
mental status correlation, 1191(ab)
^{67}Ga citrate, 889(ab)
^{201}Tl SPECT diagnosis of central nervous system lymphoma and toxoplasma, 896(ab)
Acquisition, CdZnTe with multimode digital electronics, 127(ab)
Activation study
brain, ^{15}O-water, 1302(ab)
brain SPECT, 277(ab)
cluster analysis, 1276(ab)
cochlear implant users, 1160(ab)
localization of working and episodic memory by, 1171(ab)
macro square wave jerks in torticollis spasmodicus, 268(ab)
pain and itch processing, 451(ab)
pallidal electrostimulation in Parkinson's disease, 269(ab)
PET imaging of, 1175(ab)
presurgical PET assessment of eloquent brain areas, 450(ab)
SPECT, rCBF studies of speech perception, 449(ab)
subliminal perception, 1158(ab)
subthreshold high-frequency repetitive transcranial magnetic stimulation, 290(ab)
three-dimensional PET, 1190(ab)
Xe SPECT and functional MRI, 1181(ab)
Addiction, opioid receptor binding changes in alcohol dependency, 448(ab)
Adelstein, S. James, de Hevesy Award, 12N(6)
Adenocarcinoma, antibody imaging of, 969(ab)
Adenosine
heart, comparison of ATP with, 515(ab)
myocardial perfusion imaging protocol using, 513(ab)
quantification of myocardial blood flow in N-13 ammonia cardiac studies, 717(ab)
short infusion does not increase defect size, 517(ab)
Adenosine triphosphate, mitochondrial glycolysis, 1035(ab)
Adrenergic receptor
beta, myocardial density, parametric polar map of, 507
lipophilic ^{18}F labeled adrenergic receptor ligands, 1400(ab)
pulmonary adrenoreceptor density, 834(ab)
synthesis and evaluation of lipophilic ligand, 494(ab)
Advanced Nuclear Medicine Initiative, medicare modernization, 25N(10)
Aebersold Award, 30N(8)
SNM members, 12N(6)
Aerosol
distribution mapping, lung morphometry for, 383(ab)
PET lung imaging, comparison of, 886(ab)
Xe ventilation in diagnosis of pulmonary embolism, 883(ab)
Aging
changes related to, ^{99m}Tc ECD cerebral distribution, 1818
decreased myocardial mechanical function, 4(ab)
dopamine transporters and, healthy humans, 1812
effect on dopamine transporters, 108(ab)
Mu opioid receptor, brain changes in, 447(ab)
PET studies with 6-FMT and 6-FDOPA, 1169(ab)
Agonist
lung, C-11 procaterol as a radioligand for, 496(ab)
^{11}C ZYY-339, 1338(ab)
Alavi/Mandell Fund, Education & Research Foundation, 32N(8)
Alcohol
addiction in humans, 446(ab)
effects on regional brain glucose, 1217(ab)
moderate dose during pregnancy, 437(ab)
^{99m}Tc DTPA, index of intestinal permeability ingestion of, 370(ab)
Alcoholism, regional cerebral blood flow changes, naltrexone and, SPECT, 19
Alpha-emitting radionuclides
Bi-213, role in lymphoma therapy, 431(ab)
mutated E-cadherin, binding characteristics of radionuclides to, 433(ab)
pharmacokinetic modeling, 164(ab)
Alpha-fetoprotein antibody imaging, of hepatocellular carcinoma, 427(ab)
Alpha-particle emitters
pharmacokinetics and dosimetry of, leukemia patients, 1935
therapeutic efficacy of, in radioimmunotherapy, 1375(ab)
Alpha particles, ^{213}Bi, preparation of constructs for clinical use, 1722
Alzheimer's disease
apolipoprotein E type, glucose metabolism of, 1198(ab)
brain, ^{11}C VC-004 as a radioligand for, 1177(ab)
cerebral blood flow, ^{99m}Tc HMPAO SPECT in, 244
limbic system, 1193(ab)
longitudinal evaluation of Alzheimer-type dementia, 1192(ab)
quantitative analysis of, 1221(ab)
^{99m}Tc HMPAO cerebral blood flow, qEEG and, 522
^{99m}Tc N252 visualization of, 288(ab)
Ambulatory patient classification (APC), prospective payment system for outpatient departments, 24N(4)
American Medical Accreditation Program (AMAP), SNM Physical Evaluation Program, 26N(1)
American Medical Association, Clinical Practice Guideline Recognition Program, 23N(5)
American Society of Radiologic Technologists, news from the Technologist Section, 16N(4)
Amino acids
blood-brain transport, 584(ab)
kinetic analysis of transport, 1016(ab)
1-amino-3-fluorocyclobutane-carboxylic acid, brain tumor imaging, 331
^{18}F-labeled, transport mechanism and uptake kinetics, 1367
5-Aminosalicylic acid, absorption, ileorectal anastomosis patients, 1630
Amphetamines, neurotoxicity, 113(ab)
Amyloidosis
evaluation of proximal tubular function, 864(ab)
scintigraphic diagnosis, 898(ab)
Amytal, distribution, regional cerebral perfusion and, Wada test, 747
Anatomical standardization, ^{11}C WAY-100635 PET, localization of serotonin receptors, brain, 102
Androgen receptor, PET ligands for prostate cancer, 1136(ab)
Angina, unstable, ^{201}Tl detection of culprit lesion, 779(ab)
Angiography, pulmonary perfusion scintigraphy to evaluate pulmonary embolism, 222(ab)
Angioplasty
assessing perfusion function after PTCA, 702(ab)
cost-effectiveness of ^{99m}Tc sestamibi SPECT, 172(ab)
detection of functional myocardial recovery, 505(ab)
percutaneous transluminal coronary, myocardial salvage after, 363
Angiotensin-converting enzyme (ACE) inhibitor
effect on regulation of AT1 receptors, 373(ab)
therapy, ^{123}I-MIBG myocardial imaging, 217
Animal studies
evaluation of infection imaging, 893(ab)
high-resolution lutetium oxyorthosilicate PET scanner, 1164
myocardial perfusion imaging, 20(ab)
PET research, 1176(ed)
pinhole SPECT system, 1249(ab)
radioprotection of salivary glands, 1033(ab)
^{99m}Tc alpha-fetoprotein, scintigraphy with, 1030(ab)
Annexin
anti-annexin V antibody imaging, 818(ab)
evaluation of transplant rejection, 38(ab)
Antibodies
antibody localization to tumors, 1007(ab)
stability of, 1381(ab)
^{90}Y, pharmacokinetics and dosimetry of, 980(ab)
Antibody conjugates, blood clearance, hepatocyte-directed, 1392
Antibody fragments
improved tumor targeting, 1006(ab)
PET tumor tracers, ^{64}Cu-labeled genetically altered, 323(ab)
radioimmunotherapy with ^{99m}Tc-labeled IMMU-LL2, 949(ab)
targeting of tumor angiogenesis, 434(ab)
triglycine linker improves ^{67}Cu antibody uptake, 326(ab)
Antibody labeling
At-211-labeled antibody, in vivo stability of, 329(ab)
crosslinking potential of glycolaldehyde, 1404(ab)
stability of, 1387(ab)
^{99m}Tc humanized antibody imaging of lymphatic metastases, 1108(ab)
Antibody pharmacokinetics
compartmental modeling, 1007(ab)
pharmacokinetic-based treatment planning, 1364.5(ab)
Anticarcinoembryonic antigen, monoclonal antibodies, ^{131}I-labeled, after radioimmunotherapy, 1609
Anti-CEA antibodies, antibody fragments, genetically engineered anti-CEA antibody, 325(ab)
Antiphospholipid antibody syndrome, regional cerebral blood flow in, ^{99m}Tc HMPAO evaluation, 1446
Antisense imaging, nuclear medicine and, 693
Aorta, aortic aneurysm, surgical repair of, 744(ab)
Aortic valve, myocardial sympathetic innervation, 34(ab)
Apoptosis
imaging with ^{99m}Tc annexin V, 184
quantification of caspase, for in vivo imaging of, 316(ab)
Appendicitis, ^{99m}Tc anti-CD 15 monoclonal antibody scan, 62(ab)
Arrhythmias, influence on gated SPECT, 924
Arterial input function, plasma FDG concentration, 1282(ab)
Arthroplasty, FDG PET infection imaging, 868(ab)
Artificial intelligence
artificial neural networks, 224(ab)
brain PET, discrimination of temporal lobe epilepsy, 476(ab)
computer-based decision support system, physician benefit from, 96
Asialoglycoprotein receptor
GSA, function of, 216(ab)
hepatic, ^{99m}Tc GSA, liver after resection, 137
method for estimating, 855(ab)
scintigraphy, auxiliary partial orthotopic liver transplant, 1463
Aspiration
fine-needle, ^{201}Tl scintigraphy and, thyroid nodules, 1971
radionuclide salivagram, milk scan, 51(ab)
Astatine-211, preparation and in vivo stability testing of linkers, 329(ab)
Atherosclerosis
macrophage burden, detection and quantification of, 355(ab)
migration of monocyte in detection of, 814(ab)
Attention deficit hyperactivity disorder
methylphenidate, 113(ab)
rCBF recovery after methylphenidate treatment, 1214(ab)
Attenuation correction
additive diagnostic efficacy, myocardial SPECT, 358(ab)
analytical methods for, 1337(ab)
bone SPECT, spine, 604
cardiac imaging, PET and SPECT transmission images, 135(ab)

cardiac SPECT, 359(ab), 456(ab), 1310(ed), 1335(ab)
comparison of filtered backprojection and OS-EM methods, 1252(ab)
dual detector coincidence imaging, 1303(ab)
effect of transmission scan duration and smoothing, 1313(ab)
error estimation, 1308(ab)
esophageal cancer, FDG PET assessment, 594(ab)
false-positive myocardial ischemic study, 788(ab)
FDG coincidence imaging in oncology studies, 1311(ab)
FDG lung studies, 461(ab)
FDG PET, 562(ab)
lesion detectability in breast cancer, 2021, 2025(ed)
geometrical models, 298(ab)
image processing, 1309(ab)
improves infarct size assessment on ^{201}Tl SPECT images, 749(ab)
initial clinical validation profile, 361(ab)
iodinated contrast, accounting for the presence of, 458(ab)
iterative calculated body contour-based vs scan-ba, 730(ab)
iterative reconstruction, 1323(ab)
iterative reconstruction methods, 1326(ab)
line array source for, 1331(ab)
maximum-likelihood transmission gradient algorithm, 1312(ab)
MRP reconstruction in whole-body PET studies, 1330(ab)
multiple line source array, 15(ab)
nonuniform scatter in brain SPECT without transmission imaging, 1306(ab)
PET brain studies, 1315(ab)
processing techniques for, clinical evaluation of, 1257
reducing urinary bladder artifacts in SPECT studies, 1334(ab)
registration problems, 1296(ab)
scatter window measurements, 1277(ab)
segmented, 460(ab), 1304(ab)
simultaneous emission/transmission tomography, visual assessment of ^{201}TL perfusion images, 1303
specificity improves ^{201}Tl SPECT images, 363(ab)
three-dimesional myocardial SPECT, quantification of defect size, 817(ab)
transmission-emission myocardial gated SPECT, 752(ab)
transmission scans in cardiac SPECT, 1262(ab)
transmission SPECT cardiac images, 701(ab)
watershed segmentation algorithm, 1297(ab)
^{99m}Tc SPECT, brain imaging, 456
^{153}Gd scanning line source for noncardiac, 1327(ab)

Auger electrons
DNA cleavage, 1405(ab)
gene radiotherapy, 1009(ab)
therapeutic efficacy of, 1374(ab)
^{125}I, decrease in induction and toxicity from decay of, 1377(ab)
^{125}I in vivo therapy of neoplastic meningitis, 986(ab)

Autonomic nervous system, idiopathic dilated cardiomyopathy, prognostic value of ^{123}I MIBG in, 917

Autosynthetic device, multipurpose apparatus for radiopharmaceutical production, 1467(ab)

Avascular necrosis
bone SPECT vs MRI in detection of, 534(ab)
changes in blood flow and bone metabolism, 870(ab)

Avidin, modification, glycosylation and isoelectric point, 479

Avidin-biotin system, clearance of antigen, preinjectio of intact antibody , 1381

Avidin chase, reduction of bone marrow toxicity, 1003(ab)

B

Back pain, bone SPECT, attenuation correction, 604

Bacterial infection
in granulocytopenia, scintigraphic imaging, 2066
^{99m}Tc HNP, imaging, 2073

Barium, history of, 24N(7)

Basal ganglia
disorders, diagnosis, optimized and automated, 110(ab)
SPECT imaging of Crigler-Najjar syndrome, 914(ab)

Bench to Bedside program, NIH imaging research opportunities, 9N(4)

Benzamides, sigma receptor scintigraphy with, 488(ab)

Benzodiazepine receptor
decreased frontal cortical receptors, 578(ab)
detection of viable cortical neurons, 1166(ab)
neocortical epileptic foci, ^{11}C FMZ PET, 1985
neuroprotective agent, FK506, 1172(ab)
in vivo imaging of activated microglia, 571(ab)
^{18}F fluoroethylflumazenil imaging of, 1222(ab)

Benzodiazepines, regional brain metabolic responses, reproducibility of, 715

Beta-adrenergic receptor
cardiac imaging, 351(ab)
perfusion defects reversed by glucagon, 518(ab)
synthesis and evaluation of, 496(ab)

Beta-methyl-p-iodophenyl-pentadecanoic acid (BMIPP)
dual label studies, rat tissues, 1918
sestamibi scintigraphy and, myocardial viability, 1468

Beta-Ray emitters, pure, Bremsstrahlung radiation exposure from, 1024

Biliary dyskinesia, radionuclide prediction of clinical outcome, 856(ab)

Biliary tract stasis, scintigraphic assessment of obstruction after hepatic resection, 214(ab)

Biodistribution studies
animal experiments, ^{123}I-DES for, 403(ab)
compartmental models, 830(ab)
PET radioligands, 1167(ab)
receptor scintigraphy with substituted benzamides, 488(ab)
^{99m}Tc complexes and ^{201}Tl , tumor/background ratios, 1036(ab)
^{111}In-labeled dendritic cells, 1028(ab)
^{123}I-Pk 11195, 1354(ab)
^{188}Re, elimination study, 356(ab)

Biotin, ^{111}In-labeled, streptavidin and, pretargeting of bacterial endocarditis, 484

Bismuth-213, antibody labeled with, preparation of constructs for clinical use, 1722

Bismuth-213 HUM195, alpha-particle emitter labeled antibody, leukemia patients, 1935

Bisphosphonates, radiohalogenated, stability and bone accumulation, 1197

Bladder tumor, staging and therapy of, 399(ab)

Blood flow
assessment of relative flow to detect viable myocardium, 184(ab)
bronchial artery, perfusion scintigraphy, after lung transplant, 290
cerebral
acetazolamide challenge test, 1173(ab)
diagnosis of brain death, 1459(ab)
diagnosis of brain death with ^{99m}Tc ECD, 1464(ab)
distribution of ^{99m}Tc ECD, changes related to age, 1818
dose response of remifentanil, 291(ab)
epilepsy, SPECT image registration for, 1098
gender differences, 1220(ab)
naltrexone effects in alcohlics, SPECT, 19
noninvasive determination of, 1272(ab)
primary antiphospholipid antibody syndrome, ^{99m}Tc HMPAO evaluation of, 1446
quantification and SPECT to detect vasospasm, 1188(ab)
quantification using ^{99m}Tc ECD and SPECT, 1737
remote regional consequences of focused infarcts, 721
SPECT evaluation of acute cerebral infarction, 569(ab)
statistical parametric matching, Parkinson's disease, 1583
without blood sampling, 1273(ab)
^{99m}Tc compounds to measure brain perfusion index, 1271(ab)
muscle, PET assessment of, 391(ab)
myocardial
absolute quantification with ^{201}Tl, 312(ab)
baseline and hyperemic, ^{15}O-labeled water and PET, 1848
intersubject variability in baseline studies, 763(ab)
iterative reconstruction, PET, 862
monitoring therapeutic response, 732(ab)
oxidative metabolism abnormalities, PET, 846
parametric imaging of, 295(ab)
quantification by gated SPECT in normal subjects, 748(ab)
simultaneous measurement of brain and MBF, 841(ab)
^{13}N ammonia and PET, 1045
^{125}I iodorotenone and ^{99m}Tc sestamibi in ischemic and infarcted myocardium, 352(ab)
PET measurement of skeletal muscle, 391(ab)
tumor, PET and MRI to measure, 1029(ab)
tumoral, measurement with O-15 water, 464(ab)

Blood-pool imaging
determination of left ventricular ejection fraction, 776(ab)
evaluation of left ventricular ejection fraction, 178(ab)
gated
bull's-eye polar map display, 794(ab)
quantification of abnormal ventricular function, 712(ab)
three-dimensional analysis program for, 1278(ab)
^{99m}Tc, dose estimates, 1532

Blood sampling
programmable sampling device, 1235(ab)
^{18}F FDG as radiolabel for cells, 951(ab)

BMIPP 15-(p-iodophenyl)-3-(R,S)-methyl pentad
early detection of doxorubicin cardiotoxicity, 12(ab)
early detection of myocardial damage with, 796(ab)
myocardial viability assessment, 804(ab)

Bombesin
accumulation and retention of, 419(ab)
design and synthesis of, 318(ab)
gastrin-releasing peptide receptor, 317(ab), 418(ab)

Bone
anti-NCA granulocyte to image bone infection, 897(ab)
leukocyte imaging of painful joint replacements, 43(ab)
SPECT, OSEM vs filtered backprojection in, 1333(ab)

Bone densitometry
calcaneal ultrasound of postmenoposal osteoporosis, 538(ab)
differential bone loss in femoral neck, 533(ab)
effect of increasing tissue, 929(ab)
third-generation fan-beam bone densitometer, 1230(ab)

Bone marrow
FDG PET in acute leukemia, 956(ab)
local irradiation, effect on, 88(ab)
sparing effects of Sn-117m-DTPA for pain palliation, 978(ab)
^{99m}Tc anti-NCA 90 granulocyte imaging of, 952(ab)
^{99m}Tc MIBI, high accumulation of, 943(ab)

Bone metastases
distribution in lung cancer, 1144(ab)
FDG PET detection of, whole-body, 386(ab)
gastroenteropancreatic tumor, somatostatin receptor imaging, 1602
high-dose Ho-166-DOTMP therapy, 160(ab)
planar bone scintigrapy, vs ^{18}F PET, 1623
receiver operating curve as SUV, 387(ab)
same-day sequential FDG studies, 83(ab)
^{18}F sodium fluoride PET detection o breast cancer, 82(ab)
^{99m}Tc methylene diphosponate, detection of bone tumors, 1146(ab)

Bone neoplasm, malignant lymphoma, bone, ^{67}Ga scintigraphy and MRI comparison, 387

Bone pain
metastatic, management with systemic radionuclide therapy, 1420
palliation
breast cancer metastasis, ^{186}Re etidronate in, 639
clinical data analysis, 264(ab)
with Re-186, 1015(ab)
Re-186 HEDP, 265(ab)
Re-188, kinetics and therapeutic effect, 975(ab)
^{85}Sr therapy, 585
radiohalogenated bisphosphonates, 1197

Bone resorption
proximal femoral component remodeling, 533(ab)
usefulness of NTx in, 874(ab)

Bone scan
detection of breast cancer metastases, 82(ab)
FDG PET detection of osseous metastasis, 81(ab)
patterns in multiple stress injuries, 876(ab)
SPECT vs MRI in nasopharyngeal carcinoma, 1052(ab)

Bone scanning, radionuclide, osseous lesions, 1623

Bone scintigraphy
bone metastasis, 413(ab)
diagnostic value in prostate cancer, 874(ab)
FDG PET replacement of, primary staging of malignant lymphoma, 1407
infection imaging, 905(ab)

orthopedic infections, 901(ab)
pelvic fractures, 873(ab)
somatostatin receptor comparison, gastroenteropancreatic tumors, 1602
SPECT evaluation of back pain, 536(ab)
subtrochanteric and innominate osteotomies, 870(ab)
three-phase imaging of musculoskeletal lesions, 875(ab)
vs ultrasonography in plantar fascitis, 45(ab)
^{99m}Tc MDP in diagnosis of leukemia, 523(ab)
^{201}TL scintigraphy comparison, multiple myeloma, 1138
Bone therapy, radiohalogenated bisphosphonates, 1197
Bone tumor
FDG uptake in giant-cell tumors, 390(ab)
FDG uptake patterns in, 1141(ab)
pediatric chemotherapeutic response of osseous sarcomas, 1148(ab)
therapy with new Sn-117m formulations, 490(ab)
Brain
adjuvant radioimmunotherapy in glioma, 266(ab)
age-related defects in dopamine D2 receptors, 1218(ab)
development of novel DAT radioligands, 1340(ab)
dopamine mediates reinforcing of psychostimulants, 442(ab)
effect of methamphetamine on dopaine transporters, 443(ab)
frequency encoding, simultaneous display using, 442
glutathione localization, ^{99m}Tc HMPAO, 1056
integrated visualization of data, validation, 311
maturation, distribution of ^{99m}Tc ECD, age-related changes, 1818
metabolism, ^{99m}Tc HMPAO, in nervous tissue, 1556
neoplasms, FDG PET and coincidence detection with a gamma camera, 110
quantification of P-glycoprotein, transport in blood-brain barrier, 1159(ab)
quantification of ^{11}C FLB 457 binding to extrastriatal dopamine receptors, 436(ab)
serotonin receptors in, localization with ^{1}C WAY-100635 PET, 102
spatial normalization methods, PET, validation of, 317
SPECT, statistical parametric mapping in dementia, 1205(ab)
SPECT to differentiate cerebral infections from lymphoma, 258(ab)
^{99m}Tc SPECT, attenuation correction in, 456
Brain imaging
acetylcholinesterase, inhibitor of, 1207(ab)
brain activation to normal and degraded speech, 449(ab)
diagnosis of brain death, 1459(ab)
diagnosis of brain death with ^{99m}Tc ECD, 1464(ab)
emission-based attenuation correction, 1315(ab)
itch, central processing of, 451(ab)
neuropsychiatric disorders, 1240(ab)
radioligand transport across blood-brain barrier, in vitro testing, 1348(ab)
restless legs syndrome, 112(ab)
SPECT and TCT, using asymmetric fanbeam collimator, 1252(ab)
statistical parametric mapping, 1268(ab)
statistical parametric mapping analysis, 1187(ab)
synthesis and structure-affinity studies of pipperidine-based analogs, 1341(ab)
^{11}C as a radioligand for, 1351(ab)
^{11}C raclopride to measure endogenous dopamine release, 1209(ab)
Brain neoplasm
diagnostic test comparison, 1067(ab)
edema, 453(ab)
neurofibromatosis Type 1, 520(ab)
PET activation study, 450(ab)
role of FDG PET in clinical management of, 521(ab)
^{123}I-methyl tyrosine and ^{201}Tl in differential diagnosis of, 1064(ab)
Brain perfusion
human immunodeficiency virus, 1191(ab)
serial SPECT pre-post liver transplantation, 914(ab)
subcortical aphasia, 1194(ab)
Brain stem, focused infarcts, remote regional blood flow responses, 721
Brain tumor
enhanced ^{11}C TPMP uptake, PET, 1180
FDG PET imaging applications, 591
imaging
^{18}F FABCC PET, 331
^{18}F FET PET, 205
malignant, ^{131}I-labeled 81C6 monoclonal antibody, 631
^{18}F FMT PET, 399
Breast
correlation of mammogram and scintimammogram, 66(ab)
influence of volume and injection site, 237(ab)
lymphoscintigraphy in breast neoplasm, 557(ab)
monoclonal antibody imaging of breast lesions, 1108(ab)
normal FDG uptake, 1099(ab)
radiopharmaceuticals excreted in breast milk, 1355(ab)
tumor imaging with PET, 307(ab)
Breast biopsy
stereotactic, positron emission mammography-guided, 468(ab)
stereotactic real-time image-guided, 1256(ab)
Breast cancer
axillary lymph node metastasis and, FDG PET and dual-head coincidence imaging comparison, 1003
diagnostic protocol, ^{99m}Tc-MIBI mammography in, 296
double phase ^{99m}Tc sestamibi scintimammography, T-scan and, 376
early, sentinel node localization in, 1403(le)
lesion detectability, attenuation correction in FDG PET, 2021, 2025(ed)
metastatic bone pain with, ^{186}Re etidronate in, 639
new look, 1009(ed)
^{123}I iodovinylestradiol imaging, estrogen receptors, 1728
Breast neoplasm
antibody imaging, 67(ab)
breast cancer xenografts, comparative study of ima, 1030(ab)
comparison of scintigram and immunohistochemical, 65(ab)
FDG as predictor of pathological response of chemotherapy, 552(ab)
FDG coincidence imaging, 540(ab)
FDG PET assessment of, 554(ab)
FDG PET detection of axillary metastases, 555(ab)
FDG PET detection of recurrent breast cancer, 1109(ab)
four-view scintimammography with pinhole collimator, 1104(ab)
fusion proteins for targeting of, 1370(ab)
intratumoral uptake of sestamibi and C-14-deoxyglucose, 1022(ab)
lymphoscintigraphy
role in sentinel node biopsy, 1119(ab)
role in sentinel node detection, 70(ab)
lymphoscintigraphy to detect sentinel node, 1122(ab)
lymphoscintigraphy vs Gamma Probe, 558(ab)
multidrug resistance, 1101(ab)
PET imaging to predict therapeutic response, 1110(ab)
pinhole SPECT detection of axillary lymph node metastasis, 1105(ab)
planar and MIBI SPECT detection of axillary lymph node, 556(ab)
positioning to improve lymphoscintigraphy results, 1112(ab)
quantitative studies of metabolic images for detection, 542(ab)
scintigraphic assessment of therapeutic response, 553(ab)
scintimammography of, 1106(ab)
sentinel node mapping in, 1123(ab)
sestamibi imaging to detect preinvasive lesions, 64(ab)
single- or double-method lymph node biopsy, 1114(ab)
Z-MIVE scintigraphy, predictor of tamoxifen efficacy, 1107(ab)
^{18} FES assessment of estrogen receptors, 1111(ab)
^{99m}Tc P1410 targets breast cancer xenografts, 417(ab)
Breast scintigraphy
dual slant-angle collimation in, 1256(ab)
four-view scintimammography with pinhole collimator, 1104(ab)
improved identification of axillary sentinel nodes, 1112(ab)
procedure guidelines, 1233
sentinel node, lymphatic mapping of, 559(ab)
therapeutic response assessment, 553(ab)
^{99m}Tc sestamibi, effect on breast biopsies, 1103(ab)
Bremsstrahlung, radiation exposure, pure beta-ray emitters, 1024
Briner, Capt. William H., nuclear medicine in the military, 10N(1)
Bronchial artery, revascularization, perfusion scintigraphy, after lung transplant, 290
[^{76}Br]4-bromodexetimide, PET, imaging of temporal lobe epilepsy, 935

C

Camera systems, sensitivity of Pem-1, 542(ab)
Cancer. *see also* specific type and site
metastatic bone pain, management with systemic radionuclide therapy, 1420
postsurgical radioiodine therapy of differentiated thyroid cancer, 987(ab)
^{111}In-octreotide therapy, 73(ab)
Cancer imaging
advantage of small small solid-state gamma camera, 1121(ab)
aptamer against tenascin-C, 402(ab)
delayed FDG PET breast images, 566(ab)
farnesyl transferase distribution, 400(ab)
FDG and FLT, 245(ab)
FDG PET, 408(ab), 1040(ab)
FDG PET imaging of solitary pulmonary nodules, 225(ab)
FDG PET staging of malignant lymphoma, 247(ab)
PET detection of metastatic tumors, 1131(ab)
PET radiotracer, kinetic modeling of farnesyl transferase, 1014(ab)
PET tumor agents, ^{18}F FHBG for gene expression, 103(ab)
PETwith ^{18}F FLT, 101(ab)
potential of ^{18}F RO41-0960, 406(ab)
restaging of indeterminant colorectal cancer lesions, 93(ab)
synthesis of ^{18}F FMAU, 334(ab)
tumor localization with FDG SPECT and CT, 1281(ab)
whole-body FDG-PET detection of colon cancer metastases, 565(ab)
^{18} arabinonucleosides, synthesis of, 1368(ab)
Cancer staging
FDG PET and MRI in abdominal lymph node staging, 423(ab)
FDG PET assessment of cervical cancer, 1129(ab)
whole-body FDG PET, 226(ab)
Captopril
cardiac MIBG kinetics and, failing heart, 224
hypotensive response to, scintigraphic assessment of renal artery stenosis, 406
renal scintigraphy, hypertensive patients with renal failure, 412
Captopril renography
criteria for baseline studies, 375(ab)
differential diagnosis of transplant complications, 376(ab)
Carbon-11, activity, after injection of methyl-^{11}C thymidine, 491
Carbon-11 acetate
dual-isotope PET study to determine beta oxidation in malignant neoplasm, 1062(ab)
prostate cancer, PET imaging of, 242(ab)
renal cell carcinoma, PET imaging with, 1139(ab)
Carbon-11 DTBZ, reproducibility studies, healthy human subjects, 283
Carbon-11 epinephrine, PET imaging of neuroblastoma, 519(ab)
Carbon-11 FMZ, PET, neocortical epileptic foci, 1985
Carbon-11 hydroxyephedrine, PET assessment of aortic stenosis, 34(ab)
Carbon-11 MET
correlation of MIB-1 positive rate in brain tumors, 1065(ab)
PET, FDG PET and, thymic tumors, 1595
Carbon-11 PHEN
monoamine oxidase activity, vesicular storage and, isolated heart, 323
sensitivity to monoamine oxidase activity, heart, 232
Carbon-11 raclopride, endogenous dopamine competition with, brain response to methylphenidate, 1285
Carbon-11 thymidine, PET, validation studies, 614
Carbon-11 TPMP, enhanced uptake, brain tumor, PET, 1180

Carbon-11 tyrosine, cervical cancer, detection of, 1132(ab)
Carbon-13 breath test, orocecal transit time, 1451
Carbon-14 deoxyglucose, ^{99m}Tc HL91 comparison, detection of tumor hypoxia, 854
Carcinoembryonic antigen (CEA)
medullary thyroid cancer producing-, radioimmunotherapy, 198
in vivo tumor targeting of, 1004(ab)
Carcinoid tumor
uptake of I-123-α-MT detection of, 393(ab)
^{111}In-octreotide therapy for, 73(ab)
Carcinoma cells, ^{99m}Tc sestamibi and ^{3}H daunomycin, 672
Cardiac function
age effects on, 4(ab)
exercise-induced abnormalities of, 782(ab)
gated SPECT reconstruction of strain and stress tensors, 816(ab)
improved accuracy of gated SPECT assessment of, 740(ab)
LV volume and ejection fraction, 805(ab)
reduction of partial volume errors, 797(ab)
^{123}I MIBG sympathetic reinnervation of allografts, 911
Cardiac imaging
attenuation correction, 769(ab)
cardiac SPECT and angiography, 315(ab)
dipyridamole perfusion imaging, use in renal transplant, 707(ab)
dual-isotope imaging, prognostic value of, 22(ab), 170(ab)
gated SPECT reconstruction of strain and stress tensors, 816(ab)
Ga-67 in rheumatic carditis, 11(ab)
list mode PET, 457(ab)
metabolism and function, 832(ab)
multiple line source array TCT/ECT system, 15(ab)
quantitation of SPECT images, 16(ab)
reversible perfusion defects, outcomes for, 27(ab)
scatter correction, 462(ab)
simultaneous assessment of ventricular function, 915(ab)
SPECT leukocyte imaging in occult infective endocarditis, 9(ab)
SPECT with rotating chair and solid-state gamma camera, 750(ab)
three-dimensional alignment in PET assessment of, 18(ab)
transmyocardial laser revascularization, 764(ab)
viability and endpoint markers, 738(ab)
^{99m}Tc sestamibi, 348(ab)
Cardiac output, forward, measurements, ^{99m}Tc-labeled agents for myocardial perfusion imaging, 1874, 1882(ed)
Cardiac sympathetic function, ^{123}I-MIBG myocardial imaging, after β-blocker or ACE therapy, 217
Cardiac sympathetic innervation
adriamycin-induced cardiac toxicity, 833(ab)
cardiac transplantation, 10(ab)
PET study after orthoptic heart transplantation, 30(ab)
relationship with function and metabolism, 188(ab)
sinus bradycardia, 786(ab)
Cardiac sympathetic nerve function, MIBG scintigraphy of, 727(ab)
Cardiac sympathetic reinnervation, ^{123}I MIBG, cardia allografts, 911
Cardiac volume
bias from reconstructed filters, 1319(ab)
prognostic value of, 6(ab)
Cardiomyopathy
alterations in myocardial sympathetic innervation, 188(ab)
dilated, ^{123}I-MIBG myocardial imaging in, 217, 224
gated SPECT differentiation of ventricular dysfunction, 711(ab)
hypertrophic, impairment of BMIPP accumulation, ventricular junction, 2007
idiopathic dilated, prognostic value of ^{123}I MIBG in, 917
low cardiac MIBG uptake a predictor of, 175(ab)
potential alterations in oxygen, glucose and fatty acid metabolism, 808(ab)
quantitative SPECT to differentiate ischemic and nonischemic, 507(ab)
steal phenomenon in, 7(ab)
viability and endpoint markers, 738(ab)
^{18}F FTHA PET studies of, 187(ab)
^{123}I-BMIPP imaging of, 799(ab)
Carotid artery diseases, carotid shunt during carotid endarterectomy, 568(ab)
Catechol-O-methyltransferase (COMT) inhibition, PET imaging of estrogen metabolism, 406(ab)
CBF SPECT
evaluation of Alzheimer-type dementia with, 1192(ab)
high-field MRI in basal ganglia and, 271(ab)
CD36 deficiency, enhanced myocardial glucose use in, 239
Cellular dosimetry, S-factors, alpha particle-emitting radionuclides, 162(ab)
Central Nervous System (CNS), lymphoma vs toxoplasma, diagnostic utility of ^{201}Tl SPECT, 896(ab)
Cerebellum, focused infarcts, remote regional cerebral blood flow consequences, 721
Cerebral cortex, ^{99m}Tc HMPAO retention, nervous tissue, 1556
Cerebral glucose metabolism
adverse effects of edema on, 453(ab)
FDG PET assessment of changes in, 454(ab)
radiolabeled glucose and acetate to measure, 1165(ab)
Cerebral infarction
focused, remote regional blood flow responses, 721
prognostic value of ^{99m}Tc ECD, 1202(ab)
Cerebral ischemia
phosphoinositide turnover, evaluation with PET, 1590
^{99m}Tc HMPAO metabolism, nervous tissue, 1556
Cerebral metabolism, increased brain glucose use, Salla disease, 12
Cerebral oxygen metabolism, radiolabeled glucose and acetate to measure, 1165(ab)
Cerebral perfusion reserve, alterations in chronic traumatic brain injuries, 286(ab)
Cerebral perfusion SPECT
contralateral thalamic uptake, 1189(ab)
reproducibility of serial ictal/postictal images, 1199(ab)
Cerebrovascular disease, five-year prognosis, increased oxygen extraction fraction in, 1992
Cervical cancer, FDG PET in, 1125
Cesium-137, history corner, 18N(4)
10 CFR 35, rewrite of, 22N(1)
Chelate, rhenium-labeled chelators, 504(ab)
Chelating agents, combinatorial libraries, 499(ab)
Chemoradiotherapy, evaluated by FDG PET, 1132
Chemotactic peptides
effects of neutrophil depletion and immunosupression, 895(ab)
high-throughput screening, 497(ab)
infection and sterile inflammation imaging, 894(ab)
Chemotherapy, chemotherapy-induced neurotoxicity, ^{99m}Tc ECD SPECT assessment of, 522(ab)
Chemotherapy response
breast cancer assessed by ^{99m}Tc MIBI, 1038(ab)
changes in tumor blood flow and metabolism as predictor of, 551(ab)
Chest pain
significance of reduced BMIPP uptake in evaluation of, 14(ab)
women, myocardial perfusion imaging or dobutamine stress echocardiography, 1222(le)
Cholangiocarcinoma, hilar, ^{99m}Tc-GSA accumulation, 394
Cholecystitis, acalculous, cholecystokinin cholescintigraphy in, 2038
Cholecystokinin
acute cholecystitis, diagnosis of, 215(ab)
biliary dyskinesia, 856(ab)
radiolabeled, targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
Cholecystokinin receptor ligands, medullary thyroid cancer, staging of, 396(ab)
Cholecystokinin receptors, radiolabeled CCK analogs, evaluation of, 2081
Cholescintigraphy, cholecystokinin, 2038
Choline
cervical cancer, PET studies of, 1132(ab)
lymph node staging with FDG PET in lung cancer, 240(ab)
PET imaging of prostate cancer, 241(ab)
vs FDG lymph node staging in esophageal cancer, 239(ab)
Cholinergic neurons, high-affinity choline uptake, 1353(ab)
Circulation, *see* Blood flow; Collateral circulation
Cirrhosis
liver, prognosis with ^{99m}Tc GSA scintigraphy, 1652
umbilico-portal collaterals, 844(ab)
Cisplatin, ^{186}Re HEDP and, prostate cancer cells, 667
Clearance
camera-computer quantitation of bladder activity, 208(ab)
effect of time interval/blood sampling on Cr-51 EDTA, 210(ab)
Clinical outcome
acute pulmonary embolism, 220(ab)
aging, effect on predictive value of SPECT, 722(ab)
myocardial perfusion SPECT on angina pectoris, stress test in angina pectoris, clinical outcome, 710(ab)
online data tracking and reporting, 1468(ab)
solitary pulmonary nodules, 231(ab)
^{131}I-labeled anti-B1 antibody, 76(ab)
Clinical practice, nuclear medicine in the military, 10N(1)
Clinical Practice Guideline Recognition Program, AMA, 23N(5)
Cocaine, reduction of dopamine release, 444(ab)
Cocaine analogs, in vitro and in vivo evaluation of, 1343(ab)
Cochlear implant, pre-surgical prediction of, 452(ab)
Coding and Reimbursement, questions and answers, 16N(2)
Cognitive dysfunction, FDG PET detection of metabolic abnormalities in, 1184(ab)
Coincidence detection camera
attenuation correction for, 136(ab)
comparison with FDG PET, 1187(ab)
dual-detector, 1303(ab)
effects of uncollimated crystal exposure, 478(ab)
FDG imaging modalities, 1154(ab)
FDG lung studies, 461(ab)
FDG uptake in myocardial viability assessment, 708(ab)
oncology studies, low-activity camera vs conventional PET camera, 1152(ab)
optimization of crystal thickness, 1229(ab)
performance characteristics, high-contrast clinical images with gamma camera, 1245(ab)
performance characteristics of, 1243(ab)
performance evaluation, 482(ab)
singles rate optimization in, 479(ab)
Coincidence imaging
acquisition methods and detector performance for, 1298(ab)
cross-talk correction algorithm, 480(ab)
dual-detector, ^{18}F FDG, solitary pulmonary lesions, 574
dual-head
FDG PET comparison, breast cancer, 1003
vs ring PET, tumor patients, 1617
dual-head FDG detection cameras, 9N(3)
dual-head scintillation camera, 432
effects of uncollimated crystal exposure, 478(ab)
FDG, 1243(ab)
diagnostic accuracy in thyroid cancer, 543(ab)
FDG in oncology studies, 540(ab)
FDG PET detection of pulmonary lesions, 1094(ab)
FDG tumor imaging, 1153(ab)
gamma camera, FDG, lung cancer, 566
head and neck cancer, 1055(ab)
high-resolution with acceptable acquisition times, 1245(ab)
iterative reconstruction algorithm, 1295(ab)
lesion detectability with coincidence capability, 545(ab)
myocardial studies, 132(ab)
oncology studies, 546(ab), 1040(ab)
performance of SPECT camera with PET option, 1244(ab)
phantom studies, 479(ab)
pileup prevention, 598(ab)
simultaneous acquisition of FDG and Tc agents, 1247(ab)
staging of tumors of the mouth and tongue, 1048(ab)
task-based instrument evaluation, 483(ab)
three-dimensional acquisition, 1332(ab)
^{18}F FDG, 944(ab)
Collateral circulation, dynamic radionuclide angiography, 844(ab)
Collimation, Collimators
dual-planar circular-orbit cone-beam SPECT, 1253(ab)
effect and correction of detector sag in SPECT systems, 1260(ab)

effect on lesion detection in breast imaging, 140(ab)
fan-beam evaluation and calibration of, 1259(ab)
hole array pattern of, 1310(ab)
mapping of hole angulation errors, 1257(ab)
NEMA system plane sensitivity, penetrating photons, 1261(ab)
predicted lesion detection performance, 133(ab)
small gamma camera, 1226(ab)
ultra-high resolution uranium pinhole, 138(ab)
Colon cancer
FDG PET whole-body imaging, 93(ab)
liver metastasis from, radiolabeled antibody distribution and radioimmunotherapy, 685
transplanted to nude mice, ^{18}F FDG uptake in, 339
xenograft
fractionated external beam radiotherapy and radioimmunotherapy, 1764
MAb CC49 constructs, 1536
Colonic transit
Psyllium suspension in, 848(ab)
^{67}Ga labeling of activated charcoal capsules, 1383(ab)
^{67}G citrate transport, in constipation, 277
Colorectal cancer
biodistribution of ^{99m}Tc P1666 vasoactive peptide, 1081(ab)
correlation of PET studies with CEA levels in, 1070(ab)
diagnosis with PET, 412(ab)
FDG PET assessment of recurrence, 1074(ab)
improved FDG PET abdominopelvic evaluation, 1083(ab)
multimodality imaging, 92(ab)
potentially resectable lesions, 1068(ab)
radioimmunotherapy of small-volume disease, 428(ab)
therapeutic efficacy of combined radioimmunotherapy, 429(ab)
^{99m}Tc-labeled VIP receptor agonist, functional studies, 352
Community hospitals, FDG PET scanning in, 11N(11)
Compartmental models
accurate parameter estimates for dynamic ^{201}Tl SPECT, 313(ab)
FDG distribution, 1358
muscarinic cholinergic ligand, 119(ab)
Compton camera, predicted lesion detection performance, 133(ab)
Computed tomography (CT)
combined CT/SPECT, 596(ab)
radionuclide transmission, attenuation maps, multimodality registration, 448
tumor imaging, 1134(ab)
vs SPECT in evaluation of cerebral hypoperfusion, 572(ab)
Computer-assisted diagnosis
database tracking on the Internet, 1468(ab)
decision support system, physician benefit from, 96
D2 receptors, semi-quantiation of, 110(ab)
education, 1455(ab), 1456(ab)
interpretation of myocardial perfusion tomograms, 508(ab)
MIRDOSE 4, 1357(ab)
myocardial perfusion imaging, 1457(ab)
myocardial perfusion SPECT databases, 1290(ab)
voice recognition dictation system, 1292(ab)
Computer simulation
computer-based tutorials, 1461(ab)
Monte Carlo estimate of Cr-51-EDTA clearance, 210(ab)
Congestive heart failure
cardiac sympathetic function, 736(ab)
clues to prognosis, 1699(ed)
left ventricular dilatation as predictor of, 181(ab)
Constipation, ^{67}G citrate, segmental colonic transit after, 277
Continuing Medical Education (CME), earning credit electronically, 9N(2)
Convex hull, global spatial normalization, brain, 942
Copper-62 ATSM, comparative analysis reduction of, 330(ab)
Copper-62 PTSM, vs ^{99m}Tc sestamibi SPECT in detection of coronary artery disease, 723(ab)
Copper-64 ATSM, evaluation, hypoxic tumor model, 177
Copper-67 2IT-BAT-Lym-1, radioimmunotherapy, non-Hodgkin's lymphoma, 2014
Coronary artery bypass surgery
effects on brain perfusion, 1225(le)
gated myocardial SPECT to assess improved perfusion and function, 742(ab)
ischemic heart disease, assess regional function a, 761(ab)
myocardial perfusion SPECT, prognostic value of, 22(ab)
risk of cardiac death, 25(ab)
sternal vascularity of, 539(ab)
Coronary artery disease (CAD)
cardiac events, prediction with dipyridamole perfusion, 707(ab)
changes in myocardial tetrofosmin uptake indicate, 514(ab)
dobutamine assessment of regional myocardial blood flow, 791(ab)
improved diagnostic yield with ^{201}Tl, 360(ab)
improved myocardial perfusion after rhVEGF therapy, 342(ab)
Monte Carlo simulation, 165(ab)
multimodality detection of, 723(ab)
multivessel CAD, 733(ab)
myocardial perfusion SPECT, prognostic value of, 170(ab)
myocardial perfusion SPECT, simultaneous ^{99m}Tc sestamibi and ^{201}TL dual isotope, 895
percutaneous laser revascularization, therapeutic effect of, 337(ab)
PET, serial evaluation with, 732(ab)
prognostic value of weighter quantitative analysis, 169(ab)
rest and exercise dual-isotope SPECT, 774(ab)
rest-exercise stress and rest-ATP stress, ^{99m}Tc sestamibi scinigraphy, 512(ab)
simultaneous emission/transmission tomography, attenuation correction in, 1303
SPECT myocardial perfusion imaging, 347(ab)
stress testing, 516(ab)
^{62}Cu-ATSM vs FDG in detecting ischemic myocardium, 704(ab)
^{99m}Tc sestamibi SPECT, right ventricular uptake, 889
^{201}Tl lung uptake as discriminant indicator of, 809(ab)
Coronary flow, acute estrogen administration and coronary vasomotion, 32(ab)
Coronary flow reserve
differences in response to mental stress, 346(ab)
prominent in noninsulin-dependent diabetes, 762(ab)
steal phenomenon in pediatric hypertrophic cardiomyopathy, 7(ab)
validation of, ^{15}O-water PET studies, 31(ab)
Coronary intervention
reversible perfusion defects on ^{201}Tl SPECT, 741(ab)
^{201}Tl SPECT, perfusion defects after angioplasty, 811(ab)
Coronary syndrome, acute, fatty acid imaging, ^{123}I 9-MPA, 1999
Cortical bone, absorbed fractions of energy within, three-dimensional transport model, 2115
Cost-effectiveness
age basis for captopril baseline studies, 375(ab)
decision analysis in nuclear medicine, 1570
dipyridamole myocardial perfusion SPECT, 171(ab)
exercise ^{201}Tl SPECT, 718(ab)
FDG PET in lung cancer, 227(ab)
sentinel node biopsy in breast cancer management, 560(ab)
somatostatin analog, ^{99m}Tc depreotide, assessment of solitary pulmonary nodules, 231(ab)
Cross-talk correction
accurate estimation of myocardial perfusion on FDG and tetrofosmin images, 801(ab)
modeling Pb X-ray contamination in dual-isotope SPECT, 470(ab)
simultaneous ^{99m}Tc / ^{201}Tl imaging, 839(ab)
Cyclopentadienyl technetium, brain uptae and dopamine transporter binding of, 154(ab)
Cystography, radionuclide, direct and indirect, dosimetry in children, 2127(le)
Cytomegalovirus, ^{18}F FHPG PET in, 890(ab)

D

Data analysis
database management system, 1291(ab)
functional PET, 300(ab)
kinetic analysis of PET time-activity curves, 310(ab)
Monte Carlo probabilities of cluster formation, 1276(ab)
quantification with I-123-epidepride SPECT, 143(ab)
quantitation of condensed image, 859(ab)
tracking of left ventricular motion, 829(ab)
Database
normal confidence interval, 1466(ab)
relational management system, 1291(ab)
Decision modeling
nuclear medicine, 1570
ROC analysis, 475(ab)
Deconvolution, comparison, Patlak-Rutland plot in renography, 1503
Deep venous thrombosis
contrast-enhanced venography, ^{99m}Tc apcitide scintigraphy and, 2029, 2036(ed)
technetium-labeled peptide detection of, 613(ab)
^{99m}Tc anti-fibrin peptide detection of, 491(ab)
^{99m}Tc P424, evaluation of receptor binding agent, 887(ab)
de Hevesy Award, 12N(6), 30N(8)
Dementia
early Alzheimer detection, 283(ab)
effect of apolipoprotein E on regional brain metabolism, 281(ab)
FDG PET and SPECT, differential diagnosis with, 282(ab)
with Lewy bodies, ^{99m}Tc HMPAO SPECT study, 956
neurofibrillary tangles, 284(ab)
PET, clinical outcome with, 285(ab)
statistical parametric mapping to evaluate, 1205(ab)
Deoxyribonucleic acid, antisense and nuclear medicine, 693
Department of Energy (DOE)
ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
isotope conference, 22N(1)
Medical Isotopes Conference, 13N(5)
Depression
activation study of, 1212(ab)
amphetamine-induced dopamine release in, 1210(ab)
cortical metabolic deficits in, 1211(ab)
low serotonin synthesis in temporal lobe, 577(ab)
SPECT imaging of, 576(ab)
5HT2 receptors, 575(ab)
Detector defects, clinical relevance of, PET quality assurance, 1657
Diabetes, exercise-induced abnormalities of cardiac function in, 782(ab)
Diabetic foot
osteomyelitis in, 871(ab)
^{99m}Tc HMPAO four-phase imaging, 902(ab)
Diagnosis
aesthesioneuroblastoma with SRS, 1059(ab)
FDG PET assessment of malignant lesions, 1097(ab)
myocardial infarction with ^{99m}Tc tetrofosmin SPECT, 781(ab)
Diagnostic test comparisons, lacrimal scintigraphy and dacrocystography, 455(ab)
Diagnostic tests, HCFA ruling on, 25N(7)
DICOM image display, WEB picture archiving system, 1460(ab)
Differentiated thyroid cancer, reduces subsequent ablation in DTC, 531(ab)
Dimercaptosuccinic acid (DMSA)
diagnostic and therapeutic effects on head and neck cancer, 988(ab)
evaluation of urinary tract infection in children, 916(ab)
Re-188, in vitro and in vivo evaluation, 1384(ab)
SPECT imaging of renal scars, 865(ab)
Dipyridamole, myocardial perfusion SPECT, cost-effectiveness of in myocardial infarction, 171(ab)
Distinguished service awards, 30N(8)
Dobutamine
changes in left ventricular function, 709(ab)
estimation of ejection fraction, after His bundle ablation, 754(ab)
gated myocardial SPECT, 790(ab)
induced changes in left ventricular function, 703(ab)
predictor of improved LVEF post-revascularization, 1(ab)
stress testing with ^{99m}Tc sestamibi SPECT, 518(ab)
Donner Laboratory, history of nuclear medicine, 16N(1)
Dopamine
dopamine transporter occupancy and behavior, 440(ab)

effect of exercise on striatal dopamine release, 588(ab)
endogenous, ^{11}C raclopride competition with, brain response to methylphenidate, 1285
IBZM SPECT measure of reduced dopamine release, 444(ab)
PET measurement of receptor availability, 1176(ab)
schizophrenic psychopathology and presynaptic, 125(ab)
SPECT imaging of dopaminergic system in bipolar disorder, 580(ab)
SPECT measurement of amphetamine-induced release, 1210(ab)
^{18}F fallypride and F-18 FMT, system characterization of, 437(ab)
Dopamine D2 receptors
autosomal recessive Dopa-responsive dystonia, 272(ab)
binding potential associated with social phobia, 581(ab)
brain imaging, ^{123}I IBZM SPECT, neonatal period, 2125(le)
elevation of in schizophrenia, 121(ab)
endogenous release in thalamus, 1209(ab)
intrasynaptic dopamine level, 124(ab)
quantification, ^{123}i epidepride SPECT, 1902
raclopride, 586(ab)
regioselective and efficient synthetic method, 607(ab)
relative distribution in postmortem brain, 1157(ab)
simplified analysis to metabolite corrected distribution, 143(ab)
^{11}C PPHT, 1338(ab)
^{18}F fallypride, parametric imaging of striatal and nonstriatal binding, 1267(ab)
Dopamine neurons
FMT and FDOPA uptake in PET studies of aging, 1169(ab)
MPTP, effects on striatal transport and decarboxylation of, 587(ab)
striatal metabolism of 6-^{18}F fluoro-L-dopa, 1163(ab)
Dopamine receptors
D1 receptors, quantitative analysis of, 435(ab)
serotonergic and dopaminergic PET binding studies, 579(ab)
simultaneous SPECT studies, baboons, 660
synthesis and evaluation of ^{11}C YM-50001, as a PET radioligand, 1342(ab)
Dopamine transporters
age effects, healthy humans, 1812
autosomal recessive Dopa-responsive dystonia, 272(ab)
changes in cocaine users, 441(ab)
characterization of highly selective DAT ligand for SPECT, 153(ab)
detection presymptomatic phase of Parkinson's disease with I-123-FP CIT SPECT, 106(ab)
functional lateralization in basal ganglia in Parkinson's disease, 267(ab)
IPT SPECT assessment of decrease of, 126(ab)
nigrostriatal dopaminergic pathway, Parkinson's disease, 753
pharmacokinetics of ^{18}F FPCT, 1339(ab)
simultaneous SPECT studies, baboons, 660
SPECT, Parkinson's disease, 530
SPECT imaging with ^{99m}Tc TRODAT-1, 583(ab)
striatal quantitation with microPET, 1156(ab)
synthesis and structure-affinity studies of pipperidine-based analogs, 1341(ab)
in vitro evaluation of acyclic amine-amide analogs, 1340(ab)
^{99m}Tc labeled ligand and SPECT imaging of, 1161(ab)
^{99m}Tc TRODAT SPECT imaging of Parkinson's disease, 109(ab)
^{99m}Tc TRODAT-1 imaging agent, kinetic modeling of, 150
^{123}I FPCIT, reproducibility of SPECT images, 1201(ab)
^{123}I labeling, brain uptake and binding, 154(ab)
^{123}I labeling to monitor progression of Parkinson's disease, 111(ab)
Dose calibrator
errors related to radiopharmaceutical administration, 616(ab)
setting for ^{188}Re, 1508
Dose estimation
therapy with ^{111}In-octreotide, 982(ab)
^{90}T lipiodol after brachytherapy, 167(ab)
^{99m}Tc vasoactive peptides, 1363(ab)
Dosimetry
applications, new rectal model for, 1524
autonomous thyroid nodule, radioiodine therapy candidates, 1928
biodistribution of ^{18}F FCWAY, 168(ab)
biological, radiation adaptive response, 1378(ab)
brain
pediatric head and brain models, 1327
revised model, radionuclide S values in, 62S
clearance fitting, in thyroid cancer, 131
direct and indirect radionuclide cystography, children, 2127(le)
effective dose determination of ^{18}F FBT, 1356(ab)
error estimation, 158(ab)
influence of stents, 165(ab)
internal radiation, mouse models for, 1969(le)
internal radionuclide, EGS4 Monte Carlo code-based software for, 1517
intrapertoneal radioimmunotherapy, 979(ab)
marrow, radioactivity concentration in blood and body, 2102
MIRDOSE 4, 1357(ab)
Monte Carlo calculation of dose conversion factors, 1364(ab)
nonuniform, implications for radioimmunotherapy, 1337
nonuniform activity distributions, radionuclide S values at voxel level, 11S
normal organ estimates of I-131-NM-404, 155(ab)
patient morphology, MIRD models of, 157(ab)
radiation
biodistribution and, ^{111}In antimyosin, 464
FDG distribution, 1358
marrow dosimetry based on radioactivity concentration, 159(ab)
non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 1317
testes, after ^{131}I therapy for thyroid cancer, 1716
urinary bladder model for, MIRD, 102S
^{18}F fluorouracil, effect of 5-^{18}F EU on, 1361(ab)
^{67}Cu-2IT-BAT-Lym-1, tumor regression in lymphoma, 302
^{99m}Tc DMP-HSA serum albumin, 1532
^{99m}Tc-labeled IgM antibody to CD15 antigens, granulocytes, 625
radiation absorbed dose and response to I-131-Anti-BI therapy, 77(ab)
radiopharmaceuticals excreted in breast milk, 1355(ab)
red marrow, prediction with ^{131}I-labeled anti-CEA MAbs, 1609
therapeutic radionuclide, 596(ab)
three-dimensional transport model
absorbed fractions of energy, cortical bone, 2115
absorbed fractions of energy within trabecular bone, 1947
two-step targeting and, small cell lung cancer, 1216
^{86}Y, PET imaging with, 1237(ab)
^{90}Y-m170 and ^{111}In-m170, 969(ab)
^{123}I-Pk 11195, 1354(ab)
^{131}I-labeled 81C6 monoclonal antibody, malignant brain tumors, 631
^{131}I MIBG radionuclide therapy, errors in, 983(ab)
^{188}Re endovascular irradiation, 1359(ab)
Drug development
research, PET and, 1154
Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)
Drug-tracer interaction
biological activity of brain cannabinoid CB1 receptors, 438(ab)
PET assessment of, 440(ab)
DTPA, alpha-emitting bismuth cyclohexylbenzyl, anti-CD33 antibodies, 166
Dual-isotope imaging
accurate assessment of myocardial perfusion, ^{99m}Tc tetrofosmin and FDG SPECT, 801(ab)
assessing renal function in essential hypertension, 863(ab)
cross-talk correction, 470(ab)
dopamine transporter, 1170(ab)
false-negative studies, 733(ab)
left ventricular ejection fraction measurements, 724(ab)
prostate cancer, 394(ab)
SPECT, in vivo prediction of radioresistance and multidrug resistance, 1084(ab)
spectral factor analysis in, 471(ab)
Dynamic SPECT
accurate parameter estimates, 313(ab)
acquisition protocol design for, 589(ab)
detection of doxorubicin cardiotoxicity with I-123-BMIPP, 12(ab)
physiological parameter estimation, kinetic modeling, 312(ab)
quantification of dopamine transporter, 144(ab)
simultaneous emission/transmission, 382(ab)
D2-like dopamine receptor density, reproducibility, 270(ab)
D2 receptors, SPECT study of schizophremia, 123(ab)

E

Echocardiography (ECG)
acute chest pain, 174(ab)
dobutamine, ^{99m}Tc sestamibi comparison, 1683
gated SPECT
automatic ejection fraction determination, 797(ab)
left ventricular function and volumes, 1857
myocardial contrast, salvage after primary PTCA, 363
vs gated SPECT in determining left ventricular volume and ejection fraction, 778(ab)
Echocardiograpy (ECG)
dobutamine stress, myocardial perfusion imaging or, chest pain in women, 1222(le)
Ecstacy, upregulation of 5HT2A receptors in occipital cortex, 1216(ab)
Education & Research Foundation, Society of Nuclear Medicine, 32N(8)
Ejection fraction
automated gated SPECT calculations, 314(ab)
calculation with gated SPECT, 364(ab)
ECG-gated SPECT evaluation of, 747(ab)
gated PET determination of, 755(ab)
gated SPECT measure, 768(ab)
supernormal automated LVEF, 714(ab)
Electroencephalography, quantitative, ^{99m}Tc HMPAO SPECT and, Alzheimer's disease, 522
Embryonic antigen-1, anti-stage-specific, infection imaging, granulocyte membranes, 2107
Embryonic antigen-1 antibody, anti-stage specific, radiation dosimetry, granulocytes, 625
Emission computed tomography
limited memory quasi-Newton reconstruction, 301(ab)
segmentation-based reconstruction vs gamma-regularized Bayesian reconstruction, 299(ab)
Emphysema, diffuse lung disease, scintigraphy, 85
EMT6 cells, hypoxic tumor model, ^{64} ATSM evaluation of, 177
Endocarditis, bacterial, pretargeting with streptavidin and ^{111}In-labeled biotin, 484
Endothelial cells, labeling with ^{99m}Tc HMPAO, cell-biomaterial interactions, 1756
Enrico Fermi Award, Presidential award given for PET research, 10N(4)
Enzyme inhibitors, hypoxic accumulation and metabolism of BRU59-21, 1019(ab)
Epidermal growth factor receptor antibody, 99m-Tc-labeled antihuman, tumors of epithelial origin, 768
Epilepsy
artificial neural network classifier for, 476(ab)
brain perfusion, 277(ab)
extratemporal and temporal, ^{18}F FDG PET studies, 737
FDG PET as predictor of surgical outcome, 1195(ab)
foci localization with FDG PET, 274(ab)
fractionated ECD kits in epileptogenic zone detection, 1393(ab)
ictal SPECT predictor of epileptogenic region, 280(ab)
image registration and subtraction in ictal brain SPECT, 278(ab)
influence of anti-epileptic drugs on cerebellar glucose metabolism, 1186(ab)
localization of seizure foci, ictal SPECT in children, 786
neocortical foci, ^{11}C FMZ PET, 1985
normalization of ictal and interictal SPECT, 279(ab)
partial, dual-isotope ^{99m}Tc and ^{123}I SPECT in, 677
postictal SPECT images of prolonged hyperperfusion, 275(ab)
postoperative neuropsychological changes, PET, 1180(ab)

reproducibility of serial ictal/postictal SPECT images, 1199(ab)
SPECT image registration in, quantitative and clinical analysis, 1098
SPECT in, quantitative differences, 730
temporal lobe, imaging with new PET tracer ^{76}Br, 935
thalamic asymmetry on interictal SPECT, 1204(ab)
^{15}O-water PET, 1196(ab)
Epithelial tumors, ^{99m}Tc-labeled AntiEGF-R, scintigraphy, 768
Erythrocytes
FDG radiolabeling of, 951(ab)
mass, obesity and, 422
nonprimate, glucose permeability in, 2125(le)
E-selectin, binding peptide, infection imaging with, 1399(ab)
Esophageal cancer
dynamic FDG PET studies, 1075(ab)
FDG coincidence imaging of, 1077(ab)
FDG PET evaluation of, 95(ab)
FDG PET in clinical staging of, 97(ab)
FDG PET quantification, 550(ab)
FDG PET staging, 98(ab)
FDG PET staging of, 96(ab)
immunohistochemistry, 1076(ab)
lymph node staging with ^{11}C choline and FDG PET, 239(ab)
Esophageal scintigraphy
esophageal transit time after endoscopic injection, 859(ab)
pharmaceutical dosage forms in, 365(ab)
treated and untreated body myositis, 853(ab)
Esophagus, scintigraphy, with semisolid meal, systemic sclerosis and Raynaud's phenomenon, 77
Estrogen receptor ligand
mamma-carcinoma, estrogen-analog with high specificity, 403(ab)
pharmacokinetics of I-123 and I-125-DES, 1372(ab)
^{18}F FES uptake in breast neoplasm, 1111(ab)
Estrogen receptors, ^{123}I iodovinylestradiol imaging, breast cancer, 1728
Exercise
heart, perfusion defect of, 735(ab)
running, muscle activity, FDG PET imaging of, 70
Exercise capacity, value of myocardial perfusion imaging in women, 348(ab)

F

Fab fragment, antiTac, glycolated, 837
Factor analysis
coronary reserve measurements, 31(ab)
dynamic myocardial PET, 309(ab)
dynamic structures, cardiac gated studies, 1676
Factor analysis of dynamic structure (FADS), somatostatin receptor imaging, neuroendocrine tumors, 33
Factors, noise reduction in functional PET images, 300(ab)
Fatty acid imaging
BMIPP detection of viable myocardium, 765(ab)
differentiation of ischemic and idiopathic cardiomyopathy, 799(ab)
dysfunctional but viable myocardium, 13(ab)
noninvasive assessment of myocardial beta oxidation, 354(ab)
relation with dobutamine echocardiogram, 745(ab)
^{18}F FTP in PET liver studies, 502(ab)
Fatty acids
DMIPP, kinetics of, 827(ab)
extraction in isolated hearts, 840(ab)
free, myocardial utilization, gated SPECT, 1840
long-chain, deficiency, enhanced myocardial glucose use in, 239
metabolism
accumulation at ventricular junction, impairment, hypertrophic cardiomyopathy, 2007
animals and humans, 1484
hibernating myocardium during potassium channel opener therapy, 767(ab)
imaging with ^{123}I 9-MPA, acute coronary syndrome, 1999
significance of reduced uptake in evaluation of acute chest pain, 14(ab)
wall motion recovery precedes normalization of, 195(ab)
prognosis, quantitative SPECT evaluation, 770(ab)
radioiodinated, metabolism, rat tissues, 1918
radioiodinated analogs, ischemic and hypoxic canine myocardium, 1204
^{123}I IPPA, low flow or after acute infarction and reperfusion, myocardium, 821
Fermi Award, 12N(6)
Fever, whole-body FDG PET, diagnostic role of, 899(ab)
Field uniformity, acceptance testing, 1264(ab)
Filtering, significant bias in left ventricular cavity, 1319(ab)
First-pass radionuclide angiogram, velocity gradient imaging, 806(ab)
Flouro-dopa, 6-flouro-dopa, 6-flouro-L-dopa, in vivo microdialysis of, 1163(ab)
Flow cytometry, ^{201}TL uptake, nuclear DNA content, and clinical behavior relations, metastatic thyroid cancer, 963
Fluorine-18
electrophilic fluorination, 604(ab)
fatty acid imaging in hepatic studies, 502(ab)
PET tracer to detect pulmonary fibrosis, 379(ab)
serotonin receptors, 149(ab)
transferrin receptors, targeting in tumors, 1547
tropanes, 1344(ab)
vs trans-4-fluorocyclohexane derivatives, 150(ab)
Fluorine-18 altanserin, quantification of 5HT2a, 1208(ab)
Fluorine-18 FACBC, synthesis and evaluation, brain tumor imaging, 331
Fluorine-18 FDG
biodistribution in glycerol-treated mice, 90(ab)
cardiac study after transcoronary ablation of septal hypertrophy, 185(ab)
chemotherapy response in bone tumors, 388(ab)
coincidence detection with a gamma camera, brain disorders, 110, 250(ab), 544(ab)
coincidence imaging in lung cancer, 384(ab)
coincidence imaging of esophageal cancer, 1077(ab)
coinicidence imaging in oncology studies, 546(ab)
comparison of restoration filters in myocardial SPECT image, 1324(ab)
correlation of PET studies with CEA levels in recurrent colon cancer, 1070(ab)
cross-talk algorithm in simultaneous coincidence and ^{99m}Tc SPECT, 480(ab)
detection of metastatic cervical lymph nodes with PET, 1044(ab)
detection of recurrent breast cancer with PET, 1109(ab)
dual-head coincidence PET vs ring PET, tumor patients, 1617
ECAT vs ECAM, 1154(ab)
functional viability, dual-isotope assessment of, 193(ab)
head and neck tumors, 1055(ab)
immunohistochemical markers, 1076(ab)
incremental value over CT in esophageal cancer, 95(ab)
irradiation of bone marrow, 88(ab)
I-123-labeled iododeoxyuridine monophosphate, 1066(ab)
lumped constant for, skeletal muscle, 1798
lymph node uptake of, 85(ab)
myocardial glucose use, CD36 deficiency, 239
oncology studies, low-activity camera vs conventional PET camera, 1152(ab)
orbitofrontal glucose utilization, 1219(ab)
pancreatic tumor staging, 422(ab)
PET
^{11}C MET and, thymic tumors, 1595
extratemporal and temporal epilepsy, 737
pancreatic cancer, liver metastases from, 250
planar bone scintigraphy vs, osseous lesions, 1623
primary staging of malignant lymphoma, 1407
physiological uptake in gastrointestinal tracts, 89(ab)
positron imaging, solitary pulmonary lesions, 574
quantitative MIBI/FDG SPECT, 1322(ab)
radiation-induced lung injury, 1039(ab)
radionuclide studies of neuroblastoma, 912(ab)
regional left ventricular function, after revascularization, 1866
SPECT imaging of left ventricular dysfunction, 192(ab)
staging of primary bone tumors, 392(ab)
therapy monitoring, 550(ab)
uptake mechanisms, colon cancer transplanted to nude mice, 339
uptake patterns in bone tumors, 1141(ab)
uptake pattern in pulmonary tuberculosis, 380(ab)
in vitro uptake of, 888(ab)
vs I-123-BMIPP and ^{201}Tl SPECT to assess myocardial viability, 804(ab)
vs ^{18}F FMT whole-body imaging, 1018(ab)
vs ^{99m}Tc tetrofosmin to assess myocardial viability, 803(ab)
Fluorine-18 FDOPA
constraints on distribution volume, 142(ab)
effects of MPTP on, 587(ab)
MRI-aided spatial normalization, 1179(ab)
Fluorine-18 FETA
characterization of, detecting tumor hypoxia, 1072
tumor imaging, brain tumor, 205
Fluorine-18 FHPG, improved synthesis of, 333(ab)
Fluorine-18 FLT
cancer imaging, 245(ab)
PET tumor tracer, 335(ab)
pharmacokinetics of, 101(ab)
S-phase fraction vs FLT cell uptake, 100(ab)
Fluorine-18 fluorocarazolol, studies in isolated rat heart, 1400(ab)
Fluorine-18 fluoro-L-dopa, amino acid effects on distribution volume of FDOPA, 585(ab)
Fluorine-18 fluorouracil
modulation by ethynyluracil, 1361(ab)
uptake in tumors, 1032(ab)
Fluorine-18 FMISO
biological characterization of, 1365(ab)
limitations in evaluating hypoxia in nasopharyngeal carcinoma, 244(ab)
modified synthesis of, 605(ab)
simultaneous study with ^{11}C acetate, 1062(ab)
Fluorine-18 FMT, PET, brain tumor patients, 399
Fluorine-18 FPCT, basal ganglia, detection of, 1339(ab)
Fluorine-18 FTHA
noninvasive assessment of myocardial oxidation, 354(ab)
PET studies of dilated cardiomyopathy, 187(ab)
Fluorine-18 setoperone, serotonin receptor distribution with, neocortex, parametric PET imaging of, 25
Fluorodeoxyglucose (FDG)
bioreductive antitumor agent, 91(ab)
cerebral glucose metabolism, brain responses to lorazepam, 715
diagnostic and therapeutic value, 407(ab)
differential uptake with various oncogenes, 1000(ab)
distribution, mathematical model for, 1358
dual-head coincidence detection cameras, 9N(3)
dual-head gamma camera coincidence imaging, lung cancer, 566
extent of viable tissue determines improved LVEF postrevascularization, 190(ab)
heart and skeletal muscle uptake, insulin action on, hypertriglyceridemia patients, 1116
PET
brain, predictive value for cochlear implantation, 452(ab)
brain tumors, colorectal cancer lymphoma, and melanoma, 591
cervical cancer patients, 1125
chemoradiotherapy evaluated by, 1132
differentiation, from osteradionecrosis, 1049(ab)
drug research and development, 1154
hematocrit correction, 1282(ab)
in lung cancer, 814
for management of lesions failing biopsy, 409(ab)
metabolic measurements of malignant tumors, 1771
metastatic thyroid cancer, 993(ed)
optimal interpretation, pancreatic cancer, 1784
papillary thyroid carcinoma, 986
preoperative investigation with FDG and a hybrid PET camera system, 541(ab)
prognostic value in malignant pleural mesothelioma, 1241
skeletal muscle, glucose transport and phosphorylation, 977
SPECT or gamma coincidence imaging, myocardial viability, 1893(ed)

therapy control, 941(ab)
tumor response after photodynamic therapy, 876
PET, oncologic imaging applications, 1706
PET imaging, muscle activity in runners, 70
phantom for system evaluation and design, 1241(ab)
splenic uptake, granulocyte colony-stimulating factor therapy, PET imaging, 1456
tyrosine imaging and, soft tissue tumors, 381
uptake, glucose transporters and, non-small cell lung cancer, 536
urinary excretion, optimization during PET, 1352
Fluoro-m-tyrosine, oxygen difluoride, 604(ab)
Fontan procedure, congenital heart disease, scintigraphic evaluation of whole-body blood flow patterns, 1477
Food and Drug Administration (FDA), ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
Fourier space method, PET quality assurance, clinical relevance of detector defects, 1657
Fractal dimension, quantification of radioisotope distribution, 1287(ab)
Fractional cold kits, cost-effectiveness of, 1393(ab)
Fractionation
metabolic studies of ^{18}F alpha-methyl tyrosine, 336(ab)
nonuniform tumor doses, radioimmunotherapy and, 1337
Frequency encoding, simultaneous display using, brain, 442
Fungal infection, in granulocytopenia, scintigraphic imaging, 2066
Furosemide
diuresis renography, infants and children, 1805
optimal timing of diuretic administration, 204(ab)
Fused image tomography
integrative force, 13N(8)
where do we go from here?, 30N(10)
Fv fragment, adverse effect of circulating antigen, 1381

G

Gallbladder, cholecystokinin cholescintigraphy, 2038
Gallium, tumor cell uptake, photodegraded nifedipine and, 2129(le)
Gallium scintigraphy
gynecologic lymphoma with SPECT and CT, 955(ab)
predictor of residual tumor viability in NHL, 251(ab)
renal uptake of Ga-67, 1140(ab)
rheumatic carditis, 11(ab)
Gallium-67
scintigraphy
MRI comparison, bone neoplasms, 387
non-Hodgkin's lymphoma, 40
transferrin-independent uptake, nifedipine promotion of, tumor cells, 159
transferrin receptors CD71, 960(ab)
Gallium-67 citrate
oral, segmental colonic transit after, in constipation, 277
solid colonic transit study, 1383(ab)
SPECT imaging of pretreated vertebral osteomyelitis, 48(ab)
Gallium-67 Cu-2IT-BAT-Lym-1, pharmacokinetics, tumor regression in lymphoma, 302
Gamma camera
coincidence imaging, FDG, lung cancer, 566
diverging collimator, 1226(ab)
FDG-PET, quantification of uptake, 1246(ab)
measured attenuation correction fo FDG imaging, 1311(ab)
performance characteristics of quantitized camera, 1225(ab)
solid-state photodetector, 599(ab)
^{99m}Tc MAG3, evaluation of renal function, 793
Gamma detectors, intraoperative detection of tumors, ^{111}In-labeled radiopharmaceuticals, 2094
Gastric banding, laparoscopic adjustable silicone, 99m-Tc pertechnetate scintigraphy, 783
Gastric cancer
FDG PET staging of, 94(ab)
whole-body FDG PET, 1073(ab)
Gastric emptying
four-hour vs two-hour studies, 854(ab)
in hypothyroid patients undergoing radioiodine treatment, 527(ab)
motility and, procedure guidelines, 1236
quantitation and interpretation of liquid emptying studies, effect of, 52(ab)
rate assessment, intra-abdominal radioactivity in the stomach, 1106
Gastrin, radiolabeled, targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
Gastritis, FDG uptake in gastric wall, 851(ab)
Gastroenteropancreatic tumors, somatostatin receptor scintigraphy in, 539
Gastroenteropancreatic tumor, bone metastases from, somatostatin receptor imaging, 1602
Gastroesophageal reflux
gastric emptying rate, relationship between, 849(ab)
upper GI series, barium swallow, 51(ab)
Gastrointestinal bleeding
detection with intra-arterial scintigraphy, 852(ab)
Meckel's diverticulum and, procedure guidelines, 1226
Gastrointestinal tract
bowel preparation for FDG uptake, 89(ab)
clinical utility of whole gut transit scintigraphy, 366(ab)
FDG uptake in, 563(ab)
four-hour vs two-hour gastric emptying studies, 854(ab)
salivary secretory function in Sjogren's syndrome, 857(ab)
Gender differences
radionuclide angiography, 26(ab)
voice recognition dictation system, 1292(ab)
Gene expression
adenoviral-mediated, 1012(ab)
genetic constitution of serotonin transporter, 445(ab)
probe assay for herpes simplex virus Type 1, 102(ab)
^{123}I FIAU imaging of, 104(ab)
Gene therapy
development of, PET imaging in, 995
PET with ^{18}F FHPG, 333(ab)
quantitative evaluation, in myocardial angiogenesis, 760(ab)
viral transfer of nucleoside transporter, 1011(ab)
5-FU pretreatment with HSV thymidine kinase, 1010(ab)
^{18}F FHBG, PET imaging agent of gene expression, 103(ab)
^{131}I FIAU, 105(ab)
Glioblastoma, malignant glioma brachytherapy, 971(ab)
Glioma
enhanced ^{11}C TPMP uptake, PET, 1180
prognostic assessment with ^{201}Tl SPECT, 1063(ab)
SPECT delineation of, 397(ab)
Glomerular filtration rate
count based camera method, to measure, 207(ab)
estimation, renography, 1968(le)
Glucose
cerebral metabolic rate of, FDG PET noninvasive measurement, 1441
metabolism
blood-brain transport ^{11}C methyl-D-glucose measure of metabolic rate of glucose, 293(ab)
brain tumors, after stereotactic radiosurgery, 1085
cerebral, regional brain metabolic responses to lorazepam, 715
cerebral cortex, statistical mapping of, 294(ab)
dynamic changes in, 1174(ab)
FDG uptake in human inflammatory cells, 888(ab)
FDG uptake of prazosin, 828(ab)
heart and skeletal muscle, insulin action effects on FDG uptake, 1116
myocardial PET imaging of, lump constant variability, 824(ab)
myocardial uptake, ischemic cardiomyopathy patients, FDG PET, 1292
permeability, nonprimate erythrocytes, 2125(le)
tumor localization, 1369(ab)
underestimation of MGU with C-11, 842(ab)
uptake, myocardial, FDG PET measurement, 1186
^{11}C vs ^{18}F FDG to measure MGU, 836(ab)
Glucose metabolic rates, cortical metabolic deficits in depression, 1211(ab)
Glucose transport, phosphorylation and, FDG PET, 977
Glucose transporter
FDG uptake and, untreated primary non-small cell carcinoma, 536
putative hypoxic tracer, detection of tumor hypoxia, 854
^{11}C O-methyl-D-glucose, 293(ab)
Glutathione
kit preparation of, 1395(ab)
localization, brain, ^{99m}Tc HMPAO, 1056
GLUT-1 (glucose transporter)
expression in bronchioloalveolar lung carcinoma, 86(ab)
Ki-67 score, 998(ab)
mitochondrial hexokinase, 999(ab)
Glycolate, conjugation, biodistribution of humanized antitac Fab fragment, 837
Glycosylation, isoelectric point relations, tumor accumulation of avidin, 479
Government Relations Update, 1998 year end report, 25N(2)
Granulocyte colony-stimulating factor therapy, splenic FDG uptake, PET evaluation of, 1456
Granulocytopenia, bacterial and fungal infection, scintigraphic imaging, 2066
Graves' disease
anti-thyroid drugs, 932(ab)
dose calculation, 528(ab)
retreatment with radioiodine, 215(le)
somatostatin receptor scintigraphy of, 925(ab)

H

HCFA reimbursement, PET, Town Hall Meeting, 10N(3)
HCPCS codes, 1999, 26N(3)
Head and neck cancer
chemoradiotherapy, evaluated by FDG PET, 1132
cost-effectiveness of FDG PET imaging, 255(ab)
diagnosis of with FDG PET, 253(ab)
diagnostic and therapeutic assessment with DMSA, 988(ab)
differentiation of tumor recurrence and post-treatment effects, 259(ab)
dual-tracer lymphoscintigraphy, 257(ab)
FDG PET assessment, 1051(ab)
nuclear medicine in, 91
primary staging and recurrence, 254(ab)
prognostic value of ^{201}Tl -chloride, 1057(ab)
staging primary tumors with dual-head PET camera, 1056(ab)
^{186}Re-labeled monoclonal antibody, radiommunotherapy with, 263(ab)
Head and neck tumors
cervical lymph node metastases, 1150(ab)
diagnosis of recurrent tumor with IMT SPECT, 256(ab)
dualt-time point FDG PET imaging of, 1054(ab)
FDG PET imaging of, 1053(ab)
lymphoscintigraphy, double tracer technique, 776
sestamibi scintigraphy, prediction of radiotherapeutic response, 985(ab)
SUV, 1049(ab)
Head injury, PET vs CT/MRI in closed-head injury, 287(ab)
Health Care Financing Administration (HCFA)
hospital outpatient prospective payment system (HOPPS), 24N(4), 16N(12)
Medicare coverage of PET, 23N(5)
ruling on diagnostic tests, 25N(7)
Y2K, 16N(12)
Health Professions Network, news from the Technologist Section, 16N(4)
Heart
chronic heart failure, PET measures of, 19(ab)
congenital anomalies, surgical intervention, scintigraphic assessment, 1477
failing, cardiac MIBG kinetics and metoprolol, 224
gated images, using factor analysis of dynamic structures, 1676
hibernating myocardium, 822(ab)
sensitivity of ^{11}C PHEN kinetics, monoamine oxidase activity and, 232
Heart disease, ischemic
computer-assisted decision support system use in, 96
^{123}I BMIPP myocardial metabolism in, 471
Heart rate, variability, ^{123}I MIBG kinetics after myocardial infarction and reperfusion, 904

Heart transplantation
allograft rejection, 5(ab)
reinnervation, effect on myocardial metabolism, 30(ab)
sympathetic reinnervation, by ^{123}I MIBG, 911
^{13}N ammonia PET study with angiography in allograft vasculopathy, 719(ab)
Helicobacter pylori, oral flora, a false-positive factor of, 367(ab)
Hemodialysis, left ventricular function and volume in patients on, 739(ab)
Hepatic cancer, radiotherapy with Ho-166-chitosan, 1360(ab)
Hepatobiliary scan
cholescintigraphy, 215(ab)
differential diagnosis of extrahepatic metastases, 1071(ab)
^{99m}Tc DISIDA, assessment of biliary obstruction after hepatic resection, 214(ab)
Hepatocellular cancer
alpha-fetoprotein antibody imaging, 427(ab)
class differentiation with ^{99m}Tc sestamibi, 1072(ab)
detection of extrahepatic tumors with ^{99m}Tc PMT, 1071(ab)
Hepatocytes, ^{111}In labeled, biodistribution of, 850(ab)
Hepatoma, combination gene therapy enhanced by 5-FU, 1010(ab)
Herpes simplex virus thymidine kinase
gene imaging, 1012(ab)
genetic targeting of radiation therapy, 105(ab)
^{11}C FMAU imaging of, 890(ab)
Hexamethyl propyleneamine oxime (HMPAO), stereo-selective synthesis of, 1350(ab)
Hibernating myocardium, blood flow/metabolism mismatch pattern, 186(ab)
Histidine, ^{99m}Tc-labeled, unprecedented high specific activity, 1913
History corner
barium enigma, 24N(7)
The Heritage Project, 21N(11)
Hodgkin's disease
comparison with CT and ESR, 941(ab)
FDG PET and ^{67}Ga in staging and follow-up of patients, 252(ab)
primary staging and therapy control, 248(ab)
Holmium-166
feasibility study using micro-TLD chips, 1358(ab)
pharmacokinetics, 160(ab)
radiotherapy for hepatic cancer, 1360(ab)
Human immunodeficiency virus (HIV), myocardial damage, 3(ab)
Hydrazinonicotinamide, annexin V coupled with, imaging of apoptosis, 184
Hydrazino nicotinyl, liposomes labeled, ^{99m}Tc, 192
Hydronephrosis, Extra-renal pelvis, 860(ab)
Hydroxyurea, assessment of therapeutic effects on splenic function with, 958(ab)
Hypercholesterolemia, detection of early silent ischemia in hypercholesterolemia, 737(ab)
Hyperglycemia, effect on improved myocardial flow reserve, 762(ab)
Hyperparathyroidism
following total thyroidectomy, 936(ab)
oxyphil cell content, ^{99m}Tc sestamibi relations, 1402(le)
parathyroid adenomas, 202(ab)
Hypertension
essential, in cardiac sympathetic nervous system, ^{123}I MIBG imaging, 6
gated SPECT measure of myocardial cavity and mass volumes, 807(ab)
hypertrophic heart, 796(ab)
hypotensive response to captopril, renal artery stenosis assessment and, 406
renal failure and, captopril renal scintigraphy in, 412
resting glomerular filtration rate variability, 372(ab)
Hyperthyroidism, randomized control trial, 934(ab)
Hypertriglyceridemia, FDG uptake, heart and skeletal muscle, insulin action on, 1116
Hypofunctional thyroid nodules, variable scintigraphic patterns of chronic thyroiditis, 1458(ab)
Hypothyroidism, congenital, pertechnetate scintigraphy in, 799
Hypoxia
bioreductive characteristics of Tc-ATSM2, 493(ab)
clinical PET study, 605(ab)
cytochrome P450 reductase, 1019(ab)
FDG vs blood flow as an indicator of, 1110(ab)
isolated perfused rat heart, 823(ab)
neurotoxicity result of free radicals, 1174(ab)
noninvasive assessment of, 401(ab)
noninvasive assessment with ^{99m}Tc metronidazole, 1366(ab)
oxygenation status in tumor xenografts, 1021(ab)
radiation necrosis, limitations of F-19-FMISO PET, 244(ab)
tumor model, ^{64} ATSM evaluation of, 177
^{62}Cu ATSM, as hypoxic tissue tracer in myocardial ischemia, 704(ab)
^{99m}Tc labeled HL-91, kinetic analysis of, 353(ab)
^{99m}Tc nitroimidazole, effect of lipophilicity, 331(ab)

I

Ileorectal anastomosis, 5-aminosalicylic acid absorption, radioenema imaging, 1630
Image analysis
attenuation correction, PET and SPECT myocardial perfusion imaging, 362(ab)
automated lesion volume estimation, 466(ab)
automated ROI generation, 1279(ab)
computer-based tutorials, 1461(ab)
covariance of three-dimensional Bayesian reconstructions, 129(ab)
effect on noise propogation in SPECT, 1317(ab)
pixel-to-pixel regression analysis, 279(ab)
SPECT and PET brain studies, 1289(ab)
tumor detection, improved by ROC analysis, 1314(ab)
Image coregistration, wavelet-based image registration, 467(ab)
Image fusion
oncology, anatomical and functional image fusion, 597(ab)
three-dimensional datasets, 1454(ab)
Image orientation, scintigraphic assessment of the elbow, 869(ab)
Image processing
denoising technique for PET, 1307(ab)
network ,TCP/IP, 1460(ab)
Poisson impulse field analysis, 1317(ab)
portable image processing package, 1294(ab)
resolution recovery, 1327(ab)
wavelet-based image registration, 467(ab)
Image reconstruction
EM algorithm, 297(ab)
kinetic modeling, 311(ab)
modeling dynamic data during, 589(ab)
optimization of, 1320(ab)
ordered subsets expectation maximization (OSEM), 593(ab)
quantitation of spatially varying fanbeam collimation, 1325(ab)
sampling pattern compensation, 1234(ab)
spiral PET, implementation of, 1232(ab)
three-dimensional, evaluation of, 1255(ab)
Image registration
automated, 3-D multimodality registration maps using, 448
need for in multicoincidence SPECT, 1281(ab)
prior to interactive subtraction, 200(ab)
SPECT, epilepsy studies, 1098
Image smoothing, denoising technique for PET, 1307(ab)
Imaging figure of merit
detection of lesions in vessels, 1280(ab)
dual-head PET, performance of, 481(ab)
quantification of performance, 482(ab)
Immunoassays
Compound W in maternal serum and urine, 922(ab)
third generation TSH assay, 923(ab)
Immunohistochemistry, GLUT-1 expression in breast and lung cancer, 87(ab)
Immunoscintigraphy
new management algorithm, 67(ab)
^{99m}Tc HIG in postoperative spinal infection, 63(ab)
^{99m}Tc labeled antibody fragments for osteomyelitis, 47(ab)
Indium-111
antibody fragment labeled with, 327(ab)
antimyosin, cardiac imaging, 3(ab)
intraoperative detection of tmors, gamma detectors for, 2094
pharmaockinetics of CDTA-Di-XASP dyes, 1396(ab)
^{90}Y-labeled antiTac monoclonal antibody distribution, differences, 268
Indium-111 antimyosin
biodistribution and radiation dosimetry, idiopathic inflammatory myopathies, 464
hereditary muscular dystrophy, 1222(le)
Indium-111 diethylenetriamine pentaacetic acid, antibody conjugates, blood clearance, 1392
Indium-111 DOTATOC, 111-In-DTPAOC comparison, tumor uptake, 762
Indium-111 DTPAOC, 111-In-DOTATOC comparison, tumor uptake, 762
Indium-111 octreotide
imaging in Grave's ophthalmopathy, 925(ab)
somatostatin receptor imaging
meningioma, 1246
pituitary adenoma, 1252
Indium-111 oxine, tumor vaccination with, 1028(ab)
Indium-111 pentetreotide
Langerhans' cell histiocytosis, 962(ab)
radiolabeling with Fe-59-ferric chloride, 1389(ab)
somatostatin receptor imaging, FADS in, neuroendocrine tumors, 33
Infection imaging
bacterial detection in orthopedic patients with ^{99m}Tc ciprofloxacin, 60(ab)
bone/gallium study of painful joint replacements, 43(ab)
bone scintigraphy of diabetic foot, 871(ab)
fungal infections, 907(ab)
in granulocytopenia, 2066
labeled leukocyte scintigraphy, 905(ab)
labeled leukocytes in orthopedic infections, 901(ab)
leukocyte vs ciprofloxacin imaging, 59(ab)
tuberculosis, 380(ab)
^{99m}Tc chemotactic peptide, 1398(ab)
^{99m}Tc ciprofloxacin, 904(ab)
^{99m}Tc ciprofloxacin in prosthetic joint infection, 893(ab)
with ^{99m}Tc glutathione kit, 1395(ab)
^{99m}Tc HNP, bacterial infections, 2066
^{99m}Tc-labeled murine immunoglobulin M antibody, granulocyte membranes, 2107
^{99m}Tc labeled Peg liposomes, 58(ab)
^{99m}Tc labeled receptor antagonist, 892(ab)
^{99m}Tc P483H, uptake in E. coli, 954(ab)
^{99m}Tc P483H binding to monocytes and leukocytes, 950(ab)
^{125}I labeled Blankophor for fungal infection imaging, 907(ab)
Inflammation
accumulation of ^{99m}Tc labeled chemotactic peptide, 895(ab)
cartilage alterations by I-123-Alp, 537(ab)
detection of plantar fascitis, 45(ab)
esophageal function in treated and untreated body myositis, 853(ab)
FDG-labeled WBC and FDG PET evaluation of colorectal cancer, 1083(ab)
Inflammation/infection imaging
E-selectin binding peptide, in vivo studies of, 1399(ab)
FDG PET differentiation of prostheses loosening, 389(ab)
membrane probe, with ^{111}In-CDTA-Di-XASP, 1396(ab)
radiolabled antibodies in diagnosis of equivocal appendicitis, 62(ab)
SPECT leukocyte imaging in occult infective endocarditis, 9(ab)
^{99m}Tc labeled N-formylpeptide antagonist analog, 497(ab)
^{99m}Tc labeled Peg liposomes, 58(ab)
^{99m}Tc labeled peptide, 900(ab)
^{99m}Tc P483H peptide imaging, 57(ab)
Inflammatory bowel disease, ^{99m}Tc white blood cell imaging in, 50(ab)
Inhalation scintigraphy, distribution quantification, validation of, 886(ab)
In memoriam
Glenn T. Seaborg, 31N(5)
Joseph F. Ross, 28N(5)
Input function
derivation from brain O-15-water PET images, 146(ab)
image-derived, PET studies, 463(ab)
quantitative PET, venous ROI, 1666

Institute of Medicine, 24N(12)
Instrumentation
breast cancer imaging system, 1223(ab)
compact quantitized gamma camera, 1225(ab)
detectors
avalanche photodiode array, 304(ab)
high resolution gamma ray, 303(ab)
micro-PET, lutetium oxyorthosilicate scanner for, 1164
penetration, determination of, 1261(ab)
PET, high resolution camera, 1233(ab)
PET scanner for neuropsychiatric disorders, 1240(ab)
scintigraphic findings of HIS-RIS interface, 1465(ab)
segmentation algorithms, effect of acquisition time on, 459(ab)
solid-state photodetector, 599(ab)
Insulin, hepatic targeting property, 498(ab)
Insulin-resistance syndrome, effect on FDG uptake, 939(ab)
Integrin antagonists, radiolabeled, tracers for tumor targeting, 1061
Interleukin-2, pharmacokinetic differences of, 1027(ab)
Intralesional therapy, P-32 radiotherapy for unresectable pancreatic cancer, 984(ab)
Intraoperative detection, gamma detectors for, ^{111}In-labeled radiopharmaceuticals, 2094
Intraperitoneal tumor (IPT)
enhanced accumulation of albumin in, 1371(ab)
pharmacokinetics of Lu-66-CC49, 967(ab)
Iodine-123
AChE activity imaging, 289(ab)
comparison with I-131 scintigraphy, 526(ab)
dual-isotope SPECT, partial epilepsy, 677
FIAU, gene expression, 104(ab)
scatter correction, downscattered component compensation method, 1300(ab)
synthesis and radiolabeling of serotonin transporter ligand, 1346(ab)
Iodine-123 α-methyl tyrosine
recurrent head and neck tumors, 256(ab)
role in radiotherapy of glioma, 397(ab)
uptake in carcinoid tumors, comparison with ^{111}In, 393(ab)
uptake in soft-tissue tumors, proliferation rate, 398(ab)
Iodine-123 β CIT,
dopamine transporters, 107(ab)
SPECT data, Parkinson's disease, 530
Iodine-123 BMIPP
accumulation at ventricular junction, impairment, hypertrophic cardiomyopathy, 2007
metabolic marker of ventricular pressure overload, 800(ab)
myocardial metabolism, ischemia model, 471
^{99m}Tc MIBI and, myocardial viability studies, 707
Iodine-123 epidepride
outcome measures, 270(ab)
SPECT, quantification of dopamine D_2 receptors, 1902
Iodine-123 FPCIT
defects of functional dopaminergic system, automatic algorithm, 1091
SPECT, nigrostriatal dopaminergic pathway in Parkinson's disease, 753
Iodine-123 IBZM
dopamine D2-receptors, 122(ab)
efficient synthesis, 607(ab)
reliable synthesis for clinical studies, 606(ab)
SPECT study of schizophrenia, 123(ab)
synthesis for routine clinical studies, 606(ab)
Iodine-123 IMP
interictal SPECT imaging of frontal lobe epilepsy, 1204(ab)
radioiodinated amphetamine, simplified chemical synthesis, 1391(ab)
SPECT estimation of regional cerebral blood flow, 1273(ab)
SPECT rCBF study to differentiate dementia, 1185(ab)
Iodine-123 IMT, pharmacokinetics in glioma cells, 1017(ab)
Iodine-123 IMZ, ischemia-reperfusion injury, 1172(ab)
Iodine-123 iomazenil, SPECT assessment of post-traumatic stress disorder, 578(ab)
Iodine-123 MIBG
Behcet's disease, 39(ab)
cardiac allografts evaluated with, sympathetic reinnervation of, 911
cardiac sympathetic denervation detection, 744(ab)
cardiac uptake, idiopathic ventricular tachycardia and fibrillation, 1
cardiomyopathy, 736(ab)
early essential hypertension, cardiac sympathetic nervous system in, 6
effect of exercise on, 734(ab)
kinetics
after myocardial infarction and reperfusion, 904
elevated plasma norepinephrine effects, 2088
myocardial imaging, cardiac sympathetic activity, 217
myocardial sympathetic innervation in sinus bradycardia, 786(ab)
prognostic value, idiopathic dilated cardiomyopathy, 917
sympathetic nerve alterations assessed with, failing heart, 224
vs ^{201}Tl and ^{99m}Tc MIBI gated SPECT in sympathetic cardiac innervation, 10(ab)
Iodine 123 9 MPA, fatty acid imaging with, acute coronary syndrome, 1999
Iodine-125, radiobiologic effects, 1377(ab)
Iodine-125 BMIPP, gated SPECT, myocardial free fatty acid utilization and left ventricular function, 1840
Iodine-125 DTPA, camera-computer quantitation of bladder activity, 208(ab)
Iodine-125-labeled antitac ds Fv, biodistribution of, adverse effect of circulating antigen, 1381
Iodine-131
Graves' disease retreatment with, 215(le)
radiation dosimetry, non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 1317
stunning radiosensitivity of, 931(ab)
therapy
nontoxic multinodular goiter, 1313
vocal cord paralysis after, 505(le)
Iodine-131 BMIPP, pharmacokinetics and metabolism, animals and humans, 1484
Iodine-131 MIBG, uptake, heart, effects of Parkinson's disease, 371
Iodine-131 orthoiodohippurate, single-sample clearance, renal, reproducibility of, 1122
Iodine-131 sodium iodide
rapid automated blood volume analyzer, 961(ab)
uptake measurement in thyroid remnants, 930(ab)
Iodine-131 sodium therapy, stunning, well-differentiated thyroid carcinoma, 1046(ab)
Iodine-131 whole-body scan
comparison of measurement techniques, 989(ab)
diagnostic and post-therapeutic imaging, 1046(ab)
Ischemia
effects on glucose utilization, 828(ab)
three-dimensional location, size and intensity of ischemia, 729(ab)
Ischemic heart disease
effect pf exercise on myocardial perfusion, 734(ab)
prognostic value of dual SPECT studies of, 13(ab)
Ischemic left ventricular dysfunction, ^{201}Tl, fixed defects on stress-reinjection SPECT, 731(ab)
Ischemic penumbra, detection of viable cortical neurons, 1166(ab)
Iterative reconstruction
coded aperture imaging, 1305(ab)
comparison of two methods with nonuniform attenuation correction, 1326(ab)
heart study, PET, 862
limited-memory quasi-Newton, 301(ab)
maximum likelihood, bone SPECT, 1978
mixed continuity image, 1299(ab)
OSEM vs standard filtered backprojection in brain studies, 592(ab)
reconstruction methods for PET detection of small lesions, 591(ab)
segmentation-based reconstruction vs gamma-regularized Bayesian reconstruction, 299(ab)
SPECT, 202(ab)
time-dependent compensation methods for, 1298(ab)

J

Journal of Nuclear Medicine (JNM)
outstanding article, 15N(9)
Sandler, Martin P., Editor, Directions, 9N(1)
single-case study, 2130(le)

K

Kawasaki disease, reverse mismatch of myocardial perfusion and metabolism, 909(ab)
Kidney
failure, hypertensive patients, captopril renal scintigraphy in, 412
function
automated technique to assess, 862(ab)
radionuclide therapy with ^{111}In-DTPA-octreotide, 416(ab)
renal depth as predictor of, 867(ab)
hypotensive response to captopril, renal artery stenosis assessment and, 406
plasma flow, ^{99m}Tc EC clearance, radionuclide renography, 429
reconstruction of inconsistent SPECT data, 128(ab)
reproducibility of ^{99m}Tc DMSA, 56(ab)
scarring, ^{99m}Tc DMSA use in, 60
tumor enucleation, function after, ^{99m}Tc DMSA SPECT assessment of, 968
ureteropelvic junction obstruction, SPECT of ^{99m}Tc DMSA uptake, infant, 1111
^{99m}Tc MAG3 uptake, reproducibility and accuracy, 972
Kidney function
^{99m}Tc DMSA quantitative SPECT uptake, children, 56
^{99m}Tc EC clearance, radionuclide renography, 429
^{99m}Tc MAG3 clearance, reproducibility of, 1122
Kidney transplantation, captopril renal scintigraphy of complications, 376(ab)
Kinetic analysis
neuroreceptor modulation, 1265(ab)
quantitation of dynamic FDG PET oncology images, 465(ab)
Kinetic modeling
eproducibility studies of ^{11}C carbonyl-WAY 100635, 1162(ab)
PET dopamine D1 receptors, 435(ab)
serotonin transporters, 114(ab)
simplified modeling protocol, 583(ab)
^{11}C carbonyl-WAY-100635 and endogneous serotonin, 117(ab)
Kinetics
radionuclide distribution, 163(ab)
reconstruction of inconsistent SPECT data, 128(ab)

L

Labia, biopsy, salivary gland scintigraphy in Sjögren's syndrome, 64
Latin America, nuclear medicine in, 9N(9)
Lawrence, John, Donner Laboratory, 16N(1)
Left bundle branch block
fatty acids added in, myocardial viability and, 213(le)
pattern of myocardial perfusion abnormality, 783(ab)
Left ventricular dysfunction
after acute MI, prediction of recovery, 1683
chronic, BMIPP imaging, 1468
severe, ^{99m}Tc tetrofosmin SPECT for prediction of, 1824
Left ventricular ejection fraction
automatic, echocardiographic-gated ^{99m}Tc tetrofosmin SPECT, 1693
blood-pool imaging of, 776(ab)
gated SPECT techniques to assess left ventricular function, 753(ab)
gated SPECT vs radionuclide ventriculography in assessment, 757(ab)
gated thallium SPECT in, major myocardial infarction patients, 513
large perfusion defects and, gated SPECT, 805
perfusion and, gated SPECT, 650
radionuclide, sympathetic nerve alterations, failing heart, 224
simultaneous dual-isotope gated SPECT study for, 724(ab)
viability in chronic infarction, BMIPP maging, 1468
Left ventricular function
free fatty acid utilization and, ^{125}I BMIPP gated SPECT assessment of, 1840
gated myocardial perfusion SPECT assessment of, 705(ab)
improvement in, after pulmonary thromboendarterectomy, 173(ab)
prediction by BMIPP in chronic infarction, 706(ab)

quantitative assessment with FDG PET, 35(ab)
volume and, gated SPECT and echocardiography, 1857
Left ventricular mass, cardiac sympathetic nervous system and, ^{123}I MIBG imaging, 6
Left ventricular volume
gated sestamibi SPECT measure of, as predictor of CHF, 181(ab)
myocardial viability with rest ^{201}Tl, 743(ab)
Leptomeningeal metastases, cerebrospinal fluid study of, 1206(ab)
Leukemia
anti-CD33 in, pharmacokinetics and dosimetry, 1935
chronic lymphocytic, non-Hodgkin's lymphoma and, radiation dosimetry, 1317
early and delayed whole-body scan to detect, 523(ab)
minimal residual disease, 942(ab)
^{188}Re labeled antibodies to treat leukemia, 262(ab)
Leukocytes, utility of delayed HMPAO in diabetic foot, 903(ab)
Lewy body disease, discrimination from Alzheimer's-type dementia, 1185(ab)
Limp perfusion, hyperthermic isolated, soft-tissue sarcoma and skin cancer, 262
Liposomes, ^{99m}Tc labeled, hydrazino nicotinyl derivative, 192
Liver
hemodynamic change and uptake ratio of, 217(ab)
hilar cholangiocarcinoma, ^{99m}Tc GSA accumulation, 394
ischemia-reperfusion injury,FK506, 847(ab)
lesion detection, scatter subtraction in SPECT, 1011
metastasis, radiolabeled antibody distribution and radioimmunotherapy, 685
partial resection of, 212(ab)
portal hemodynamics, 858(ab)
resection
residual functional reserve, ^{99m}Tc GSA SPECT, 1644
^{99m}Tc GSA, recovery of asialoglycoprotein receptors, 137
transferrin receptors, ^{18}F targeting in tumors, 1547
^{99m}Tc annexin assessment of transplant rejection, 846(ab)
Liver clearance, comparison between Tc-99 -Sn colloid and ^{99m}Tc GSA, 211(ab)
Liver disease
chronic, functional calculation with liver-spleen scan, 1745
pathophysiology of biliary secretion, 845(ab)
Liver function
liver, quantitative evaluation of, 213(ab)
segmental estimation of, 216(ab)
Tc-labeled fatty acid analog to assess, 1406(ab)
Liver malignancies, SPECT assessment of PGP expression, 426(ab)
Liver metastases, pancreatic cancer, FDG PET, 250
Liver-spleen scan, functional spleen volume calculation, 1745
Liver transplantation, auxiliary partial orthotopic, asialoglycoprotein recepor scintigraphy in, 1463
Loevinger-Berman Award, 15N(9)
Low flow, fatty acid imaging of ischemia, 840(ab)
Lung
aerosol scintigraphy, ^{99m}Tc-labeled exogenous natural surfactant in, 1080
detection of pulmonary lesions with coincidence imaging, CT and MRI, 1094(ab)
FDG uptake, errors in, 385(ab)
fibrosis in, 379(ab)
muscarinic receptors, PET detection of, 1270
pulmonary adrenoreceptor density, 834(ab)
scintigraphy, pulmonary segmented reference charts in, 1402(le)
Lung cancer
chemosensitivity of, reproducibility by ^{99m}Tc MIBI SPECT, 1778
diagnosis, staging and management of, 544(ab)
diagnosis with FDG PET, 230(ab)
differential diagnosis with Met PET and FDG PET, 1091(ab)
distribution of bone metastases in, 1144(ab)
dynamic 30-minute PET imaging of, 1088(ab)
FDG detection of pulmonary lesions, 1092(ab)
FDG detection of skeletal metastases, FDG, 1145(ab)
FDG gamma camera coincidence imaging in, 566
FDG PET diagnosis of, 228(ab)
FDG PET evaluation of chemotherapeutic effect, 1090(ab)
FDG PET staging, 229(ab), 547(ab), 561(ab)
FDG PET tumor detection, 1039(ab)
FDG uptake as prognostic marker, 548(ab)
lesion detection, FDG PET, ROC analyses, 2043
lymph node staging with ^{11}C choline and FDG PET, 240(ab)
multidrug resistance, and radioresistance, 1084(ab)
non-small cell
glucose transporters and FDG uptake in, 536
P-glycoprotein and ^{99m}Tc tetrofosmin uptake in, 1223(le)
non-small-cell
chemotherapeutic effect of, 1086(ab)
response monitoring, 564(ab)
staging of, with coincidence imaging, 1093(ab)
PET imaging, patterns and pitfalls of, 1462(ab)
PET in, 814
preoperative assessment of mediastinal lymph nodes, 1085(ab)
pulmonary nodules, evaluation of, 36(ab)
small cell
targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
two-step targeting and dosimetry, 1216
SPECT ^{99m}Tc MIBI imaging of, 1087(ab)
uptake of FDG in, 1089(ab)
validation of three-dimensional PET imaging, 1096(ab)
^{111}In-DOTA-lanreotide scintigraphy, 395(ab)
Lung disease, diffuse, threshold of detection, 85
Lung perfusion
prognostic value of, 880(ab)
quantification of regional pulmonary artery flow, 877(ab)
Lung scintigraphy
detection bronchiolitis obliterans syndrome after lung transplantation, 525(ab)
helical computed tomography, 881(ab)
partial ventilation/perfusion mismatch, 221(ab)
whole-body blood flow patterns, congenital heart anomalies, 1477
Lutetium oxyorthosilicate PET scanner, high-resolution, animal imaging, 1164
Lyme neuroborreliosis, reduced cerebral perfusion, 1197(ab)
Lymphadenopathy, FDG PET vs CT in assessment of metastasis, 69(ab)
Lymphedema, prediction of infection risk, 49(ab)
Lymph nodes
axillary, metastasis, breast cancer, FDG PET and dual-head coincidence imaging comparison, 1003
axillary lymph node detection with planar and ^{99m}Tc MIBI SPECT, 556(ab)
sentinel
localization, early breast cancer, 1403(le)
^{99m}Tc serum albumin identification of, in melanoma, 1143
Lymphoma
brain SPECT, lesion size determinant of scan accuracy, 891(ab)
clinical behavior of CB-CC variant, 957(ab)
colorectal cancer, FDG PET imaging applications, 591
FDG coincidence imaging of, 249(ab)
FDG PET staging of, 247(ab)
high-dose chemotherapy, 946(ab)
malignant
bone, ^{67}Ga scintigraphy and MRI comparison, 387
primary staging, FDG PET replacement of bone scintigraphy in, 1407
non-Hodgkin's
B-cell, ^{67}-GA scintigraphy in, 40
chronic lymphocytic leukemia and, radiation dosimetry, 1317
conventional treatments, 1967(le)
^{67}Cu 2IT-BAT-Lym-1 radioimmunotherapy, 2014
low-dose radioimmunotherapy, compared to high-dose, 992(ab)
radiommunotherapy with Y-90 and IDEC=Y2B8, 260(ab)
response monitoring with FDG PET, 953(ab)
radionuclide imaging and MRI of, 251(ab)
staging and follow-up with FDG, 944(ab)
tumor regression in, ^{67}Cu-1IT-BAT-LYM-1 pharmacokinetics in, 302
tumor staging with FDG coincidence imaging, 250(ab)
Y-90 imaging of, 965(ab)
^{67}Ga SPECT assessment of primary gynecologic, 955(ab)
^{67}Ga uptake, in vivo and in vitro studies, 960(ab)
Lymphoscintigraphy
clinical significance of intercalated lymph nodes, 233(ab)
complete groin dissection in vulvar cancer, 235(ab)
detection of lower extremity lymphedema, 49(ab)
diagnosis of breast cancer, 559(ab)
double tracer technique, head and neck tumors, 776
dual-tracer imaging of head and neck tumors, 257(ab)
influence of volume and injection site in breast cancer, 237(ab)
internal mammary drainage, 557(ab)
nodal drainage patterns of, 1120(ab)
primary melanoma of the trunk management of, 1125(ab)
reproducibility of sentinel lymph node detection, 234(ab)
vs subdermal and peritoneal injections, 238(ab)
^{99m}Tc sulfur colloid sentinel node detection, 236(ab)

M

Magnetic resonance imaging (MRI)
chronic synovitis, radiation synovectomy effects, 1277
combination of Fourier space with 1H20 MR image, 1301(ab)
correlation to SPECT in acute cerebral infarction, 569(ab)
dopamine receptor sensitivity, 582(ab)
frequency encoding, simultaneous display using, brain, 442
gated, severe left ventricular dysfunction, recovery from, 1824
partial volume correction schemes based on, PET, 2053
tumor membrane metabolism, 973(ab)
use with SPECT, to quantify pulmonary arterial flow, 877(ab)
vs gated SPECT assessment of left ventricular volume and LVEF, 180(ab)
^{67}Ga scintigraphy comparison, bone neoplasms, 387
^{201}TL SPECT and, neck metastases, 1414
Malignant disease, FDG-PET in lung lesions without tissue, diagnosis, 409(ab)
Mammography, scintimammography and, suspected breast cancer, 296
Managed care, 9N(12)
Marrow imaging, FDG PET of multiple myeloma, 945(ab)
Mass spectrometry, BMIPP pharmacokinetics and metabolism, animals and humans, 1484
Mathematical modeling
analytic formula, 1310(ab)
blood flow, 1269(ab)
McIntyre, Patricia A., 20N(6)
MDS Nordion, MAPLE reactors, 20N(6)
Meckel's diverticulum, gastrointestinal bleeding and, procedure guidelines, 1226
Medical Internal Radiation Dose (MIRD) method
dosimetry, 166(ab)
dynamic urinary bladder model, 102S
internal dosimetry, pediatric head and brain models for, 1327
radionuclide S values, revised dosimetric model and, adult brain, 62S
techniques for radiation dose methods, 37S
^{99m}Tc DMP-HSA serum albumin, dose estimates, 1532
Medical Isotopes Conference, nuclear physicians and the political process, 13N(5)
Medical specialty integration, nuclear medicine in the 21st Century, 13N(7)
Medulla, focused infarcts, remote regional cerebral blood flow consequences, 721
Melanoma
affinity for ^{99m}Tc complexes, 487(ab)
FDG PET imaging, 78(ab), 591
FDG PET vs scintigraphy in outcome analysis, 79(ab)
lymphoscintigraphy, 234(ab)
lymphoscintigraphy in management of, 1125(ab)
lymphoscintigraphy in sentinel node biopsy, 1124(ab)
sentinel lymph nodes in, ^{99m}Tc serum albumin identification of, 1143
TNF perfusion, TYR PET in, 262
tumor targeting of ^{99m}Tc cyclic melanotropin peptide, 484(ab)
^{99m}Tc sulfur colloid filtration effects, 236(ab)

Melanoma scintigraphy
dynamic lymphoscintigraphy, 232(ab)
prognostic value of ^{99m}Tc sestamibi, 80(ab)
radioguided surgery, 1124(ab)
^{99m}Tc peptide 829, detection of melanoma, 1126(ab)
Melhase, Margaret, history corner, 18N(4)
Meningioma, somatostatin receptor imaging, 1246
Mental performance, neurotoxic deficit after Pfiesteria exposure, 454(ab)
Mesothelioma, malignant pleural, value of FDG PET, 1241
Metaiodobenzylguanidine (MIBG)
evaluation of cardiac adrenergic nerve, 833(ab)
low cardiac uptake as predictor of cardiomyopathy, 175(ab)
plasma cortisol levels on myocardial uptake of, 726(ab)
scintigraphy in dilated cardiomyopathy, 8(ab)
sympathomimetic effects, comparison with tyramine, 1342
uptake, heart, effects of Parkinson's disease, 371
Metastasis
carcinoma of unknown primary (CUP), 1149(ab)
optimize treatment, 164(ab)
Metastatic carcinoma, unknown primary sites, 1151(ab)
Methionine, lymph node uptake of, 85(ab)
11β-Methoxy-(17α,20E/Z)-^{123}I iodovinylestradiol, imaging of estrogen receptors, breast cancer, 1728
Methylphenidate, brain response to, repeated measures of dopamine release, 1285
Metoprolol, cardiac MIBG kinetics and, failing heart, 224
MicroPET I
myocardial blood flow, dynamic aquisition of, 20(ab)
myocardial imaging on, 826(ab)
Military medicine, 10N(1)
Modeling
kinetic, dopamine transporter imaging agent, ^{99m}Tc TRODAT-1, 150
myocardial glucose utilization measurements, blood activity corrected/uncorrected for metabolites, 842(ab)
quantification of FHT2, 1266(ab)
Modeling software, SPECT, improved detectability of perfusion defects, 218(ab)
Molecular imaging, topics, 497
Molecular probes, oncogenes, cancer, and imaging, 498
Monoamine oxidase, activity, sensitivity of ^{11}C PHEN kinetics, heart, 232
Monoamine oxidase B, effect of cigarette on, 1215(ab)
Monoclonal antibodies (MAb)
anticarcinoembryonic antigen, ^{131}I-labeled, after radioimmunotherapy, 1609
anti-CD33, alpha-emitting bismuth cyclohexylbenzyl DTPA, 166
anti-colon cancer xenografts with deoxyglucose, 430(ab)
anti mucin antibody, to stage bladder cancer, 399(ab)
biodistribution of ^{86}Y- and ^{111}In-labeled ^{86}Y, 328(ab)
CC49, constructs, colon carcinoma xenografts, 1536
mutation specificity of 6H8, 433(ab)
red marrow, dosimetry of, 972(ab)
therapy, biodistribution and dosimetry of I-131-TNT antibody, 971(ab)
vs MIBI in breast tumor imaging, 1106(ab)
^{90}Y, dosimetry of, 261(ab)
^{213}Bi labeled, preparation of constructs for clinical use, 1722
Monomine transporter 2, vesicular, reproducibility studies with, 283
Monte Carlo simulation
absorbed fractions of energy, within cortical bone, 2115
accurate modeling of photon interactions, 473(ab)
code-based software for, EGS4, internal radionuclide dosimetry, 1517
effect and correction of detector sag in SPECT systems, 1260(ab)
effects of cardiac chamber size determined by, 314(ab)
mathematical anthropomorphic phantoms, 157(ab)
rectal model, dosimetry applications, 1524
three-dimensional transport model, absorbed fractions of energy within trabecular bone, 1947
Motion artifacts
head immobilization device for PET, 1242(ab)
myocardial SPECT studies, 510(ab)
Motion correction
diverging circle algorithm for, 1329(ab)
head immobilization device for PET, 1242(ab)
respiratory compensation in cardiac PET, 457(ab)
Motor activation, PET quantitation of, 1178(ab)
Movement disorders, ^{99m}Tc ECD SPECT study of, torticollis spasmodicus, 268(ab)
Moyamoya disease
cerebral hemodynamics in, 1203(ab)
pregnancy and, 214(le)
Multidrug resistance (MDR)
breast neoplasm, 1102(ab)
overexpression of MDR1 P-glycoprotein, 1024(ab)
prediction of chemosensitivity by MIBI, lung cancer, 1778
radionuclide imaging of, 1025(ab)
^{99m}Tc MIBI, as a substrate for P-glycoprotein, 1086(ab)
^{99m}Tc MIBI as a tracer, carcinoma cells, 672
Multidrug resistance (MDR) reversing agents
tumor, effect of, 1023(ab)
^{99m}Tc sestamibi in evaluation of, 1026(ab)
Multimodality display
epilepsy, 1270(ab)
three-dimensional datasets, 1454(ab)
Multimodality imaging
FDG PET, contractile function using MRI, 821(ab)
perfusion, 315(ab)
X-ray CT and radionuclide imaging, 127(ab)
Multinodular goiter, nontoxic, radioiodine treatment for, 1313
Multiple myeloma, 246(ab)
evaluation, ^{201}TL scintigraphy, 1138
FDG PET imaging, 945(ab)
whole-body ^{99m}Tc MIBI imaging of, 959(ab)
Multivessel disease, acute myocardial infarction, reverse flow-metabolism mismaich pattern on PET, 1492, 1499(ed)
Mu opioid receptor
alcohol, brain changes due to, 446(ab)
neuroreceptors, sex differences in, 447(ab)
regional cerebral blood flow study, 291(ab)
Muscarinic acetylcholine receptor, distribution PET studies of, 1177(ab)
Muscarinic cholinergic ligand, compartmental models, 119(ab)
Muscarinic receptors
imaging of, temporal lobe epilepsy, 935
PET detection of, lung, 1270
Muscle
metabolism, runners, FDG PET imaging, 70
skeletal
glucose transport and phosphorylation, FDG PET, 977
involvement in malignant lymphoma, primary staging, FDG PET replacement of bone scintigraphy in, 1407
^{18}F FDG, lumped constant for, 1798
Muscular dystropy, hereditary, ^{111}In-labeled antimyosin scintigraphy for, 1222(le)
Musculoskeletal sarcoma
FDG vs ^{99m}Tc MDP evaluation of chemotherapy, 388(ab)
staging with FDG PET vs conventional methods, 392(ab)
^{201}Tl , evaluation of chemotherapeutic effect, 535(ab)
Myelotoxicity
preclinical therapy with antioxidant vitamins, 981(ab)
radiation-induced, factors influencing, 1380(ab)
Myocardial fatty acid metabolism, heterogeneity, 831(ab)
Myocardial flow reserve, cardiac allograft vascularity, 719(ab)
Myocardial gated SPECT, improved myocardial perfusion and function, assessment of, 742(ab)
Myocardial imaging agents
beta-adrenergic receptors, 351(ab)
comparison of thallium and technetium, 344(ab)
myocardial biokinetics, 830(ab)
Tc-labeled agents perfusion imaging, with and without fatty meal, 343(ab)
tetrofosmin scintigraphy, 725(ab)
^{11}C neostigmine, 495(ab)
^{99m}Tc glucarate detection of myocardial necrosis, 815(ab)
Myocardial infarction
acute
assessment of myocardial viability with ^{201}Tl, 505(ab)
detecting salvage after, 363
detection, ^{99m}Tc glucarate, 1832
fusion imaging to diagnose, 746(ab)
glycemic state, effect on ^{99m}Tc glucarate uptake ratios, 838(ab)
left ventricular dysfunction after, prediction of recovery, 1683
prediction of recovery wall motion, 745(ab)
prognostic value of scintigraphically assessed myocardial salvage, 24(ab)
reverse flow-metabolism mismatch pattern on PET, 1492, 1499(ed)
reverse redistribution of ^{99m}Tc sestamibi and risk area after PTCA, 713(ab)
^{99m}Tc tetrofosmin SPECT after reperfusion, 781(ab)
clinical variables or time-interval as predictor of tissue viability, 773(ab)
gated SPECT, 789(ab)
major, gated thallium SPECT in, 513
recovery of left ventricular dysfunction, 194(ab)
size determination with ^{201}Tl SPECT, 749(ab)
^{123}I IPPA low flow, acute infarction and reperfusion, 821
^{123}I MIBG kinetics after, 904
Myocardial ischemia
abnormal images of peripheral vascular disease, 795(ab)
differences in BMIPP uptake, 831(ab)
ischemic memory imaging with I-123-DTPA, 818(ab)
laser revascularization, 340(ab)
myocardial perfusion imaging, 347(ab)
radioiodinated fatty acid analogs, 1204
stress perfusion imaging in octogenarians, 350(ab)
Myocardial metabolism, 827(ab)
effect of alterations in hypertrophic cardiomyopathy, 808(ab)
Myocardial perfusion imaging
acute chest pain patients, detection of acute MI in, 1832
adjunctive value of left lateral planar view, 810(ab)
automated LVEF, as predictor of normal study, 714(ab)
detection of silent ischemia in hypercholesterolemia, 737(ab)
dobutamine stress echocardiography or, chest pain in women, 1222(le)
expert system of interpretation of myocardial perfusion tomograms, 508(ab)
gated
left ventricular function and volumes, echocardiography vs, 1857
left ventricular modeling assessment, 702(ab)
utility of stress only ^{99m}Tc sestamibi, 759(ab)
gated SPECT
accuracy and reproducibility of, 810(ed)
arrhythmia effects, 924
gated SPECT to assess CAD, 787(ab)
large SPECT databases improve diagnostic decision making, 1290(ab)
left ventricular ejection fraction, perfusion and, 650
left ventricular function, 777(ab)
polar map analysis of PET and SPECT images, 362(ab)
sestamibi, echocardiography vs, salvage after primary PTCA, 363
simultaneous ^{99m}Tc sestamibi and ^{201}TL dual isotope, coronary artery disease, 895
stress imaging in octogenarians, 350(ab)
^{99m}Tc-labeled agents, forward cardiac output measurements, 1874, 1882(ed)
^{99m}Tc sestamibi, right ventricular uptake, in coronary artery disease, 889
^{99m}Tc tetrofosmin, left ventricular volumes and ejection fraction, 1693
^{201}TL, simultaneous emission/transmission tomography, 1303
^{201}Tl rest redistribution, prognostic indicator, 28(ab)
Myocardial redistribution, ^{201}Tl SPECT vs stress-rest abnormalities, 28(ab)
Myocardial scintigraphy, ^{201}Tl, attenuation correction and resolution recovery, 701(ab)
Myocardial uptake
myocardial functional characterization, 1466(ab)
plasma cortisol levels on MIBG, 726(ab)
Myocardial viability, 721(ab)
after coronary revascularization, SPECT prediction of improvement, 1866
assessment of relative myocardial blood flow in detection of, 184(ab)
assessment, FDG PET, SPECT or gamma coincidence imaging, 1893(ed)
automatic assessment of, 821(ab)

BMIPP detection of, 765(ab)
cardiac PET management of congestive heart failure, 189(ab)
clinical variables or time-interval as predictor of, 773(ab)
comparison of I-125-Iodorotenone and ^{99m}Tc sestamibi in detecting, 352(ab)
determinant of improved LVEF postrevascularization, 190(ab)
dobutamine echocardiography, 777(ab)
dual-isotope assessment of, 193(ab)
effect of filtering on MIBI/FDG SPECT, 1322(ab)
fatty acid imaging, ^{123}I 9-MPA, acute coronary syndrome, 1999
fatty acids added in left bundle branch block, 213(le)
FDG PET study of, 708(ab)
gated FDG vs static NH3 in assessment of, FDG, 183(ab)
gated SPECT and dobutamine echo assessment of, 338(ab)
gated ^{99m}Tc sestamibi imaging, segmental thickening by, 177(ab)
ischemic left ventricular dysfunction, BMIPP imaging, 1468
I-123-BMIPP and ^{99m}Tc MIBI, mismatching, 707
I-^{123}IPPA, low flow or after acute infarction and reperfusion, 821
left ventricular dysfunction, 725(ab)
LVEF, postrevascularization improvement of, 196(ab)
PET, spatial coregistration techniques, 18(ab)
post-stress ECG-gated SPECT assessment of, 798(ab)
recovery of left ventricular dysfunction, 194(ab)
recovery post-revascularization, 706(ab)
wall thickening or wall motion, 790(ab)
^{99m}Tc MIBI vs ^{201}Tl SPECT, 2(ab)
^{99m}Tc sestamibi defect severity, poor prognostic indicator of function, 716(ab)
^{99m}Tc tetrofosmin assessment, models of coronary occlusion and reperfusion, 142
^{201}Tl reverse redistribution to assess, 756(ab)
^{201}Tl SPECT imaging of, 191(ab)
Myocardium
glucose uptake, FDG PET measurement of, 1186
glucose use, in CD36 deficiency, 239
influx and efflux of ^{99m}Tc MIBI, 835(ab)
ischemic, 99m-Tc-MIBI and ^{123}I-BMIPP studies, 707
ischemic and hypoxic, radioiodinated fatty acid analogs, 1204
oxidative metabolism abnormalities, PET, 846
reperfusion therapy, 770(ab)
^{123}I MIBG kinetics, elevated plasma norepinephrine effects, 2088
^{201}Tl SPECT, distribution of image amplitude, 730(ab)
Myopathies, inflammatory, biodistribution and radiation dosimetry of ^{111}In antimyosin in, 464

N

Naltrexone, regional cerebral blood flow changes, alcoholics, SPECT, 19
Nasopharyngeal carcinoma
PET study of malignant tumor, 1050(ab)
SPECT imaging of skull base involvement, 1052(ab)
National Cancer Institute, prostate cancer, 33n(10)
National Institute of Biomedical Imaging, Academy of Radiology Research (ARR), 9N(6)
National Institutes of Health (NIH), imaging research opportunities, 9N(4)
National licensure
public affairs update, 25N(10)
rewrite of 10 CFR 35, 22N(1)
Neck, metastases, ^{201}TL SPECT and and MRI, 1414
NEMA, acceptance testing, 12N(12)
NEMA protocol, signal-to-noise ratio, evaluation of, 481(ab)
Nephron-sparing surgery, ^{99m}Tc MDP renal retention after, 418
Neural networks
PET activation study of cochlear implant users, 1160(ab)
PET studies of sound processing and memory process, 1175(ab)
Neuroblastoma
image analysis, 912(ab)
somatostatin receptor scintigraphy and FDG PET, 1059(ab)
^{11}C epinephrine PET imaging of, 519(ab)
Neuroendocrine tumors
somatostatin receptor imaging, factor analysis of dynamic series in, 33
somatostatin receptor scintigraphy in, 539
^{99m}Tc P829 vs ^{111}In-Pentetreotide in detection, 369(ab)
Neuroimaging
CBF with flow-sensitive alternating inversion recovery, 574(ab)
database for image analysis and documentation, 1289(ab)
revised dosimetric model, adult head and brain, 62S
Neurophysiology, functional neuroanatomy, 1190(ab)
Neurotensin, ^{99m}Tc-labeled, unprecedented high specific activity, 1913
Nicotinic acetylcholine receptors
kinetic modeling of, 1164(ab)
occupancy by nicotine doses, 439(ab)
PET imaging with, 1349(ab)
Nicotinic receptors, acetylcholine, with [^{18}F]fluoro-A-85380, 1374
Nifedipine, photodegraded
promotion of gallium uptake in tumor cells, 159
tumor cell uptake of gallium and, 2129(le)
Nitrogen-13 ammonia, PET, myocardial blood flow, 1045
NMDA (N-methyl-D-aspartate) receptor, glycine site of, 1351(ab)
Noise, removal, using factor analysis of dynamic structures, 1676
Norepinephrine, plasma, extrinsically elevated, myocardial MIBG kinetics and, 2088
Norepinephrine transporter, vesicular storage and monoamine oxidase activity, isolated heart, 323
Normal uptake, myocardial perfusion baseline studies, inter- and intrasubject variability, 763(ab)
Nuclear medicine
advances, fused image tomography, 13N(8)
clinical practice, 10N(1)
decision analysis in, 1570
history of, Donner Laboratory, 16N(1)
Latin America, 9N(9)
lines from the president, 21N(9), 38N(8)
in managed care, 9N(12)
in the military, 10N(1)
U. S. Congress, 20N(3)
Nuclear Medicine Archives, The Heritage Project, 21N(11)
Nuclear Medicine Pioneer Series
McAfee, John G., 15N(11)
Wagner, Henry N., 13N(10)
Nuclear Regulatory Commission (NRC)
ACNP/SNM Government Relations Activities, 1998 year end report, 25N(2)
DOE isotope conference, 22N(1)
instructions to patients following radioiodine therapy, 990(ab)
10 CFR Part 35, Sustained Growth Rate System, 25N(11)

O

Obesity
laparoscopic adjustable silicone gastric banding, ^{99m}Tc pertechnetate scintigraphy in, 783
red cell mast and, 422
Octreotide
evaluation of experimental radiation pneumonitis, 37(ab)
peptide receptor radionuclide therapy, 415(ab)
radiolabeled, thymic concentration of, 1967(le)
Oligodeoxynucleotide
DNA cleavage conjugated to, 1405(ab)
MDR1 gene, 1009(ab)
synthesis of ^{18}F labeled, 332(ab)
Oligonucleotide
radiotherapy, problems with, 1582(le)
Oncogenes, cancer and imaging, 498
Oncologic imaging, FDG PET, 1706
Oncology, head and neck, nuclear medicine in, 91
Ordered subsets expectation maximization (OSEM)
cardiac, rotating slant-hole, 134(ab)
COSEM iterative algorithm, 1295(ab)
Fourier rebinning technique, 1302(ab)
scatter and attenuation correction of, 1318(ab)
whole-body PET, 1316(ab)
Orocecal transit, ^{13}C breath test, scintigraphy, 1451
Osteitis, diagnosis of in diabetic foot disease, 903(ab)
Osteogenic sarcoma
FDG PET evaluation of chemotherapy in, 1143(ab)
multidrug resistance, 919(ab)
neoadjuvant therapy response, FDG PET, 1637
tumor necrosis, 524(ab)
Osteomyelitis
assessment and efficacy of imaging vetebral osteomyelitis, 906(ab)
bacterial detection with ^{99m}Tc ciprofloxacin, 60(ab)
FDG PET exclusion of, 61(ab)
pediatric imaging of, 47(ab)
^{99m}Tc HMPAO four-phase imaging, 902(ab)
Osteosarcoma, radiotherapy with high-dose Sm-153-EDTMP, 977(ab)
Ovarian cancer
experimental ovarian carcinoma, effect of radioimmumotherapy, 432(ab)
ovarian cancer, using a hybrid PET scanner, 541(ab)
recurrency, detection of with whole-body FDG PET, 424(ab)
^{131}I-labeled chimeric monoclonal antibody, 966(ab)
Oxygen extraction fraction, increased, prognosis in cerebrovascular diseases, 1992
Oxygen metabolism, myocardial, iterative reconstruction, PET heart studies, 862
Oxygen-15 water
calculated input function in relative rCBF study, 1272(ab)
derivation of input function on PET brain images, 146(ab)
echocardiography, 791(ab)
multiplane factor analysis in PET images, 309(ab)
PET and, baseline and hyperemic myocardial blood flow measurement, 1848
O-(2-[^{18}F]fluoroethyl)-L-tyrosine, transport mechanism, uptake kinetics and, 1367

P

Pancreatic cancer
FDG PET, optimal interpretation of, 1784
FDG PET assessment of treatment response, 1079(ab)
FDG PET vs CT in management of, 421(ab)
liver metastases from, ^{18}F FDG PET, 250
preoperative FDG uptake, correlation with Ki-67 immunostaining, 368(ab)
unresectable, intraoperative radiation therapy, FDG PET evaluation of, 1424
Pancreatic tumor, PET preoperative diagnosis of, 422(ab)
Pancreatitis, Ga infection imaging, 371(ab)
Parametric imaging
cluster analysis, 1269(ab)
myocardial beta-adrenoceptor density, 507
myocardial perfusion study, 295(ab)
representation in image format, 163(ab)
ridge regression, 147(ab)
striatal and nonstriatal binding, 1267(ab)
Parathyroid
hyperfunctional, ^{99m}Tc MIBI correlated with histology, 1792
rapid scintigraphy with ^{99m}Tc tetrofosmin, 920(ab)
scanning accuracies, 361(le)
Parathyroid adenoma
SPECT, diagnostic utlity and cost-effectiveness of, 940(ab)
^{99m}Tc MIBI correlated with histology, 1792
^{99m}Tc sestamibi, pre- and postoperative localization of, 197(ab)
^{123}I subtraction and delayed ^{99m}Tc MIBI imaging, 199(ab)
Parathyroid imaging
effect of cell type of sestamibi sensitivity, 201(ab)
sequential pertechnetate-sestamibi imaging, 200(ab)
Parathyroid scintigraphy
perchlorate in, 1769(le)
radioguided surgery, comparison of, 203(ab)
Parkinson's disease
cardiac sympathetic dysfunction in, 727(ab)
dementia with Lewy bodies, 1179(ab)
differential diagnosis vs multiple system atrophy, 271(ab)
disease progression, 107(ab)
dopamine degeneration in, 111(ab)
dopamine D2 receptors, 273(ab)
dopamine SPECT in, 530

dopamine transporter and D2/D3 receptors, 1170(ab)
lipophilicity of glucose analogs in, 1352(ab)
loss of ^{131}I MIBG uptake, heart, 371
movement disorders, 1178(ab)
nigrostriatal dopaminergic pathway in, ^{123}I-FPCIT SPECT, 753
pallidal electrostimulation, 269(ab)
parietal abnormalities in, 1184(ab)
presymptomatic phase detection with I-123-FP-CIT SPECT, 106(ab)
regional metabolic covariance patterns, FDG PET, 1264
specificity of dopamine transporter imaging agents, 152(ab)
SPECT image analysis, statistical parametric matching, 1583
^{99m}Tc HMPAO SPECT study, 956
^{99m}Tc sestamibi vs N-13-ammonia detection of, 21(ab)
^{99m}Tc TRODAT-1 and motor activation, 1200(ab)
^{123}I-bCIT SPECT imaging of, 267(ab)
Partial-volume correction, for PET, based on MR, 2053
Partial volume effect
averaging of noisy PET data, 474(ab)
mixed continuity image, 1299(ab)
small spheroids, radioactivity concentration of, 118
Partition coefficient, peptidic chelator, 331(ab)
Patient privacy, HHS regulations for, 25N(11)
Patlak-Rutland plot, deconvolution comparison, renograpic analysis, 1503
Pediatric patients
applications of pinhole magnification imaging, 1896
direct and indirect radionuclie cystograpy, dosimetry in, 2127(le)
diuresis renography in, 1805
dosimetry, head and brain models for use in, 1327
PET evaluation of noncentral nervous system tumors, 908(ab)
quantitative gravity-assisted drainage, diuretic renography, 55(ab)
seizure foci, subtraction ictal SPECT, 786
thyroid cancer, UICCA/AJCC classification in, 2125(le)
urinary tract infection, ^{99m}Tc DMSA clearance and, 52
validation of F+0 diuretic renography, 54(ab)
^{99m}Tc DMSA quantitative SPECT uptake, kidney, 56
^{99m}Tc white blood cell imaging of inflammatory bowel disease, 50(ab)
^{123}I IBZM SPECT, dopamine receptor brain imaging, neonatal period, 2125(le)
Peptide receptor imaging
angiogenesis, intravascular agent for detection of, 319(ab)
calcitonin receptor imaging, 417(ab)
cholecystokinin-B/gastrin receptor ligands, preclinical development of, 420(ab)
GPIIb/IIIa, 887(ab)
melanoma, 485(ab)
metastatic medullary thyroid cancer, staging of, 396(ab)
^{99m}Tc labeled leukotriene-B4 receptor antagonist, 892(ab)
^{99m}Tc vasoactive intestinal peptide, 1081(ab)
^{111}In-labeled analogs, 320(ab)
Peptide-receptor radiotherapy
for lymphoma with Interleukin-15, 1027(ab)
medullary thyroid cancer, 420(ab)
somatostatin analog radionuclide therapy, 414(ab)
^{111}In-DTPA-octreotide, nonimpairment of renal function, 416(ab)
Peptides
epidermal growth factor receptor targeting of breast cancer, 1370(ab)
infection imaging multicenter trial results, 57(ab)
pharmacokinetics and biodistribution of ^{111}In-DTPA-G-CSF, 1031(ab)
uptake and pharmacokinetics in E. coli, 954(ab)
in vivo and in vitro properties of ^{99m}Tc labeled, 1397(ab)
^{99m}Tc labeled infection imaging, 950(ab)
Peptidic chelator
single isomer, 504(ab)
tumor uptake of Cu-67-labeled antibody fragments, 326(ab)
Perchlorate, attribution of use, parathyroid scintigraphy, 1769(le)
Percutaneous transluminal coronary angioplasty
defect severity, prognostic indicator of function, 716(ab)
postrevascularization recovery, 767(ab)
Perfusion agents
BMIPP, metabolism in rat tissues, 1918
for measurement of forward cardiac output, 1874, 1882(ed)
Perfusion imaging
aging, 349(ab)
ECG-gated ^{201}Tl SPECT imaging, 771(ab)
exercise and adenosine, effect on defect size, 517(ab)
quantitated prognosis of coronary artery disease, 169(ab)
rest and exercise dual-isotope SPECT, 774(ab)
SPECT depiction of improved blood flow after treatment with rhVEGF, 342(ab)
variability in SPECT studies, 509(ab)
^{99m}Tc sestamibi, regional quantification of, 506(ab)
^{99m}Tc sestamibi cardiac study, 361(ab)
Perfusion lung scan
lung volume reduction surgery, 381(ab)
sequential SPECT study, 882(ab)
SPECT acquisition of, 219(ab)
P-glycoprotein, quantification of, facilitates transport in blood-brain barrier, 1159(ab)
Phage display, peptide libraries, identification of receptor ligands with, 883
Pharmacokinetics
biomodulation of 5-FU, 1032(ab)
characteristics of I-131-anti-B1 (anti-CD20) antibody, 991(ab)
compartmental analysis, heterogeneous tissue model of ^{11}C acetyl aminoisobuytric acid, 1016(ab)
design of oral pharmaceutical dosage forms, 365(ab)
drug formulation evaluation, 610(ab)
^{111}In antimyosin, idiopathic inflammatory myopathies, 464
Pharmacologic stress test, imaging protocol for, 513(ab)
Pharmatokinetic studies
dosimetry of ^{99m}Tc vasoactive peptides, 1363(ab)
PET data processing, 1288(ab)
Phelps, Michael, Fermi Award, 12N(6)
Phelps, Michael E., Presidential award given for PET research, 10N(4)
Phosphoinositide, turnover, ischemic brain, PET, 1590
Phosphorus-32
palliation, in skeletal metastases, 256
radiocolloid treatment of joint hemorrhage, 44(ab)
Photodynamic therapy, tumor response after, high-resolution PET, 876
Physical Evaluation Program (PEP), earning CME credit electronically, 9N(2)
Physician fee schedule
CHCPP news, 26N(3)
SNM Physical Evaluation Program, 26N(1)
Pinhole magnification imaging, pediatric applications of, 1896
Pituitary adenoma, octreotide in, somatostatin receptor scintigraphy, 1252
Platelet imaging, kinetic measurements with probes, 948(ab)
Polycythemia, red cell mass, obesity effects, 422
Pons, focused infarcts, remote regional cerebral blood flow consequences, 721
Positron camera
comparison to SPECT camera with PET option, 1244(ab)
dynamic PET imaging, Yappet scanner for, 302(ab)
large-area positron camera (PETRRA), 1224(ab)
small animal imaging device, 1258(ab)
Positron emission tomography (PET)
activation study, 1171(ab)
age-related defects in dopamine D2 receptors, 1218(ab)
akinetic wall motion depicted on gated scans, 183(ab)
animal model of dysfunctional viable myocardium, 822(ab)
assessment of abnormal CEA levels in recurrent colorectal cancer, 412(ab)
attenuation correction, 1308(ab), 1309(ab)
automated synthesis system for ^{11}C bicarbonate, 1401(ab)
autoradiographic-based activity distributions, 131(ab)
biliary bicarbonate secretion, 845(ab)
brain activation study, 290(ab)
camera performance measurements, 308(ab)
cerebral blood flow study, 1220(ab)
clinical performance of CPET camera, 1239(ab)
closed-head injury, 287(ab)
coincidence imaging of non-small-cell lung cancer, 1093(ab)
combination of Fourier space with 1H20 MR image, 1301(ab)
computer-aided education, 1457(ab)
correlation with bone scan in detection of bone tumors, 1145(ab)
correlation with per rectal portal scintigraphy, 858(ab)
Cu-62-ETS myocardial perfusion imaging, 775(ab)
dedicated system for breast cancer imaging, 1223(ab)
delineation of serotonin receptors with ^{18}F MPPF, 116(ab)
detection of muscarinic receptors, lung, 1270
detectors compact high resolution gamma ray, 304(ab)
diagnostic capability of FDG in pediatric tumors, 908(ab)
differential diagnosis of lung tumors, 1091(ab)
dopamine receptor density measurement, 145(ab)
dopamine receptor mediation, 442(ab)
dopamine receptor sensitivity, 582(ab)
dopamine transporter changes in cocaine users, 441(ab)
dopamine transporter damage due to methamphetamine, 443(ab)
drug research and development, 1154
dual-head camera, detection of head and neck cancer with, 259(ab)
dual-head coincidence, vs ring PET, tumor patients, 1617
early detection of small breast lesions, 307(ab)
effect of apolipoprotein E on regional brain metabolism, 281(ab)
enhanced ^{11}C TPMP uptake, brain tumor, 1180
estrogen administration and coronary vasomotion, 32(ab)
evaluation of phosphoinositide turnover, cerebral ischemia, 1590
FDG, 1058(ab)
acute effects of anti-insulin resistance on uptake of, 939(ab)
angiography of brain and carotid arteries, 1274(ab)
APOE-4 genetic risk, 283(ab)
assessment of hepatic metastases, 92(ab)
assessment of mediastinal lymph node metastasis, 69(ab)
assessment of oral ethanol on regional brain glucose, 1217(ab)
assessment of radiotherapy for nasopharyngeal cancer, 1050(ab)
attenuation correction of whole-body images, 561(ab)
brachial plexopathy, evaluation of, 554(ab)
brain glucose use in Salla disease, 12
brain responses to lorazepam, 715
brain tumors, colorectal cancer lymphoma, and melanoma, 591
cancer of unknown primary, 1150(ab)
cardiac study after transcoronary ablation of septal hypertrophy, 185(ab)
cerebellar hypometabolism, 1186(ab)
cervical cancer patients, 1125
characterization of solitary pulmonary nodules, 225(ab)
chemoradiotherapy evaluated by, 1132
clinical management of pediatric brain tumors, 521(ab)
clinical staging and follow-up of, 97(ab)
coincidence detection with a gamma camera, 110
coincidence imaging comparison, breast cancer, 1003
coincidence imaging of lymphoma, 249(ab)
colorectal cancer, assessment of recurrence, 1074(ab)
correlation of clinical outcome in neurofibromatosis, 520(ab)
cost-effectiveness in lung carcinoma, 227(ab)
delayed imaging of malignant lesions, 1097(ab)
detection of breast neoplasm, 566(ab)
detection of carcinoma of unknown primary, 1149(ab)
detection of recurrence in gynecology, 1131(ab)
detection whole-body early detection of recurrent ovarian cancer, 424(ab)
diagnosis of head and neck cancer, 253(ab)
diagnosis of head and neck neoplasms, 1053(ab)
diagnosis of mouth and tongue tumors, 1048(ab)
diagnostic role in fever unknown origin, 899(ab)
differentiation of prostheses loosening and infection, 389(ab)
differentiation of tumor and inflammatory sites, 1054(ab)
efficacy in recurrent testicular carcinoma, 425(ab)
evaluation of cervical cancer pre and post-radiation therapy, 1130(ab)
evaluation of chemotherapeutic effect, 1090(ab)

evaluation of endocrine therapy in prostate cancer, 1137(ab)
evaluation of global left ventricular function, 35(ab)
evaluation of intraoperative radiotherapy in pancreatic cancer, 1424
exclusion of chronic osteomyelitis, 61(ab)
flow-metabolism mismatch, 1196(ab)
gated, LVEF determination with, 755(ab)
germ-cell tumor staging, 1133(ab)
head and neck cancer, 91
heart and skeletal muscle uptake, insulin action on, 1116
hematopoetic bone marrow, 956(ab)
histopathological correlation with aortic uptake, 355(ab)
human cancer cell lines, 999(ab)
infection imaging of hip prosthesis, 868(ab)
lesion detectability, attenuation correction on, breast cancer, 2021, 2025(ed)
lesion detection, ROC analyses, 2043
liver metastases from pancreatic cancer, 250
lumped constant for, skeletal muscle, 1798
in lung cancer, 814
lung cancer staging, 229(ab)
malignant melanoma, diagnosis of, 78(ab)
management costs in head and neck cancer, 255(ab)
management of solitary pulmonary nodules, 228(ab)
metabolic measurements of malignant tumors, 1771
metabolic response to treatment, 946(ab)
metabolism in low-grade lymphoma, 957(ab)
metaplastic gastritis, 851(ab)
metastatic thyroid cancer, 993(ed)
muscle activity in runners, 70
myocardial glucose uptake, 1186
myocardial glucose uptake in ischemic cardiomyopathy patients, 1292
neoadjuvant chemotherapy, evaluation of, 1143(ab)
neoadjuvant therapy response of osteosarcoma, 1637
noninvasive measurement of cerebral metabolic glucose, 1441
normal breast uptake of FDG, 1099(ab)
occult malignancy, identification with, 410(ab)
oncological applications, 1706
optimal interpretation, pancreatic cancer, 1784
papillary thyroid carcinoma, 986
Patlak analysis, 1075(ab)
postsurgery an post-irradiation imaging of head and neck cancer, 1051(ab)
predictive value in soft-tissue sarcoma, 1147(ab)
predictor of pathological response to chemotherapy in breast cancer, 552(ab)
predictor of prognosis in lung cancer, 1095(ab)
preoperative lymph node staging of esophageal cancer, 98(ab)
preoperative uptake in breast cancer, 555(ab)
presurgical evaluation of recurrence in cervical lymph nodes, 529(ab)
primary staging and detection of recurrent head and neck cancer, 254(ab)
primary staging of malignant lymphoma, 1407
prognostic value in malignant pleural mesothelioma, 1241
proliferation index, 998(ab)
quantitation, correlation with histopathologic tumor contro, 547(ab)
regional metabolic covariance patterns, 1264
role in oncology management, 408(ab)
routine follow-up procedure with thyroid carcinoma, 1043(ab)
same-day sequential studies, 83(ab)
sequential studies in AIDS patients, 889(ab)
skeletal muscle, glucose transport and phosphorylation, 977
splenic uptake, granulocyte colony-stimulating factor therapy, 1456
staging of gastric cancer, 94(ab)
staging of primary head and neck cancer, dual-head camera, 1056(ab)
staging of testicular carcinoma, 1135(ab)
temporal lobe hypometabolism, 276(ab)
thyroglobulin elevation in differentiated thyroid cancer, 1041(ab)
tumor volume assessment in cervical cancer, 1129(ab)
uptake as prognostic marker to therapeutic response, 548(ab)
uptake in giant cell-rich primary bone tumors, 390(ab)
uptake in intestine, skeleton and myocardium, 563(ab)
uptake in non-small-cell lung cancer, 1089(ab)
uptake of bronchioloalveolar lung carcinoma, 86(ab)
urinary excretion during, 1352
value of 30-minute scan in lung cancer, 1088(ab)
vs coincidence imaging in lesion detection, 545(ab)
vs coincidence imaging of thyroid cancer, 543(ab)
vs Ga-67 in Hodgkin's disease, 252(ab)
vs MRI in abdominal lymph node staging in cervical cancer, 423(ab)
vs whole-body ^{18}F FMT to detect malignancies, 1018(ab)
vs ^{99m}Tc chemotactic peptide in infection/inflammation imaging, 894(ab)
whole-body imaging, follow-up of thyroid cancer, 1042(ab)
whole-body imaging in Hodgkin's disease, 248(ab)
whole-body imaging of potentially resectable colorectal cancer lesions, 1068(ab)
whole-body scanning of gastric cancer, 1073(ab)
whole-body scanning of metastatic cervical lymph node, 1151(ab)
whole-body tumor imaging, 1134(ab)
FDG and tyrosine imaging, soft tissue tumors, 381
FDG imaging vs ^{99m}Tc bone scan bony metastasis, 386(ab)
FDG management of differentiated thyroid cancer, 411(ab)
FDG PET diagnosis of primary or secondary lung cancer, 81(ab)
FDG quantification, 564(ab), 953(ab)
FDG vs CT in management of pancreatic cancer, 421(ab)
flow/metabolism imaging, 19(ab)
frequency encoding, simultaneous display using, brain, 442
frontotemporal metabolism in Alzheimer's disease, 1198(ab)
glucose metabolism, brain tumors, after stereotactic radiosurgery, 1085
hepatic, scatter subtraction effects, 1011
high-resolution, tumor response after photodynamic therapy, 876
high-resolution cardiac study, 832(ab)
image analysis, 1279(ab)
Impressions on the HCFA Town Hall Meeting, 10N(3)
increased oxygen extraction fraction, cerebrovascular diseases, 1992
integrated visualization, anatomic brain data, 311
iterative reconstruction, heart study, 862
LSO-based camera, Lu-176 radiation effects on, 305(ab)
lump constant variability during MGU measurement, 824(ab)
mammography-guided stereotactic beast biopsy, 468(ab)
MAP reconstruction, 129(ab)
measurement of dopamine receptor availability, 1176(ab)
Medicare coverage of, HCFA expansion of, 23N(5)
melanoma staging, 79(ab)
methyl-^{11}C thymidine, ^{11}C activity after, 491
micro, performance evaluation, 1164
microgravity, 1451(ab)
missing data effect on image quality, 1234(ab)
monoamine oxidase B, 1215(ab)
myocardial beta-adrenoceptor density, 507
myocardial blood flow, quantitative assessment of, 29(ab)
myocardial fatty acid metabolism, 911(ab)
myocardial hibernation, 186(ab)
myocardial oxidative metabolism, 33(ab)
myocardial perfusion imaging in CAD, 346(ab)
new high-resolution research tomograph, 306(ab)
new tracer, imaging of temporal lobe epilepsy, 935
nicotinic acetylcholine receptors, 439(ab)
nicotinic acetylcholine receptor studies, 1164(ab)
noise suppression in image reconstruction of, 297(ab)
nonhuman primate
  human vs nonhuman primate, comparison of, 294(ab)
  nicotinic acetylcholine receptors, 1349(ab)
noninvasive assessment of hypoxia, 401(ab)
nuclear medicine, clinical, 11N(11)
N-13-ammonia detection of ischemia, 21(ab)
O-methyl-^{18}F L-DOPA, blood-brain transport, 584(ab)
oxidative metabolism abnormalities, sympathetically denervated myocardium, 846
parametric, $5HT_{2A}$ receptor distribution, neocortex, 25
partial volume averaging of noisy data, 474(ab)
partial volume correction schemes, MR-based, 2053
patterns and pitfalls in lung cancer imaging, 1462(ab)
PET, bone and soft-tissue sarcoma, 84(ab)
potential applications of, developing novel cancer therapies, 995
preoperative FDG evaluation of Liver metastases, 1069(ab)
probe for imaging gene expression, 332(ab)
prognostic value of regional brain metabolism in assessment of dementia, 285(ab)
prostate cancer detection with ^{11}C acetate, 243(ab)
quality assurance, clinical relevance of detector defects, 1657
quantification of myocardial glucose utilization, 836(ab)
quantitation
  analytic scatter correction, 1236(ab)
  automated lesion volume estimation, 466(ab)
  brain studies with reversible ligands, 1265(ab)
  cascade gamma rays, effects on, 1238(ab)
  chemotherapy response in esophageal cancer, 594(ab)
  comparison of SUV, visual grading and ROC, 565(ab)
  conditions of physics and reconstruction methods, 591(ab)
  CO2 quantitation in brain and myocardium, 841(ab)
  dopamine D1 receptor binding, 120(ab)
  equilibrium modeling, 5HT2a, 1208(ab)
  errors in FDG lung uptake, 385(ab)
  FDG and ^{11}C aminoisobutyric acid in tumors, 1061(ab)
  hottest pixel analysis, 1286(ab)
  image-derived input function, 463(ab)
  image evaluation on personal computers, 1288(ab)
  lung, deposition studies of, 383(ab)
  myocardial blood flow by N-13 ammonia PET, 1304(ab)
  OSEM vs standard filtered back projection in brain studies, 592(ab)
  phantom testing of I-120, 501(ab)
  post-adenosine data, 717(ab)
  reconstruction of small animal images, 1321(ab)
  response to therapy, 1246(ab)
  serotonergic innervation with ^{11}C McN5652 PET, 115(ab)
  standardized uptake value, time corrections, 469(ab)
  standardized uptake value distribution features, 1283(ab)
  statistical bias in Logan graphical method, 141(ab)
  striatal dopamine transporter, 1156(ab)
  ^{11}C FLB457, 436(ab)
  ^{15}O water and ^{68}Ga EDTA, 147(ab)
  ^{86}Y, quantitative accuracy, 1237(ab)
quantitative, venous sinuses as input functions for, 1666
receiver operating curve as SUV in bone marrow tumor, 387(ab)
registration, vascular structure for, pelvis, 347
reverse flow-metabolism mismatch pattern, acute myocardial infarction, 1492, 1499(ed)
reverse mismatch of myocardial perfusion and metabolism, 909(ab)
role in management of congestive heart failure, 189(ab)
R-82, wavelet-base noise reduction, 720(ab)
segmentation algorithms for transmission scanning, 459(ab)
senile plaques, 284(ab)
short-segmented transmission scans, effect on lesion detection and image quality, 1320(ab)
small-animal
  dedicated PET camera for, 303(ab)
  imaging device, 1258(ab)
  new era in research, 1176(ed)
small spheroids, radioactivity concentration of, 118
Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)
spatial normalization methods, anatomic validation of, 317
table-based standardized uptake value, 1284(ab)
tumor tracers
  assessment of presurgical chemotherapy with, 551(ab)
  correlation of tumor blood flow, 1029(ab)
  FDG and FMT uptake in sarcoidosis, 878(ab)
  FDG and ^{11}C aminoisobutyric acid, 1061(ab)

FDG assessment of pancreatic cancer, 1079(ab)
FLT vs DG uptake, 100(ab)
kinetic analysis of farnesyl transferase, 1014(ab)
^{18}F arabinonucleosides, 1368(ab)
^{18}F FMAU, 334(ab)
two-dimension and three-dimension acquisition modes, 477(ab)
TYR, soft-tissue sarcoma and skin cancer, 262
unconscious perception and retrieval, 1158(ab)
in vivo validation of reporter gene/reporter probe assay for imaging herpes simplex virus Type 1, 102(ab)
vs NMR in seizure focus localization, 274(ab)
whole-body
attenuation correction with MRP reconstruction, 1330(ab)
attenuation correction with watershed segmentation algorithm, 1297(ab)
attenuation correction with ^{137}Cs in, 1257
CPET camera, 1239(ab)
diagnosis and staging of pleural lung lesions with FDG, 230(ab)
FDG cancer screening, 1155(ab)
FDG evaluation of esophageal cancer, 1078(ab)
FDG scanning in multiple myeloma, 246(ab)
FDG staging of lung cancer, 226(ab)
image reconstruction methods on FDG studies, 593(ab)
parameters, optimization of, 1232(ab)
simlutaneous emission and transmission scanning, 1231(ab)
transmission scans, 460(ab)
whole-body imaging, tumor detection with FDG, 567(ab)
^{11}C Nad-299 receptor imaging, 151(ab)
^{11}C raclopride, repeated measures of dopamine release, 1285
^{11}C WAY-100635, localization of serotonin receptors, brain, 102
^{13}N ammonia and, myocardial blood flow, 1045
^{15}O-labeled water and, baseline and hyperemic myocardial blood flow measurement, 1848
^{18}F and ^{11}C, 1353(ab)
^{18}F FET, tumor imaging, 205
^{18}F fluorine, central nicotinic acetylcholine receptors, 1374
^{18}F FMT, brain tumor patients, 399
^{18}F-labeled amino acids, transport mechanism and uptake kinetics, 1367
^{18}F labeled ligands for prostate cancer, 1136(ab)
^{18}F 5-fluoro-2'-deoxyuridin, 1388(ab)
^{94m}Tc, radioisotope mixture and decay correction for, 472(ab)

Positron imaging
biodistribution of FDG uptake, 1241(ab)
combined PET/CT scanner, design and operation, 597(ab)
space, 1451(ab)

Positron volume imaging
large-area positron camera (PETRRA), 1224(ab)
new high-resolution research tomograph, 306(ab)
small animal imaging, 302(ab)

Practice expense, CHCPP news, 26N(3)

Pregnancy, moyamoya disease and, 214(le)

Pretargeting
bispecific antibody studies with ^{99m}Tc/Re-188-labeled peptides, 1002(ab)
bispecific tumor-targeting radiotherapeutics, 324(ab)
lymphoma, 75(ab)

Probe
coincidence detection, using ^{111}In, 601(ab)
sentinel node detection, 1228(ab)

Probe system
beta-sensitive probe, 600(ab)
intraoperative detection, development of a compact, 602(ab)
sentinel node detection, 1228(ab)

Procedure guidelines
breast scintigraphy, 1233
gastric emptying and motility, 1236
Meckel's diverticulum, gastrointestinal bleeding and, 1226

Prognosis
dipyridamole stress myocardial SPECT, 23(ab)
FDG PET as predictor of surgical outcome, 1195(ab)
FDG SPECT in ischemic left ventricular dysfunction, 192(ab)
gender differences in ischemic heart disease, 722(ab)
reversible perfusion defects, 27(ab)
SPECT perfusion and functional studies to predict cardiovascular death, 26(ab)
value of FDG in non-small-cell lung cancer, 1095(ab)

Proliferation
correlation of FDG and MIBI uptake with, 65(ab)
MIB-1 and ^{11}C methionine uptake in brain tumors, 1065(ab)
preclinical validation of ^{11}C thymidine, 1013(ab)
preoperative FDG uptake, correlation with Ki-67 immunostaining, 368(ab)

Prospective payment systems, HCFA, 24N(4)

Prostate cancer
cisplatin and ^{186}Re HEDP in, 667
CT-SPEC registration, pelvis, vascular structure for, 347
dose-escalation study in osseous metastases from prostate cancer, 974(ab)
dual-isotope staging, 394(ab)
effect of ^{11}C Choline on hormonal therapy, 241(ab)
FDG and carbon-11-acetate images of, 243(ab)
FDG PET evaluation of endocrine therapy, 1137(ab)
immunodetection of residual/recurrent lesions, 1138(ab)
National Cancer Institute initiatives, 33n(10)
radioimmunotherapy, 1008(ab)
radioimmunotherapy with ^{111}In and Y-90, 963(ab)
in vivo evaluation of I-131-labeled monoclonal antibodies, 1001(ab)
^{11}C acetate, PET imaging with, 242(ab)
^{99m}Tc labeled bombesin receptor binding analog in, 318(ab)

PTCA. *see* Angioplasty, percutaneous transluminal coronary

Pulmonary embolism
automated interpretation, image processing algorithm, 224(ab)
blood-pool subtracted SPECT imaging techniques, 42(ab)
diagnosis with SPECT, 219(ab)
helical computed tomography, role in ventilation-perfusion imaging, 881(ab)
perfusion lung scintigraphy, ^{99m}Tc technegas, 579
pulmonary perfusion scintigraphy, evaluation with, 222(ab)
short-term prognosis, 220(ab)
SPECT detection of, 218(ab)
systematic lung scan depiction of, 223(ab)
variations in ventilation/perfusion scan interpretation, 879(ab)
Xe ventilation in diagnosis of pulmonary embolism, 883(ab)
^{99m}Tc bitistatin as a ligand for, 492(ab)
^{133}Xe imaging of ventilation/perfusion mismatch, 221(ab)

Pulmonary hypertension, ventricular pressure overload, 800(ab)

Pulmonary lesions, solitary, ^{18}F FDG positron imaging, 574

Pyelonephritis
acute, renal changes in acute phase and follow-up, 916(ab)
declining diagnostic yield of ultrasound, 53(ab)
experimental, ^{99m}Tc DMSA uptake in, 643

Q

Quality assurance, arrhythmia effects, gated SPECT, 924

Quality control
attenuation correction of transmission scans in cardiac SPECT, 1262(ab)
dose calibration and radiopharmaceutical administration, errors in, 616(ab)
evaluation and calibration of fan-beam collimation, 1259(ab)
generator, tungsten-188/Re-188, 1385(ab)
PET camera performance measurements, 308(ab)
polarographic technique, 1394(ab)
portable image processing package, 1294(ab)
SPECT validation program, 1263(ab)
using collimated flood source, 1257(ab)

Quantitative image analysis
kinetic analysis or brain perfusion SPECT studies, 1275(ab)
table-based standardized uptake value, 1284(ab)

Quantification
FDG PET and SPECT images of dementia, 282(ab)
nonuniform transmission in brain SPECT, 1250(ab)
photon energy recovery, 1336(ab)
^{110}In PET and ^{111}In SPECT, 982(ab)

Quantitation
activity estimation in coincidence imaging systems, 483(ab)
nonlinear ML estimation at low SNR, 475(ab)
tissue concentration of FDG, 826(ab)

R

Radiation
Bremsstrahlung, exposure, pure beta-ray emitters, 1024
protection, code-based software for Monte Carlo simulation, 1517

Radiation pneumonitis, ^{111}In-pentetreotide evaluation of, 37(ab)

Radiation synovectomy, MRI, chronic synovitis, 1277

Radioactivity, intra-abdominal, stomach, gastric emptying rate assessment based on, 1106

Radioaerosol, deposition and clearance quantification, 382(ab)

Radiobiological effectiveness
biological effect, 1379(ab)
radiation adaptive response in lymphocytes, 1378(ab)

Radioenema imaging, 5-aminosalicylic acid absorption, ileorectal anastomosis patients, 1630

Radioimmunodetection
biodistribution of ^{125}I-labeled antitac dsFv, 1381
glycolate conjugation, biodistribution of humanized antitac Fab fragment, 837
lymphoma, antibody localization to tumor, 949(ab)
^{99m}Tc labeled monoclonal antibody G250, renal cell carcinoma, 829
^{111}In-DTPA-anti-CEA Mab to improve, 1005(ab)

Radioimmunodiagnosis, MAb CC49 constructs, colon cancer xenografts, 1536

Radioimmuno PET, microPET I, murine xenograft model, 323(ab)

Radioimmunoscintigraphy, 99m-Tc-labeled AntiEGF-R, tumors of epithelial origin, 768

Radioimmunotherapy
alpha-particle dosimetry, leukemia patients, 1935
antioxidant vitamins to reduce gastrointestinal and hematopoietic toxicity, 981(ab)
beta emitters vs alpha-emitters, therapeutic efficacy of, 1375(ab)
beta emitters vs Auger conversion-electrons, 1374(ab)
brain, imaging and dosimetry of, 138(ab)
characteristics of I-131-anti-B1 (anti-CD20) antibody, 991(ab)
concentration in blood and body, patient-specific marrow dose using, 2102
dosimetry of IDEC0Y2B8 in non-Hodgkins lymphoma, 260(ab)
fractionated external beam radiotherapy and, human tumor xenograft, 1764
gamma camera-based dosimetry-, 158(ab)
hematologic toxicity after, prediction with ^{131}I-labeled anti-CEA MAbs, 1609
high-dose therapy, compared to low-dose in acute lymphatic leukemia, 992(ab)
humanized Mabs, 968(ab)
implications of nonuniform tumor doses for, 1337
labeled antibodies for prostate cancer, 963(ab)
liver metastasis, 1003(ab)
marrow dosimetry based on radioactivity concentration, 159(ab)
medullary thyroid cancer xenograft, 198
non-Hodgkin's lymphoma, chronic lymphocytic leukemia, 1317
optimization of combination therapy with radiolabled antibodies, 156(ab)
ovarian cancer, 966(ab)
progeny radioisotopes, 162(ab)
prostate cancer, 1001(ab)
radiation protection after radioiodine therapy, 990(ab)

radiolabeled antibody distribution and, liver metastases model, 685
stability of monoclonal antibodies, 1381(ab)
synergic effects of, 430(ab)
treatment planning, dose estimation system and, 1151
vs chemotherapy in colorectal cancer, 428(ab)
5-fluorouracil/leucovorin as radiosensitizer, 429(ab)
^{67}Cu, pharmacokinetics and dosimetry of, 980(ab)
^{67}Cu-2IT-BAT-LYM-1, lymphoma patients, 302
^{67}Cu 2IT-BAT-Lym-1, non-Hodgkin's lymphoma, 2014
^{90}Y biotin therapy in glioma, 266(ab)
^{90}Y DOTA biotin, 75(ab)
^{90}Y DTPA-anti-CEA Mab to improve, 1005(ab)
^{90}Y HMFG1 in ovarian cancer, 432(ab)
^{111}In and Y-90 study of non-Hodgkin's lymphoma, 965(ab)
^{131}I anti-B1, comparison of treatment techniques, 989(ab)
^{131}I-anti B1 in lymphoma, 77(ab)
^{131}I-labeled chimeric antibodies, 970(ab)
^{131}I-labeled 81C6 monoclonal antibody, malignant brain tumors, 631
^{131}I-lableled anti-B1 antibody, 76(ab)
^{186}Re-labeled monoclonal antibody, 263(ab)
^{188}Re-labeled antibodies in leukemia, 262(ab)
^{212}Bi-labeled anti-CD19 antibody in lymphoma, 431(ab)

Radioiodine therapy
adjuvant effect of lithium, 934(ab)
autonomous thyroid nodule, dosimetry study in, 1928
bone and lung metastasis, 530(ab)
cost-effectiveness, 528(ab)
dose to public, 935(ab)
hemithyroidectomy, 927(ab)
lesion uptake, thyroid cancer, 131
patient education, 1453(ab)
post-therapy scan, discrepancy of, 1045(ab)
radioiodine reduces subsequent ablation, 531(ab)
remnant thyroid dosimetry of I-131, 937(ab)
retreatment, Graves' disease, 215(le)
^{131}I biokinetics, 932(ab)

Radioisotopes, availability, Medical Isotopes Conference, 13N(5)

Radiolabeled antibodies
radioimmunodiagnosis, 1008(ab)
^{90}Y DOTA conjugates, 603(ab)

Radiolabeled peptides
multiple dose regimen, effect on biodistribution, 997(ab)
pretargeting studies with, 1002(ab)

Radiolabeling, antisense, 693

Radiometals, Lut177, facile labeling with, 968(ab)

Radionuclide angiography
brain imaging with ^{18}F FDG, 1274(ab)
estimation of brain perfusion index, 1271(ab)
liver scintigraphy, 217(ab)

Radionuclide cocktails, peripheral neuropathy in osseous metastases, 976(ab)

Radionuclide cystography, incidence of vesico-ureteral reflux/infection, 860(ab)

Radionuclide imaging
computer-assisted decision support system, ischemic heart disease, 96
diagnosis of GER by radionuclide imaging, 849(ab)
osteosarcoma, neoadjuvant therapy response, FDG PET, 1637
^{94m}Tc, radioisotope mixture with, 472(ab)
^{99m}Tc tetrofosmin, myocardial viability after coronary occlusion, 142
^{120}I, phantom sutdy to test positron emitter, 501(ab)
^{123}I IPPA, low flow or after acute infarction and reperfusion, 821

Radionuclides, S values at voxel level, dosimetry of nonuniform activity distributions, 11S

Radionuclide studies, frequency encoding, simultaneous display using, brain, 442

Radionuclide therapy
concentration in blood and body, patient-specific marrow dose using, 2102
dose conversion factors, 1364(ab)
dose to household members, 935(ab)
efficacy of copper-64-TETA-Y3-octreotate, 997(ab)
interstitial administration, dosimetry from, 161(ab)
peripheral neuropathy following Re-186-HEDP/Sr-89-chloride therapy, 976(ab)
radiolabeled CCK analogs, medullary thyroid cancer, 2081
synovectomy in hemophiliac children, 44(ab)
systemic, management of metastatic bone pain, 1420
^{47}Sc as a replacement for ^{67}Cu, 489(ab)
^{85}Sr, bone pain palliation, 585
^{117m}Sn citrate, 490(ab)
^{188}Re-labeled colloids, 1392(ab)
^{212}Bi-labeled octreotide, 415(ab)

Radionuclide ventriculography
estimation of ejection fraction, after His bundle ablation, 754(ab)
exercise capacity, 739(ab)
vs gated SPECT in assessment of left ventricular ejection fraction, 757(ab)

Radiopharmaceutical chemistry
multipurpose autosynthesis apparatus, 1467(ab)
nuclear pharmacy, radioiodination method, 1391(ab)
radiochemical studies with ^{99m}Tc, 1402(ab)
radiolabeled antibody preparation, 1404(ab)
reduction of Re-188 perrhenate, 1382(ab)
stannous chloride, 1379(ab)
^{99m}Tc depreotide, characterization of, 321(ab)
^{111}In-pentetreotide labled with Fe-59-ferric chloride, 1389(ab)

Radiopharmaceutical development
biliary secretion studies, 1401(ab)
dosimetry for two PET tracers, para- and meta-^{18}F PFBG and MFBG, 1362(ab)
FLT labeling substrate design, 335(ab)
iodine-labeled estrogen receptor ligands, 1372(ab)
peptide receptor radionuclide therapy, 322(ab)
radioligand transport across blood-brain barrier, 1348(ab)
Sep Pak purification, 608(ab)
5-HT2 receptor, 1347(ab)
^{18}F labeled benzamides, 118(ab)

Radiopharmaceuticals
generator-produced PET myocardial perfusion agents, 775(ab)
medication utlilization evaluation, 1390(ab)
quantitative biodistribution, MIRD Pamphlet No. 16, 37S
radiolabeled monocyte chemoattractant protein-1, 814(ab)
Tc myocardial perfusion imaging with and without fatty meal, 343(ab)
thallium vd technetium for MPI, 344(ab)
tumor-locating, imperfect, 554 (ed)
uptake ratio of ^{99m}Tc glucarate in acute myocardial infarction, 838(ab)
^{18}F YP501, analog of altanserin and MDL 10, 148(ab)

Radioprotection, amifostine to reduce parenchymal damage from I-131, 71(ab)

Radiosurgery, stereotactic, glucose metabolism after, brain tumors, PET, 1085

Radiosynovectomy, efficacy in inflammatory joint disorders, 46(ab)

Radiotherapy
cervical cancer, 1130(ab)
delivery efficacy of radiopharmaceuticals, local drug delivery device, 837(ab)
efficacy of Lu-177-DOTA-Y3-octreotate, 993(ab)
fractionated external beam, radioimmunotherapy and, human tumor xenograft, 1764
intraoperative, unresectable pancreatic cancer, FDG PET evaluation of, 1424
oligonucleotide, problems with, 1582(le)
optimization of combination therapy with radiolabeled antibodies, 156(ab)
pharmacokinetics and biodistribution of ^{111}In-DTPA-G-CSF, 1031(ab)
registration, vascular structure for, pelvis, 347
Sm-153 and Lu-177-DTPA, biodistribution of, 996(ab)
three-dimensional assessment of pulmonary injury, 882(ab)
unresectable pancreatic carcinoma, 984(ab)
uptake of ^{99m}Tc sestamibi and ^{201}Tl , effect of irradiation on, 1376(ab)

Raynaud's phenomenon, esophageal dysmotility, scintigraphy with semisolid meal to evaluate, 77

Receiver operating characteristic curve
PET brain imaging, 477(ab)
three-dimensional moving match filter on simultaneous SPECT images, 1280(ab)

Receptor-binding radiopharmaceutical
IQNP, rapid purification of, 608(ab)
radiolabeling methods for, 322(ab)
synthesis and preliminary evaluation of, 494(ab)
^{99m}Tc RP527, accumulation and retention of, 419(ab)
^{111}In-labeled, 317(ab)
^{111}In-labeled analogs, 418(ab)

Receptor genes, Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)

Receptor imaging
alcohol dependency, 448(ab)
cannabinoid receptor radioligand, 438(ab)
dopamine receptor radioligand, effects of amphetamines, 586(ab)
Galactosyl-insulin, 498(ab)
IPT/IBZM analysis of pre and postsynaptic dopaminergic system, 112(ab)
P-gp modulation, 292(ab)
predictor of therapeutic response, 1107(ab)
synthesis, labeling and evaluation of ^{99m}Tc ECD-folate, 404(ab)

Receptor ligands, identification, phage display peptide libraries, 883

Receptors, effective dose determination of ^{18}F FBT, 1356(ab)

Reconstruction
algorithms, impact on activity quantitation, 595(ab)
effect of transmission scan duration and smoothing, 1313(ab)
effects on ROC analysis lesion detection, 130(ab)
iterative, 590(ab)
matrix inversion for image, 296(ab)
PET, normalization corrections, 1233(ab)

Rectal model, dosimetry applications, 1524

Reflex sympathetic dystrophy, responsiveness to NSAID/steroid, 1189(ab)

Regional cerebral blood flow (rCBF), PET, activation studies with oxygen-14-CO2, 503(ab)

Regional metabolic covariance patterns, FDG PET, 1264

Regional myocardial blood flow, transmyocardial laser revascularization vs PMR, 337(ab)

Region of interest, hottest pixel analysis, 1286(ab)

Renal artery stenosis
PET imaging after treatment with lisinopril, 373(ab)
scintigraphic assessment, hypotensive response to captopril, 406

Renal cell carcinoma
fractionated radioimmunotherapy, 1364.5(ab)
^{11}C acetate, PET imaging with, 1139(ab)
^{99m}Tc labeled monoclonal antibody G250, characterization, 829
^{131}I-labeled chimeric antibodies, 970(ab)

Renal cortical scintigraphy, pediatric applications of pinhole magnification imaging, 1896

Renal imaging
duplicated collecting systems, 913(ab)
renal uptake of Ga-67, 1140(ab)
stereoisomerism effects on structure and clearance, 1403(ab)

Renal scintigraphy
ACE inhibition in diagnosis of RVH, 374(ab)
assessment of cardiac function during, 378(ab)
captopril vs captopril exercise to detect RVH, 866(ab)
communicating bladders in conjoined twins, 861(ab)
urologic management, 913(ab)

Renography
diuretic
evaluate paranchymal effects in renal transplant, 377(ab)
infants and children, 1805
optimal timing of diuretic administration, 204(ab)
quantitative gravity-assisted drainage, 55(ab)
stratification of acute renal colic, 206(ab)
suprapubic tapping maneuver, 205(ab)
validation of F+0 in pediatric patients, 54(ab)
dual-isotope assessment of renal function, 863(ab)
glomerular filtration rate estimation from, 1968(le)
Patlak-Rutland plot in, deconvolution comparison, 1503
radionuclide, ^{99m}Tc EC clearance, single plasma sample, validation of, 429
resistance vessel dysfunction, 372(ab)
^{99m}Tc MAG3, evaluation of renal function, 793

Renovascular hypertension
captopril/exercise imaging to detect RVH, 866(ab)
lorsatan vs captopril in depiction of, 374(ab)

Reperfused, reversible trapping, 813(ab)

Reperfusion therapy, myocardial infarction and, ^{123}I MIBG kinetics after, 904
Reproducibility
camera-based clearance measurements, 209(ab)
myocardial perfusion SPECT studies, 509(ab)
PET studies, malignant tumors, 1771
^{11}C DTZB, healthy human subjects, 283
^{123}I FPCIT SPECT imaging of dopamine transporters, 1201(ab)
Research radionuclides, thymidine as a cell proliferation marker, 1013(ab)
Resolution improvement, cardiac SPECT imaging, 359(ab)
Resource-based practice expense, SNM Physical Evaluation Program, 26N(1)
Restenosis
brachytherapy, 837(ab)
inhibition of, after angioplasty, 819(ab)
Re-188 prevention of, after PTCA, 341(ab)
Revascularization
adjunctive transmyocardial laser, 339(ab)
PET and transmyocardial laser, 340(ab)
Reverse flow-metabolism mismatch, PET, acute myocardial infarction, 1492, 1499(ed)
Rhenium-186 etidronate, breast cancer, with metastatic bone pain, 639
Rhenium-186 HEDP, cisplatin and, prostate cancer cells, 667
Rhenium-188
biodistribution and elimination, 356(ab)
comparison of radiation absorbed dose, 166(ab)
dose calibrator setting for, 1508
DTPA liquid-filled to inhibit restenosis, 819(ab)
labeled antibody, stability study, 1387(ab)
labeled colloids as radiotherapeutic agent, 1392(ab)
labeled agents, preparation of, 1382(ab)
on-demand labeling of metal stents, 825(ab)
palliative treatment of metastatic bone pain, 975(ab)
phosphonate ligands, 1015(ab)
prevention of restensosis after PTCA, 341(ab)
radiation dose measurements of, 1359(ab)
spectral analysis, 1385(ab)
in vitro stability to prevent restenosis, 611(ab)
in vivo and in vitro analysis of stereoisomers, 1384(ab)
^{188}Re HEDP, dose-escalation study, 974(ab)
Rheumatoid arthritis
experimental antigen-induced arthritis, 537(ab)
inflammation imaging of, 872(ab)
osteoarthritis and inflammatory joint disorders, 46(ab)
Right lateral, ^{99m}Tc MIBI SPECT, diagnostic accuracy, 785(ab)
Right ventricular function
gated SPECT to measure, 758(ab)
improvement in, after pulmonary thromboendarterectomy, 173(ab)
^{99m}Tc sestamibi SPECT, in coronary artery disease, 889
ROC curve, whole-body PET lesion detection with, 130(ab)

S

Salivary gland, scintigraphy, in Sjögren's syndrome, 64
Salivary glands
impaired function after radioiodine therapy, 1033(ab)
protection from parenchymal damage by amifostine, 71(ab)
quantitative scintigraphic indices, variability of, 2129(le)
Salla disease, brain glucose use in, FDG PET, 12
Samarium-89, palliation, in skeletal metastases, 256
Samarium-153 EDTMP
structure-activity-relationships of, 1386(ab)
treatment of bone sarcomas, 977(ab)
Sandler, Martin P., JNM Editor, Directions, 9N(1)
Sarcoidosis, uptake of ^{18}F FMT and FDG in, 878(ab)
Sarcomatoid carcinoma, predictive value of FDG PET in progressive disease, 1147(ab)
Scandium-47, replacement for Cu-67, 489(ab)
Scatter correction
analytic methodology for, 1236(ab)
cardiac SPECT, 456(ab)
cross-talk correction in dual-isotope imaging, 471(ab)
detection and quantitation with, hepatic SPECT, 1011
high-energy photon compensation, 1300(ab)
ROC curve in myocardial SPECT, 358(ab)
spectral deconvolution, 1336(ab)
TEW method for, 1331(ab)
SCFV fragments, radioimmunotherapy, 324(ab)
Schizophrenia
dopamine D1 receptor binding in, 120(ab)
IPT SPECT of decrease dopamine transporter binding, 126(ab)
receptor ligand imaging of, 609(ab)
SPECT imaging of amphetamine-induced striatal dopamine, 122(ab)
SPECT imaging of endogenous dopamine, 121(ab)
^{18}F FDOPA assessment of, 125(ab)
Scintigraphy. *see also* specific type
esophageal, with semisolid meal, systemic sclerosis and Raynaud's phenomenon, 77
lung, threshold of detection of diffuse disease, 85
perfusion, bronchial artery revascularization, after lung transplant, 290
whole-body, congenital vascular malformation, 751(ab)
Scintillation camera
dual-head, coincidence imaging with, 432
gas detector, detection of electrons emitted by ^{99m}Tc, 868
optimization of crystal thickness, 1229(ab)
Scintimammography
assessment of chemotherapy response, 1038(ab)
breast cancer, scintimammography in recurrent, 68(ab)
breast neoplasm, 1100(ab)
cone-beam, 1254(ab)
correlation of scan patterns with ^{99m}Tc MDP, 66(ab)
effect of lesion size on ^{99m}Tc sestamibi, 64(ab)
lesion detection with, 140(ab)
patterns in radionuclide uptake, 1463(ab)
reduction in breast biopsies, 1103(ab)
ROC analysis to improve tumor detection in, 1314(ab)
sestamibi SPECT vs planar imaging, 1098(ab)
^{99m}Tc MIBI
dedicated nuclear mammography use in, 46
suspected breast cancer, 296
^{99m}Tc sestamibi, T-scan and, breast cancer diagnosis, 376
^{99m}Tc tetrofosmin, 1102(ab)
Sclerosis, systemic, esophageal dysmotility, scintigraphy with semisolid meal to evaluate, 77
Scrotal scintigraphy, pediatric applications of pinhole magnification imaging, 1896
Seizures
postoperative neuropsychological changes, PET, 1180(ab)
temporal lobe hypometabolism, 276(ab)
Sentinel nodes
active uptake of macromolecule tracers, 1117(ab)
biopsy, role of lymphoscintigraphy in breast cancer, 1119(ab)
biospy, cost-effectiveness in breast cancer management, 560(ab)
detection with lymphoscintigraphy, 70(ab)
dynamic lymphoscintigraphy, 232(ab)
filtered or unfiltered Tc-sulfur colloid for lymphoscintigraphy, 612(ab)
imaging
advantage of small small solid-state gamma camera, 1121(ab)
melanoma and breast cancer staging, detection of, 602(ab)
nonvisualization in patients with breast neop, 1122(ab)
single- or double-method lymph node biopsy, 1114(ab)
imprint cytology, 1115(ab)
localization, early breast cancer, 1403(le)
lymphoscintigraphic imaging, 233(ab)
lymphoscintigraphy in breast cancer, 238(ab)
mapping
^{99m}Tc serum albumin detection, 1149(ed)
^{99m}Tc serum albumin identification of, in melanoma, 1143
needle free tracer injection, 1113(ab)
preoperative management of, counting properties of gamma probes used in, 1227(ab)
radiation safety of lymphoscintigraphy, 1116(ab)
sensitivity of gamma probe in localization of, 558(ab)
sentinel node biopsy, 1118(ab)
Serotonin
low synthesis in temporal lobe indicator of major depression, 577(ab)
receptor distribution, neocortex, parametric PET imaging of, 25
turnover rate and orbitofrontal glucose utilization, 1219(ab)
Serotonin receptors
binding studies of depression pre- and post-treatment, 579(ab)
biodistribution and dose estimates for ^{18}F FCWAY, 168(ab)
competition between ^{11}C carbonyl-WAY 100635 and endogenous serotonin, 117(ab)
hereditary depression, 575(ab)
localization with ^{11}C WAY-100635, brain, PET, 102
PET brain studies, 150(ab)
PET imaging of, 151(ab)
P-glycoprotein modulation, 1167(ab)
preparation of 5HT1A antagonist C-11 WAY100635, 609(ab)
quantification of 5HT2, 1266(ab)
regional distribution in human brain, 116(ab)
reproducibility studies of ^{11}C carbonyl-WAY 100635, 1162(ab)
visualization with I-123-R91150 SPECT in Ecstasy users, 1216(ab)
^{11}C PET, 1347(ab)
^{18}F-labeled, 149(ab)
^{18}F YP501, PET radiotracer for 5-HT2A, 148(ab)
Serotonin transporters
effect on alcohol neurotoxicity, 445(ab)
kinetic modeling of ^{11}C Mcn5652, 114(ab)
kinetic model in nonhuman primates, 115(ab)
radiolabled FEINT for mapping serotonin, 1344(ab)
in vitro activity of, 1346(ab)
in vitro and in vivo evaluation of, 1343(ab)
^{123}I B-CIT, follow-up SPECT study, 576(ab)
^{123}I DAM SPECT imaging of, 1345(ab)
Sestamibi
assessment of regional myocardial blood flow, 1100(ab)
breast cancer, in suspected recurrent, 68(ab)
delayed imaging to detect adenoma, 940(ab)
early and delayed ECG-gated SPECT, 812(ab)
femoral marrow imaging of minimal residual disease in acute leukemia, 942(ab)
high accumulation in bone marrow, 943(ab)
imaging of multiple myeloma, 959(ab)
quantitative SPECT method to identify cardiomyopathy, 507(ab)
reverse redistribution of, in acute myocardial infarction after direct PTCA, 713(ab)
stress testing, comparison of rest-exercise and rest-ATP stress, 512(ab)
uptake patterns in benign and malignant disease, 1463(ab)
uptake ratio indicator of multidrug resistance, 919(ab)
vs furifosmin and tetrofosmin in depicting tumor multidrug resistance, 1025(ab)
vs tetrosfosmin in detection of mild-to-moderate coronary artery disease, 345(ab)
Sickle cell anemia
perfusion imaging in children with, 910(ab)
sulfur colloid assessment of hydroxyurea therapy on splenic function, 958(ab)
Sigma receptors
pharmacological targeting, 1127(ab)
^{18}F labeled benzamides as, 118(ab)
^{125}I imaging in breast cancer, 405(ab)
^{125}I PMS tumor imaging agent, 486(ab)
Simulations, small animal PET system, 131(ab)
Simultaneous dual-isotope imaging
myocardial SPECT, validation of photon-energy recovery, 839(ab)
SPECT coincidence system, 1247(ab)
Single photon emission computed tomography (SPECT)
accurate determination of head boundary, 1277(ab)
alcoholics, naltrexone effects on cerebral blood flow, 19
attenuation and point response correction, 1254(ab)
attenuation correction, 137(ab)
application in Tl-201, 363(ab)
attenuation correction for, 1251(ab)
bone
maximum likelihood reconstruction and ordered subsets in, 1978
spine, attenuation correction techniques, 604

brain
bipolar disorder, depiction of, 580(ab)
cerebral cortical blood flow in children, 917(ab)
compared with DDST II in cerebral palsy, 918(ab)
coregistration study, 1193(ab)
differential diagnosis of brain tumors, 1064(ab)
evaluation of intracranial malignancy, 1182(ab)
frequency distance relation, 1328(ab)
ictal scan predictor of epileptogenic region, 280(ab)
nonuniform scatter without transmission image, 1306(ab)
normal patterns, age-related changes, 1183(ab)
obsessive compulsive disorders, 1213(ab)
reduced cerebral blood flow to white matter in Lyme disease, 1197(ab)
rotating parallel-hole collimator, 139(ab)
statistical parametric mapping, 1268(ab), 1583
stroke studies, automatic analysis of, 570(ab)
three-dimensional volume visualization, 1270(ab)
vs Xe CT in evaluation of cerebral hypoperfusion, 572(ab)
brain, distribution of ^{99m}Tc ECD, age-related changes, 1818
camera performance, 1264(ab)
cardiac imaging, quantitative image reconstruction, 1325(ab)
cerebral perfusion
chemotherapy-induced neurotoxicity in children, 522(ab)
image registration, 278(ab)
quantitation, graphical method and rectified algorithm, 1275(ab)
similarity of MRI in, 574(ab)
coincidence detection camera, 598(ab)
comparison of restoration filters in F-18 collimated SPECT image, 1324(ab)
coronary revascularization, prediction of improvement after, 1866
cost-effectiveness of ^{99m}Tc sestamibi, 172(ab)
dopamine, Parkinson's disease, 530
dopamine transporters, 273(ab)
dual-isotope imaging, retention index, 1101(ab)
dynamic myocardial scan, 311(ab)
epilepsy, quantitative differences, 730
evaluation of back pain, 536(ab)
FDG, uterine cervical carcinoma, 1128(ab)
F-18 FDG, extratemporal and temporal epilepsy, 737
gated
assessment of ventricular function recovery, 338(ab)
automatic quantitation of left ventricular function, 728(ab)
blood-pool imaging of infarcted myocardium, 712(ab)
blood-pool study of left ventricular volume, vs contast ventriculography, 805(ab)
cardiac ejection fraction measurements, 758(ab)
comparative studies of different zoom factors, 768(ab)
correlation of functional data with right ventriculography, 772(ab)
differences in stress and rest ejection fraction images, 182(ab)
differentiation of left ventricular dysfunction, 711(ab)
dobutamine-induced changes in left ventricular function in myocardial perfusion studies, 709(ab)
dobutamine-induced ventricular function changes, 703(ab)
effect on nonuniform attenuation correction on simultaneous emission-transmission images, 752(ab)
evaluation of left ventricular ejection fraction in CAD, 178(ab)
Fourier analysis, 794(ab)
heterogeneity in myocardial perfusion, 748(ab)
hospital cost considerations for ^{99m}Tc sestamibi, 176(ab)
identification of ischemic viable myocardium, 798(ab)
influence of arrhythmias on, 924
large perfusion defects and left ventricular dysfunction, 805
left ventricular ejection fraction and perfusion, 650
left ventricular function and volumes, 1857
left ventricular volume and LVEF assessment, 180(ab)
LVEF and end-diastolic volume from sestamibi and Tl-201 studies, 784(ab)
measurement of myocardial cavity and mass volumes, 807(ab)
myocardial free fatty acid utilization and left ventricular function, 1840
myocardial infarction, 789(ab)
myocardial perfusion imaging in CAD, 787(ab)
myocardial viability assessment, 2(ab)
myocardial viability assessment with ^{99m}Tc tetrosfosmin, 803(ab)
new method of cardiac function analysis, 705(ab)
overestimation of left ventricular ejection fraction, 17(ab)
overestimation of left ventricular volumes, 179(ab)
pinhole collimator, 1249(ab)
post-dobutamine left ventricular function, 766(ab)
poststress ventricular volume, 6(ab)
prognostic and diagnostic value of ^{99m}Tc sestamibi, 759(ab)
QGS program, early and delayed ^{99m}Tc sestamibi, 812(ab)
quantitation of myocardial perfusion studies, 364(ab)
quantitative assessment of regional wall thickening, 792(ab)
quantitative evaluation of gene therapy in myocardial angiogenesis, 760(ab)
reconstruction Tl-201 images with end-diastolic frames, 771(ab)
regional wall motion, quantitative measure of, 802(ab)
scatter and attenuation correction, 788(ab)
severe left ventricular dysfunction, recovery from, 1824
small hearts, 915(ab)
Tc99m-MIBI, regional function assessed by, 761(ab)
Tl-201, reversible perfusion defects, 741(ab)
two techniques to assess left ventricular function, 753(ab)
vs echocardiography in determining left ventricular volume and ejection fraction, 778(ab)
^{99m}Tc tetrofosmin, left ventricular volumes and ejection fraction, 1693
^{201}Tl LVEF measurements, 743(ab)
gated myocardial perfusion, accuracy and reproducibility of, 810(ed)
HMPAO, amytal and cerebral perfusion, Wada test, 747
image analysis, statistical parametric matching, Parkinson's disease, 1583
image reconstruction with matrix inversion, 296(ab)
image registration, epilepsy studies, 1098
integrated visualization, anatomic brain data, 311
iterative reconstruction, 462(ab)
motion correction in ^{201}Tl imaging, diverging circle algorithm for, 1329(ab)
myocardial
absolute quantitation of myocardial activity, 820(ab)
brain natriuretic peptides after, 735(ab)
coincidence imaging, 132(ab)
diagnostic accuracy of quantitative right lateral ^{99m}Tc MIBI, 785(ab)
motion artifacts of, 510(ab)
prognosis of, 23(ab)
three-dimensional color modulated display, 511(ab)
myocardial perfusion
adjunctive transmyocardial laser revascularization, 339(ab)
adjunctive value of left lateral planar view, 810(ab)
detection of culprit lesion, 779(ab)
evaluation of acute chest pain, 174(ab)
OSEM algorithm for attenuation correction, 1318(ab)
quantification of ^{99m}Tc sestamibi defect size, 817(ab)
rest ^{201}Tl activity enhanced by constant infusion, 721(ab)
risk of cardiac death in patients early and late CABG, 25(ab)
risk stratification, 349(ab)
myocardial perfusion imaging, ^{201}Tl studies in children with sickle cell disease, 910(ab)
neurological, partial epilepsy, 677
postictal images of prolonged hyperperfusion, 275(ab)
principal component analysis, 1296(ab)
quality control validation program, 1263(ab)
quantitation in cardiac imaging, 595(ab)
quantitative
attenuation correction, 1335(ab)
correlated X-ray CT images, use of, 1248(ab)
correlation of visual assessment and automated computer analysis, 729(ab)
dipyridamole and exercise stress, 516(ab)
evaluation of left ventricular function, 728(ab)
normal databases, clinical validation of, 506(ab)
partial volume correction, 820(ab)
prediction of palliative response, 265(ab)
^{201}Tl, CEqual map in, 515(ab)
radioiodinated derivatives, 1352(ab)
reducing urinary bladder artifacts, 1334(ab)
registration, vascular structure for, pelvis, 347
rotating chair and solid-state gamma camera, 750(ab)
scatter, attenuation, collimator response correction, 16(ab)
serotonin transporter imaging, 1345(ab)
simultaneous studies, baboons, 660
stress myocardial perfusion SPECT in angina pectoris, 710(ab)
subtraction ictal, seizure foci in children, 786
thallium-gated, major myocardial infarction patients, 513
thoracolumber spine, 413(ab)
three-dimensional image reconstruction, 134(ab), 1255(ab)
transcranial magnetic stimulation, 1212(ab)
truncation effects, 1253(ab)
weighted ordered subsets expectation maximization, 1316(ab)
^{99m}Tc, attenuation correction in, brain imaging, 456
^{99m}Tc DMSA
quantitative uptake, kidney, children, 56
renal scarring, 60
renal tumor enucleation, 968
uptake, kidneys with ureteropelvic junction obstruction, infant, 1111
^{99m}Tc ECD, quantification of cerebral blood flow, 1737
^{99m}Tc ECD measurement of rCBF, 1173(ab)
^{99m}Tc HMPAO
Alzheimer's disease, 522
cerebral blood flow, Alzheimer's disease, 244
dementia with Lewy bodies, 956
^{99m}Tc MDP vs MRI in detection avascular necrosis, 534(ab)
^{99m}Tc TRODAT-1 derivatives, 152(ab)
^{123}I BMIPP, ischemic heart disease, 471
^{123}I epidepride, quantification of dopamine D_2 receptors, 1902
^{123}I FPCIT, defects of functional dopaminergic system, 1091
^{123}I FPCIT, Parkinson's disease, 753
^{123}I IBZM, dopamine receptor brain imaging, neonatal period, 2125(le)
^{123}I IBZM imaging of dopamine D2 receptor binding, 581(ab)
^{123}I iodovinylestradiol imaging, breast cancer, 1728
^{125}I to image farnesyl transferase distribution, 400(ab)
^{201}TL, MRI and, neck metastases, 1414
^{201}Tl , perfusion defects after angioplasty, 811(ab)
^{201}Tl myocardial imaging, 1(ab)
Sjögren's syndrome, salivary gland scintigraphy in, 64
Skeletal metastases, ^{89}Sr and ^{32}P palliation of, 256
Skeletal scintigraphy, pediatric applications of pinhole magnification imaging, 1896
Sn-117m DTPA
clinical data, long-term analysis, 264(ab)
marrow sparing effects in mice, 978(ab)
Society of Nuclear Medicine Imaging in Drug Development (SNIDD), 22N(7)
Society of Nuclear Medicine (SNM)
annual meeting preview, 16N(5)
Education & Research Foundation, 32N(8)
fused image tomography, 13N(8)
lines from the president, 15N(4)
Medical Internal Radiation Dose (MIRD) Committee, 1S, 3S
Pamphlet #17, 11S
web site, earning CME credit electronically, 9N(2)
Soft-tissue sarcoma, limb perfusion with TNF, TYR PET in, 262
Soft-tissue tumor
bone scan in staging of soft-tissue sarcomas, 1146(ab)
imaging, FDG and tyrosine, 381
uptake of I-123-α-methyl-tyrosine, 398(ab)
Somatostatin
MAURITIUS therapy, 74(ab)
receptor-mediated tumor imaging, 72(ab)

Somatostatin receptor imaging
bone metastasis, gastroenteropancreatic tumors, 1602
factor analysis of dynamic series in, neuroendocrine tumors, 33
melanoma metastases, 1126(ab)
predictor of allograft rejection, 5(ab)
^{99m}Tc P829, tumor binding agent, 321(ab)
Somatostatin receptors
comparison of In-labeled analogs, 320(ab)
dose-dependent tumor suppression of, 994(ab)
radionuclide therapy, 414(ab)
radiotherapy studies of, 996(ab)
scintigraphy, gastrinoma patients, 539
Somatostatin receptor scintigraphy
four-hour ^{111}In-pentetreotide SPECT imaging, 843(ab)
lung metastases, 1082(ab)
pituitary adenomas, efficacy octreotide, 1252
primary and metastatic soft-tissue sarcomas, 1142(ab)
pulmonary nodules, scintigraphic detection of, 36(ab)
24-hour delayed imaging, meningioma, 1246
^{111}In-Mauritius imaging of lung tumors, 395(ab)
Spatial normalization
global, using convex hulls, brain, 942
PET, anatomic validation of, brain, 317
Spine, bone SPECT, attenuation correction, 604
Spleen
FDG uptake, granulocyte colony-stimulating factor therapy, PET evaluation, 1456
volume, functional calculation with liver-spleen scan, 1745
Spondylodiscitis, ^{67}Ga citrate activity in, 48(ab)
Sports nuclear medicine
bone scan patterns, multiple stress injuries, 876(ab)
scintigraphic assessment of the elbow, 869(ab)
Squamous cell carcinoma
head and neck, FDG PET, 91
neck metastases, ^{201}TL SPECT and and MRI, 1414
Staging, monitoring tumor response with FDG PET, 96(ab)
Standardized input function, noninvasive measurement, cerebral metabolic rate of glucose, 1441
Standardized uptake value
lognormal distribution and diagnosis implications, 1283(ab)
time corrections from an empirical model, 469(ab)
Steady state technique, gray matter perfusion imaging, 503(ab)
Stents
intracoronary stenting, 780(ab)
on-demand labeling of metal stents in treating restenosis, 825(ab)
Stevens, Sen. Ted, nuclear medicine and, 20N(3)
Strategic plan, SNM, lines from the president, 15N(4)
Streptavidin
specific activity of, 614(ab)
^{111}In-labeled biotin and, pretargeting of bacterial endocarditis, 484
Stress testing, pattern of myocardial perfusion abnormality, 783(ab)
Stroke
activation in regions of diaschisis, 1181(ab)
PET in vivo imaging of activated microglia, 571(ab)
^{99m}Tc ECD, 1194(ab)
Strontium-85, therapy, bone pain palliation, 585
Strontium-89, radionuclide therapy, management of metastatic bone pain, 1420
Student fellowships, JNM honor research, 15N(9)
Stunned myocardium, disturbances in fatty acid metabolism, 195(ab)
Stunning
changes in urinary iodine excretion, 921(ab)
gated sestamibi perfusion SPECT, 766(ab)
Subarachnoid hemorrhage, detection of with ^{99m}Tc ECD, 1188(ab)
Substance abuse, NIH imaging research opportunities, 9N(4)
Sulfur colloid, liver-spleen scan, functional of spleen volume, 1745
Surfactant, exogenous natural, in aerosol lung scintigraphy, 1080
Surgery
endoscopy, miniature beta-sensitive probe for, 600(ab)
utility of myocardial scintigraphy before vascular, 795(ab)
Sympathetic denervation, myocardial, oxidative metabolism abnormalities, PET, 846
Sympathetic nervous system, cardiac overactivity in hypertension, ^{123}I MIBG imaging, 6
Parkinson's disease, 371
Sympathetic nervous system, vesicular storage and monoamine oxidase activity, isolated heart, 323
Sympathomimetic actions, MIBG, tyramind comparison, 1342
Synovitis, chronic, effects of radiation synovectomy, MRI, 1277

T

Tachycardia, idiopathic ventricular, ^{123}I MIBG uptake in, 1
[sndx1]*Talairach Atlas*, global spatial normalization, brain, 942
Technegas
three-dimensional fractal analysis, 1287(ab)
ventilation scan, 884(ab)
^{99m}Tc, pulmonary embolus, 579
Technetium-99m
acute ischemic injury, 1369(ab)
aptamers, 357(ab)
chrysamine G, 288(ab), 898(ab)
combinatorially designed radiopharmaceuticals, 499(ab)
dual-isotope SPECT, partial epilepsy, 677
ECD, synthesis of, 1367(ab)
electrons emitted by, scintillation gas detector used to localize, 868
IgM antibody labeled with, granulocytes, 625
infection imaging with ciprofloxacin, 904(ab)
labeling of highly selective DAT ligand for SPECT, 153(ab)
liposomes labeled with, hydrazino nicotinyl derivative, 192
melanoma scintigraphy, 485(ab)
metabolization of fatty acid analogs, 1406(ab)
metal binding ligands, 500(ab)
murine immunoglobulin M antibody labeled with, granulocyte membranes and, 2107
nonivasive assessment of hypoxia with metronidazole, 1366(ab)
SPECT imaging of dopamine transporter sites, 1161(ab)
stereoisomerism effects on structure and clearance, 1403(ab)
synthesis, labeling and evaluation of ECD-folate, 404(ab)
tumor targeting with labeled cyclic melanotropin peptide, 484(ab)
VIP receptor agonist labeled with, colorectal tumors, 352
in vitro and in vivo properties of labeled peptides, 1397(ab)
^{13}C breath test, orocecal transit, 1451
Technetium-99m annexin V, imaging of apoptosis with, 184
Technetium-99m-antibody labeling
MAG3-chelator for, 327(ab)
mercaptoacetyltriglycine chelator for, 1006(ab)
monoclonal antibody Fab' fragment in infection of, 897(ab)
Technetium-99m apcitide, early and delayed scintigrapy, acute deep vein thrombosis, 2029, 2036(ed)
Technetium-99m Aquaion, peptide label, unprecedented high specific activity, 1913
Technetium-99m benzamides, affinity in melanoma, 487(ab)
Technetium-99m biotin, solid-phase labelling, 614(ab)
Technetium-99m colloid, double tracer technique, head and neck tumors, 776
Technetium-99m colloidal albumin, mucoadhesive drug formulation, 610(ab)
Technetium-99m complexes
formulation of NADH-sensitive Tc ligands, 493(ab)
infection/inflammation imaging, 59(ab)
synthesis of cysteine-oxime ligands, 1402(ab)
Technetium-99m DMP-HSA, serum albumin, biodistribution and absorbed radiation dose estimates, 1532
Technetium-99m DMP 444, detection of deep venous thrombosis, 613(ab)
Technetium-99m DMSA, 52(ab)
clearance, overall and single-kidney, urinary tract infection and, children, 52
renal SPECT, in renal scar, 60
SPECT, renal measurements with, 56(ab)
SPECT, renal tumor enucleation, 968
uptake
experimental pyelonephritis, 643
SPECT, ureteropelvic junction obstruction, 1111
Technetium-99m DTPA
camera-based method to evaluate renal function, 867(ab)
estimation of renal clearance, 207(ab)
increase urinary excretion of, 370(ab)
metronidazole complex for imaging hypoxia, 1373(ab)
Technetium-99m ECD
brain death determination, 1390(ab)
cerebral distribution, changes related to age, 1818
clearance, single plasma sample, validation of, 429
prognostic value in acute cerebral infarction, 1202(ab)
quantitative analysis, regional cerebral blood flow studies, 1183(ab)
Technetium-99m ECT, SPECT and, quantification of cerebral blood flow, 1737
Technetium-99m ENS, different freeze-dried formulations, in aerosol lung scintigraphy, 1080
Technetium-99m ethylnedicysteine, nonuniform attenuation correction of, 1328(ab)
Technetium-99m glucarate
acute chest pain patients, detection of acute MI in, 1832
myocardial viability assessment, 815(ab)
Technetium-99m GSA
accumulation, hilar cholangiocarcinoma, 394
asialoglycoprotein receptors, 847(ab)
dynamic SPECT to predict postoperative liver function, 212(ab)
evaluation of chronic liver disease with, 211(ab)
hepatic asialoglycoprotein receptors, recovery after hepatic resection, 137
liver, biodistribution study of, 213(ab)
radioligand for asialo-glycoprotein receptor, 855(ab)
SPECT
prognosis, cirrhosis of the liver, 1652
residual hepatic functional reserve, 1644
Technetium-99m HL91
applicability, detection of tumor hypoxia, 854
hypoxic tissue metabolism of, 330(ab)
kinetic study in isolated perfused rat hearts, 353(ab)
oxygenation status in tumor xenografts pre- and post-radiotherapy, 1021(ab)
perfusate oxygen level, 823(ab)
trapping in hypoxic myocardium during low-flow ischemia, 813(ab)
Technetium-99m HMPAO
acetazolamide challenge, 573(ab)
assessment of alterations in chronic traumatic brain injuries, 286(ab)
biodistribution of enantiomeric, 1350(ab)
cerebral blood flow, qEEG and, Alzheimer's disease, 522
dementia, Lewy bodies, Alzheimer's disease and Parkinson's disease, 956
endothelial cell labeling, cell-biomaterial interactions, 1756
glutathione localization with, brain, 1056
regional cerebral blood flow, primary antiphospholipid antibody syndrome, 1446
retention, nervous tissue, cerebral cortex slices, 1556
semiquantitative analysis in cerebral palsy, 918(ab)
SPECT
cerebral blood flow deficits in Alzheimer's disease, 244
epilepsy, quantitative differences, 730
Technetium-99m HNP, imaging, bacterial infections, 2073
Technetium-99m human serum albumin, active uptake of macromolecule tracers, 1117(ab)
Technetium-99m HYNIC-folate, targeted radiopharmaceutical, tumor imaging, 1563
Technetium-99m labeled red blood cells
acute gastrointestinal bleeding, detection of, 852(ab)
congenital vascular malformation, 751(ab)
plasma volume determinations, 961(ab)
Technetium-99m MAG3
assessment of cardiac function during renal imagin, 378(ab)
camera-based MAG3 and creatinine clearance measure, 209(ab)
clearance estimation by semi-automoated ROI, 862(ab)

diuresis renography, infants and children, 1805
MAG3 to differentiate nephrotoxicity in transplant, 377(ab)
renal uptake, 972
renography, evaluation of renal function, 793
single-sample clearance, renal, reproducibility of, 1122
ureteropelvic junction obstruction in neonate, 205(ab)
^{99m}Tc MAG3 clearance to measure tubular function, 864(ab)
^{99m}Tc MAG3 for triage in acute renal colic, 206(ab)
Technetium-99m MDP, after nephron-sparing surgery, 418
Technetium-99m MIBI
cardiac perfusion, diagnosis of, 1251(ab)
deoxyglucose in intratumoral accumulation, 1022(ab)
detectability of metastatic lesions, 1047(ab)
detection of residual thyroid cancer, after ^{131}I therapy, 1434
evaluation of chemotherapeutic response, 1087(ab)
hyperfunctional parathyroid glands, correlated with histology, 1792
influx and efflux in myocardial cells, 835(ab)
I-123-BMIPP and, myocardial viability studies, 707
I-123 subtraction imaging of adenomas, 199(ab)
MDR tracer, carcinoma cells, 672
multidrug resistance reversing agents, evaluation of, 1026(ab)
scintimammography
dedicated nuclear mammography use in, 46
suspected breast cancer, 296
SPECT, chemosensitivity of lung cancer, 1778
use in differeniated thyroid cancer, 1769(le)
vs CT in mediastinal lymph node involvement, 1085(ab)
Technetium-99m monoclonal antibody, G250 preparations, characterization, 829
Technetium-99m-peptide conjugates
abscess imaging, 1398(ab)
brain tumor imaging with, 1080(ab)
detection of deep venous thrombosis, 491(ab)
inflammation imaging agent, 872(ab)
inflammation/infection imaging, 900(ab)
metal binding ligands, 500(ab)
potential for imaging cytosolic targets, 316(ab)
Technetium-99m pertechnetate
double tracer technique, head and neck tumors, 776
scintigraphy, laparoscopic adjustable silicone gastric banding, 783
Technetium-99m P829
colorectal adenocarcinomas, 1082(ab)
diagnostic value of in neuroendocrine tumors, 369(ab)
Technetium-99m serum albumin
blue dye and, sentinel node detection, 1149(ed)
identification of sentinel lymph nodes, melanoma, 1143
Technetium-99m sestamibi
baseline-nitrate SPECT, 196(ab)
cardiac tomography, dobutamine echocardiography comparison, after acute MI, 1683
chemotherapy response of osseous sarcomas, 1148(ab)
double-phase scintimammography, T-scan and, breast cancer diagnosis, 376
effect of revascularization on hosital costs, 176(ab)
enhanced uptake in malignant cell lines, 1037(ab)
fusion images, 746(ab)
KR-30035, tumor uptake of, 1023(ab)
localization of parathyroid adenomas, 197(ab)
lymph node imaging, 80(ab)
metastases of colorectal cancer, 426(ab)
multidrug resistance, 549(ab)
oxyphil cell content relations, hyperparathyroidism, 1402(le)
reperfusion success, 24(ab)
sensitivity by cell type in adenomas, 201(ab)
simultaneous ^{201}Tl dual-isotope SPECT, coronary artery disease, 895
SPECT, right ventricular uptake, in coronary artery disease, 889
uptake and characterization in HCC, 1072(ab)
vs planar breast imaging, 1098(ab)
whole-body imaging in thyroid cancer, 532(ab)
Technetium-99m sulfur colloid
colonic reservoir, evaluation of, 848(ab)
sentinel node detection with, 612(ab)
Technetium-99m technegas, perfusion lung scintigraphy, pulmonary embolus, 579
Technetium-99m tetrofosmin
comparison with FDG PET in lung cancer, 384(ab)
detection of axillary lymph node metastasis, 1105(ab)
detection of differentiated thyroid cancer, 198(ab)
functional imaging of Pgp transport activity, 1024(ab)
gated SPECT, left ventricular volumes and ejection fraction, 1693
gated SPECT myocardial perfusion imaging, 740(ab)
measurement, forward cardiac output, 1874, 1882(ed)
myocardial uptake, indicator of severe coronary artery disease, 514(ab)
myocardial viability, models of coronary occlusion and reperfusion, 142
SPECT, functional recovery in severe left ventricular dysfunction, 1824
stability of labelling, 615(ab)
uptake, P-glycoprotein and, non-small cell lung cancer, 1223(le)
velocity gradient iImaging, 806(ab)
Technetium-99m TRODAT-1
age effects on dopamine transporters, 108(ab)
assessment of motor function in Parkinson's disease, 1200(ab)
dopamine transporter imaging agent, kinetic modeling of, 150
dopamine transporter imaging in Parkison's disease, 109(ab)
dopamine transporters, age effects, 1812
Telemedicine, low-cost, variable-resolution teleradiology system, 1293(ab)
Temporal lobe, dysphoric mood, 124(ab)
Testes, radiation dose, after ^{131}I therapy for differentiated thyroid cancer, 1716
Testicular neoplasms
FDG PET in recurrent testicular neoplasm, 425(ab)
multicenter trial, necessary standardization, 1133(ab)
staging of, 1135(ab)
Tetrofosmin scintigraphy
dipyridamole and SPECT vs ^{99m}Tc sestamibi in detection of coronary artery disease, 345(ab)
left ventricular ejection fraction ,evaluation with, 747(ab)
Thallium, gated SPECT
large perfusion defects and left ventricular dysfunction, 805
major myocardial infarction patients, 513
Thallium reinjection imaging
acute myocardial infarction, detection of, 756(ab)
correlation of gated SPECT with right ventriculography, 772(ab)
fixed defects on, 731(ab)
Thallium-201
AIDS, intracranial lesions in patients with, 891(ab)
bone scans to evaluate chemotherapeutic response, 524(ab)
evaluation, multiple myeloma, bone scintigraphy comparison, 1138
gated SPECT studies of LVEF and end-diastolic volume, 784(ab)
overestimation of left ventricular volumes, relation to infarct size, 179(ab)
planar scintigraphy, fine-needle aspiration and, thyroid nodules, 1971
rest-redistribution vs reinjection as predictor of functional recovery, 191(ab)
scintigraphy, detection of residual thyroid cancer after ^{131}I therapy, 1434
simultaneous ^{99m}Tc sestamibi dual-isotope SPECT, coronary artery disease, 895
SPECT
attenuation correction to diagnose CAD, 360(ab)
cost-effectiveness analysis, 718(ab)
lung uptake, discriminant indicator of coronary artery disease, 809(ab)
survival analysis of cerebral glioma, 1063(ab)
uptake, nuclear DNA content relations, metastatic thyroid carcinoma, 963
uptake and retention of, 1035(ab)
vs early and delayed scintigraphy in predicting chemotherapeutic response, 535(ab)
Thallium-201 chloride
quantitative analysis of metal impurities, 1394(ab)
radiotherapy in head and neck cancer, 1057(ab)
SPECT and MRI, neck metastases, 1414
three-phase imaging of musculoskeletal lesions, 875(ab)
Therapy
effect of carvedilol therapy with I-123-MIBG, 8(ab)
intrathecal tumors, 986(ab)
myelotoxicity, factor influencing, 1380(ab)
PET quantitation, 933(ab)
^{188}Re-labeled P829, dose-dependent tumor suppression, 994(ab)
Three-dimensional imaging
color modulated display, 511(ab)
validation and practical strategies for PET, 1096(ab)
whole-body PET, interactive data integration display system, 1452(ab)
Three-dimensional volume imaging
ordered subset expectation maximization, 1321(ab)
relative distribution of D2 dopamine receptors, 1157(ab)
Thrombocytopenia, cardiopulmonary bypass, 947(ab)
Thrombolytic therapy, bleeding reversal with platelet transfusion, 947(ab)
Thrombosis imaging
P-selectin, 357(ab)
^{99m}Tc apcitide sensitivity and specificity of, 40(ab)
^{99m}Tc FBD to detect acute deep vein thrombosis, 41(ab)
^{99m}Tc itistatin, 492(ab)
^{111}In-labeled platelets in, 780(ab)
Thrombus
identification of biological markers, 40(ab)
peptide-based imaging of, 41(ab)
Thymic cancer, differential diagnosis, ^{11}C MET PET and FDG PET, 1595
Thymidine
methyl-^{11}C, ^{11}C activity after, 491
radiolabeled, evaluation of tumor response and recurrence, 1702
2-^{11}C, PET, validation studies, 614
Thymoma, differential diagnosis, ^{11}C MET PET and FDG PET, 1595
Thymus, radiolabeled octreotide concentrations, 1967(le)
Thyroglobulin, chromatography, 938(ab)
Thyroid
congenital anomalies in infants with congenital hypothyroidism, 928(ab)
congenital hypothyroidism, pertechnetate scintigraphy, 799
dosimetry, 933(ab)
postsurgical radioiodine therapy of differentiated carcinoma, 987(ab)
variable scintigraphic patterns of chronic thyroiditis, 1458(ab)
Thyroid cancer
brain metastasis of, 530(ab)
childhood, UICCA/AJCC classification in, 2125(le)
comparative studies of I-131 ^{99m}Tc ^{201}Tl, 1047(ab)
detection of recurrence, 938(ab)
diagnosis and treatment with lanreotide, 74(ab)
differentiated
postsurgical remnants, ^{131}I therapy for, radiation dose to testes and, 1716
^{99m}Tc MIBI use in, 1769(le)
dosimetry, using clearance fitting, 131
effect of irradiation on ^{99m}Tc sestamibi and ^{201}Tl uptake, 1376(ab)
FDG PET detection of, 1044(ab)
FDG PET follow-up studies, 1043(ab)
FDG PET scans in follow-up of, 411(ab)
FDG PET when radioiodine scan negative, 1041(ab)
lobar ablation, 927(ab)
management with recombinant human thyrotropin, 926(ab)
medullary
CEA-producing, radioimmunotherapy in, 198
radiolabeled CCK analogs, evaluation of, 2081
Re-188-DMSA diagnosis of, 924(ab)
targeting cholecystokinin-B/gastrin receptor-expressing tumors, 1029
metastatic
FDG PET role in, 993(ed)
^{201}TL uptake, nuclear DNA content, and clinical behavior relations, 963
monitoring TSH-suppressive therapy, 923(ab)
papillary, FDG PET in, 986
post-therapy scan, stunning of, 1045(ab)
presurgical evaluation of recurrence in cervical lymph nodes, 529(ab)
radionuclide imaging of, 973(ab)

radiotherapy, 198(ab)
remnant thyroid dosimetry of, 937(ab)
residual, after ^{131}I therapy, 1434
stunning due to changes in urinary iodine excretion, 921(ab)
uptake measurements in thyroid remnants, 930(ab)
whole-body FDG PET in follow-up of, 1042(ab)
^{99m}Tc sestamibi whole-body imaging of, 532(ab)
^{123}I scintigraphy in management of, 526(ab)
Thyroid disease
fetal hypothyroidism diagnosis and management, 922(ab)
radioiodine therapy, 1453(ab)
stunning parameter in, 931(ab)
thyroid visualization on lung scan, 884(ab)
Thyroid hormones
cardiac effects, 33(ab)
gastric emptying in hypothyroidism, 527(ab)
Thyroid nodule
autonomous, dosimetry study in, 1928
fine-needle aspiration, ^{201}Tl scintigraphy and, 1971
TLD, intraperitoneal dose measurement, 1358(ab)
Tomography
blurring tomography and positron coincidence detection, 1332(ab)
FBP or OSEM reconstruction, 1333(ab)
four-hour ^{111}In-pentetreotide SPECT imaging, 843(ab)
gating errors in, 715(ab)
ML-EM iterative reconstruction, 1305(ab)
Trabecular bone, absorbed fractions of energy within, three-dimensional transport model, 1947
Tracer kinetic modeling
effects of metabolic alterations on brain retention of perfusion tracers, 1168(ab)
FDOPA distribution volume, 142(ab)
SPECT, dopamine transporter, 144(ab)
statistical bias in Logan graphical method, 141(ab)
^{18}F FDOPA, striatum and cerebellar distribution volumes, 585(ab)
Trainee Awards, Education & Research Foundation, SNM, 32N(8)
Transferrin, ^{18}F, targeting in tumors, 1547
Transferrin receptor, expression, ^{67}-GA scintigraphy in non-Hodgkin's lymphoma, 40
Transmission computed tomography
cardiac imaging, 135(ab)
cone-beam collimation, 137(ab)
Cs-137 fanbeam collimation, 136(ab)
geometrical models, 298(ab)
ordered subsets, 1323(ab)
scatter correction in emission/transmission SPECT, 1312(ab)
simultaneous emission and transmission whole-body imaging, 1231(ab)
static line sources in brain SPECT, 1250(ab)
Transplantation. *see also* specific type
biodistribution of ^{111}In-hepatocytes via portal vein infusion, 850(ab)
diagnostic accuracy of ventilation-perfusion scan, 525(ab)
lung, bronchial artery revascularization after, 290
prognostic value of lung scan, 880(ab)
^{99m}Tc annexin assessment of rejection, 846(ab)
^{99m}Tc annexin V to evaluate lung transplant rejection, 38(ab)
Transport model, three-dimensional, absorbed fractions of energy within cortical bone, 2115
Trapping mechanism, effects of metabolic alterations on brain retention of perusion tracers, 1168(ab)
Triphenylphosphonium, enhanced uptake in malignant cell lines, 1037(ab)
Triple-energy window scatter correction, optimization of, 1337(ab)
Tumor. *see also* specific type and site
blood flow, noninvasive estimation of input function, 464(ab)
breast, FDG biodistribution in, 90(ab)
cultured cells, nifedipine promotion of gallium uptake in, 159
differential uptake of FDG in cultured cells, 1000(ab)
proliferation, 1034(ab)
radiotherapy structure-activity-relationships, 1386(ab)
Tumor detection
abdominal tumors, 562(ab)
FDG PET, 1128(ab)
FDG PET oncology studies, 465(ab)
FDG PET study of esophageal cancer, 1078(ab)
intracellular distribution in tumor cells, 1036(ab)
intraocular tumor, 1058(ab)
linear discriminant, use for tumor detection, 601(ab)
localization ROC, 590(ab)
whole-body FDG PET, 1155(ab)
Tumor grading, IdUMP SPECT vs FDG PET, 1066(ab)
Tumor hypoxia
detection of, ^{99m}Tc HL91 and ^{14}C -deoxyglucose comparison, 854
PET agents for evaluation of, 1365(ab)
synthesis of DTPA-metronidazole, 1373(ab)
^{18}F FETA detection of, 1072
^{99m}Tc labeled-HL91 imaging of vs ^{201}Tl, 1020(ab)
Tumor imaging
automated radiochemical synthesis, 1388(ab)
diagnostic potential of human antibody fragment E8, 434(ab)
evaluation of anti-angiogenic effect with ^{99m}Tc ECD, 1367(ab)
FDG coincidence imaging, 1153(ab)
sestamibi uptake as predictor chemotherapeutic response in lung cancer, 549(ab)
tumor-to-normal tissue ratios, 567(ab)
^{99m}Tc HYNIC folate, targeted radiopharmaceutical, 1563
^{99m}Tc VIP imaging of brain tumors, 1080(ab)
^{201}Tl brain SPECT, 1182(ab)
Tumor localization, imperfect radiopharmaceuticals, 554 (ed)
Tumor markers
abnormalities, scan yields with, 410(ab)
FDG detection of pulmonary lesions, 1092(ab)
Tumor necrosis factor, limb perfusion with, TYR PET in, 262
Tumor recurrence, tracer for, radiolabeled thymidine, 1702
Tumor response
DNA precursors, kinetics, 99(ab)
lactate production with bioreductive antitumor agent, 91(ab)
sestamibi imaging as predictor of, 985(ab)
tracer for, radiolabeled thymidine, 1702
Tumor-seeking agents
mannosylated albumin, 1371(ab)
tissue uptake of ^{18}F alpha-methyl tyrosine, 336(ab)
^{99m}Tc labeled HL91 vs ^{201}Tl, 1020(ab)
Tumor-suppressor genes, oncogenes, cancer, and imaging, 498
Tumor targeting
angiogenesis, 995(ab)
biodistribution of radioiodinated vs radiometal anti-CEA antibody fragments, 325(ab)
dosimetry and, small cell lung cancer, 1216
integrin antagonist, tumor detection using, 319(ab)
phospholipid ether agent for, 155(ab)
radiolabeled integrin antagonists for, 1061
Tumor-to-normal tissue ratio, aptamer tumor targeting, 402(ab)
Tyramine, sympathomimetic effects, MIBG comparison, 1342

U

U. S. Congress, nuclear medicine and, 20N(3)
Ulcerative colitis, 5-aminosalicylic acid absorption, radioenema imaging, 1630
Ultrasound
declining diagnostic value in urinary tract infection, 53(ab)
detection of postmenopausal osteoporosis, 538(ab)
University of California Los Angeles (UCLA), nuclear medicine in the 21st Century, 13N(7)
Urea breath test, clinical significance of oropharyngeal urease, 367(ab)
Ureteropelvic junction, obstruction, SPECT of ^{99m}Tc DMSA uptake, infant, 1111
Urinary bladder
diagnosis of dual communicating bladder system, 861(ab)
radiation absorbed dose, dynamic model, MIRD, 102S
Urinary tract infection, ^{99m}Tc DMSA clearance and, children, 52

V

Validation, brain data
integrated visualization, 311
spatial normalization methods, PET, 317
Vascular endothelial growth factor receptors, peptide uptake and in vitro profile, 995(ab)
Vascular graft, cell-biomaterial interactions, labeling with ^{99m}Tc HMPAO, 1756
Vasculitis
diaschisis, 573(ab)
pulmonary uptake of I-123-MIBG, 39(ab)
Vasoactive intestinal peptide, receptor agonist, ^{99m}Tc-labeled, 352
Venograpy, contrast-enhanced, ^{99m}Tc apcitide scintigraphy and, deep venous thrombosis, 2029, 2036(ed)
Venous sinuses, as input function, quantitative PET, 1666
Venous thrombosis, silent pulmonary embolism in deep venous thrombosis, 223(ab)
Ventilation/perfusion imaging, CT and nonradioactive xenon inhalation, 885(ab)
Ventilation perfusion scintigraphy, variations in image interpretation, 879(ab)
Ventilation scintigraphy, Technegas vs CT ventilation map, 885(ab)
Ventricular fibrillation, idiopathic, ^{123}I MIBG uptake in, 1
Ventriculography
cerebrospinal fluid study, 1206(ab)
gated SPECT to assess wall motion defects, 1278(ab)
Vertebral osteomyelitis, efficacy of imaging, 906(ab)
Vesico-ureteral reflux, voiding cystourethrography, 865(ab)
Visualization, integrated, functional and anatomic brain data, validation, 311
Vocal cords, paralysis, after ^{131}I therapy, 505(le)
Volume visualization, whole-body PET data integration display system, 1452(ab)
Voxel S values, radionuclides, nonuniform activity distributions, 11S

W

Wada test, amytal distribution, regional cerebral perfusion and, 747
Wall thickening
artifactual changes in, 715(ab)
evaluation by ECG-gated SPECT, 802(ab)
gated SPECT assessment, 792(ab)
gated ^{99m}Tc sestamibi, 177(ab)
Welch, Michael J, 24N(12)
Wolf, Walter, Aebersold Award, 12N(6)
World Federation of Nuclear Medicine and Biology (WFNMB), Santiago Meeting 2002, 16N(6)

X

Xenon-133, mean absolute cerebral cortical blood flow, 917(ab)

Y

Y2K
HCFA, 16N(12)
Medicare payment updates, 20N(6)
Yttrium-86
PET imaging of antibodies, 328(ab)
quantitation of PET images, 1238(ab)
Yttrium-90
facile labeling of DOTA-MAb conjugates, 603(ab)
radiation dose calculation after brachytherapy, 167(ab)
Yttrium-90-labeled antiTac, ^{111}In differences, 268

Z

Zollinger-Ellison syndrome, somatostatin receptor scintigraphy in, 539